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Mechanical injury and inflammatory cytokines affect cartilage integrity and tissue
homeostatis: A mass spectrometric analysis of proteins with relevance to arthritis.
by
Anna L. Stevens
Submitted to the Division of Biologcal Engineering on August 3, 2006 in Partial Fulfillment
of the requirements for the Degree of Doctor of Philosophy in Molecular and Systems
Toxicology at the Massachusetts Institute of Technology
Osteoarthritis is characterized by synovial joint degeneration, and its cardinal pathological
feature is degeneration and loss of the articular cartilage joint surface. While the aetiology of
osteoarthritis is unknown, risk factors include gender, age, obesity, and prior joint injury. Joint
injuries, including tears of the anterior cruciate ligament (ACL) and meniscus, increase the risk
for the development of OA and involve both mechanical damage to cartilage, meniscus and
synovial tissues, and tissue degradation associated with cytokine-induced inflammation. While
the role of inflammatory cytokines in OA is still controversial, their role in rheumatoid arthritis is
evidenced by the successful use of anti-TNF-ca and anti-IL-I therapies to abrogate disease
symptoms and progression. In vitro, both IL-1P and TNF-cc promote chondrocyte-mediated
matrix degradation and inhibit cartilage matrix synthesis, while mechanical damage causes cell
death, matrix damage, and decreased cell biosynthesis. Understanding the similarities and
differences in cartilage responses to inflammatory cytokines and mechanical injury is important
in understanding the catabolic-anabolic shifts that typify OA progression. Therefore, the
objectives of this thesis were (1) to identify the role of TNF-a and IL-l [ induced nitric oxide
(NO) as a mediator of cartilage tissue damage; (2) to characterize and compare the regulation by
IL-1 IP, TNF-cc, and mechanical injury of secreted factors, matrix degradation, and mechanisms of
chondrocyte cell death using an SDS-PAGE-LC/MS/MS protein profiling approach; and (3) to
further quantify the effects of IL-1p, TNF-c and injury using an isobaric isotope labeling
(iTRAQ) based 2D-LC/MS/MS approach. Together these studies were designed to provide
better understanding of matrix degradation, cell death, immune response, and evidence of cell-
mediated repair processes.
NO is produced by chondrocytes in response to inflammatory cytokines TNF-a, IL-i [ and
IL-17, and can mediate cellular and extracellular events through cGMP signaling, protein
modifications (e.g., S-nitrosation or tyrosine nitration), altered transcript stability, and altered
sugar and lipid chemistry. Cartilage was treated with IL-1IP or TNF-ct left untreated in the
presence or absence of the NO synthase inhibitor, L-N-methylarginine (L-NMA), and changes in
gene expression and matrix breakdown were measured. We found that L-NMA treatment
partially inhibited TNF-a-induced, aggrecanase-mediated aggrecan degradation as indicated by a
decrease in sGAG loss to the medium and by an increase in the generation of aggrecanase-
specific aggrecan fragments. No change was observed upon addition of L-NMA to IL- Ip treated
explants, but addition of L-NMA to combined IL-i [P and TNF-a treated explants increased
sGAG loss, suggesting that the effects of NO may be contextual. We hypothesized that this
might be due to differences in aggrecanase expression (ADAMTS4 vs. ADAMTS5) or post-
translational modification, but no aggrecanase was consistently identified in the samples. No
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difference in MMP expression or activation was noted following addition of L-NMA, and no
change in NO chemistry between IL-l IP and TNF-a treatment was evident by nitrate and nitrite
production. Gene expression analysis was conducted on a battery of 32 genes, including matrix
proteins, inflammatory mediators, proteases, cytokines and growth factors, and housekeeping
proteins. While IL-1P and TNF-a both increased the expression of proteases and inflammatory
mediators, addition of L-NMA did not significantly affect expression of the genes tested. We
concluded that the effects of TNF-a and IL- 1P-induced NO production may depend on
differences in cellular responses to each of these cytokines and possibly to differences in
signaling or aggrecanase expression.
In the second study, newborn bovine calf cartilage explants were treated with 10 ng/ml IL-Ip,
100 ng/ml TNF-a, radially-unconfined injurious compression (strain: 50%; strain rate
100%/sec), or no treatment, and cultured for five days. Pooled medium was subjected to SDS-
PAGE-LC/MS/MS, and data were analyzed by Spectrum Mill proteomics software, focusing on
protein identification, differences between treatments and matrix protein proteolysis. Over 250
proteins were identified among the four protein groups including CD 109, platelet derived growth
factor like protein, and scrapie responsive protein, which have not been previously identified in
cartilage. IL-1P and TNF-a caused an increase in YKL39, YKL40, complement factor B, MMP-
3, ECM-1, haptoglobin, serum amyloid A3, and clusterin. Injurious compression caused the
release of intracellular proteins including GRP58, GRP78, alpha 4 actinin, pyruvate kinase, and
vimentin, suggesting a loss of membrane integrity in a population of chondrocytes. Data on
actin release within the first 24 hours suggested that this loss of membrane integrity occurred by
mechanical cell disruption. Injurious compression also caused proteolysis of collagen type VI
subunits, collagen type II, and COMP. Thrombospondin 1 fragments were seen in all treatment
groups, and aggrecan proteolysis was predominant with cytokine treatment. Cartilage explants
subjected to injurious compression released intracellular proteins and showed enhanced
degradation of matrix proteins, while explants subjected to IL- 11P or TNF-cc released proteins
involved in innate immunity and stress response.
In the third study, cartilage explants were subjected to injurious compression, TNF-a
(100 ng/ml) or IL- IP (10 ng/ml), or no treatment, cultured in equal volumes of medium, and the
medium was collected, pooled and the proteins deglycosylated by treatment with chondroitinase
ABC. The proteins were subjected to trypsinization, and the peptides were labeled with one of
four iTRAQ labels each containing a unique signature ion. The labeled peptides were subjected
to nano-2D-LC/MS/MS on a QStar, quadrupole time of flight instrument. The study was done in
analytical replicate on a pooled sample of greater than 70 explants from a total of 6-12 different
animals. Data were analyzed by ProQuant to obtain a ProGroup peptide report containing
identified spectra, which were combined to achieve a peptide, and then a protein level output of
mean ratios, standard deviations of those ratios, and significance based on either Wilcoxan sign
rank or Student's t-test both corrected for multiple comparisons. Because of our interest in
catabolic and anabolic shifts, a targeted data analysis approach was taken in addition to a systems
level PCA and K-means clustering approach. By focusing on particular protein domains, we
identified a decrease in the synthesis of most fibrillar collagen subunits (p<0.05), and an increase
in the release of the aggrecan G2 and G3 domains with IL-1p and TNF-a treatment (p<0.05).
We also noted a significant increase in MMP-1, MMP-3, MMP-9, and MMP-13 in at least one
condition and, in most cases, all conditions compared to the untreated sample. Increases in
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proteins involved in innate immunity and immune cell recruitment were noted with IL-1[ and
TNF-a treatment, while an increase in intracellular protein release was seen most dramatically
with mechanical compression injury. Since anabolic effects are often driven by the insulin-like
growth factor family and the TGF-p superfamily, we specifically identified members of these
pathways to understand which factors may mediate early repair processes. At the systems level,
2 principal components were sufficient to describe 97% of the covariance in the data. IL-1[P and
TNF-a caused a similar response in proteins identified; in contrast, a 'Y'-shaped distribution was
observed upon projection of proteins based on their response injury vs. cytokine treatment. K-
means clustering revealed six main clusters to further characterize the biology of mechanical
injury versus cytokine effects on cartilage.
Thesis Supervisors: Dr. Alan J. Grodzinsky and Dr. Steven R. Tannenbaum
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Chapter 1: Introduction
1.1 Arthritis Overview
Arthritis is characterized by degeneration of one or more synovial joints. Joint
degeneration results from degradation and loss of the articular cartilage joint surface and leads to
bone on bone contact and the accompanying clinical symptoms of pain, stiffness, swelling, and
loss of joint motion [1]. The two major forms of arthritis include osteoarthritis and rheumatoid
arthritis. Rheumatoid arthritis is a multi-system autoimmune disease which is characterized by a
"persistent inflammatory synovitis" which ultimately leads to cartilage degeneration and bone
erosion [2]. Osteoarthritis is a degenerative joint disease that has classically been considered a
disease of mechanical wear-and-tear and is frequently localized to weight-bearing joints such as
the knees and hips [2].
1.2 Epidemiology
A recent study by the Center for Disease Control suggests approximately 1 in 3 adult
Americans suffer from symptoms of arthritic disease, which is significantly higher than the
previous estimate of 16% from the Arthritis Foundation [1, 3]. The incidence of rheumatoid
arthritis is approximately 1% of the population with women being approximately 3 times more
likely to suffer from the disease than men [2]. The disease may be quite variable in presentation.
While some cases may be of limited duration and cause only mild damage, many others will
progress to cause complete joint destruction. Osteoarthritis is the most common joint disease [2].
While age is the most important risk factor for OA, joint trauma, repetitive joint use, obesity, and
gender are also risk factors for the diseases [2]. Arthritis is the number one cause of disability in
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the United States affecting a significant proportion of the population and making it an important
focus for improving medical treatments and prevention.
1.3 Diarthrodial Joint and the Knee
Diarthrodial or synovial joints occur at the interface of two bones and allow for low
friction mobility and force dissipation. Mobility and force dissipation are achieved by the
articular cartilage covering the surface of the bones within a joint cavity, where synovial
membrane cells secrete a lubricating substance known as synovial fluid [4]. The knee joint is a
load bearing hinge joint that allows movement in one axis for flexion and extension [4]. The
knee joint is formed by the articulation of the medial and lateral femoral condyles between the
tibial plateau and the articulation between the patella and patellofemoral groove [4]. The joint is
directly stabilized by the menisci that also serve to absorb shock and by ligaments including the
anterior cruciate ligament, the posterior cruciate ligament, and the medial and collateral
ligaments [4]. The leg muscles, particularly the quadriceps femoris provide additional stability
and strength to the joint.
1.4 Cartilage Structure and Composition
Articular cartilage is an approximately 1 mm thick white, glistening material covering the
surface of the bone in synovial joints [1]. The articular cartilage is responsible for weight
distribution, dissipation, and low-friction joint motion [1]. Cartilage contains only a single cell
type, called chondrocytes, which are responsible for production and maintenance of the dense
extracellular matrix (ECM) [1]. Because cartilage is an avascular and aneural tissue, the
chondrocytes must rely on diffusion from the synovial fluid or from the underlying bone for
nutrients and oxygen. Making up approximately 90-99% of the cartilage volume, the ECM is
composed primarily of collagen type II and aggrecan, which are responsible for the weight-
-14-
bearing properties of the tissue [5, 6]. Aggrecan is a large negatively charged proteoglycan
responsible for the compressive stiffness of cartilage while the type II collagen network is
thought to provide tensile strength to the tissue and thus prevents tissue swelling [5, 6]. In
addition, the ECM contains a number of small proteoglycans, growth factors, structural proteins,
proteins involved in cell-matrix interactions, and hyaluronic acid [1].
1.4.1 Aggrecan Structure
Aggrecan is a large aggregating proteoglycan of approximately 2-3 MDa in size, and it
makes up approximately 35% of the dry weight protein of cartilage [7]. The aggrecan core
protein is composed of four domains: the first globular domain, the second globular domain, the
central sGAG rich domain, and the third globular domain. The first globular domain, often
referred to as G1, is responsible for hyaluronan-binding and interacts with proteoglycan link
protein [8]. The purpose of the second globular domain, G2, is unknown; however it may play
an active role in inhibiting aggrecan secretion prior to addition of the sGAG chains [9, 10].
Between the GI and G2 sits a 127 amino acid, rigid interglobular domain which is highly
susceptible to protease cleavage [11, 12]. The sGAG binding region follows the G2 domain, and
it is broken down into the keratin sulfate rich region and the chondroitin sulfate rich region. The
keratin sulfate rich region of aggrecan contains a hexapeptide repeat in which between 4-23
keratin sulfate chains which are O-linked to serine residues [12-14]. There are two chondroitin
sulfate rich regions which contain a total of 120 consensus sequences for chondroitin sulfate
attachment [12, 15-17], from which chondroitin sulfate chains up to 50-100 disaccharide units
long may be attached [7]. These chondroitin sulfate chains are responsible for the high fixed
charge density of aggrecan which is critical to the function of the molecule [5]. The third
globular domain, G3, makes up the C-terminal region of aggrecan. The G3 domain may be
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important in aggrecan intracellular trafficking [18], it may protect the aggrecan molecule against
degradation of the core protein [19], and it also may play a role in aggrecan aggregate formation
and interaction with other matrix components [19].
In young cartilage, each aggrecan interacts with one molecule of proteoglycan link
protein to form a strong non-covalent bond with hyaluronic acid [20]. However, as cartilage
ages, aggrecan gets cleaved in various regions including the IGD domain and various locations
within the chondroitin sulfate binding region (CS2), which leads to the accumulation of aggrecan
fragments within the tissue that no longer resist compression, as well as the full length molecule
due to loss of the sGAG binding regions.
1.4.2 Type i collagen
Collagen accounts for approximately 2/3 of the tissue dry weight with fibril forming collagen
type II accounting for 90% of collagen composition [21]. The collagen fibril network of
cartilage is a heteropolymeric structure of collagen type II, collagen type XI, and collagen type
IX with collagen type II making up the majority by weight [21]. The type II collagen fibril is
composed of triple helices which are homotrimers composed of three alpha 1 (II) subunits [22].
The alpha 1 (II) subunit contains N-terminal and C-terminal pro-peptides, important for fibril
formation and post-translational processing, and an uninterrupted fibril forming region [1]. The
fibril-forming region usually contains a triplet repeat Gly-X-Y peptide where X is often proline
and Y hydroxyproline [23]. Collagens contain a number of modifications including
glycosylation, proline hydroxylation, lysine hydroxylation, and various cross-links that are
important for the overall stability of the collagen helix and the fibril [21]. The type II/XI/IX
collagen heterofibril network is laid down early in development, and it possesses little capability
for repair if damage in late life [21]. Collagen fibril direction varies with cartilage depth.
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Superficial collagen fibrils run parallel to the surface in thin fibrils while those of the
intermediate layer tend to be thicker and appear to run in a more random pattern when visualized
by TEM [21]. Finally, collagen fibrils of the deep layer appear to be orthogonal to the joint
surface and run in larger bundles. These differences in collagen fibril patterns contribute to the
zonal architecture of the tissue. The contribution of collagens IX and XI are greater in thin
fibrils of the superficial surface than in thicker fibrils of the deeper cartilage. Cartilage collagen
structure also varies between the pericellular matrix region and the interterritorial matrix regions
with the fibrils in the pericellular matrix more fine than those of the interterritorial matrix.
1.4.3 Other Matrix Molecules
In addition to aggrecan and type II collagen, cartilage contains a number of other
important ECM structural proteins and protein complexes including other collagens, COMP,
matrilins and other large proteoglycans. The cartilage collagen fibril network is composed
primarily of type II collagen, type XI collagen and type IX collagen, accounting for
approximately 2-3% of the collagen in adult cartilage[ 1, 21, 24]. Type XI collagen, more highly
expressed in young tissue, may contribute to the collagen fibril formation and size while collagen
IX plays an important role in fibril cross-linking which is essential for the stability of the
collagen network [24]. Other collagens such as collagen VI, XII, and XIV may be expressed in
the pericellular matrix of cartilage [1]. Though initially considered a sign of disease or
contamination from vasculature in the underlying bone, small amounts of collagen III may co-
localize with type II collagen fibrils, and likewise, collagen type V subunits may be associated
with collagen XI fibrils [21].
In addition to collagens, matrilins and cartilage oligomeric matrix protein (COMP) may
aid in maintaining the structural integrity of the extracellular matrix. COMP forms a disulfide-
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bonded pentameric structure which binds calcium in the ECM [25]. In adult cartilage, COMP is
primarily located in the interterritorial matrix, where it is thought to help stabilize the collagen
framework [1]. COMP is susceptible to proteolytic cleavage, and its fragments may serve as
useful biomarkers of active arthritic disease [26, 27]. Matrilin-1 and matrilin 3 are expressed by
chondrocytes and are capable of forming collagen-dependent and collagen independent filaments
(for review, [28]). In addition, Matrilin-1 also binds tightly to aggrecan and may become
covalently attached, particularly as tissue ages. Although matrilin-3 is an integral ECM
component in cartilage, increased expression may be associated with an increase in disease
severity [29].
Large aggregating (aggrecan and versican) and non-aggregating proteoglycans (perlecan)
may also be present in the matrix. Versican, like aggrecan is a large aggregating proteoglycan
normally found in many connective tissues. Perlecan is a non-aggregating large proteoglycan
thought to play a greater role in the pericellular environment interacting with cellular adhesion
molecules and other matrix molecules and sequestering growth and differentiation factors in the
pericellular matrix [1, 30, 31].
In addition to large structural ECM components, a number of matrix proteins may bridge
the chondrocytes with the surrounding matrix. These cell-matrix interactions may be important
in transmitting mechanical loads and maintaining cell phenotype. Proteins known to be involved
in chondrocyte matrix interactions include fibronectin, thrombospondin-1, tenascin-c, collagen
VI, collagen II, and perlecan. Fibronectin is present in cartilage in a number of different splice-
variant isoforms; some of these isoforms are thought to be cartilage specific and critical for
normal development and maintenance of the tissue (for review [32]). Fibronectin binds to cell
surface proteins known as integrins, through specific alpha subunits (alpha v, alpha 3, and alpha
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5) of the integrin a-p heterodimer. Fibronectin fragments have been shown to activate
chondrocytes to release matrix proteases through their interactions with the alpha 5 integrin
subunit [32, 33]. Thrombospondin-1 is also present in normal and arthritic cartilage and may be
involved in cell-matrix interactions by binding to CD36 (GPIIIb, GPIV) and CD51 (a-v integrin
via an RGD domain) present on the surface of chondrocytes in the superficial and middle/deep
layers respectively [34, 35]. Tenascin-c is a large ECM protein found primarily in the
pericellular matrix of deep cartilage, and like fibronectin and perlecan, it is thought to play a
critical role in the development and maintenance of the articular cartilage phenotype through its
interaction with cell surface receptors (for review [36]. Although tenascin is up-regulated in
arthritic and in normal cartilage exposed to IL- 1, this process is not associated with the loss of
proteoglycans and may play a role in early repair processes [37].
In addition to the large structural proteins and proteoglycans in the extracellular matrix,
small leucine-rich repeat proteoglycans (SLRPs) are also present in the matrix and are thought to
play a role in regulating collagen fibril formation, cell adhesion, and growth factor regulation
[38, 39]. While SLRPs such as decorin and biglycan have a well-characterized role in regulating
collagen type II fibril size, a number of the other SLRP such as PRELP, epiphycan, and mimecan
are less understood. The role of SLRPs in the ECM may extend beyond collagen fibril
formation, for example, chondroadherin, a SLRP known to play a role in cell-matrix interactions
through binding to type II collagen and a-0 2 integrin on the chondrocyte cell surface [40, 41].
1.5 Cartilage proteases: Damage and remodeling
Finally, the extracellular matrix contains proteases and protease inhibitors important for
remodeling and for maintaining the extracellular matrix. Chondrocytes mediate matrix
degradation primarily through the production of proteases, in particular, two classes of
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metalloproteinases, matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase
with thrombos pondin motifs (ADAM-TSs) (for review [42, 43]). The MMP family currently
contains 24 enzymes while the ADAM-TS contains 19 enzymes [42, 44]. All metalloproteinases
are neutral proteases that possess zinc at the active site, which is responsible for coordinating a
water molecule to attack the amide bond of particular substrates and sites. In addition to
metalloproteases, the chondrocytes may release serine and cysteine proteases including
cathepsins, calpains, and HTRA1, and plasmin [45, 46].
1.5.1 Matrix Metalloproteinases in Cartilage
The MMP family is composed of neutral proteases that can cleave a wide variety of
substrates, and many of the MMPs are found in cartilage. The MMP family possesses three
collagenases (MMP-1, MMP-8, MMP-13) that are capable of cleaving collagen fibrils with
MMP- 13 having the greatest affinity for type II collagen fibrils [47]. Gene expression of both,
MMP-1 and MMP-13, is present in normal and OA cartilage; however MMP-13 gene expression
is up regulated in OA cartilage [48, 49]. Immuno-histochemical analysis shows increased
expression of all three collagenases (MMP-1, MMP-8, and MMP-13) in OA cartilage compared
to an almost undetectable expression in normal cartilage [50]. The gelatinases, MMP-2 and
MMP-9, are responsible for degrading partially denatured collagen fibrils, and they are present in
normal cartilage with MMP-9 up regulated in osteoarthritic cartilage [49]. The stromelysins
(MMP-3, MMP-10 and MMP- 11) are a third group of MMPs with only MMP-3 present in
cartilage. MMP-3 cleaves a wide range of substrates, including aggrecan [51], COMP[52], and
fibronectin[53], and is up regulated following joint injury and in early OA at the protein level
[50, 54]. A number of other MMPs such as MMP-12, MMP-19, and MMP-27 are present at the
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mRNA level in cartilage [49]; however their role in matrix damage and remodeling has not been
well studied and their functions are less well understood.
1.5.2 Cartilage ADAMTS's - the Aggrecanases
"Aggrecanase" was the named given to the proteolytic activity that cleaved Glu373-
Ala374 bond (G1-NITEGE-COO- neo-eptiope) bond in aggrecan [55]. It was the identification
of this unique cleavage site that led to the discovery that MMP-3 was not the enzyme responsible
for acute aggrecan degradation in response to IL-I and retinoic acid, and it began the search for
the aggrecanases [51, 56, 57]. Reports over the next 7-8 years suggested a soluble and a
membrane bound aggrecanase activity as determined by immunoreactivity with neo-epitope
antibodies [58, 59]. In 1999, Tortorella et al. published the identification of the first
aggrecanase purified from bovine nasal cartilage; aggrecanase 1 was identified as ADAMTS4
[60]. Shortly after, aggrecanase 2 was purified, cloned and identified as ADAMTS5 [61, 62].
Since then, there is evidence that ADAMTS 1, 4, 5, 8, 9 may all have some aggrecanase ability
meaning that they are all capable of cleaving aggrecan [63-66]. However, only ADAMTS4 and
ADAMTS5 have been shown to have potent activity to the E373-A374 bond that originally
characterized aggrecanase activity [64]. Real time PCR results indicate that ADAMTS 1,
ADAMTS4 and ADAMTS5 are expressed in normal and osteoarthritic cartilage, and ADAM-
TS4 has been shown to be up-regulated at a transcription level in late stage osteoarthritic
cartilage[48]. Aggrecanases (ADAMTS4 and ADAMTS5) are thought to be synthesized as a
pre-protein and enter the secretory pathway where they are activated by an intracellular pro-
protein convertase, furin, prior to secretion [67, 68]. The actual localization of the aggrecanases
after secretion is still somewhat in question. Tortorella et al. extracted ADAMTS4 and
ADAMTS5 from osteoarthritic cartilage using the chaotropic agent, guanidine, suggesting that
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the enzyme may be associated with the proteoglycans [69]. To further support this possibility,
Flannery et al. showed that both ADAMTS4 and ADAMTS5 have high sGAG binding affinity
which is localized predominantly to the thrombospondin motif region [70]. At the same time,
work by Pratta et al. using immunofluorescence in monolayer chondrocyte culture showed that
ADAMTS4 remains associated with the cell surface rather than being released into the medium
[71]. The work by Gao et al. and Patwari et al. have shown optimal ADAMTS4 isolation using a
detergent lyses rather than guanidine extraction suggesting the molecule may be associated with
the membrane or membrane proteins [67]. At the same time, they were also able to detect
enzyme in the medium suggesting that it may simply be freely secreted [67]. Most in vitro work
has focused on ADAMTS4; however recent in vivo work using ADAMTS4 and ADAMTS5
knockout mice indicate that only the ADAMTS5 knockout mice are protected against cartilage
destruction in both joint trauma and inflammatory arthritis [72-74]. While often difficult to find
in cartilage, aggrecanases are hypothesized to play a significant role in cytokine and retinoic acid
induced aggrecan degradation in cartilage explants generating a G 1 -NITEGE373 neoepitope [67].
1.5.3 Cartilage Protease Inhibitors - Tissue inhibitor of metalloproteinases
(TIMPs)
Matrix metalloproteinases and aggrecanases may be inhibited by one or more of the four
tissue inhibitors of matrix metalloproteinases (TIMPs) [43]. TIMP-1 and TIMP-2 are broad
spectrum inhibitors of the MMP family including collagenases, gelatinases, matrilysins, and
stromelysins. In addition, TIMP-1 and TIMP-2 may have additional roles in regulating
activation and proteolytic activity among the latent MMPs [75, 76]. TIMP-3 is a potent inhibitor
of the aggrecanases, ADAMTS4 and ADAMTS5, as well as inhibiting many members of the
MMP family [43]. TIMP-4 is also a broad spectrum MMP inhibitor that was originally
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identified in the heart and is found in lesser abundance in other tissues [77]. TIMP-1 and TIMP-
3 gene expression has been shown to be up regulated in OA cartilage, and they are generally
thought to play a protective role [49].
1.5.4 Other classes of proteases and inhibitors in cartilage
In addition to the MMPs and their inhibitors, the TIMPs, cartilage contains the serine
proteases, urokinase, tissue plasminogen activator (tPA) and serine protease (HTRA 1), and at
least two serine protease inhibitors, plasminogen activator inhibitor-I (PAI- 1) and alpha-I -
antitrypsin[46, 78-81]. Urokinase, tPA, and HTRA 1 are increased in OA cartilage while PAI is
decreased [78].
Cysteine proteases known as cathepsins are also thought to play an important role in
cartilage damage in arthritis. Cathepsin G and neutrophil elastase secreted from PMNs are
immunolocalized to the cartilage surface in some cases of rheumatoid arthritis where the
enzymes may play a role in cartilage breakdown[82]. The intracellular protease, cathepsin B is
up regulated in synovial cells from RA patients compared to normal [83]. HTRA1 is a newly
identified serine protease found in cartilage which degrades extracellular matrix proteins, such as
decorin, fibromodulin, fibronectin, aggrecan and gelatins, and it inhibits TGF-s signaling[45,
46]. In addition, HTRA1 is elevated synovial fluid from OA and RA patients as well as in
mouse models of experimental arthritis [45, 46, 82, 83]. Under normal conditions, the
proteases and their inhibitors are at an equilibrium that allows for constant matrix remodeling;
however, under inflammatory conditions, these proteases may enhance matrix degradation
creating an imbalance between degradation and synthesis associated with arthritis [84].
1.6 Cartilage changes with Osteoarthritis disease development
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Arthritis results from a progressive wearing away of the articular cartilage of the joint
surface caused by mechanical injury, by joint instability, or by an inappropriate response to
normal mechanical stimuli [84]. The molecular pathogenesis of the disease seems to require
loss of aggrecan, damage to the collagen framework, and ultimately loss of normal chondrocyte
phenotype and (some limited) chondrocyte cell death [84]. In response to joint injury or
cytokine stimulation, latent matrix proteases or newly secreted proteases may rapidly degrade
aggrecan [42, 60, 61, 85]. Although loss of aggrecan may significantly alter the mechanical
properties of the tissue [86], chondrocytes may synthesize and replace lost aggrecan with a
concomitant return of the tissue moduli and function without long term damage [87, 88]. Unlike
aggrecan degradation, collagen damage and/or degradation are thought to constitute an
irreversible step in the pathogenesis of arthritis [84]. Protease induced collagen degradation
occurs after aggrecan depletion suggesting that aggrecan may protect collagen fibrils from
proteolytic degradation [71]. Chondrocyte dedifferentiation, marked by the decrease in type II
collagen and aggrecan and an increase in collagen type I and type X, occurs as the disease
progresses and marks the beginning of the inevitable end as dedifferentiated cells can no longer
synthesize useful matrix material [84]. Although the mechanism of matrix loss and the driving
force for the disease progression are not completely understood, acute mechanical injury and
prolonged inflammatory insult increase the risk of developing arthritis [54].
1.7 Joint Injury in osteoarthritis development
Research in vivo and in vitro suggests that mechanical injury leads to damage of the
extracellular matrix and, at times, death to the chondrocytes. This damage, resulting in a change
in matrix composition and mechanical properties, may be partly responsible for increasing the
risk of arthritis, given that the chondrocytes are rarely able to repair the damage [89]. Knee
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injury, particularly anterior cruciate ligament (ACL) tears and meniscal tears, may dramatically
increase the risk for developing osteoarthritis. Joint injury including ACL or meniscal tear may
significantly increase the relative risk of developing OA with the mean relative risk values
ranging from 3 to 20 with the risk increasing with age of injury and time following injury [90-
92]. While joint instability may contribute to secondary disease development, ACL correction
has not been shown to decrease risk of OA development, implying that the acute traumatic event
may have been sufficient to trigger a cascade of events initiating arthritic progression [93-96].
Acute knee injury is accompanied by an increase in pro-inflammatory cytokines, TNF-ca and IL-
1p [97-99], as well as by increases in MMP-3, COMP fragments, collagen II cross-links and
aggrecan fragments [100-104].
1.8 In vitro joint injury/ cartilage injury models
In vitro models of injury have attempted to better characterize the effects of high stress
and high strain mechanical compression on both the chondrocytes and the matrix. Most
compression injury models suggest that chondrocytes may undergo apoptosis in response to
injury [67, 105-107]; however high stress repetitive loading induces necrosis [108]. Loening et
al. showed that apoptosis correlated with a decreased unconfined equilibrium and dynamic
stiffness in response to unconfined compression injury [105]. These changes in physical
properties were accompanied by an increase in swelling in hypotonic solution suggesting damage
to the collagen framework [105]. Apoptosis by TUNEL was observed at peak stresses as low as
4.5 MPa, which was well below the -12 MPa loads required to induce significant changes in
mechanical properties compared to the free swelling control [105]. To validate the TUNEL
findings, Patwari et al. subjected explants to a single 50% strain at 100 %/sec strain rate single
compression, and showed that the TUNEL staining was consistent with the EM morphology
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findings of apoptosis [67]. D'Lima et al. showed a similar apoptotic response from loading [106,
107]. A single mechanical compression injury, yielding a peak stress of 14 MPa, resulted in
34% of the chondrocytes undergoing apoptosis by DNA fragmentation assay 96 hours after
injury [106]. Only 4% of the chondrocytes were apoptotic in the uninjured control group [106].
Lucchinetti et al. used a stress-controlled confined compression with many repetitions [108]. In
this model, chondrocyte death occurred soon after the injury, and chondrocytes were determined
to be necrotic by morphology by TEM [108]. In vitro injury models usually involve the
application of high-strain/ high strain rate or high stress/ high stress rate controlled mechanical
compression which may be either confined (more characteristic of the physiologic situation) or
unconfined. The high rate of compression causes tissue pressurization in the center of the
explants while the periphery may experience more strain [19] suggesting a spatial gradient of
how the tissue experiences and responds to the compression. While this spatial gradient may
exist, most studies have focused on the pressurized central region of the cartilage to avoid cutting
artifacts [105] which is where abundant apoptosis can be seen by DNA fragmentation or by EM
morphology. Patwari et al. suggests that compression injury may alter cell-matrix interactions
sufficiently to initiate apoptosis [67]. Mechanical injury-induced cell death and accompanying
damage to the extracellular matrix may explain why acute injury so frequently leads to arthritis;
however the contribution of cell death to arthritis is still somewhat controversial [19, 109, 110].
In addition to studies on apoptosis, research has focused on characterizing biosynthetic
responses to cartilage following injury. Kurz et al. showed that increasing strain rate of
mechanical injury significantly decreased tissue recovery from injury (as measured by
biosynthetic rates) [19]. Kurz et al. observed that higher strain rates (0.1 and 1Hz but not 0.01
Hz) led to a small increase in cell death with a more dramatic decrease in S-sulfate
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incorporation and 3H-proline incorporation three days after the injury even in the presence of
stimulatory dynamic compression[ 19]. Quinn et al. similarly showed a decrease in biosynthesis
and increased cell death at the higher strain rates when testing osteochondral explants at strain
rates between 0.003 Hz and 0.7 Hz and peak stresses between 3.5 and 14 MPa [111]. The study
also showed that matrix damage occurred primarily in the superficial zone with higher strain
rates[ 111]. While these studies included observations only early time points following injury,
they suggest that mechanical injury may cause a change in chondrocyte behavior leading to
decreased extracellular matrix production, which may potentiate further degeneration.
Mechanical injury may also cause loss of matrix molecules. Studies by Chen et al. and
Thibault et al. tested the effects of mechanical injury on the production the collagenase-generated
neoepitope of type II collagen [112, 113]. In both confined and unconfined compression injury
models, injury caused an increase in collagenase-generated collagen fragments, which Thibault
et al. postulated may be the result of mechanical denaturation of the collagen fibril making it
susceptible to cleavage by latent metalloproteinases [113]. A study focusing on repair
secondary to mechanical compression injury suggested that both fibronectin and proteoglycan
synthesis were increased relative to controls over the ten days following injury which is similar
to that seen in early OA [112]. DiMicco et al. characterized sulfated glycosaminoglycan release
to the medium over the seven days following injury [19]. In this study, they noted a small but
statistically significant increase in sGAG release, which they attributed to mechanical disruption
of the matrix as well as a longer period of sGAG release that, while not elevated over the
untreated, controls, is responsive to an MMP inhibitor [19].
Recent work, using real time RT-PCR and gene array technology, has focused on
characterizing the initial changes in chondrocyte gene expression that may suggest a cause for
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the changes in behavior observed with injury. Lee et al. performed real-time PCR time course
profiles on 24 cartilage genes involved in normal cartilage maintenance to look for changes in
gene expression following unconfined compression injury [67]. In this study, Lee et al identified
MMP-3, ADAMTS5, and TGF-p which were elevated more than over 5 fold within four hours
of injury and remained elevated at 24 hours after injury [67]. Transcription of MMP-1, MMP-9,
and MMP- 13 were also increased at the 24 hour time point, but matrix proteins aggrecan, type II
collagen and fibronectin were not significantly altered. Additionally, increased transcription of
c-Fos and c-Jun within the first hour of injury suggested that the AP- 1 pathway may be an
important response pathway in injury [67]. A similar study by Chan et al. used a combination of
gene arrays and real time PCR to look for changes in transcription three hours after unconfined
compression injury [114]. This study identified a decrease in transcription of adhesion
molecules and growth factors ICAM-3, NCAM, N-cadherin, VCAM-1, and IGF-1 while the
chemokine receptor CCR10, HMGB2, neurogranin, and ezrin were among the proteins that were
up regulated [114].
1.9 Cytokines and Inflammation in cartilage damage
In vivo mechanical injury occurs with concomitant inflammation. Osteoarthritis has an
inflammatory component, which involves the production of cytokines and local low-level
inflammation without inflammatory cell migration and accompanying systemic immune
response. Pro-inflammatory cytokines IL-I and, to a lesser extent, TNF-alpha are known to
cause cartilage extracellular matrix breakdown and may contribute to osteoarthritis.
1.9.1 Tumor Necrosis Factor alpha (TNF-a) and cartilage damage
Tumor necrosis factor alpha (TNF-a) is a 17 kDa protein produced primarily by
inflammatory cells but it may be produced by synoviocytes and by chondrocytes [114-118].
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TNF-alpha has been identified in the synovial joints of patients with inflammatory arthritis [119].
TNF-alpha is thought to play a role in joint disease because of its ability to initiate an
inflammatory response and because it may play a role in cartilage and bone damage [114]. In
vitro, TNF-alpha inhibits proteoglycan synthesis [120, 121], and increases proteoglycans
degradation, though at a higher concentration than IL-1 [120]. TNF-alpha also stimulates the
production of MMP- 13 (collagenase-3) and MMP-9 (gelatinase-2) that may be responsible for
collagen degradation [122, 123]. TNF-alpha also increases inflammatory mediators, such as
PGE2 and nitric oxide [124, 125], and up-regulate adhesion molecules on endothelial cells
leading to an inflammatory cell migration into the synovium [126, 127]. TNF-alpha up regulates
the transcription of IL-1, TNF-alpha, and IL-6 genes in cartilage from osteoarthritic joints[128],
and the production of IL-1 and GM-CSF by synovial cells [129, 130]. In vivo, transgenic mice
over-expressing TNF-alpha spontaneously develop inflammatory arthritis[131]. In addition,
anti-TNF-alpha antibody therapy has decreases inflammation and histological scores in mice
[132-135], and is used successfully to treat humans with poorly controlled rheumatoid arthritis
[134-137]. TNF-alpha and TNF-alpha receptors are not only present in rheumatoid arthritis but
are increased in a canine model of osteoarthritis [138] as observed by immuno-histochemistry.
TNF-alpha clearly plays an important role in rheumatoid arthritis through its ability to enhance
inflammation and to promote breakdown of cartilage; however, less is known about the role of
this cytokine in OA.
1.9.2 Interleukin 1beta in cartilage damage
Interleukin- 1 or IL-I is an 18 kDa protein present in two primary forms, IL-i alpha and
IL- Ibeta [1]. IL-I was first described as "mononuclear cell factor" for its ability to stimulate
stellate synovial fibroblasts to produce collagenase in culture and then as "lymphocyte activating
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factor" and "endogenous pyrogen" (for review [139]). Dingle et al. also identified IL-1 as
secreted from synovium and described it as 'catabolin' for its ability to enhance chondrocyte
mediated extracellular matrix degradation [140-142].
IL-1 plays a critical role in driving cartilage destruction in inflammatory arthritis,
rheumatoid arthritis, and osteoarthritis [124]. IL-1, like TNF-alpha, can act on chondrocytes,
synovial cells, and endothelial cells to enhance the production of collagenase, prostaglandins,
cytokines, chemokines (IL-8 and leukotrienes), nitric oxide and cell adhesion molecules [42, 87,
120, 124, 143-145]. In inflammatory arthritis models, inhibition of TNF-alpha and IL-I limits
inflammation, and inhibition of IL-I protects against cartilage (and bone) destruction [146]. IL-1
is frequently present in the synovial fluid of arthritic joints [147], and the inhibition of IL-I may
help to decrease cartilage and bone resorption in human disease[148]. While inhibition of IL-1
can be protective, IL- Ibeta gene deletion in mice may lead to an increased risk of osteoarthritis
suggesting that IL-I plays a critical but complex role in normal matrix remodeling [149].
In vitro studies suggest that IL-1 enhances cartilage degradation by activating
chondrocytes to increase protease expression. IL-I increases the loss of aggrecan, and thus
sGAG, through the production of ADAM-TS4 (aggrecanse-1), possibly ADAM-TS5, and to a
lesser extent MMP-3 [55, 56]. Using specific neoepitope antibodies, proteoglycan fragments
released from IL-I-treated cartilage explants and cell cultures were shown to be primarily the
result of aggrecanase cleavage (Gi -NITEGE 373) along the core protein rather than MMP-3
cleavage (GI-VDIPEN34 1 ) [55]. Recent work by Gao et al. suggests that activation of ADAM-
TS4 by C-terminal cleavage appears to be associated with GPI-linked MT4-MMP (MMP17)[67,
150]. Following cleavage, the active form of ADAM-TS4 remains near the cell through its
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association with syndecan- 1 [67]. This mechanistic model may begin to explain Dingle's
observation that aggrecan cleavage occurs near the cells[67, 141].
Type II collagen molecules are cleaved by collagenases (MMP-1, 8, 13) into a 1/4 and
3/4 fragment, which can be further degraded by gelatinases, MMP-2 and MMP-9[42, 143].
Chondrocytes express MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 in response to IL-I
while MMP-2 is constitutively expressed by chondrocytes in explant culture[48, 79, 143, 150-
157]. IL-1 induced up-regulation of collagenases, especially in the presence of the gelatinases,
may lead to substantial damage to the collagen fibrillar network with concomitant decrease in
tissue tensile strength visible as tissue swelling in hypotonic solution [6, 71, 158]. While MMP-
3 is substantially upregulated in response to IL-1, its actions are unclear, as it does not play an
active role in aggrecan or collagen breakdown early in the response to IL-1 [55]. In addition to
collagen and aggrecan, IL-I may also play a role in the degradation of COMP and fibromodulin
while sparing most of the small leucine rich repeat proteoglycans[26, 159].
At a broad level, IL-I inhibits the synthesis of proteins including aggrecan and collagen.
At a gene expression level, IL-I inhibits the synthesis of aggrecan, collagen type II and collagen
IX as well as cartilage derived retinoic acid sensitive protein (CD-RAP) [160-162]. IL-I
significantly decreases extracellular matrix protein synthesis including collagens as measured by
3H-proline incorporation and hydroxyproline, decorin, biglycan, and tenascin-c [37, 142, 163].
IL-I-induced chondrocyte mediated extracellular matrix degradation results from up-regulation
of proteases and inflammatory mediators that may damage the matrix.
1.9.3 Mechanical changes associated with IL-1 beta treatment
To study the effects inflammatory cytokines on tissue mechanical properties, Bonassar et
al. studied the change in mechanical properties of cartilage explants treated with 1 OOng/ml of IL-
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low-
1 P [158, 164]. IL-i I treatment led to a substantial and significant reduction in the compressive
equilibrium modulus, dynamic stiffness and streaming potential as a result of sulfated
glycosaminoglycan loss [158, 164]. By the eighth day of IL-I treatment, ninety percent of the
sulfated glycosaminoglycan had been released, large amounts of hyaluronic acid had also been
released, the equilibrium modulus was only 20% of the starting value, and the tissue showed
signs of swelling in hypotonic solution suggesting damage to the collagen network [158, 164].
Aggrecan loss in this study was shown to be mediated by aggrecanase cleavage and not by
MMP-3, though the overall changes in mechanical properties were similar to those seen by
Bonassar et al. upon treatment with APMA, a mercurial compound known to activate matrix
metalloproteinases [164, 165]. Clearly, aggrecan was associated with much of the compressive
stiffness of the tissue; however, there may be other structural proteins that may also contribute to
the tissue mechanical properties or the response of the chondrocyte to the mechanical loads.
1.9.4 Combining cytokine treatment with cartilage mechanical compression injury
Because joint injury involves both injury to the joint and inflammation secondary to that
injury, in vitro modeling of both components may be helpful in understanding the outcome
caused by injury. Patwari et al. combined high strain, high strain rate compressive injury with
exogenous IL-I (1-Ong/ml) and TNF-a (1OOng/ml) which resulted in synergy with respect to
sulfated glycosaminoglycan loss compared to either cytokine or by mechanical injury alone [67,
166]. This study was critical in that it suggested that mechanical injury and cytokine-induced,
chondrocyte-mediated degradation caused changes in tissue behavior and properties in
complementary and synergistic ways.
1.9.5 The role of nitric oxide in cytokine-induced, chondrocyte-mediated cartilage
damage
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In addition to cytokines and other inflammatory mediators, Farrell et al. observed that
synovial fluid from rheumatoid arthritic joints and osteoarthritic joints also contained large
amounts of nitrite suggesting the up-regulation of nitric oxide production in inflamed synovial
joints [167]. In vitro studies have shown that inflammatory cytokines, in particular IL-1, induce
abundant production of nitric oxide by chondrocyte cultures and cartilage explants [144]. In
vitro studies on chondrocyte or cartilage explant cultures have tested the role of nitric oxide in
IL-I induced catabolic effects using inhibitors such as L-NMA, L-NAME, and L-NIO [168-176].
Inhibition of IL-I and TNF-alpha induced nitric oxide production was associated with increased
proteoglycan synthesis as measured by a decrease in 35S-sulfate incorporation in all species
tested (human, rabbit, equine, bovine) [125, 169, 171-173, 175, 176]. In addition to inhibition of
synthesis, studies suggest that the inhibition of IL-I-induced nitric oxide may inhibit matrix
breakdown [168], have no significant effect on matrix breakdown [20], or enhance matrix
breakdown [172, 173]. At a mechanistic level, nitric oxide activates matrix metalloproteinases
[133, 168, 177], which may degrade collagen and aggrecan. Activation of MMPs would likely
result in increased matrix degradation and not protection. Further research will have to be done
to determine how nitric oxide affects collagen breakdown and further evaluate the findings
suggesting that it protects against aggrecan degradation.
1.10 Biomarkers of osteoarthritis
Biomarkers in arthritis typically target indicators of inflammation or indicators of matrix
degradation. To date, joint space narrowing as determined by radiographic imaging is the only
tried-and-true indicator of arthritis and disease progression. Joint space narrowing occurs only
after much cartilage degeneration making it reasonably specific; however this metric is likely not
sufficiently sensitive to diagnose the disease for early intervention. Thus, better biomarkers are
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needed to diagnose, to assess disease activity, to predict disease outcome, and to evaluate new
therapeutics [178]. While there are many candidate biomarkers for OA, a method to test the
sensitivity and specificity of the marker for OA and disease progression is not yet available. A
method to test biomarkers requires the ability to show a dose response relationship - a marker
must increase with disease progression and decrease with treatment. Unfortunately, no disease
modifying therapy exists for OA, and therefore no control for disease progression exists. With
no sensitive biomarker indicating disease progression/regression, candidate disease modifying
agents will remain difficult and costly to test. Thus, identification of good biomarkers will
benefit from disease modifying therapies, and the development and testing of good disease
modifying therapies will require decent biomarkers. The lack of efficacious therapies and decent
biomarkers for disease are evidence of how little we understand the disease.
Despite these challenges, new, more sensitive biomarkers for OA are needed and
biochemical and imaging biomarkers are being tested. Biochemical biomarker candidates
mainly focus on evidence of cartilage turnover and include hyaluronic acid, type II collagen N-
propeptide, type II collagen C-propeptide (CTX-II), cross-linked collagen II peptides from the C-
telopeptide, collagen III N-terminal propeptide (PIIINP), COMP, osteocalcin, pyridinoline,
AgKS (keratan sulfate containing aggrecan fragment), ykl-40 [178]. In a cross sectional study
evaluating several biomarkers in patient knee OA, Glc-Gal-PYD and CTX-II correlated well
with WOMAC index scores and joint damage respectively [179].
Osteoarthritis is very much defined by its cardinal pathological feature -- cartilage
degeneration. Thus, osteoarthritis is then the clinical endpoint of a pathologic process, but it is
not the pathological process itself. Therefore defining biomarkers of disease around an endpoint
sets the system to fail because the effects of the pathologic process (disease) are visible, but the
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cause, which may be the cartilage or aspects of the joint itself, may be no longer present for
evaluation. To treat the disease requires understanding of the pathologic process or the ability to
ablate the clinical symptoms associated with the outcome. While we have certainly achieved the
latter with joint replacement surgeries, we still struggle with the former.
1.11 Thesis Objectives
Cartilage degeneration is driven by the entire synovial joint, but the chondrocyte, by virtue of its
position within the tissue, must play a primary role in this degeneration by producing matrix
degrading proteases, by altering synthesis of matrix molecules, and by producing inflammatory
cytokines and inappropriate levels of morphogenetic or growth factors [180]. To further
characterize the mechanisms by which chondrocytes may sense and respond to its surrounding
physical and chemical environment, we have chosen to use an in vitro explant model system.
While we recognize the limitations of the system, we also believe that an in vitro model is
necessary to begin to dissect the potential role of the chondrocyte in cartilage degeneration. In
this work, we focused on the role of injurious mechanical compression and inflammatory
cytokines, TNF-a and IL- 1p, to characterize the cartilage and chondrocyte response at a tissue
level. We recognize that such a model cannot recapture the component effects of traumatic joint
injury or even RA, where TNF-a and IL-1 IP are known to play a very key role in the disease
process. At the same time, this model may help elucidate the contribution of the chondrocyte to
the disease process as well as provide hints of particular cartilage specific biomarkers that may
be useful in monitoring cartilage damage in arthritic diseases.
The goal of this thesis is to better understand the contributions of inflammatory cytokine
and nitric oxide induced (IL-i p and TNF-a), chondrocyte-mediated matrix degradation and
injurious mechanical compression to cartilage damage which may be important in the
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pathogenesis of arthritis. To this end, Chapter 2 will focus on the contribution of IL-1 p and
TNF-a induced nitric oxide to cartilage matrix degradation and changes in gene expression.
Chapter 3 begins description of the systems-level analysis of proteins released from cartilage
treated with IL-i 1P or TNF-ax, mechanical injured, or untreated using an SDS-PAGE-LC/MS/MS
approach with the purpose of understanding chondrocyte and matrix response to each of these
treatments. Chapter 4 continues with the goals of Chapter 3, but the purpose is to quantify and
to identify real similarities and real differences between the treatments using an iTRAQ-2D-
LC/MS/MS approach in order to understand the anabolic and catabolic shifts that are known to
occur with treatments. Finally Chapter 5 concludes with the basic points taken from each of the
studies.
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Chapter 2:
The role of nitric oxide in TNF-a-induced, chondrocyte-mediated extracellular
matrix damage compared to IL-1p in bovine cartilage explant cultures
Anna L. Stevens(1), Cameron A. Wheeler(1), Alan J. Grodzinsky(1,2,3), Steven R.
Tannenbaum (1,4)
Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA, USA (1);
Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology,
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Cambridge, MA, USA (3); Department of Chemistry, Massachusetts Institute of Technology, Cambridge,
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2.1 Abstract
Objective: Chondrocytes produce large amounts of nitric oxide (NO) when stimulated
with pro-inflammatory cytokines, and thus NO may mediate some of the deleterious
effects of cytokine treatment. The objective of this study was to determine the role of
NO in TNF-i induced chondrocyte mediated extracellular matrix damage compared to
IL-1 IP in bovine cartilage explant cultures
Methods: Cartilage explants were subjected to treatment with TNF-ca (100 ng/ml) and
with IL-1f (10 ng/ml) and with or without nitric oxide synthase inhibitor, N-
methylarginine (L-NMA; 1.25 mM) for 24 hours (RNA) or five days with 10% medium
collection and supplementation every 24 hours to monitor NO and sulfated
glycosaminoglycan (sGAG) release. After 24 hours, explants were for RNA and real
time PCR. The final collected medium was analyzed for sGAG, nitrate and nitrite, MMP
activity by zymography, collagen degradation and aggrecan degradation by
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immunoblotting of collagen type II and aggrecan GI and aggrecan-G 1 -NITEGE
respectively.
Results: TNF-a and IL-l p treatment caused a 3- to 5-fold increase sGAG release with
an increase in aggrecanase specific aggrecan breakdown, an increase in nitrate and nitrite
production, an increase in transcription of protases(MMP3, MMP 13, ADAMTS4 and
ADAMTS5) and pro-inflammatory enzymes iNOS and COX2, a decrease in 3S-sulfate
incorporation as a measure of new sGAG synthesis, and an increase MMP3 and MMP9
secretion. N-methylarginine treatment partially inhibited sGAG release induced by TNF-
ax treatment with concomitant decrease in the aggrecanase-specific neo-epitope of
aggrecan released into the medium. However, the addition of L-NMA with IL-i IP or
TNF-a treatment had no detectable effect on sGAG biosynthesis, gene expression among
the 31 genes tested, MMP secretion or activation, or collagen breakdown.
Conclusion: Inhibiting NO production in response to TNF-ca partially suppressed
aggrecan proteolysis by the aggrecanases and the concomitant release of sGAG-
containing aggrecan fragments to the culture medium. L-NMA had a global effect on
protein synthesis as measured by 3H-5-proline where it partially reversed the cytokine
induced inhibition. IL-i 1p-induced matrix degradation was unaffected by the inhibition of
NO production by L-NMA; however nitric oxide was protective against sGAG release
due to IL-i I1 and TNF-a in combination.
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2.2 Introduction
Nitric oxide (NO) is a neutral free radical with potent biological effects through its
actions as a signaling molecule activating cGMP production as well as through various
oxidative and nitrosative chemistries that have been shown to modulate gene expression
and to alter protein structure and function [1]. While the role of NO in many diseases is
well characterized, its role in the pathogenesis of arthritis remains unclear.
In 1991, Stadler et al. first showed that lapine chondrocytes in monolayer
produced substantial amounts of NO in response to IL-1P, LPS, or in combination with
TNF-ax [2]. Shortly after, inducible nitric oxide synthase (iNOS) was cloned from human
chondrocytes treated with IL-1, and studies demonstrated that iNOS mRNA expression
increased in response to IL-1fP, TNF-ca, and endotoxin treatment [3-5]. Since these first
reports, numerous studies have shown that chondrocyte or explant cultures may produce
NO in response to IL-1p, IL-I cc, and TNF-ca in most species tested [6-11]. Other pro-
inflammatory factors such as IL- 17, IL- 18, ICE, and fibronectin fragments may increase
NO production in chondrocytes [12-15].
With the identification of NO production by iNOS, a number of in vitro studies
have used NOS inhibitors, L-NMA (L-N-methyl-arginine), L-NAME, aminoguanidine,
and L-NIO (N-iminoethyl-L-omithine) to evaluate the role of nitric oxide in IL- 1-
induced changes in chondrocyte metabolism and matrix degradation in explant, hydrogel,
and monolayer culture. With the exception of the bovine explant studies [7], inhibition of
NOS partially reversed IL-I-induced inhibition of proteoglycan synthesis in rabbit,
human, and rat cartilage explants or chondrocyte cultures [16-20]. TNF-a has been
shown to decrease proteoglycan synthesis in a NO-dependent manner as well [10]. The
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exogenous NO donor, SNAP (100 uM), also decreased proteoglycan synthesis [16, 17].
IL-I-stimulated NO production as well as exogenous NO donors decreased collagen
synthesis in an mRNA independent fashion indicating that NO may post-transcriptionally
regulate collagen production possibly through its actions on prolyl-hydroxylase, which is
consistent with findings that protein disulfide isomerases may be susceptible to regulation
via S-nitrosation [21, 22] .
Studies on matrix degradation have focused on the role of NO on IL- Ip-mediated
degradation and have suggested that NO may alter matrix degradation. Inhibition of NO
production induced by IL-i 13 treatment enhances [7, 8, 23] or has no effect [24] on
aggrecan degradation as measured by sGAG release. While studies have not yet explored
the role of NO in collagen or other matrix damage, they suggest that NO produced in
response to IL-I does not induce proteoglycan degradation.
Studies focusing on mechanisms of matrix degradation indicate that IL-I induced
NO may enhance matrix metalloproteinase activity or expression in cartilage. Despite
differences in methods, most findings supporta role for NO (exogenous or endogenous by
IL-I activation) in altering gelatinase (MMP-2 and MMP-9) [2, 25, 26] and stromelysin
(MMP-3) [7, 25] expression or activity. Inhibition of NOS decreased IL-1p induced
gelatinase activity and expression [2, 25]. Stadler et al. further showed that treating
chondrocytes with a combination of either IL-i 1P and LPS or IL-i p and TNF-aL and
inhibiting NOS by L-NMA actually increased gelatinase activity [2]. Studies of
stromelysin activity are less clear. Murrell et al. showed that inhibiting NOS decreased
LPS induced MMP-3 activity with an insignificant decrease seen with IL-i p treatment.
Similarly, treatment with SNAP was also able to stimulate MMP-3 activity, and the
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effects were shown to be dependent on new protein synthesis [25]. Stefanovic-Racic, et
al. showed that inhibiting NO production in response to IL-I caused an increase in
stromelysin activity [7]. These findings indicate that nitric oxide alone or in response to
IL-i Is treatment may enhance gelatinase activity while having a less straight-forward
effect on MMP-3 activity.
Following the discovery of NO production by chondrocytes in response to
inflammatory stimuli, Farrell et al. showed that the NO end-product, nitrite, was elevated
in the synovial fluid of rheumatoid and to a lesser extent in osteoarthritic joints [27].
Since this discovery, animal models of inflammatory arthritis and osteoarthritis have been
employed to test the role of NO in disease development and progression. Studies using
rodent arthritis models have generally shown that prophylactic inhibition of NOS with a
non-specific NOS inhibitor may lead to partial or full protection against the disease
development with less promising results reported with more selective inhibitors [28-34].
At the same time, studies using NOS2-/- mice in inflammatory arthritis models generally
show a decrease in tissue damage compared to the wild-type controls [35-37]. Further,
Kato et al. also saw a decrease in nitrotyrosine, a decrease in apoptosis via TUNEL, a
decrease in MMP-3 and MMP-9, and a decrease in serum IL-i 13 and NO derivatives in
iNOS deficient animals.
In a canine osteoarthritis model (ACL resection/joint instability), the effects of
nitric oxide inhibition by selective iNOS inhibitor, L-NIL, has shown promising effects,
reducing cartilage damage, reducing MMP- 1 and MMP-3 expression, reducing IL-18 and
ICE production, and reducing apoptosis [14, 38-40]. NOS2-/- mouse models have shown
both an increase and decrease in OA development with joint instability [37, 41]; however
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NOS2-/- models are physiologically distinct from those treated with iNOS inhibitors, in
which nitric oxide production decreases to baseline while NOS2-/- animals have no
baseline iNOS activity. Additional complexity may exist as few NOS inhibitors are
completely specific to one form or the other of the enzyme. Despite these caveats, these
results suggest that nitric oxide may play a deleterious role in the development of
osteoarthritis.
In addition to nitric oxide and IL-1, TNF-ax also plays an important role in
rheumatoid arthritis and likely in osteoarthritis as well. TNF-ax was identified in synovial
exudates of rheumatoid and osteoarthritic joints [42, 43]. In RA patients, TNF-ca may
contribute to IL-I production as determined by anti-TNF therapy [44]. Hukkanen et al.
found a correlation between nitric oxide production and the development and progression
of polyarthritis in a transgenic TNF-ax mouse model [45]. While TNF-ax may play a
greater role in inflammation than in tissue damage, in vitro evidence suggests that TNF-ca
alone or in combination with IL-I may cause cartilage breakdown and a decrease in new
matrix synthesis by chondrocytes [46].
TNF-ca may play a role in the pathogenesis of osteoarthritis. Brennan et al.
showed that spontaneous IL-I production in OA synovial cells was low even though
TNF-ax was high suggesting a role for TNF-a in driving disease progression [44].
Shinmei et al. showed that OA chondrocytes had a larger population of IL-1, TNF-ca, IL-
6 and MMP3 positive chondrocytes compared to chondrocytes from healthy joints [47,
48]. At the same time, OA cartilage explants are more susceptible to IL-I and TNF-ax
treatment [49-51]. Increased susceptibility to TNF-a may in part be the result of
increased TNF-ca receptor expression, as Webb et al. showed that there is a strong
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correlation between TNF-R p55 (but not p75) expression and sGAG loss in cartilage [52].
In addition, synovial fluid from OA joints increased TNF-R p55 (and p75) receptor
expression, which was partially blocked with IL-I and IL-6 neutralizing antibodies [53].
TNF-a may be present in synovial fluid and serum from OA patients as well as being
expressed in chondrocytes in OA tissue [54, 55]. Finally, using a high-through-put
screening method, TNF-RlA was identified as a gene whose up regulation contributed to
induction of a set of OA markers [56]. These data together suggests that TNF-ca may
play a role in cartilage breakdown in osteoarthritis and this breakdown may be modulated
by the expression of iNOS via its production of nitric oxide.
IL-I and TNF-a are known to induce chondrocyte mediated sulfated
glycosaminoglycan release via cleavage of aggrecan. While a number of enzymes are
known to cleave aggrecan, two classes of proteases, the matrix metalloproteases (MMPs)
and the ADAMTSs (a disintegrin and metalloproteinase with a thrombospondin motif)
have been well studied for their ability to cleave aggrecan. Using antibodies to the
neoepitopes generated with protease-specific proteolysis of aggrecan, studies suggest
that IL-I and TNF-c induce "aggrecanase," not MMPs mediated cleavage of aggrecan
[57, 58]. After much research the "aggrecanases", ADAMTS4 and ADAMTS5, were
cloned from cartilage and shown to have a high affinity and activity against aggrecan
with the ability to cleave at the "aggrecanase" site in aggrecan interglobular domain and
be present in human arthritic joints [59-64].
The purpose of this study was to determine whether and by what mechanism
nitric oxide plays a role in matrix loss in response to TNF-a and to compare this
degradation to that found with IL-1P using NOS inhibitor, N-methylarginine (L-NMA).
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Matrix degradation was measured by sGAG release, by collagen fragment release, and
35S-sulfate incorporation on day 6 was used to monitor the effects on new sGAG
synthesis. Mechanisms of proteoglycan degradation and matrix breakdown were probed
by blotting for aggrecan fragments and by zymography for MMP activity. To test more
globally the effects of nitric oxide in modulating cytokine-induced up-regulation of pro-
catabolic genes, real time PCR on a battery of 32 genes were performed to look at the
effects of L-NMA on cytokine induced changes in gene expression. These results
suggest that NOS inhibitor, L-NMA, plays a role in decreasing TNF-ca but not IL-1 IP
induced aggrecanase-mediated aggrecan degradation. No differences were seen in
metalloproteinase activity, gene expression by real time PCR, sGAG biosynthesis, or
collagen fragments with L-NMA treatment. This suggests that the role of NO may be
limited to modulation of aggrecan degradation at early time points in this model.
2.3 METHODS
Reagents. Insulin, transferrin and selenium medium supplement (ITS) and NOS
inhibitor, N-methyl-arginine, were purchased from Sigma (St Louis, MI). Recombinant
human IL-i 1P and TNF-a were purchased from R&D systems (Minneapolis, MN),
Polyacrylamide gels and loading buffers were purchased from BioRad (Hercules, CA).
Protease-free chondroitinase and keratanase II were purchased from Seikagaku (Japan).
Common chemicals were purchased from ICN, Mallenkrodt, or Sigma.
Cartilage explant harvest and pre-experiment culture and weighing: Articular
cartilage disks were obtained from the patello-femoral groove of 1-2 week old calves as
described previously [65]. Cartilage cylinders (9 mm diameter) were cored from the
patello-femoral groove, perpendicular to the joint surface. The cylinders were then cut
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into two 1 mm thick disks using a microtome to insure similar geometry. A 6 mm
diameter dermal punch was used to core out the center of each of the 9mm slice
generating a 6 mm diameter by 1 mm thick cartilage disk. Each disk was placed into 1
well of a 12 well plate containing 2.5 ml of high glucose DMEM containing 1% ITS as
described previously [66]. The medium was changed every two days during the seven-
day resting period prior to experimentation with explant weights were taken on day 5.
TNF-a, IL-13, and L-NMA treatments. Cytokines were resuspended in 0.1% BSA at
a concentration of 10 ug/ml for TNF-ax or 2.5 ug/ml for IL- 1p . On day seven of culture,
explants were treated with 10 ng/ml of IL-1 I or 100 ng/ml of TNF-a or untreated in 2 ml
of medium without 1% ITS for five days. Two hours after cytokine treatment, samples
were treated with 1.25 mM L-NMA. Explants for real time PCR analysis were cultured
for 24 hours after the addition of L-NMA and snap frozen in liquid nitrogen. For all
other experiments, cartilage explant cultures were subjected to a 10% medium change
every 24 hours-- 200 ul of medium was removed and 200 ul of fresh medium with one-
half ascorbate was supplemented-- for an overall 40% medium change over the five day
culture period (0.6 ml medium/explant/day). On day 5, medium and explants were
collected, pooled to each treatment group, and stored at -80C.
Radiolabel incorporation as a measure of biosynthesis. For a subset of explant
experiments, five-day conditioned culture medium was removed and replaced with fresh
ITS containing medium supplemented with 10 microCi 5-3H-Proline and 5 microCi
disodium 35S-sulfate for 24 hours to measure biosynthesis. Following 24 hour radiolabel
treatment, explants were washed four times for 20 minutes in PBS containing 1mM
proline and 1 mM disodium sulfate to remove unincorporated radiolabel. The explants
were then digested overnight in 0.2 mg/ml proteinase K at 60C. A portion of the digest
was subjected to liquid scintillation counting to measure radioactive decay.
Sulfated Glycosaminoglycan (sGAG) Assay. Sulfated glycosaminoglycans were
measured as an indicator of aggrecan release. sGAG in the medium was measured by
dimethylmethylene blue (DMMB) assay using shark chondroitin C as a standard as
described previously [67].
Nitrate/Nitrite Analysis. Medium samples were diluted 1:2 in water prior to nitrate
nitrite analysis by Greiss assay [68]. Total nitrogen oxides were determined by cadmium
column reduction of nitrate to nitrite followed by direct nitrite detection by Greiss
reaction. Nitrite was assayed directly, and nitrate was calculated as the difference
between the total nitrogen oxides and the nitrite.
Gelatin and Casein Zymography for MMPs. Zymograms were performed as
described[69]. Briefly, conditioned medium from day 5 was mixed with 4X non-
reducing SDS-sample buffer and electrophoresed in a 10%/12% gelatin or casein
zymogram gels. Gels were renatured in 2.5% triton X-100 solution, and placed in
solution of 50 mM Tris and 5mM CaCl2 for 18 hours at 37C. Gels were then fixed and
stained with Coomassie brilliant blue and destained until bands became visible and
distinct. Gels were immediately scanned. EDTA was added to the incubation buffer to
verify MMP activity. MMP-3 and MMP-9 were verified by western blotting.
Ethanol Precipitation and deglycosylation for aggrecan western blot analysis. The
medium equivalent of 10 or 20 ug sGAG was precipitated by the addition of 3 volumes of
ice-cold ethanol. The samples were resuspended (50 mM Tris-Acetate, 10mM EDTA)
and sequentially deglycosylated beginning with 5 mU of protease-free chondroitinase
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ABC for three hours followed by 0.1 mU of keratanase II and 0.1 mU of endo-p-
galactosidase for an additional four hours.
Dialysis and Deglycosylation for western blot analysis. Chondroitinase ABC (80 mU)
was added to 2.0 ml of pooled sample medium from each explant experiment was
dialyzed and deglycosylated in a 7.5 kDa cutoff dialysis cassette (Pierce, city) overnight
at 37C against 10 mM Tris-acetate, 10 mM NaCl, 10 mM sodium acetate, and 5 mM
EDTA followed by dialysis against pure water at 4C for 12 hours. The sample was
frozen and concentrated to lOX. For aggrecan westerns, the appropriate amount of
sample was taken to achieve 10 or 20 ug sGAG for each sample and further
deglycosylated as described above. For the MMP and collagen western blots, equal
volumes of sample were loaded.
Western blot analysis Concentrated samples (10-15 ul) were run out on denaturing SDS-
PAGE on a 4-15% gradient gel run at 15 mA for 2 hours. Proteins were then transferred
to Immobilon (PVDF) membrane, and proteins were detected using monoclonal antibody
to type II collagen (NeoMarkers, Lab vision), monoclonal antibody to the Aggrecan-GI-
NITEGE-COOH fragment of aggrecan (C. Flannery, Wyeth Pharmaceuticals), and a
polyclonal antibody to the GI domain of aggrecan (J. Sandy).
RNA extraction and real time PCR. Two to three cartilage explants per condition
(untreated, L-NMA, TNF-a, TNF-a and L-NMA, IL-1P, and IL-1P and L-NMA) per
joint from a total of 8 joints (from 8 different animals) were pulverized under liquid
nitrogen and homogenized in Trizol (Invitrogen, San Diego,CA). Homogenates were
transferred to Phase Gel tubes according to the manufacturer's instructions (Eppendorf,
Hamburg, Germany) and spun at 10,000rpm for 10 minutes at 4' C. The clear RNA
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containing supernatant was removed from Phase Gel tubes and subjected to RNAeasy
mini-kit clean-up (Qiagen, Chatsworth, CA) according to manufacturer's instructions.
RNA quantification was determined by nano-drop method measuring absorbance at 280
nm and 260 nm. Equal amounts of RNA were subjected to reverse transcription using
AmpliTaq-Gold reverse transcription kit (ABI, Foster City, CA) to generate cDNA for
real time PCR analysis. Real time PCR analysis was performed using Applied
Biosystems SYBR-Green master mix in combination with cDNA and primers. An ABI
prism 7900HT real time PCR machine, equipped with 384 well loading plate, was used
for analysis. Both forward and reverse primers were designed using Primer3 software
based on the bovine genomic sequence. Primers from 32 cartilage relevant genes were
measured: 18S-RNA, aggrecan, collagen II, fibromodulin, fibronectin, proteoglycan link
protein, MMP1, MMP3, MMP9, MMP13, ADAMTS4, ADAMTS5, TIMPI, TIMP2,
TIMP3, COX2, iNOS, G3PDH, P-actin, IGF-1, IGF2, TGF-p, TNF-a, IL- 1s, IL-4, IL-6,
TXNIP, HSP90, CD44, HAS2, bFGF, and OP-1. Standard curves analysis was
performed on each of the primers to determine the efficiency of amplification and proper
primer concentration. The measured cycle threashold (CT) was determined and
converted to relative copy number using information from standard curves for
comparisons.
Data analysis and statistics: Real time PCR data from each sample were normalized to
the 18S-RNA and then the data were secondarily normalized to the untreated (control)
sample within each sample set (animal). The normalized data was compared as the mean
+/- SEM of each condition. Principle component analysis and k-means clustering
analysis was performed on the real time PCR data using components of the Matlab
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Statistics toolbox. The Kruskal-Wallis test and Wilcoxon sign-rank test with Bonferroni
correction for multiple comparisons were used to determine statistical significance of the
L-NMA effect and pairwise comparisons between treatments respectively. For the
remaining quantitative assays-- sGAG, biosynthesis by radiolabel incorporation, and
nitrate/nitrite assays -- multi-way ANOVA followed by a post-hoc Student's t-test with
Bonferroni correction for multiple comparisons were used to determine statistical
significance defined as p<0.05. All statistical analyses were performed using Systat 11,
Richmond CA.
2.4 RESULTS
Explant Cultures: Cartilage explants were allowed to rest one week before beginning
cytokine treatment and then treated with 100 ng/ml TNF-a, 10 ng/ml IL-1p, a
combination of TNF-a (50 ng/ml) and IL-i 1P (10 ng/ml), or left untreated in 2 ml of
DMEM. After 2 hours, one-half of each treatment group was further treated with 1OOX
L-NMA for a final concentration of 1.25 mM L-NMA. Every 24 hours, the cultures
underwent a 10% (200 ul) medium removal and supplementation, and the collected
medium was frozen for sGAG and nitrate/nitrite determination. Over the course of the
five-day experiment, there was no observable difference between the cytokine-treated
and control samples. TNF-c +/- L-NMA and IL-1p +/- L-NMA treatments were
performed as separate experiments. The results represent data collected from between 3
and 8 different animals with at least two explants per joint per condition. Because no
statistical difference was noted between the untreated or L-NMA only groups in each
experiment, the data were combined to simplify presentation.
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Nitrate/Nitrite: Nitrate and nitrite are NO end products produced from NO interacting
with superoxide or oxygen respectively. Nitrite and total nitrate and nitrite were
determined by Greiss assay with nitrate reduction to nitrite performed by flowing samples
through a cadmium column prior to Greiss reaction [68]. Nitrate was calculated as the
difference between the total NO end products and the nitrite. The graph in Figure 1
shows the accumulated total nitric oxide end products generated during the five-day
treatment period, which includes both nitrate and nitrite. IL-l IP and TNF-ca similarly
increased total nitric oxide end product production compared to the untreated control (p <
0.001), and the amounts were similar between the two cytokine treatments by day five.
Treatment of samples with L-NMA inhibited NO production to at or near control levels.
3 5S-sulfate and 3H proline incorporation. Radiolabeled sulfate and proline
incorporation were performed to measure protein and sulfate sGAG synthesis. To test the
effects of L-NMA on new sGAG biosynthesis we subjected explants to 35S-sulfate
incorporation while 3H-proline was used to measure protein synthesis. Figure 2 shows
the biosynthesis data based on the 24-hour radiolabel incorporation following the five-
day treatment. sGAG biosynthesis was significantly decreased by TNF-ax, IL-i 1P, and IL-
1p and TNF-ax treatment; however no significant effect was seen with L-NMA. Proline
incorporation, as a measure of protein synthesis, was decreased only by the IL-1f and
TNF-ax combination treatment. L-NMA partially reversed the decrease in proline
incorporation seen with cytokine treatment (p = 0.05).
Sulfated glycosaminoglycan release: sGAG release to the medium measured by
DMMB assay was used as a sensitive indicator of sGAG loss which is predominantly the
result of aggrecan degradation in cartilage explant studies. Both cytokines, TNF-a, IL-
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I P, and the TNF-ax and IL-l IP combination caused a substantial (3-7 fold) and significant
increase in sGAG release to the medium (Figure 3; p<0.001 for all three cytokine
treatments compared to control at all time points). Treatment with L-NMA partially
inhibited TNF-ax induced sGAG release (p<0.003; all time points), but L-NMA
significantly increased the rate of sGAG release with IL-1p and TNF-a in combination
compared to the cytokine combination without L-NMA (p<0.05 for days 1-4; not
significant on day 5). However with the exception of the 24-hour time point in which L-
NMA partially inhibited sGAG release, L-NMA had no effect on IL-I P-induced sGAG
release (p = 0.0 15 first 24 hours; p>0.745 for all other points). No L-NMA effect was
seen in the untreated group. These results suggest that NO is partially responsible for
sGAG release in response to TNF-ca treatment, partially protective in response to TNF-ca
and IL-i 1P in combination, and has little or no effect on IL-1 IP treatment alone.
Western blotting analysis for Aggrecan G1 domain and aggrecanase generated neo-
epitope. We then investigated whether L-NMA was able to decrease sGAG release by
decreasing aggrecanase cleavage of aggrecan. Western blotting was performed on
medium containing equal amounts of sGAG to probe for both the aggrecan first globular
domain (aggrecan G-1) and the aggrecan-GI neoepitope (GI-NITEGE-COOH) generated
from aggrecanase hydrolysis of the 373E-374G bond. The aggrecan-Gi was detected at
200-300kDa suggestive of full length aggrecan and within the region of ~50-80 kDa
which may correspond to aggrecan-Gi fragments generated from aggrecanase cleavage
(ADAMTS-4 and ADAMTS-5) (not shown). To probe specifically for aggrecanase
cleavage, an immunoblot to the aggrecan-G1-NITEGE-COOH was performed and shown
in Figure 4. The aggrecan-G 1 -NITEGE-COOH immunoblot shows that IL-i 1P and
- 62 -
TNF-ax, at the concentrations used in this study, caused the appearance of 60-80 kDa
doublet bands. While the addition of L-NMA to IL-1P treatment had no effect on anti-
aggrecan-G 1 -NITEGE-COOH stained doublet, the sample treated with TNF-c and L-
NMA showed marked decrease in both bands compared to the sample treated with TNF-
cc alone. This decrease in anti-aggrecan-GI-NITEGE-COOH neoepitope bands strongly
indicates that the decrease in sGAG release seen with the addition of L-NMA to TNF--a
treatment is the result of decreased aggrecanase proteolysis of aggrecan. NO is partially
responsible for TNF-a-induced sGAG release by increasing aggrecanase cleavage of
aggrecan. However, it remains unclear whether this is a result of decreased ADAM-TS4
or ADAM-TS5 expression or activity.
Real time PCR analysis. To determined whether L-NMA may be altering transcription
of aggrecanases and/or other proteases or matrix molecules, real time PCR analysis of a
32-gene set was performed on explants from 8 different animals subjected to 26 hours of
IL- 1p or TNF-ax treatment with or without L-NMA. The relative copy numbers were
normalized to 18S-RNA and expressed in terms of the fold increase or decrease over the
untreated, control sample within each set. Figure 5A is a representation of the 31 genes
plotted in principal component space. The data represented in the first three principle
components account for approximately 95% of the variance in the data. K-means
clustering analysis indicated that the genes segregate well into two spacially distinct
populations indicated by the red triangles and blue squares. The centroid profiles for
each group are represented in Figure 5B as the mean+/-SEM of each centroid. The first
population of genes comprises those that have little response or are slightly down
regulated by IL- 1p and TNF-a treatment (Group 1). The second population of genes
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contains those that are strongly up regulated by IL-1P and TNF-a treatment (Group 2).
Figure 5C is a list of proteins from Group 1 and Group 2 described as average-fold-
change relative the untreated sample (control) +/- SEM with asterisks representing
statistical significance compared to the untreated sample at p<0.05. While addition of L-
NMA often slightly decreased gene transcription compared to IL-1 I3 or TNF-ca alone, this
decrease was not statistically significant. However, a trend toward significance (p-0.1)
was seen in the effects of L-NMA on IL-1p induced increase of MMP-3 and TIMP-2
synthesis and on TNF-ca induced increase of HSP90 expression.
Zymography for Metalloproteinase Measurements: To determine whether inhibition
of NO production changed protease release to the medium in response to cytokine
treatment, zymography was performed to look at the expression and activation of MMPs
on day- five collected medium. Specifically, gelatin zymography was used to identify
changes in gelatinases, MMP-2 and MMP-9 (Figure 6a), while casein zymography was
used to monitor MMP-3 activity in medium samples (Figure 6b). To verify that the
bands were from MMP activity, negative controls containing EDTA were performed and
shown to be devoid of all bands (not shown).
Gelatin zymography, (Figure 6a) demonstrates two bands running between
75kDa and 50kDa (closed arrows), which represent the pro- and the active forms of
MMP-2. No qualitative differences were observed in the MMP-2 bands between
treatment groups. In addition to the MMP-2 bands, the upper band, ~90kDa (open
arrow), is indicative of pro-MMP-9 activity and is present only in the cytokine treated
samples. Results of the gelatin zymography indicate that L-NMA has no observable
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effect on either MMP-2 or MMP-9 activation or release to the medium. MMP-9
expression was verified by western blotting and mass spectrometry (data not shown).
To evaluate MMP-3 secretion and activation in response to NOS inhibition and
cytokine treatment, a casein zymogram was performed on medium samples. Figure 6b is
a representative casein zymogram on medium samples from each of the treatment groups.
Samples subjected to IL-1 p treatment show a prominent, but diffuse clearing (containing
a doublet-with the lower band most prominent) between 50 kDa and 75 kDa,
representing secreted pro-MMP-3 activity while TNF-ca treatment showed only a slight
doublet band and the control medium contained no observable band. No activated MMP-
3 band (at 45kDa) was visible in any of the samples at the medium amounts used. L-
NMA had no observable effect on pro-MMP-3 release into the medium. The results of
the zymogram were verified by Western blot analysis to show no difference in MMP-3
release to the medium in the IL-1p treated sample compared to the IL-i 1P and L-NMA
sample (not shown).
2.5 DISCUSSION
Inflammatory cytokines, IL-i 1P and to a lesser extent, TNF-a, are capable of
inducing chondrocyte-mediated extracellular matrix degradation. In vivo observations
indicate that aggrecan degradation occurs first while collagen degradation occurs later
[70]. While the role of NO in IL-1 -induced matrix damage has been explored, less is
known about the role of NO in TNF-ca induced matrix degradation. The purpose of this
study was to use an explant in vitro model to explore how NO modulates cartilage matrix
loss in response to both TNF-a and IL-1 IP. In this study, we found that treatment with
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the NOS inhibitor, L-NMA, was able to partially inhibit TNF-a induced sGAG release,
and this inhibition resulted from a decrease in cleavage of aggrecan by aggrecanase.
Beyond its effect on TNF-a induced sGAG release to medium, iNOS inhibition by L-
NMA was not shown to modulate biosynthesis, mRNA transcription of select genes
(including matrix proteins, cytokines and growth factors, and proteases), MMP secretion,
or collagen fragment release with cytokine treatment.
Differences in NO chemistry may dictate how NO modulates responses to IL-1
and TNF-ca treatment. NO may combine with oxygen to form nitrous anhydride, a
nitrosating agent, which may react with amine- or thiol-containing biomolecules or may
react with water to form nitrite. Alternatively, NO may combine with superoxide radical
to form peroxynitrite, a strong nitrosating agent that, when combined with carbon dioxide
will form nitrosoperoxicarbonate, may release nitrogen dioxide and carbonate radical,
oxidizing agents that cause lipid and protein oxidation, or may recombine to form nitrate
and bicarbonate. Figure 1 indicates that there is little difference in accumulated NO end
products between TNF-ax and IL- 1P treatments, nitrate and nitrite each correspond to
half of the nitric oxide production (not shown), suggesting similarity in the chemistry
among these samples; however NO production occurred earlier in response to TNF-a
treatment than to IL-i 1P (data not shown). It is possible that differences in rates of NO
production at an earlier time point rather than the total amount produced may have played
a role in the deleterious effects of NO.
Previous studies have explored the role of NO in IL-1p induced aggrecan
degradation and sGAG release; however this is the first study to test the effect of NO on
TNF-a induced sGAG release and its mechanism. Studies by Stefanovic-Racic et al., in
- 66 -
bovine, human, and rabbit explants, showed that treatment with L-NMA in the presence
of IL-1p caused a significant increase in sGAG release compared to IL-1p alone[7, 8].
Using an equine explant model, Bird et al., showed that IL-1 IP in combination with L-
NIO, had no effect on sGAG release compared to IL-I alone [24], but in a more recent
study, Bird et al. showed that both endogenous and exogenous NO had a protective effect
against sGAG release via inhibiting aggrecanase cleavage of aggrecan [23]. Similar to
the first study [23], we also found that IL-1 IP in combination with L-NMA was not
different than treatment with IL-i 1P alone in mediating sGAG release. We did, however,
observe some inter and intra-experiment variation in response to IL-i 1P alone and IL- 1
with L-NMA by the explants. Results of experiments with the IL-1 P and TNF-c
combination and L-NMA suggest that the cytokine combination in the presence of L-
NMA caused a significant increase in sGAG release compared to the cytokine
combination alone Figure 3. The protective effect of NO seen with the combination of
IL-1P and TNF-a was similar to that shown previously [7, 8, 24]. These results may
point to an additional factor or concentration required for the protective effects of NO.
Inhibiting NO production with L-NMA did inhibit TNF-ax-induced sGAG loss to the
medium by nearly half. The effects of NOS inhibition on sGAG release appear to be
situational: In all cases, NO has either no effect or a protective effect in the presence of
IL-1P; however NO enhances matrix degradation in response to TNF-a treatment.
Inhibition of TNF-ax-inducedsGAG loss to the medium by L-NMA may be the
result of a decrease in new proteoglycan synthesis, or it may be due to a decrease in
expression or activity of an aggrecan cleaving protease. To test whether L-NMA altered
cartilage biosynthesis in response to IL-1p or TNF-ca treatment, explants were subjected
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to 24 hour radiolabeling with 35S-sulfate to measure new sGAG synthesis following the
end of the five day cytokine treatment. Figure 2 shows both sulfate incorporation as a
measure of sGAG synthesis and proline incorporation as a measure of new protein
synthesis for each condition. Explants, subjected to cytokine treatment alone or in
combination, showed a decrease in new sGAG synthesis, however L-NMA alone or in
combination with the cytokine treatment had no statistically significant effect on sGAG
synthesis. Our findings are consistent with a study by Stefanovic-Racic et al. using
bovine explants, but differ from studies using other animal models [7, 8, 10, 16-18]. L-
NMA did cause a statistically significant effect on protein synthesis measured by 3H-
proline (p = 0.05), partially reversing cytokine-induced inhibition, which is consistent
with previous findings [21]. The effects of the L-NMA on day 6 after cytokine treatment
may vary from those seen early in response to cytokine treatment. However, because L-
NMA has little effect on biosynthesis, we can conclude that decrease in sGAG loss was
not due to a decrease in synthesis.
Because aggrecanases are known to mediate aggrecan degradation in response to
cytokines, we further hypothesized that the mechanism of L-NMA inhibition of TNF-a-
induced sGAG release was likely through a decrease in aggrecanase cleavage of
aggrecan. The ADAMTS family is a metalloproteinase family of which ADAMTS1, 4,
5, 8, 9, 15 have all been shown to cleave aggrecan with ADAMTS4 and ADAMTS5 able
to cleave the interglobular domain (IGD) of aggrecan at the 341 -E-A-342 bond, known as
the aggrecanase cleavage site [59, 63, 71]. While other proteases including the MMP
family have been shown to cleave aggrecan in the IGD, only ADAMTS4 and ADAMTS5
are known to cleave after the glutamine-341 of aggrecan making it a specific epitope
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associated with "aggrecanase" activity [57, 72]. Since the discovery of the aggrecanase
cleavage site by Sandy et al., aggrecan degradation in response to inflammatory cytokine
treatment has been attributed to aggrecanase and not to MMP activity [57, 58].
Thus, to test whether aggrecanase activity is responsible for differences in sGAG
release seen with TNF-a and NOS inhibitor treatment, we used an antibody, which
recognizes the aggrecanase-specific neo-epitope generated on the first globular domain of
aggrecan, aggrecan-G1-NITEGE-COOH. The immunoblot to the aggrecanase generated
neo-epitope resulted in the appearance of a doublet band at 60-80 kDa with a lighter band
evident with TNF-ax and L-NMA treatment compared to TNF-a alone or to IL-Ibeta and
IL-Ibeta with L-NMA (Figure 4). Thus, the addition of L-NMA to TNF-ax treatment
decreases the generation and/or release of the aggrecanase generated GI fragments.
These results are consistent with the sGAG results in this study. However the effects of
IL-1 I3 in this study differ from the Bird et al. study where they found that L-NMA and IL-
1p increased the aggrecanase cleavage fragments compared to IL-If alone [23]. These
results indicate that NO is partially responsible for TNF-a induced aggrecanase activity,
and this inhibition may result from a decrease in aggrecanase expression or a change
post-translational activation state.
To test the relative contributions of each of the ADAMTS4 and ADAMTS5
enzymes in aggrecanase degradation, we attempted to perform an immunoblot analysis of
both the medium and the detergent lysis of the explants at day 5. While we were able to
detect the recombinant protein, no reproducible signal was identified in any of the
samples (data not shown). This may be due to the low abundance of the enzymes, or it
may be that the antibodies used cannot detect bovine ADAMTS4 and ADAMTS5 since
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the antibodies were made against the human enzymes. Finally, one cannot rule out the
possibility that the aggrecanase activity is the result of another protease whose aggrecan
cleaving ability has yet to be characterized and/or species-specific differences among
those ADAMs and ADAMTS activities.
Because we were unable to find reproducibly either ADAMTS4 or ADAMTS5 at
a protein level in explant or agarose samples, real time PCR analysis was conducted on
explants subjected to IL- 1 P or TNF-c treatment in the presence or absence of L-NMA.
While we evaluated ADAMTS4 and ADAMTS5, we took the opportunity to more
broadly characterize the effects of NOS inhibition by L-NMA on IL-1 IP and TNF-a
induced changes in gene transcription. In this study we focused exclusively on the 26-
hour time point, which showed a small but significant increase in sGAG loss suggesting
that the chondrocytes had begun to respond to the cytokine treatment. The panel of 32
genes is shown in figure 5C as the mean +/- SEM fold increase over control with the bold
and asterisk indicating whether they were significantly decreased (Group 1) or
significantly elevated compared to the control (Group2). While IL-l IP and TNF-ca
treatment caused a number of large and statistically significant changes in gene
expression, L-NMA caused no statistically significant change in gene expression among
the 31 genes evaluated in this study.
Previous work with this model and by others has shown that ADAMTS4 and
ADAMTS5 are up-regulated by IL-1p and TNF-ax treatment respectively [73, 74].
Patwari et al. noted a significant increase in ADAMTS4 transcription after 24 hours of
IL-la treatment in this model system [73]. Caterson et al. reported that TNF-ax caused a
strong increase in ADAMTS5 transcription while IL-1 IP increased ADAMTS4
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transcription in young bovine explants [74]. In this study, we see a stronger increase in
ADAMTS5 with TNF-ax than with IL-1P; however the effects of ADAMTS4 are similar
at 26 hours after cytokine treatment. This may point to a role for ADAMTS5 in the NO
dependent increase in aggrecan degradation with TNF-a; however the effect of L-NMA
on ADAMTS5 gene expression was minimal and not statistically significant.
Previous work by Sasaki et al. noted a NO dependent increase in bFGF and
MMP-9 in response to IL-1p in rabbit chondrocytes grown in monolayer [75]. While we
did note an increase in the mean transcription level of bFGF and MMP-9 with TNF-ca and
IL-1 IP, the variance was sufficiently large such that no significant effect could be found,
and no L-NMA effect was observed. In addition, the time point chosen for analysis may
have been too early to probe these effects, as they noted that MMP and bFGF
transcription occurred following an increase in iNOS, which was seen in this study [75].
NO has been implicated in activating MMPs; this may occur through disruption of
the zymogen's cysteine switch via nitrosation or oxidation [76]. To evaluate whether
NO may play a role in expression or activation of MMPs in our system, we used
zymography to test whether the activation state or expression of MMPs in the explant
medium were altered in response to treatment with L-NMA. Figure 6A and 6B show the
results from the zymography. IL-1 and TNF-ax caused a consistent increase in MMP-9,
and IL-i 1P (and to a lesser extent, TNF-a) caused a consistent increase in MMP-3
secretion to medium. There was no band indicating the active form of either MMP-9 or
MMP-3, and L-NMA caused no change in these profiles. MMP-2 was expressed under
all conditions, and its expression and activation was unchanged by the presence of L-
NMA. The results of the zymograms match well to those of the real-time PCR data in
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that MMP-3 dramatically increases with IL- 1p and less with TNF-a, and in that MMP-9
transcription shows a general increase with cytokine treatment compared to control
(although these results are not statistically significant).
The zymography results were similar to those of Dozin et al. in that they failed to
see an effect of NOS inhibition on MMPs by zymography when treating chondrocyte
monolayers with a combination of IL-la + TNF-a [77], but different from those of
Tamura et al. who noted an increase in MMP-2 and MMP-9 expression by IL-i 1P that was
blocked by L-NMA in rabbit chondrocyte monolayers [26]. Work by Stadler et al. and
Murrell et al., using a gelatinase in solution activity assay, showed that inhibition of NO
decreased gelatinase activity with IL-1 treatment [2, 25]. The reason for the difference
between this study and the solution assay studies may be that zymography is not
sufficiently quantitative, and that low levels of gelatinase activity or changes in gelatinase
expression may not be readily identified. However, it is also possible that the differences
may be the result of changes in the TIMP expression rather than changes in MMP
activity. The increase in MMP-3 expression was similar to Murrell et al. who saw no
NO-dependent caseinolytic activity with IL-1p treatment [25]. However, Stefanovic-
Racic et al. saw an increase in latent caseinolytic activity using an in-solution activity
assay [7]. These differences may again be attributed to differences in sensitivity,
specificity, or model systems. The lack of qualitative differences in MMP-2, MMP-3,
and MMP-9 expression or activation state in this study suggests that NO is not likely
playing a significant role in MMP activation or expression.
No change in collagen fragment release was detected (not shown), suggesting that
no significant increase in collagen breakdown resulted from treatment with cytokines (not
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shown). In addition, L-NMA had no effect on the baseline degradation. This is not
surprising in that the culture period was short and existing aggrecan likely protected the
collagen framework against damage from collagenases [70]. Because so little collagen
degradation was seen, any conclusion about the role of NO on collagen degradation
would be premature. A longer study will be necessary to determine whether NO plays a
role in collagen breakdown.
In this work, we have attempted to better characterize the role of NO in the
catabolic responses to inflammatory cytokines, IL- 1 P and TNF-a. Inhibiting NOS
partially inhibits aggrecanase mediated aggrecan degradation and concomitant sGAG
release to the medium in response to TNF-alpha treatment. However, no effect was seen
with IL-1 IP and the inverse effect was noted with the combination of IL-1p and TNF-a.
This situational behavior of nitric oxide suggests possible differences in nitric oxide
production or chemistry between TNF-ax and IL-1 IP, but none was noted with the
exception of a slightly slower increase in nitric oxide production with IL-1p treatment,
which we attribute to a slower diffusion into the tissue due to the lower concentration
gradient compared to TNF-ax. Another possible reason for the difference may be
differences in cell death due to the cytokine treatment; however no qualitative difference
was noted by live/dead assay after the five-day cytokine treatments among any groups
(data not shown).
Differences in cell signaling between the cytokines may define a different context
for the cell response to NO chemistry and signaling. Previous studies probing
chondrocyte signaling in response to TNF-a and IL-1p have implicated ERK1/2, p38,
JNK as well as transcription factors, AP-1, NFkB, ESE- 1 in pro-catabolic and anti-
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anabolic cellular responses[78-82]. IL-1p activates C/EBP6 and C/EBPp in
chondrocytes, and TNF-ax activates C/EBP3 in MC3T3-El cells [83, 84]. While the two
cytokines share much of the same signaling machinery, differences in signaling are
necessary to explain the effects of NOS inhibition aggrecan degradation. The activation
of C/EBPp or C/EBP6 may represent a possible difference in TNF-a and IL-1 IP signaling,
and these factors are known to activate gene expression of proinflammatory molecules
such as COX-2 [84].
While inhibiting NOS has no detectable effect on IL-1 IP or TNF-ca induced MMPs
expression or activation, collagen type II fragments, or gene expression after 24 hours of
cytokine treatment, this study indicates that NO plays a complicated and situational role
in matrix degradation. Inhibiting NOS is partially protective against TNF-a induced
sGAG release, which is mediated through aggrecanase cleavage of aggrecan in the
interglobular domain (aggrecan-GI-NITEGE-COOH). However, NOS inhibition with
IL-i 1P and TNF-a treatment in combination has a deleterious impact on sGAG release,
and IL-i 1P has no detectable effect on sGAG release in this study. These results imply
that the role of NO in modulating matrix breakdown may depend on the inflammatory
stimuli driving this catabolic response in chondrocytes. These findings may help shed
light on the variability of in vivo studies that test the role of NO on arthritis development.
These findings indicate that effects of NO may depend on the characteristics of the
disease, in particular, the cytokines driving the catabolic response.
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2.6 FIGURES
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Figure 1: Five day accumulated total nitrate and nitrite release to the medium (nmol/mg
wet weight) as a measure of NO production. Medium from day 5 was dilute 1:2 in water
and analyzed by Greiss assay. IL-i IP, TNF-a and TNF-a and IL-l IP in combination
caused 7-9 fold increase total nitrate and nitrite (p<0.001 ). Treatment with L-NMA (IL-
1P + L-NMA, TNF-a + L-NMA, and IL-pI P + TNF-a +NMA) prevented the production
of nitrate and nitrite to at or near control levels. Data plotted as mean +/- SEM from
greater than 3 explants per joint from five animals.
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Figure 2: Twenty-four hour 5-3H-proline and "S-sulfate incorporation following the 5
day cytokine treatment with L-NMA. The biosynthesis data are plotted as mean+/- SEM
from at least 4 explants from at least 3 joints. The results indicate the combination of IL-
I P and TNF-a caused a decrease in sulfate and proline incorporation (sGAG and protein
biosynthesis) while TNF-a and IL- 1 P alone cause a statistically significant decrease in
sulfate incorporation. No statistically significant effect on sGAG synthesis was seen with
L-NMA treatment; however, NMA partially blocked the inhibition of protein synthesis
by cytokine treatment p = 0.05.
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Figure 3: Accumulated sulfated glycosaminoglycan (sGAG) release to medium over five
day cytokine treatment in the presence or absence of L-NMA. IL-i 1P and TNF-a alone
and in combination caused multifold increase in sGAG release to the medium (p<0.001
for all points). L-NMA inhibited roughly half the sGAG released caused by treatment
with TNF-a (p<O.01 for all time points), but L-NMA had no effect on sGAG release after
the first 24 hours in response to IL-1p treatment. L-NMA caused a significant increase in
sGAG release to the medium over the first four days in combination with IL- 1p and
TNF-a compared to IL-1 IP and TNF-ax alone suggesting an increase in the rate of release
(p<0.03 for days 1-4). No difference was seen in the untreated control when treated with
L-NMA. The data is plotted as mean +/- SEM from greater than 3 explants from at least
five different animals.
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Figure 2.4
Anti-Aggrecan-G1-NITEGE-COOH Western blot
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Figure 4: Anti-Aggrecan-GI -NITEGE-COOH immunoblot to probe mechanism of
sGAG loss in response to IL-Ip and TNF-a treatment with and without NOS inhibitor, L-
NMA. A doublet is visualized in all cytokine treated conditions; however the TNF-a and
L-NMA band is significantly lighter than that of the TNF-a alone or the IL-I P with and
without L-NMA. Immunoblot is representative blot from five experiments.
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Figure 5A: Figure 5A is a projection plot of gene behavior represented by the first three principal
components. As can be clearly seen in the figure, the genes can readily separated into 2 clusters
which correspond to genes that respond positively to the IL-1P and TNF-a treatment and those
genes that either don't respond or respond negatively to the cytokine treatment.
Figure 2.5b
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Figure 5B: Figure 5B represents the centroid profiles of the gene clusters indicated in
Figure 5A. Group 2 contains genes that are up regulated in response to cytokine
treatment while group 1 contains genes that are unresponsive or respond negatively.
While there does seem to be an overall slight decrease in Group 2 gene expression
with NMA, no genes were found to be significantly increased or decreased with the
NMA treatment.
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Figure 2.5c
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Figure 5C: The list of genes probed by real time PCR in group I and group 2 represented as the
mean fold change over control +/-SEM. The * indicates statistical significance compared to the
untreated control sample by pair-wise comparison (Wilcoxan Sign Rank test with Bonferroni
correction for multiple comparison; p<0.05). Data represent experiments from eight animals with
2 or 3 explants pooled per animal for RNA extraction.
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Figure 6. Gelatin (6A) and Casein zymograms (6B). Gelatin zymogram of five day
culture medium (figure 6A). All samples contained a 72 kDa band (arrow) and a lower 65
kDa band corresponding to the pro- and active from of MMP-2 respectively. Only
cytokine treated samples have a 92 kDa band corresponding to MMP-9. L-NMA had no
affect on MMP-9 or MMP-2 expression or activation in medium. Casein zymogram of
day 5 medium (figure 6B). The casein zymogram contains a 54 kDa band corresponding
to pro-MMP-3. On closer observation the 54 kDa band actually appears as a doublet, a
lighter upper band and a "brighter" lower band for both IL-1p and IL-ip-L-NMA. Only
a very faint doublet can be detected for TNF-a treatment. In addition, a 90 kDa band can
be seen with cytokine treatment in the casein gel as well. This may also correspond to
MMP-9, or it may correspond to another calcium dependent protease. The data are
representative zymograms from five experiments.
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Chapter 3:
An SDS-PAGE-LC/MS/MS analysis of cartilage tissue response to mechanical compression
injury and inflammatory cytokines TNF-alpha and IL-1beta
Anna L. Stevens(1), John S. Wishnok(1), Alan J. Grodzinsky(1,2,3), Steven R.
Tannenbaum (1,4)
Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, MA, USA (1); Department of
Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA (2);
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA (3);
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA (4).
3.1 ABSTRACT
Objective: The objective of this study is to compare cartilage ECM and chondrocyte response to
injurious mechanical compression, IL-1p treatment, TNF-ca treatment and no treatment by
focusing on proteins lost to the medium from in vitro cartilage explant culture.
Methods: Cartilage explants taken from young bovine stifle joint were treated with 10 ng/ml IL-
1 P, 100 ng/ml TNF-a, or subjected to radially-unconfined injurious mechanical compression
(strain: 50%; strain rate 100%/sec), and cultured for five days. Pooled medium was subjected to
SDS-PAGE-LC/MS/MS, and the data was analyzed by Spectrum Mill proteomics software
focusing on protein identification, comparisons, and matrix protein proteolysis.
Results: Just over 250 proteins were identified among the four protein groups including CD 109,
platelet derived growth factor like protein, and scrapie responsive protein 1 which have not been
previously identified in cartilage. IL-ip and TNF-ax caused an increase in YKL39, YKL40,
complement factor B, MMP-3, ECM-1, haptoglobin, serum amyloid A3, and clusterin. Injurious
compression caused the release of intracellular proteins, including GRP58, GRP78, alpha 4
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actinin, pyruvate kinase, and vimentin suggesting a loss of membrane integrity in a population of
chondrocytes. Injurious compression also caused proteolysis of collagen type VI subunits,
collagen type II, and COMP. Thrombospondin 1 fragments were seen in all treatment groups,
and aggrecan proteolysis was predominant with cytokine treatment.
Conclusion: Mechanical compression causes loss of cartilage integrity including degradation of
matrix molecules and damage to cell membrane integrity likely through strain-induced
mechanical disruption of cells at the periphery of the explant. IL-i IP and TNF-ax cause the
release of proteins invoke an innate immune and stress response by the chondrocytes, which may
play a role in host defense against pathogens or may protect cells against stress induced damage.
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3.2 INTRODUCTION
Articular cartilage is composed of chondrocytes and large amounts of extracellular matrix
(ECM) rich in collagen type II and aggrecan which are responsible for the tensile strength and
compressive stiffness of the tissue, respectively [1, 2]. A number of other ECM molecules are
also present and responsible for normal tissue homeostasis, including other structural proteins,
proteins involved in cell matrix interactions, and various extracellular signaling regulators.
Osteoarthritis is characterized by cartilage degeneration, which results from an imbalance
between matrix synthesis and matrix degradation. While OA is a disease of the entire synovial
joint, the chondrocyte likely plays a primary role in cartilage breakdown and local inflammation.
Chondrocytes are capable of causing cartilage degeneration both through production of matrix
degrading enzymes and small molecules and through modulation of the amount and type of
matrix molecules that are synthesized and incorporated into the matrix.
Tumor necrosis factor alpha (TNF-ca) is a secreted homotrimer composed of 17 kDa
protein subunits produced primarily by inflammatory cells but also by synoviocytes and by
chondrocytes, and detected in synovial fluid of OA and RA joints [3-9]. Importantly, anti-TNF-a
therapy is used successfully to treat humans with poorly controlled rheumatoid arthritis [10-13].
In cartilage explant and chondrocyte cultures in vitro, TNF-c inhibits proteoglycan synthesis
[14, 15] and increases proteoglycan degradation, albeit at a higher concentration than IL-1. TNF-
ac may also stimulate the production of aggrecanases, ADAMTS4 and 5, and matrix
metalloproteinases, MMP-3, MMP-13 (collagenase-3) and MMP-9 (gelatinase-2) [16-20]. In
addition, TNF-c may increase inflammatory mediators, such as PGE2 [20] and nitric oxide [21],
and it increases transcription of IL-1, TNF-ca, and IL-6 genes in cartilage from osteoarthritic
joints [22].
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Interleukin- 1 or IL-I is an 18 kDa protein present in two primary forms, IL-l a and IL-
1 P. IL-I is frequently present in the synovial fluid of arthritic joints [23-25], and the inhibition
of IL-I may help to decrease cartilage and bone resorption in human disease [26]. IL-I acts on
chondrocytes, synovial cells, and endothelial cells to enhance the production of inflammatory
mediators such as prostaglandins, cytokines, chemokines (IL-8 and leukotrienes), nitric oxide,
and cell adhesion molecules [27-35]. In vitro treatment of cartilage explant cultures causes a
substantial increase in aggrecan degradation that is likely mediated by ADAMTS4 and/or
ADAMTS5, followed in time by degradation and loss of type II collagen by the up-regulated
MMPs [36-39]. Chondrocytes are known to increase expression of ADAMTS4, ADAMTS5,
MMP-1, MMP-3, MMP-8, MMP-9, and MMP-13 in response to IL-1 [31, 37, 40-46], many of
which have been implicated in the degradation of a number of matrix molecules including
fibronectin, matrilins, collagens, and COMP [47-51]. In addition to promoting matrix
degradation, IL-1 also potently decreases new aggrecan and collagen synthesis [52, 53]. At a
gene expression level, IL-I inhibits the synthesis of aggrecan, collagen type II and collagen IX as
well as cartilage derived retinoic acid sensitive protein (CD-RAP) [54-56]. Thus, both IL-1 and
TNF-a are able to promote matrix destruction, increase inflammatory mediators, and decrease
new matrix synthesis.
Joint injury is a significant risk factor for developing osteoarthritis. Development of
osteoarthritis secondary to joint injury varies from roughly 15% to 75% over follow-up periods
of 14 to 22 years which translates to an average relative risk of between 3 and 20 of developing
osteoarthritis given traumatic joint injury [57-60]. Further, corrective surgery has little or no
impact on the risk of developing OA post traumatic joint injury [58, 61, 62]. In vitro injury
models have been developed to better understand the contribution of acute, mechanical
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compression injury to the development of osteoarthritis. Studies have shown that high stress or
high strain injury may lead to chondrocyte apoptosis[63-66], tissue fissuring and swelling,
changes in the dynamic tissue modulus consistent with damage to the collagen network, increase
in type II collagen degradation particularly at the boundaries of the tissue where the strain is
highest, and increased proteoglycan loss [63, 67-74]. In addition, cytokines and injury together
may enhance matrix damage compared to either stimuli alone[72]. Finally, co-culture with joint
capsule tissue may also enhance cartilage degeneration by decreasing proteoglycan composition
and decreasing stiffness of the tissue (Lee, J et al. in press).
To better understand changes in chondrocyte behavior following injury, studies have
focused on changes in transcription within the first 24 hours following injury. Lee et al.
performed real-time PCR time course profile on 24 cartilage genes involved in normal cartilage
maintenance to detect changes in gene expression following unconfined compression injury [75].
In this study, Lee et al. identified MMP-3, ADAMTS5, and TGF-p which were elevated more
than over 5 fold within four hours of injury and remained elevated at 24 hours after injury.
Transcription of the matrix proteins, aggrecan, type II collagen, and fibronectin, and of matrix
proteases, MMP-1, MMP-9, and MMP-13, were also increased at the 24 hour time point [75].
Additionally, increased transcription of c-fos and c-jun within the first hour of injury suggests
that AP- 1 pathway may be an important response pathway in injury. A similar study by Chan et
al. used a combination of gene arrays and real time PCR to detect changes in transcription three
hours after unconfined compression injury [76]. This study identified a decrease in transcription
of adhesion molecules and growth factors, ICAM-3, NCAM, N-cadherin, VCAM-1, and IGF-1,
while the chemokine receptor, CCR10, HMGB2, neurogranin, and ezrin were among the proteins
that were upregulated [76].
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Mass spectrometry has recently been used for protein identification and protein profiling
to identify arthritis biomarkers and study changes in disease phenotype. Recent studies
searching for protein biomarkers for OA and RA in synovial fluid have led to the identification
of serum amyloid A, calgranulin A, B, and C, which are proteins correlated with increased RA
disease severity [77, 78]. A study by Hermannson, et al., using a 2D gel approach to identify
differences in newly synthesized protein released into the medium between osteoarthritic and
normal cartilage, identified inhibin beta A and the C-terminal telopeptide of collagen in OA
cartilage but not in cartilage from healthy joints. In addition, they were able to identify the
production of connective tissue growth factor (CTGF) and cytokine like protein C17 in both
normal and OA cartilage samples. Finally, studies on the effects of bFGF and IL-I used 35S-
methionine labeling for new synthesis to show increased expression of TIMP-1, MMP-1, MMP-
3, gp38 (ykl40), and serum amyloid A in response to these stimuli [79-81].
Mechanical injury and cytokines, TNF-ca and IL-1 IP, cause changes in tissue properties
and chondrocyte behavior, and both injury and long term cytokine exposure may lead to long
term cartilage degeneration. The objective of the study was to identify and compare changes in
protein release from cartilage explants into the medium in response to acute mechanical
compression injury and to treatment with cytokines IL-1 I3 or TNF-ca. In this study, we use a
systems-level mass spectrometry based proteomics method to identify and compare proteins
released, including matrix protein proteolytic fragments. Protein level differences in the medium
may reflect both differences in matrix degradation and differences in new protein synthesis. The
goal of this study was to better understand the contribution of mechanical injury and cytokines to
cartilage degeneration.
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3.3 METHODS
Cartilage explantation and culture. Joints from 2-3 week old calves were obtained from the
local abattoir (Research '87, Hopkinton, MA) and explanted as described previously [82].
Briefly, articular cartilage was removed from the femoropatellar groove as 9 mm cylinders cored
out perpendicular to the joint surface, and the cores were sliced by microtome into 2 - Imm thick
slices which were punched by with 6 mm diameter dermal punch or by 3 mm dermal punch.
Explanation yielded either 1 - 6mm diameter by 1 mm thick disk per slice (for untreated and
cytokine treated studies) or 4 -3 mm diameter by 1mm thick explants per slice (for injury
studies). Each 6 mm diameter disk or a set of 4- 3 mm diameter disks was placed into 1 well of
a 24 well plate containing approximate 2.0 ml of culture medium with 1% ITS (high glucose
(25mM glucose) DMEM supplemented with 10mM HEPES, 0.1 mM non-essential amino acids,
115 uM ascorbic acid, 400 uM L-proline, 100 U/ml penicillin, 100 ug/ml streptomycin, and 0.25
ug/ml amphotericin B powder (PSA for tissue culture), and ImM sodium pyruvate). All
treatments were performed on day 7 post explantation.
Mechanical Injury: Injurious compression was performed using an incubator-housed custom
designed loading apparatus as described previously [72, 73, 75, 83]. Briefly, 3mm diameter x 1
mm thick cartilage disks were individually loaded into a polysulfone chamber and placed in the
compression apparatus that performs unconfined compression by placing the cartilage between
two impermeable platens. Explants were subjected to a single compression to 50% strain at a
strain rate of 100%/second and a velocity of 1 mm/second which resulted in a load cell measured
peak stress of 18.3+/-0.7 MPa (mean+/- SEM). The injured explants were placed in sets of four
explants per culture well in 2.0 ml of medium, yielding the same cartilage volume per ml of
medium as a single 6 mm diameter explant used for the cytokine and untreated explants.
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TNF-cc and IL-1p and post-treatment culture: Cytokines were resuspended in 0.1% BSA at a
concentration of 10 ug/ml (TNF-a) or 2.5 ug/ml (IL-1p). On day seven of culture, 6 mm
diameter explants were treated with 10 ng/ml of IL-l P or 1 OOng/ml of TNF-ax or untreated in 2.0
ml of medium without 1% ITS for five days. All explant cultures were subjected to a 10%
medium removal and 10% medium supplementation every 24 hours until the cultures were ended
on day 5 (0.6 ml medium/explant/day) by placing the medium and explants at -80C.
Deglycosylation and SDS-PAGE. Medium from explants taken from at least 5 different joints
were pooled, and a 2 ml aliquot of the pooled medium was treated with 3 mM EDTA and
subjected to deglycosylation prior to SDS-PAGE. Samples were dialyzed in a 7.5 kDa cutoff
membrane for 2 hours against buffer containing 10 mM Tris acetate, 10 mM NaCl, 10 mM
sodium acetate, and 3 mM EDTA. After 2 hours, 50 mU of chondroitinase ABC was added to
the dialyzing samples with buffer change, and the samples were dialyzed at 37C overnight. The
samples were dialyzed against pure water at 4C overnight before freezing and concentrating
samples by speedvac. Concentrated samples (10-15 ul) were combined with equal volume of
2X SDS-sample buffer containing 10 mM DTT. Samples were boiled for eight minutes, and
loaded on a 4-15% gradient gel and run at 15 mA. Gels were washed with water, stained with
Coomassie Blue Safestain (Invitrogen, Carlsbad, CA) for 30 minutes, and destained overnight
with a change of water to enhance resolution. Gels were scanned using an Epson scanner, and
saved as jpeg images.
Western blotting of fibronectin, type VI collagen, and actin. Equal amounts of concentrated
medium (150ul/200ul) from injured or untreated explants from 4 randomly chosen experiments
were run out on a 4-15% gel and transferred to PVDF for immunoblotting. Fibronectin blots
were done using a monoclonal antibody to fibronectin (1:2000; BD Biosciences) while the type
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VI collagen and actin antibodies were goat polyclonal antibodies (1:250; Chemicon -AB782;
1:500; Santa Cruz-Cl 1). Appropriate secondary antibodies conjugated to HRP (anti-mouse-
Amersham and anti-goat- Santa Cruz) were used for chemiluminescence detection.
Reduction, alkylation, trypsinization, and extraction from gel slices. Each sample,
contained within a lane of the PAGE gel, was divided into approximately 30+/-2 equal slices
(figure 1). The gel slices were destained, reduced, alkylated and in-gel digested as described by
Shevchenko et al. with minor modifications [84]. Briefly, each gel slice was reduced with 1
mg/ml TCEP for 10 minutes, alkylated with 10 mg/ml iodoacetamide in the dark for 45 minutes,
and treated with 10 ng/ml of trypsin gold (Promega, Madison, WI) in 50 mM ammonium
bicarbonate for one hour on ice followed by overnight incubation at 37C. The extracted peptides
were desalted using Millipore C18 Ziptip according to the manufacturer's instructions. Peptides
from adjacent gel slices were combined to yield approximately 16 peptide samples for injection
per treatment condition.
RP-LC. Capillary columns were prepared in-house using pulled and fritted capillaries
purchased from New Objective. Capillaries were packed with 5um, 300A Vydac protein/peptide
C 18 material (Vydac, Hesperia, CA) to yield final column dimensions of 75 um ID X 160 mm
with a 10 um tip. Samples were injected by manual injection with a Rheodyne injector
possessing a 0.5ul internal sample loop. Chromatography was carried out on an Agilent micro-
flow HPLC attached to a passive splitter which allowed about a 250 nl/min flow rate through the
column. Peptides were eluted on a linear gradient from 0% B to 60% B (1.2% v/v/v in 93.8%
acetonitrile, 5% water) over 120 minutes before equilibrating at starting conditions (Buffer A:
1.2% Acetic Acid (v/v) in water) over the following 80 minutes.
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Tandem Mass Spectrometry. The LC was connected to an Applied Biosystems QStar XL,
quadrupole-time-of-flight, equipped with a nanospray source and running Analyst version 1.0
[85]. Data was acquired during the entire chromatographic run (200 minutes) using an
information dependent acquisition method with a16 second cycle time. Each cycle consisted of
one MS scan (m/z 400-1800) followed by 3 MS/MS scans (m/z 100-2000) of the three most
abundant ions exceeding 10 counts with a charge of 2 to 4 and m/z of 400 to 1800 and excluding
previous ions and isotopes for 60 seconds.
Spectrum Mill data extraction, peptide validation, and protein identification and
comparison. Data was analyzed using Spectrum Mill proteomics software Rev A.03.02.060.
Raw data was extracted under default conditions. The data extractor extracted only spectra that
have good signal to noise ratio (S/N>25), and all spectra that may represent peptide
fragmentation (sequence tag > 1). The extracted data was searched against bovine sequences in
the NCBInr database compiled in February of 2006 using trypsin as the protease, allowing 2
missed cleavages, and including variable modifications of oxidized methionine and N-terminal
glutamine conversion to pyroglutamic acid in the search. Protein identification scores are
calculated as the sum of the unique peptide scores, and a protein score of greater than 20 is
considered sufficient for identity. Peptide identification scores are determined using a "shared
peak count" scoring system where the 25 most abundant ions are matched with points given for b
and y ions and unmatched ions result in penalties [86]. Peptides with a forward-reverse score of
greater than 2 and a rank 1- rank 2 score of greater than 2 were considered valid with the
following charge, score threshold, and % scored peak intensity (SPI): z = 2; score: 7.67, 60%
SPI; z = 1, score: 7.67, 70% SPI; z = 3; score: 8.0, 70% SPI; z= 4; score: 8.0; 70% SPI. Doubly
charged peptides were considered valid with a score greater than 7.67 and an SPI of 90% if the
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differences in forward - reverse scoring and rank 1-2 score was greater than 1.0. These criteria
should yield a false positive rate of less than 1% according to Kapp et al. [86]. Because the
bovine database is not completely annotated and protein sequences not yet released, all
unidentified spectra were subjected to a second search against the NCBInr mammalian databases
in identity mode to increase chances of protein identification. Only proteins, with 2 or more
validated peptides and a total score greater than 25, were considered valid for reporting. To
compare proteins identified between each of the treatment groups, the number of spectra and
summed ion intensity of peptides for each protein (total ion intensity) were used as indicators of
protein amounts. Because these are semi-quantitative metrics, only qualitative information can
be gained from this approach. Thus, we only consider those proteins with at least 5 additional
spectra and at least a 10-fold increase in total ion intensity sufficiently different for reporting.
Spectrum Mill approach for Matrix degradation. To evaluate extracellular matrix
degradation, we composed a database containing ECM proteins that were identified by the
searches described above. To focus on matrix breakdown, we chose to eliminate all pro-peptides
sequences from the matrix molecule protein sequences contained in our database. In order to
achieve a complete database, we used as many bovine specific sequences as were available. The
remainder of the protein sequences consisted of mammalian homologs that matched in the
original Spectrum Mill identification search and of sequences that were spliced together between
the bovine and the human protein sequences currently available. To allow better identification of
collagens and other matrix molecules known to be rich in post-translational modifications, we
added a number of "custom" amino acid modifications including hydroxyl-prolines, hydroxyl-
lysine, sulfotyrosine, glucosamine N-linked to asparagines, and hexose O-linked to threonine or
serine. These alterations to the search resulted in an efficient and focused search of the
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maximum number of peptides (and their modifications) from the abundant ECM proteins. We
set validation criteria slightly higher (peptides with a score >13; with all other criteria the same
as described for standard identification procedures) and manually validated peptides with
modifications. Using this method, we were able to identify modified peptides, particularly
collagen type II peptides containing hydroxyproline and hydroxylysine modifications suggesting
that both the database and the custom amino acid modifications were in fact picking out the
appropriate spectra and proteins. Using our database consisting of only the structural regions of
the ECM proteins of interest in conjunction with molecular weight obtained from the gel slice,
we were able to identify signs of matrix degradation.
3.4 RESULTS
Explant treatment and culture. At least 3 explants per joint were taken from at least five
different animals. Explants were allowed to rest one week before being subjected to mechanical
compression, or treatment with 100 ng/ml TNF-a or 10 ng/ml IL-1p, or no treatment in 2 ml of
serum-free DMEM without ITS. No difference was observed between the treatment groups.
The medium was collected and pooled for analysis by SDS-PAGE-LC/MS/MS. The
deglycosylated samples were subjected to SDS-PAGE followed by in-gel digestion of the gel
slices to extract peptides [84]. The samples were then injected onto a reversed phase column
connected to a QStar XL (quadrupole-time-of-flight) mass spectrometer with a nanospray source
for peptide separation and data dependent MS/MS analysis for peptide identification.
Spectrum Mill Identification of proteins. Using an SDS-PAGE-LC/MS/MS technique and the
Spectrum Mill criteria outline above, we identified 252 proteins with a score of 25 or greater
which corresponds to MS/MS sequences that match 2 or more unique peptides from each
protein. A complete list of identified proteins can be found in the supplementary table. Core
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protein pIs ranged from <4.16 (aggrecan) to 11.06 (histone H2a) with the mean core protein pI of
6.86. The molecular weight (MW) similarly ranged from a core protein MW of~482 kDa of
perlecan to -11 kDa of S100beta suggesting that the technique is compatible with proteins of
varying pIs and MWs. The identification statistics for Spectrum Mill are shown in Table 1
including the number of spectra collected and identified, the number of peptides identified, and
the number of proteins identified. Using the identity conditions outline above and setting the
threshold at 25, Spectrum Mill was able to identify approximately 15-20% of the spectra
obtained for each sample set. Over 100 proteins per sample were identified with over 900
peptides positively identified from each sample. Figure 2A describes the overlap in
identification between samples. For simplicity, TNF-ca and IL- 1p were grouped together as
"cytokine" given that of the 153 and 138 proteins identified in each, 115 proteins were identified
in common. The highest scoring and highest total intensity proteins were predominantly proteins
that comprise the extracellular matrix. Among the 12 highest scoring cartilage proteins were
aggrecan and collagen c 1 (II), perlecan, fibronectin, COMP, collagen c 1 (VI) and c 3 (VI),
thrombospondin 1, and chitinase 3 like 1, link protein, and complement factor B. In addition to
these proteins, we identified proteins such as AEBPl(likely ACLP)[87], CD109, scrapie-
responsive protein 1, nucleobindin, and platelet derived growth factor receptor like protein, and
peptidoglycan recognition protein all of which to our knowledge have not been identified
previously in cartilage. We also identified a number of proteins recently described in cartilage
including cytokine-like protein C17, CTGF, IL-17B, HTRA1, mimecan, retinoic acid binding
protein, and follistatin like protein [88-98].
Differences between treatment groups. We wanted to focus on global differences and well as
differences seen between individual proteins. Figure 2B is a set a pie graphs that show the
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protein composition of the medium samples broken down by the protein location. While, both
cytokine-treated samples look very similar to the control, the injury sample possesses a large
number of intracellular proteins compared to the other treatments. To look more specifically at
these differences, we have chosen to use spectra number and total ion intensity as an indicator to
compare protein amounts between samples. Only differences of greater than 5 spectra and
greater than 10 fold elevation in total ion intensity are reported. Based on these criteria, Table 2
provides a list of elevated proteins, function, and location with the total ion intensity fold
elevation over control or magnitude of total ion intensity (indicated by + signs) in the case when
no spectra were identified in the control. Proteins increased in the medium in response to both
IL-1p and TNF-a treatment include complement factor B, chitinase 3 like 1 and 2 (ykl39 and
ykl40), MMP-3, clusterin, serum amyloid A3, ECM-1, haptoglobin, and acid-I-glycoprotein. In
addition at the cutoff level specified, CD14, complement Clq , lactoferrin, and CIr are also
increased in the medium with IL-1 IP treatment, and VCAM- 1, annexin A8, annexin A2, N-
acetylmuramoyl-L-alanine amidase (PGRP-long), C1 inhibitor, and angiopoeitin-like 7 are
increased only with TNF-ax. While these proteins are somewhat of a mix, most appear to have
something to do with innate immunity and stress response.
The largest increases in protein release to the medium in response to injury were due to
prolyl-4-hydroxylase (beta subunit), GRP58, vimentin, alpha-4-actinin, pyruvate kinase, and
UDP-glucose pyrophosphorylase, which are all intracellular proteins. GRP58 and prolyl-4-
hydroxylase beta subunit are both protein disulfide isomerases, which reside in the endoplasmic
reticulum and are important for the proper folding of proteins in the secretory pathway.
Vimentin and alpha-actinin are proteins involved in actin cytoskeletal organization while
pyruvate kinase Ml /M2 is a key enzyme in the glycolysis pathway. Because the increase in
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intracellular proteins suggests a loss of membrane integrity, we performed an anti-actin Western
blot (Figure 3a) on medium from four sets of 3 mm diameter explants to verify the increases in
intracellular protein release. Figure 3a shows that, in medium from four different experiments,
mechanical injury increases release of actin to the medium with little variability, no band was
visible with the untreated sample. This is consistent with the SDS-PAGE-LC/MS/MS findings
and suggests that there is some loss of membrane integrity in a population of the chondrocytes
present in the tissue.
In addition to the release of intracellular proteins, SDS-PAGE-LC/MS/MS results
indicated that fibronectin, MMP-3, chitinase 3 like protein 1, and epiphycan, were also elevated
in the medium compared to the control. Because fibronectin fragments are known to promote
catabolic behavior of chondrocytes, an anti-fibronectin Western blot was performed on medium
from 3 mm diameter explants to verify the increase in fibronectin release and to determine
whether there were signs of fibronectin breakdown. Fibronectin release was increased with
mechanical compression injury compared to the untreated controls in all four of the experiments
(Figure 3b). MMP-3 and chitinase 3 like protein 1 were also elevated in the cytokine-treated
samples suggesting that there may be an overlap in response to these treatments, which is
consistent with the findings of Gruber et al [81]. The increase in MMP-3 was verified by
zymography (not shown).
Matrix protein degradation. One major focus of this work was to evaluate ECM degradation.
The SDS-PAGE LC/MS/MS method provides molecular weight information that may be used to
interpret whether the protein is full-length or cleaved to fragments of lower molecular weight.
Using a custom database of matrix proteins that excludes sequences from signal peptides and
telopeptides and searching for custom amino acid modifications that are known to exist in matrix
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proteins, we searched for peptides from matrix protein in molecular weight regions that are
smaller than that of the full length protein.
Using the methods outlined, proteins degraded irrespective of treatment and proteins that
were degraded specifically with either cytokine or injury treatment were identified (Figure 4-7).
The degradation data was graphed as total ion intensity versus approximate molecular weight
which was based on the gel slice position and the proteins present within the slice. Each sample
is represented by a different curve on the graph. Among those degraded regardless of treatment
was thrombospondin 1 (Figure 4). The increased total ion intensity (sum of all the peptide
extracted ion intensities) at 30-50 kDa suggests that thrombospondin 1 is actively degraded and
released into the medium irrespective of treatment conditions. A closer look at the peptides
present in the gel slices from the 30-50 kDa region indicated that they are from the N-terminal
region of the protein (first 500 or so amino acids).
Collagen type II, collagen type VI and COMP were among proteins that showed signs of
proteolysis in the medium from the injuriously compressed explants. Figure 5 is a graph of the
fibril-forming region of collagen type II. The peak around 100-150 kDa represents the full-
length collagen type II which appears to be most abundant in the untreated sample. The increase
total ion intensity around 35 kDa and near 75 kDa in the injury sample is likely indicative of type
II collagen proteolysis at or near the collagenase cleavage site. The finding of increased collagen
degradation with injury is supported by Western blotting using an antibody that binds to a region
within the C-terminal quarter fragment (not shown). This result is consistent with the findings
from other injury models [68, 69].
Type VI collagen showed signs of degradation in response to injury compared to
untreated explants as well. Figure 6a is a plot of all three type VI collagen subunits in the
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control and injured samples. Collagen alpha 1 (VI) gave the highest intensity of all of the
collagen VI subunits with a peak intensity at 100-150 kDa in the untreated and injured explant
medium. An additional increase in intensity was also present at 50-75 kDa in the injury sample.
Similarly, collagen alpha 3 (VI) and collagen alpha 2 (VI) had an elevated total ion intensity in
the 50-75 kDa region consistent with proteolysis. To verify this finding, we performed a
Western blot of type VI collagen to compare medium from untreated and injured explants from
four different experiments (Figure 6b) using a polyclonal antibody against type VI collagen
which may identify one or more of the collagen type VI subunits. A doublet at roughly 50-75
kDa may represent one or all of the collagen VI subunit fragments based on mass spectrometry
data. Further, the band at 150 kDa fragment may correspond to the increase in either an alpha
3(VI) fragment or full-length alpha 1 (VI) based on the mass spectrometry findings. Together
these data indicate a possible increase in collagen type VI subunit proteolysis in response to
injury.
In addition to degradation of collagens, signs of COMP degradation were also evident
with mechanical injury. Figure 7 is a plot of COMP total ion intensity versus molecular weight.
A peak at roughly 100 kDa is indicative of the full length protein. The shoulder in the band from
IL- 1 treated explants toward lower molecular weight is consistent with COMP cleavage from
120 kDa to the 110 kDa form which is frequently present with IL-1 treatment. The peaks at 60
kDa and 40 kDa in the injury sample may represent cleavage near the middle of the protein.
3.5 DISCUSSION
The purpose of the study was to characterize and compare, at the protein level, the
cartilage tissue response to injurious mechanical compression and to treatment with pro-
inflammatory cytokines, TNF-a and IL- 11, all of which are stimuli known to cause cartilage
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damage and increase the risk of developing arthritis. Equal volumes of media from explants
subjected to no treatment, to injurious mechanical compression, or to treatment with IL-1p or
TNF-a were probed for differences in protein composition as well as protein degradation
compared to the untreated (control) sample. Because of the small sGAG-associated variations in
sample electrophoresis, because of the stochastic nature of the mass spectrometry analysis, and
because of the small surface area differences between the 6 mm diameter and 4- 3mm diameter
explants, a strict quantitative analysis of these data is not possible. However, a comparative
study focusing on large differences is both useful and warranted. Total ion intensity is the sum
of the extracted ion chromatograms for each of the peptide peaks identified for a protein, and it
provides a means of performing a semi-quantitative comparison of the data to identify protein
level differences [78]. Protein difference criteria were set high at a 10-fold elevation in total ion
intensity and an increase in 5 spectra or more over the untreated sample to insure only good
quality findings. Changes with mechanical injury compared to untreated controls were validated
by immunoblotting using explants of the same geometry. Matrix protein degradation was
determined using molecular weight information for each of the gel slice fractions, and a custom
database was generated to exclude telopeptides and signal peptides from complicating analyses.
Proteins accumulated in the medium over the five days of culture represent a combination
of new protein synthesis and secretion as well as passive diffusion of pre-existing proteins
previously sequestered in the matrix. To help eliminate the contributions of sequestered plasma
proteins, the cartilage explants were rested for seven days with four medium changes prior to
treatment. Cartilage explants were incubated in treatment medium for five days because the
sGAG accumulation in the medium plateaued between day 4 and day 5 of cytokine treatment
suggesting the approaching of an equilibrium state following the treatment (data not shown) -
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The early response of the cartilage to each treatment was represented in the accumulated protein
in the medium. Although this experiment was not designed to distinguish between newly
synthesized protein secretion and passive release of molecules from the matrix, the relative
amount of some proteins in response to IL- 13 and TNF-a treatment was many fold increased
over the untreated control compared to the elevation of aggrecan suggesting that these proteins
are newly synthesized rather than sequestered and then released from the matrix. Further support
for new synthesis and secretion comes from the identity and biological activity of many of these
proteins. Thus, the time scale and design of the experiment seemed suitable to identify
differences among the various treatment groups.
As expected, many of the proteins present in the medium were present irrespective of
treatment (figure 2). The matrix proteins were among the proteins present in all samples
including collagen type 1I, XI, IX, VI, XII, XIV, XVI, and III. Proteoglycans and small leucine-
rich repeat proteoglycans were also identified, including aggrecan, perlecan, NG2, lumican,
fibromodulin, mimecan, biglycan, decorin, chondroadherin, and epiphycan. Other cartilage
ECM proteins were also found including COMP, matrilin 1, matrilin 3, fibronectin,
thrombospondin 1, nucleobindin, and osteonidogen.
In addition to the well-characterized cartilage proteins, other proteins such as CD 109,
scrapie responsive protein 1, platelet derived growth factor receptor like, angiopoeitin like 7, and
peptidoglycan recognition proteins were also observed. CD 109 is a 170 kDa GPI-linked protein
recently identified as a member of the a-2-macroglobulin and the complement C3, C4, and C5
gene family, which are proteins which contain activated thioesters [99, 100]. The similarity of
CD 109 to a-2-macroglobulin suggests that it may serve as a protease inhibitor in cartilage.
Alternatively, CD 109 may play a role in complement activity as there is evidence of other
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complement factors present in the tissue. Scrapie responsive protein 1 is a small secreted protein
whose transcription is increased with that of glial fibrillary acidic protein following neuron
infection with Creutzfeldt-Jakob disease [101, 102]. Glial fibrillary acidic protein has been
previously identified in articular cartilage and cartilage tissue within gliomas [103-105]. No
biological function has been attributed to scrapie like protein 1. Similarly, no biolgocal role for
platelet derived growth factor receptor like protein has been reported beyond its similarity to the
PDGF receptor; however we may speculate that release of this protein may represent a way of
regulating the PDGF pathway in cartilage. Angiopoeitin-like-7 has been identified as a product
of the cornea stromal cells, and it may serve to inhibit angiogenesis and promote cornea stromal
cell phenotype [106, 107]. Finally, peptidoglycan recognition protein L (PGRP-L), or N-
acetylmuramoyl-L-alanine amidase, was also released from the cartilage [108, 109]. PGRP-L, a
transmembrane and secreted protein, is capable of binding and cleaving the lactylamide bond
between the peptide chain and muramic acid of the peptidoglycans which form the cell wall of
bacteria [109-111]. While the family of PGRPs are generally bacteriolytic, PGRP-L may play a
role in decreasing the biologic response to peptidoglycans [110, 112]. The release of PGRP-L
may aid in quelling the inflammatory response to peptidoglycan. The presence of these proteins
suggests that the cartilage and likely chondrocytes play a role in regulating pathways as diverse
as angiogenesis and innate immunity.
Proteins listed in Table 2 are elevated with each treatment compared to the untreated
control. Overall, the proteins identified with IL-1 IP treatment and TNF-a treatment were similar
suggesting that the cytokines may have similar global effects, which include the secretion of
proteins including chitinase 3 like protein 1 and 2, MMP-3, complement factor B, haptoglobin,
and serum amyloid A3. Chitinase 3 like 2 but not chitinase like 1 may be elevated with OA
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[113]. Chitinase 3 like 1 is elevated by IL-I treatment in rat cartilage explants but not in human
explants [113-115]. This may represent a species-specific difference or could possibly result
from differences in experimental methods. Addition of chitinase 3 like 1 counters the effects of
IL-I, suggesting that it may be tissue protective [116]. Complement factor B expression is
elevated in OA cartilage compared to normal cartilage, and it is also expressed in developing
cartilage [88, 117]. Lactoferrin is not known to be expressed by chondrocytes, but it has been
identified in articular joints together with lysozyme, RNase7, and p-defensin 2 and 3 [118] and
does play a role in innate immunity.
Serum amyloid A, haptoglobin and alpha-I-acid glycoprotein are acute phase proteins
that were increased with IL-I P and TNF-c treatment. Gruber et al. noted an increase in protein
synthesis of porcine serum amyloid A3 when the tissue was treated with IL-i 15 [81].
Furthermore bovine serum amyloid A3 is similar to human serum amyloid A, which is elevated
in synovial fluid of patients with rheumatoid arthritis [77, 78, 119, 120]. Similarly, elevation of
haptoglobin is associated with increased RA severity, and alpha-I-acid glycoprotein glycation
varies in synovial fluid of RA patients compared to normal suggesting that there may be local
expression in the joint [77, 121, 122]. While elevated serum amyloid A, complement factor B,
alpha-I-acid glycoprotein, and haptoglobin in synovial fluid has been attributed the systemic
response to inflammation, the cartilage itself may be contributing to the production of these
proteins and may increase the local concentration of these proteins, which may play a role in the
disease process. For example, serum amyloid A3 induces an increase in catabolic behavior by
chondrocytes which suggests that it may play an active role in degradation [119].
In addition to secreted proteins, membrane proteins CD 14 and VCAM- 1 were elevated
by IL-i 1P and TNF-ax treatment respectively. VCAM- 1 is increased in TNF-ax treated medium,
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and previous work indicates that chondrocytes increase expression of VCAM- 1 when treated
with IL-I and TNF-c [33]. Additionally, VCAM-1 is shed from endothelial cells in response to
IL-I and TNF-ax treatment possibly through the action of a metalloproteinase [123, 124].
VCAM- 1 is known to be expressed in synovial tissue and soluble VCAM- 1 in synovial fluid and
serum correlates with RA severity[125-127]. CD14 is expressed on the surface of chondrocytes
by FACs analysis, although the antigen is susceptible to degradation during enzymatic cell
isolation[128]. Our results suggest that CD14 may be released in response to IL-1p treatment.
Soluble CD14 may be important to enhance the LPS response in tissue expressing no or low
copy number of CD14 [129] consistent with its role in LPS signaling.
While TNF-ax induced some changes similar to mechanical compression injury, the latter
produced proteins that were globally different from the other three treatments in that there were a
higher proportion of intracellular proteins present. As indicated in Table 2, most proteins
elevated in the medium of explants subjected to radially-unconfined compression injury are of
intracellular origin suggesting that membrane integrity in at least a subpopulation of cells must
have been compromised. To verify the release of intracellular proteins, we performed an anti-
actin immunoblot on medium from four different experiments comparing untreated (free swell
explants) medium from explants subjected to mechanical injury. The Western blot analysis
confirmed the SDS-PAGE finding that explants subjected to mechanical injury release actin and
thus likely the other intracellular proteins identified in Table 2.
Loss of membrane integrity may occur with both apoptosis and necrosis; however the
release of ER and heat shock proteins is more common during necrosis than apoptosis [130].
Some of the heat shock proteins, namely hsp70, gp96, and calreticulin, may serve as adjuvants
when complexed with antigenic peptides and presented to antigen-presenting cells (APCs) [131-
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134]. This ability to stimulate antigen-specific immunity may be dictated through binding to
CD91, lipoprotein receptor like protein, on APCs [134, 135]. At the same time, previous work
on this injury model implicates apoptosis as the primary mechanism of cell death-both TUNEL
and EM imaging support this finding [63, 136]. These microscopic evaluations characterizing
apoptosis and necrosis avoided the explant periphery, as it is common to have cell death due to
cutting which could complicate the interpretation of the effects of loading [63, 137].
Work done with confined and unconfined compression injury models suggests that cell
death, as determined by live-dead assay, is most abundant at the explant surface or around the
periphery of the explant where the strain is highest [68, 69, 73, 138, 139]. Lucchinetti et al. also
reported that chondrocytes nearest to the loading surface in confined loading were not only dead
by live-dead cell assay but stained negative by TUNEL suggesting necrotic cell death. This cell
death occurred over 6-12 hours of stress-controlled loading in which creep may play a role in cell
death. Because the peripheral regions are typically excluded from apoptosis/necrosis
characterization, it is possible that these cells may be undergoing mechanical lysis or necrosis
and have not been well-characterized beyond live-dead cell assays.
Loss of membrane integrity with apoptosis is likely to occur over time during the five-
day culture period, while mechanical cell lysis is likely to occur at the time of injury and
intracellular proteins are released relatively rapidly in culture. Using medium collected over the
five days in culture, we compared actin release at day 1 and day 4 to determine whether release
of actin occurred at early time points or whether it accumulated over time. Figure 8 shows a
representative actin immunoblot, which suggests that release of actin occurred primarily in the
first 24 hours in culture, consistent with loss of membrane integrity as a result of acute
mechanical cell lyses. While some leaking of intracellular proteins may occur with time, this
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early release of intracellular proteins indicates that mechanical disruption is likely a primary
mechanism of actin release in this unconfined compression model. While cells in the internal
portion of the cartilage explants are susceptible to apoptosis, a population of cells at the surface,
on the periphery, and around the occasional blood vessel found in these immature cartilage
explants may experience mechanical disruption in response to the high strain. However, we
cannot rule out the possibility that there is population of cells that may leak some intracellular
proteins, yet they still appear to undergo apoptosis by TUNEL or EM. These results extend the
previous work using this unconfined compression injury model by demonstrating that there may
be spacial, or at least population, differences in the chondrocyte response to the unconfined
compression.
The final major goal of this work was to identify protein degradation fragments released
into the medium. The SDS-PAGE-LC/MS/MS method provides a means to probe for matrix
protein degradation by proteolysis. Inflammatory cytokines are known to increase the release of
a number of proteases that can degrade matrix structural proteins -- such as aggrecan, collagens,
COMP, and matrilins; however, much less is known about whether matrix damage by
mechanical compression injury leads to matrix remodeling. Thrombospondin 1, a protein that
links the chondrocytes to their surrounding matrix, showed signs of degradation in all samples
analyzed (Figure 4). Thrombospondin 1 is present on platelets and is readily cleaved by
thrombin to release a 30 kDa heparin binding fragment and a 150 kDa fragment, and both
fragments are capable of binding to fibronectin [140, 141]. In addition, thrombospondin 1 is
known to bind to pro-MMP-2 and active MMP-2 as well as LRP1 (LDL receptor like protein 1)
suggesting that it may play a role in the clearance of MMP-2 by LRP 1 in the pericellular matrix
of chondrocytes [142]. Thrombospondin 1 has also been implicated in the activation of latent
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TGF-beta [143]. Because all samples show signs of thrombospondin 1 proteolysis, this
breakdown cannot be attributed to any of the treatment in this study. However, such a means of
MMP-2 regulation may be plausible in this tissue, and degradation of thrombospondin-1 may
reflect normal remodeling regulation of the chondrocyte pericellular matrix. More work will
need to be done to test whether thrombospondin 1 is playing a role in gelatinase regulation in
cartilage.
Signs of protein degradation with injury include fibronectin, collagen type II, collagen
type VI, COMP and aggrecan. As indicated in Figure 3b, injury causes an increase in
fibronectin release. Injury also causes a small increase in fibronectin proteolysis as indicated by
the laddering of bands seen on immunoblot which are more pronounced in the injured explant
medium compared to the untreated explant medium (not shown). The increase in fibronectin
release with injury is consistent with previous work by Burton-Wurster et al. who showed that
compressive loading increases synthesis of fibronectin [144-146]. Fibronectin accumulation is
increased in OA cartilage compared to cartilage from healthy joints [147, 148]. In addition,
some fibronectin fragments may provoke a catabolic response by chondrocytes [149], so more
specific evaluation of the role of fibronectin fragments with injury may be warranted.
Searching with custom amino acid modifications, we were able to identify a small
increase in collagen type II staining around the 25 kDa region suggesting an increase in type II
collagen fibril degradation which we were able to show by western blotting and is consistent
with previous injury models [68, 69]. These data are consistent with the hypothesis that
mechanical injury causes collagen proteolysis secondary to collagen fibril denaturation [68];
however because this is young tissue, proteolysis of newly synthesized collagen cannot be
excluded as a possible explanation.
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Collagen type VI also showed signs of possible degradation with a particularly large
increase the roughly 75 kDa band from collagen alpha 1 (VI) and a less dramatic fragment of
collagen alpha 3 (VI) around 150 kDa (Figure 6A). Using an antibody to type VI collagen, we
were able to detect bands in the molecular weight region consistent with the collagen alpha 1
(VI) and collagen alpha 3 (VI) fragments. These data may represent an increase in collagen type
VI subunit proteolysis; however it is unclear whether this is indicative of damage to the matrix or
to newly synthesized collagen VI subunits. Previous work indicates that mature cartilage
pericellular matrix (PCM) may stain more intensely for collagen VI than immature cartilage[150,
151]. Work on the mechanical properties of the chondron suggests that while the PCM is much
more compliant than the surrounding ECM, and the variations in the PCM stiffness may still be
important in transmitting forces to the chondrocyte [152] . Work on correlating load induced cell
death to the collagen VI staining intensity in the PCM indicates that 1 MPa loading for 1 hr
caused a generalized flattening of the superficial zone chondrocyte PCM in immature compared
to mature tissue [150]. It is possible that this flattening of the PCM may be associated with
damage to the collagen VI network which could explain the apparent collagen VI fragment
release in this study.
Mass spectrometry analysis indicated signs of COMP degradation (Figure 7) with injury
and possibly with IL- 1p treatment. COMP release from cartilage is known to be elevated in
response to exercise and to injury [153-157], and COMP levels in serum and synovial fluid
correlates with arthritic disease progression [157]. COMP fragments between 50 and 90 kDa
have also been identified in synovial fluid from RA, OA, and reactive arthritis patients; and these
fragments may be produced by synovial fibroblasts in vitro [158, 159]. Small COMP fragments
(50-90 kDa) have also been demonstrated in synovial fluid within the first 2 months after
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anterior cruciate ligament tear but not in synovial fluid from the healthy contralateral knee joint
[160]. The results of this study indicate the injurious mechanical compression may cause the
release of 50-70 kDa COMP fragments from cartilage, which may be the source of some of the
COMP fragments identified in synovial fluid in vivo. COMP fragmentation with injury could be
the result of mechanical denaturation and proteolysis of the pentameric COMP molecule or it
may be the result of increase protease activity. In addition, COMP fragmentation in response to
IL-1p treatment leads to the release of a 11 OkDa and a 10 kDa fragment respectively, and this
activity may be mediated by ADAMTS4 [48].
The SDS-PAGE-LC/MS/MS was chosen because it provided a means to do systems level
profiling as well as identify signs of protein degradation both of which were important in
characterizing the effects of mechanical injury and inflammatory cytokine treatment. The power
of this study is the ability to look at protein differences and protein degradation at a systems-
level without being limited to proteins already known to be present in the system. The weakness
is that the study does not provide quantitative data, that the study is limited to high abundance
proteins, and that the findings are only correlations in which further work will be necessary to
ascertain mechanisms and causation. The profiling aided in the identification of small secreted
factors in response to IL-i IP and TNF-ca and the molecular weight information from the gel
allowed protein degradation to be carefully evaluated for a number of matrix proteins in response
to mechanical injury. In response to IL-1P and TNF-ca cartilage explants release complement
proteins, acute phase proteins, and stress response proteins as well as aggrecan fragments. We
were surprised by the predominantly "generic" response. Acute phase proteins are
predominantly produced by the liver in response to IL-6 even though IL-1p and TNF-a are
sufficient to release some of these proteins [161]. While the presence of these proteins may be
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the result of sequestered plasma proteins in the explant, the seven day rest period and large
differences between treatments suggests that acute phase and complement proteins are likely the
result of new protein synthesis in response to the cytokine treatment. The results of this study
indicate chondrocytes are also capable of producing several of the acute phase and complement
proteins in response to TNF-a and IL-1 IP, many of which play a role in innate immunity.
Explants subjected to this unconfined compression injury model have been shown to
display changes in gene expression, small but significant loss of sGAG, apoptosis, changes in
biosynthesis, and dynamic tissue stiffness [63, 71, 73, 75, 136]. This study demonstrates that
injury is causing loss of cell membrane integrity early after injury which may be indicative of
mechanical cell disruption and may be in part responsible for the decrease in biosynthesis. In
addition the release of intracellular proteins may cause a change in gene expression or trigger
apoptosis in surrounding cells. Release of matrix proteins and protein fragments with
mechanical compression injury suggests damage to the matrix which is supported by the change
in dynamic modulus. Damage to the matrix may lead to changes in cell-matrix interactions
which could be responsible for apoptosis, for changes in gene expression, or for the decrease in
dynamic compression induced stimulation of biosynthesis.
This work describes differences in cartilage and chondrocyte protein level response to
mechanical injury and treatment with inflammatory cytokines TNF-a and IL-l IP compared to
control. In this work we identified proteins that were increased in response to treatment
including intracellular proteins involved protein folding, glycolysis, and cytoskeletal structure
with injury and proteins involved in innate immune or stress response such as MMP3, ykl39,
ykl40, haptoglobin, lactoferrin complement factor B, serum amyloid A3, and clusterin. In
addition we used the molecular weight information from the SDS-PAGE, to identify proteolysis
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of thrombospondin 1, collagen type 1I and VI, fibronectin, aggrecan and COMP. Overall, this
method provided information about cartilage damage and chondrocyte response to known
damaging stimuli.
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3.6 FIGURES
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Figure 1: Flow chart of SDS-PAGE-LCIMS/MS approach used for protein
identification and comparisons as well as degradation. Like samples are pooled
together and separated out by SDS-PAGE. Gels are divided into 17 +/- 1 fraction for
nano-RP-LC/MS/MS analysis. Data collected is searched in identity mode (modifications
limited to pyroglutamic acid and oxidized methionine). Based on these results, the
sequences (excluding signal sequences and telopeptides) from the highest scoring matrix
proteins were entered into a custom database, and the data was subjected to a second
global search which include modifications that were known to be present in matrix
proteins including hydroxyl-proline, hydroxylysine, N-linked hexosamine, sulfotyrosine,
Table 3.1
ID statistics Control IL-1 TNF-a Injury
# extracted 15238 16974 21525 21689
spectra
# identified 3407 6466 6001 4252
spectra
#peptides 994 931 1136 1200
# proteins 114 139 153 167
identified
(SCORE >25)
# protein ID'd 106 125 136 153
by bovine
database
Table 1: Spectrum Mill identification statistics. Identification statistics for each
sample is shown above including the number of extracted spectra, number of identified
spectra, number of peptides, number of proteins identified by 2 peptides and a score of
greater than 25, and number of proteins that were identified with the bovine database
(which included at least a partial sequence of each of the identified proteins)
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Figure 2: Global analysis of proteins identified with each experimental condition. Figure
2A is a Venn diagram of the proteins identified in the untreated, injuriously compressed, and the
cytokine-treated (which includes both TNF-a and IL-1 IP). Eighty-two proteins were identified
among all four samples while 119 proteins were identified in only a single treatment class.
Significant overlap was noted between the TNF-a and IL-I p such that 115 of the 153 and 138
proteins were identified by both respectively. Figure 2B are a pie charts describing the
composition of the medium protein samples based on the protein location. This figure shows a
larger component of intracellular proteins in the injury samples compared to the other treatments.
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Figure 3.2b
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Glucose regulated 58 kDa (GRP-58)
Fibronectin
Pyruvate kinase Ml M2
UDP1-glucose pyrophosphorvlase 2
Cytoskeletal associated protein 4
Protein disulfide isom. A6 (PDl-A6)
Ilsp 9 0 alpha
78 kDa glucose regulated (GRP-78)
Phosphoglycerate kinase I
Tumor rejection antigen 1 (gp96)
Dermatan sulfate proteoglycan 3
(epiphycan)
Protein disulfide isomerase A4
(ERp72)
Lysine hydroxylase
ERp46
Glucose-6-phosphate isomerase
Caireticulin
Nucleotide diphosphate kianse
FK506 binding protein 9
Rab GDI beta
Parkisons disease 7
Enolase 1
PRDX2
Collagen alpha 1 (IX)
Collagen alpha 1 (XVI)
XLMP-2
Fibulin 4
PIGlF receptor-like protein
13
++++
0.02
0.08
0.09
++++
Table 2: Proteins identified by SDS-PAGE-LC/MS/MS from medium samples collected from
cartilage treated with IL-1p, TNF-(x, or unconfined compression injury. The proteins listed
represent those proteins identified to be elevated with treatment compared to the untreated control.
The table contains fold increase in total ion intensity over control, or if no spectra are identified in
the untreated sample, the + signs represent the order of magnitude of the total ion intensity of each
of the proteins.
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Figure 3A: Anti-Actin western blot of medium from explants subjected to injurious
mechanical compression or untreated from four different experiments. The blot represents
medium from four different explant experiments with each control and injury samples in
adjacent lanes. These results indicate that mechanical compression injury causes release of
actin and suggest possible loss of membrane integrity in at least a fraction of chondrocytes.
Figure 3B: Anti-fibronectin western blot of medium from explants subjected to injurious
mechanical compression or untreated from four different experiments which ordered
according to experiment with the untreated and injured samples adjacent for comparison.
These results suggest that injury causes an increase in fibronectin release and breakdown
(laddering more pronounced with longer exposure).
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Figure 4: Graph of Thrombospondin 1 total ion intensity vs. molecular weight (MW) (as
determined by proteins present in each slice). To determine whether matrix proteins were being
broken down, we graphed the total ion intensity (summed ion intensity for all the peptides for
thrombospondin in each gel slice and for each sample) versus the approximate molecular
weight of each gel slice. Full length thrombopondin I has a molecular weight of
approximately 130-180 kDa. Increased ion intensity in the 30-50 kDa regions indicates
thrombospondin fragments which appear in all four treatment groups..
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Figure 5: Total ion intensity of peptides from the fibril portion of type II collagen release
as a function of molecular weight. The high intensity peak in the control sample at 100-150
kDa is indicative of full-length type II collagen release probably as a result of passive release
of newly synthesized type II collagen. The sample subjected to injurious mechanical
compression shows a slight increase in total ion intensity in the 20-35 kDa regions with
peptides corresponding to the C-terminus suggesting collagen degradation possibly at the
collagenase cleavage site.
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Figure 6A and 6B: Collagen type VI degradation. Figure 6A indicates the total
ion intensity for each of the three collagen VI subunits vs approximate molecular
weight (as determined by molecular weight marker and protein constituents) of
untreated and injured medium from cartilage explants. Both collagen alpha I (VI)
and collagen alpha 3 (VI) possess an increased intensity in the 50-75 kDa regions
that is likely indicative of collagen VI breakdown. Figure 6B is a immunoblot of
collagen type VI which indicates a stronger band at 150 kDa with injury as well as a
doublet between 50 and 75 kDa in which the upper band appears to be more intense
in the injury samples.
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Figure 7A: COMP degradation in response to mechanical injury and treatment with cytokines,
TNF-a and IL-1 IP, compared to control. The shift in COMP total ion intensity to lower
molecular weight with mechanical injury suggests that COMP may be degraded in response to
injury.
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Figure 3.7
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Figure 8 is a representative anti-actin immunoblot from two different experiments to compare
actin release to the medium at 24 hour and the 96 hour time point. Actin is only detected with
injury and in the cell lysis (as a positive control), and there is little difference in the intensity of
the bands at 24 hours and at 96 hours indicating that actin is primarily released into the medium
within the first 24 hours of injury. This early release is suggestive of mechanical cell lysis.
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Chapter 4:
An iTRAQ-2D-LC/MS/MS based quantitative comparison of cartilage response to
mechanical compression injury and inflammatory cytokines, TNF-a and IL-
13 - catabolism, immunity, cell death, and possible repair
4.1 ABSTRACT
The objective was to perform a quantitative comparison of proteins released from
cartilage explants in response to IL-1 IP, TNF-ca, and mechanical compression injury and
to interpret their release in the context of the anabolic-catabolic shifts known to occur in
cartilage in response to injury and cytokine treatment. Cartilage explants were subjected
to injurious compression, TNF-a (100 ng/ml) or IL-1p (10 ng/ml), or no treatment,
cultured in equal volumes of medium, and the medium was collected, pooled and the
proteins deglycosylated by treatment with chondroitinase ABC. The proteins were
subjected to trypsinization, and the peptides were labeled with one of four iTRAQ labels
each containing a unique signature ion. The labeled peptides were subjected to nano-2D-
LC/MS/MS on a QStar, quadrupole time of flight instrument. The study was done in
analytical replicate on a pooled sample of greater than 70 explants from a total of 6-12
different animals. Data were analyzed by ProQuant to obtain a ProGroup peptide report
containing identified spectra which were combined to achieve a peptide and then a
protein level output of mean ratios, standard deviations of those ratios, and significance
based on either Wilcoxan sign rank or Student's t-test both corrected for multiple
comparisons. Because of our interest in catabolic and anabolic shifts, a targeted data
analysis approach was taken in addition to a systems level PCA and K-means clustering
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approach. By focusing on particular protein domains, we identified a decrease in the
synthesis of most fibrillar collagen subunits (p<0.05), and an increase in the release of the
aggrecan G2 and G3 domains with IL-1P and TNF-a treatment (p<0.05). We also noted
a significant increase in MMP-1, MMP-3, MMP-9, and MMP-13 in at least one condition
and, in most cases, all conditions compared to the untreated sample. An increase in
proteins involved in innate immunity and immune cell recruitment were noted with IL-1p
and TNF-ax treatment, while an increase in intracellular protein release were seen most
dramatically with mechanical compression injury. Anabolic effects are often driven by
the insulin-like growth factor family and the TGF-p superfamily, so we specifically
identified members of these pathways to understand which factors may mediate early
repair processes. At the systems level, 2 principal components were sufficient to describe
97% of the covariance in the data. IL-l IP and TNF-a caused a similar response in
proteins identified; in contrast, a 'Y'-shaped distribution was observed upon projection of
proteins based on their response injury vs. cytokine treatment. K-means clustering
revealed six main clusters to further characterize the biology of mechanical injury versus
cytokine effects on cartilage.
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4.2 INTRODUCTION
Cartilage is the thin, glistening white tissue that covers the surface of the bone in
diarthrodial joints where it is responsible for low friction movement and force dissipation
with motion. Cartilage contains a single cell type, the chondrocyte, which composes
approximately 2-5% of the tissue volume and is responsible for maintaining the
encapsulating proteoglycan and collagen type II rich extracellular matrix that constitutes
the remaining tissue volume.
Degeneration of cartilage is the cardinal feature of osteoarthritis, and this
degeneration is characterized by changes in composition, changes in mechanical
properties, and changes in chondrocyte phenotype [1-5]. While osteoarthritis is a disease
of the entire joint, the chondrocytes are thought to play a primary role in cartilage
destruction with changes in the biochemical, physical, and mechanical environment of
the chondrocytes driving changes in normal chondrocyte phenotype which may further
potentate disease progression [6]. Targeting the chondrocyte for arthritis therapy requires
an understanding of the tissue as a whole and how the chondrocyte senses and responds
to the various catabolic, anabolic, and morphogenetic stimuli in its matrix environment.
Pro-inflammatory stimuli, particularly inflammatory cytokines, TNF-a and IL-1 ,
are commonly present in both rheumatoid arthritic and osteoarthritic joints and synovial
fluid [7-14], and these cytokines can promote cartilage degeneration and stimulate local
and systemic inflammation [15-19]. IL-13 and, to a lesser extent, TNF-a are very potent
pro-catabolic cytokines that cause a rapid loss of aggrecan, a transcriptional and post-
transcriptional decrease in matrix molecule synthesis, and an increase in protease
production - particularly neutral metalloproteinases, MMPs and ADAMTSs [20-25]. In
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addition, both cytokines are capable of causing an increase in pro-inflammatory
mediators such as nitric oxide, PGE2, IL-8, IL-6 as well as adhesion molecules necessary
for immune cell recruitment [26-28]. IL-1p and TNF-a are produced by synovial
fibroblasts, by immune cells (macrophages) and by the chondrocytes themselves, and all
of these cells respond to the cytokines in a pro-catabolic manner [29, 30]. The
importance of these cytokines to rheumatoid arthritis has been illustrated by the
effectiveness of anti-TNF-a and anti-IL-I therapies which have abrogated disease
progression in many with the disease [31-34]. Intraarticular injection of IL-1 leads to
cartilage breakdown also induces proteoglycan release from cartilage and
polymorphonuclear and mononuclear inflammatory infiltrates [16]. However, cartilage is
capable of returning to normal following an injection with IL-1 [18]. Cartilage is capable
of repairing itself following brief cytokine induced matrix breakdown and inflammation,
but long term exposure may prove damaging to the tissue. While arthritis is a total joint
disease, the contribution of pro-inflammatory cytokines to the degeneration of cartilage is
likely significant, so understanding how chondrocytes respond to cytokine treatment may
aid in identifying new disease treatments for OA and RA.
Joint injury may dramatically increase the risk for developing osteoarthritis. Knee
injury, such as ACL or meniscal tear, may significantly increase the relative risk of
developing OA with mean relative risk values ranging from 3 to 20 and increasing with
age and time after injury [35-37]. Although joint instability may contribute to secondary
disease development; ACL correction has not been shown to decrease the risk of
secondary OA implying that the acute traumatic event may have been sufficient to trigger
a cascade of events to initiate arthritic progression [38-40]. Acute knee injury is
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normally accompanied by an increase in pro-inflammatory cytokines, TNF-a and IL-
1p [41], as well as by an increase in MMP-3, COMP fragments, collagen II cross-links,
and aggrecan fragments [42-46]. In vitro cartilage compression injury models have
shown that compression injury may promote cell death, predominantly by apoptosis [47,
48], decrease matrix synthesis and abrogate synthesis stimulation with dynamic loading
[49], increase collage type II degradation [50, 51], increase protease production [52], and
alter gene transcription and subsequent protein release from the tissue [53, 54].
Following injury, cartilage makes initial, but often unfruitful attempts at repair (for
review [55, 56].
Mass spectrometry has opened up the opportunity to perform systems level
analyses in understanding the tissue level response of cartilage to both cytokines and
mechanical injury, both of which can promote cartilage degeneration. Studies on the
effects of "injury" and cytokines have led to the identification bFGF release with cutting
injury to cartilage[57]. MMP-3, MMP-1, ykl40, serum amyloid A, and TIMP-1 synthesis
have been shown to increase with IL-1 P treatment compared to control [58]. A more
recent study suggests that peroxiredoxin 1 may be released from chondrocytes and that
MMP-1, MMP-3, ykl40, and cyclophilin fragments have also been identified with
cytokine treatment [59]. A study comparing OA and normal cartilage identified new
collagen synthesis and inhibin P secretion as the major protein differences [60]. In
addition to in vitro cartilage studies, synovial fluid analysis for arthritis biomarkers have
identified calgranulin A, B, and C as well as C reactive protein which were correlated
with erosive RA [61]. While focusing specifically on proteins that are increased in
response to various treatment or disease processes provides some information about
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disease, it is difficult to appreciate the impact of its release without understanding the
context in which the protein is expressed.
The emerging proteomics technologies provide a variety of means to identify and
compare samples. While SDS-PAGE-LC/MS/MS is ideal for protein profiling and
molecular weight determination, sample complexity prohibits quantifying protein on the
gel, so the mass spectrometer must provide quantitative information. The 2D-PAGE
approach allows appropriate level of separation for spot comparison and secondary
protein identification; however, the complexity of the post-translational modification in
many cartilage matrix proteins makes it difficult to visualize and compare individual
spots without extensive sample clean up [59, 60]. In addition, it is not possible to look at
all the spots in a 2D gel, and so most analyses are done only on spots that are
differentially regulated. While peptide based separation techniques offer good separation
and good protein coverage, sample comparison/quantitation must again occur by the mass
spectrometer via isotope labeling. Protein samples can also be compared at the peptide
level by mass spectrometry using chemical isotope labels such as ICAT or iTRAQ [62,
63]. iTRAQ is an amine-reactive NHS ester coupled to an isobaric reporter tag that
contains 4 differentially isotope-labeled signature ions and balance groups which release
signature ions (m/z 114.1, 115.1, 116.1, 117.1) with CID providing relative quantitation
at the MS/MS level [63].
Our work using an SDS-PAGE-LC/MS/MS profiling approach indicated that pro-
inflammatory cytokines may cause a release of proteins involved in innate immunity and
stress response, and that mechanical injury may compromise the integrity of both cells
and the surrounding matrix causing the release of fibronectin, collagen type II, collagen
-144-
type VI, and COMP fragments. The objective of this work is to take a quantitative mass
spectrometry approach to understand how cartilage responds to inflammatory cytokines,
TNF-a and IL-1p, and injurious mechanical compression probing the mechanisms and
contributions of the cartilage tissue to damage, to inflammation, and to repair as well as
to the potential development of arthritic disease. In particular, we hoped to begin to pull
out biological pathways and consequences of treatments that may represent a shift in the
anabolic-catabolic axes of the cartilage tissue. Proteins released from a controlled
volume of cartilage into a controlled volume of medium are compared using an internal
standard for normalization. IL-i IP, TNF-a, and injury cause a decrease in collagen
synthesis and an increase in a number of matrix metalloproteinases implicated in matrix
degradation. IL-i 1P and TNF-ax caused an increase in aggrecan degradation. Proteins
involved innate immunity and inflammation are primarily elevated with TNF-a and IL-
1fP treatment. Anabolic pathways including TGF-p superfamily members and IGF- 1 are
altered with all treatments indicating a potential for tissue repair. This work also verifies
the increase in release of intracellular proteins in response to injury which were found
previously as well as increases in CTGF, semaphorin 3C, proenkephalin, and semaphorin
3C which may also contribute to repair processes.
4.3 METHODS
Overview. A diagram of the experimental process is outlined in Figure 1 and described
in detail in the methods section above. Equal volumes of cartilage from six or 12 animals
were treated with one of the following treatments in equal volumes of medium: (1.)
unconfined mechanical compression (injury) to 50% strain at 100%/s, (2) 10 ng/ml IL-
1P, (3) 100 ng/ml TNF-a, or (4) subjected to no additional treatment. After five days,
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the medium samples were collected, and the entire set was pooled and analyzed in
analytical duplicate. Chondroitinase ABC was used both as a deglycosylase and as an
internal standard to correct for any sample loss during work-up and labeling. Each sample
(treatment condition) possessed a unique iTRAQ signature ion for quantitation -
untreated: m/z /114.1; IL- IP treated: m/z 115.1; TNF-a treated: m/z 116.1; mechanically
injured: m/z 117.1. The samples were combined and fractionated into approximately 45
injectable fractions by SCX chromatography. The fractions were subjected to RP-
LC/MS/MS and the data was combined and analyzed using ProQuant and ProGroup
report (ABI). The quantitative comparisons represent an average response of the
cartilage to cytokine treatment and injury treatment compared to untreated controls, and
the analytical variance and not biological variance is measured in this study to determine
robustness and reproducibility for future studies.
Cartilage explantation and culture. Cartilage explants were obtained from the stifle
joints of 2-3 week old calves as described previously [64]. Briefly, articular cartilage
was obtained from the femoropatellar groove by coring 9 mm diameter cartilage-bone
cylindrical cores perpendicular to the cartilage surface. Each core was then sliced into 2
- 9mm diameter by 1 mm thick slices using a microtome. Finally, 4 -3 mm diameter
punches were taken from each 9 mm diameter by 1 mm thick slice and placed into
individual wells of a 48 well culture plate. Between 8 and 12 explants, 3 mm diameter by
1 mm thick, per condition per animal were obtained from greater than six animals.
Approximately, 75% of the cartilage was taken from the first 1-mm layer while the
remaining 25% were taken from the second millimeter of cartilage. The cartilage
explants were rested for 5 days prior to start of treatment and cultured in medium
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containing 1% ITS (high glucose (25mM glucose) DMEM supplemented with 10mM
HEPES, 0.1 mM Non-essential amino acids, 115 uM ascorbic acid, 400 uM L-proline,
100 U/ml penicillin, 100 ug/ml streptomycin, and 0.25 ug/ml amphotericin B powder
(PSA for tissue culture), and 1mM sodium pyruvate. On the day of treatment, explants
from each location-matched-slice were placed in different groups and cultured in sets of
four in 2.0 ml of medium without ITS supplementation.
Mechanical Injury. Strain and strain rate-controlled unconfined compression was
performed in an incubator housed loading apparatus as described previously [53, 65-67].
Each 3mm diameter explant was individually loaded into a polysulfone chamber which
was placed into the loading apparatus for compression. The thickness (zero point) of the
explant was found by slowly (-20 um/second) decreasing the displacement until a small
load (25 g) was measured. The explant was then subjected to a single unconfined
compression at a strain of 50% and a strain rate of 100%/second against a non-porous
platen. The injured explants were then cultured in sets of four with medium not
supplemented with ITS.
TNF-a and IL-1p and post-treatment culture. IL-lp and TNF-a were resuspended in
0.1% BSA at concentrations of 10 ug/ml and 2.5 ug/ml respectively (R&D systems). To
begin treatment, explants were placed in sets of four with medium without ITS containing
10 ng/ml of IL-1p or 100 ng/ml of TNF-a or no additional treatment (untreated).
Following treatments, explants were cultured for 120 hours with a 10% medium removal
and 10% supplementation every 24 hours. Medium and explants were collected and
stored at -80C.
- 147 -
Desalting and sGAG removal. Medium from between six and twelve animals were
pooled for each condition - injuriously compressed, untreated, IL-1 IP treated, and TNF-a
treated. Two sets of 3.0 ml of the pooled medium from each condition (sample set 1 and
sample set 2) were supplemented with 5 mM EDTA, 100 ug/ml PMSF, and 5 mg/ml
iodoacetamide. Samples were dialyzed in a 7.5 kDa cutoff membrane for 3 hours at
room temperature against buffer containing 10 mM Tris acetate, 40 mM NaCl, and 5 mM
EDTA. Seventy milli-units of chondroitinase ABC were added to the dialyzing samples
to serves as both a deglycosylating enzyme and as an internal standard. The samples
underwent deglycosylation by chondroitinase ABC and dialysis at 37C overnight. The
samples were then dialyzed against 2 mm triethylammonium bicarbonate (TEAB) and 0.5
mM EDTA for 8 hours at room temperature followed by dialysis against 500 um TEAB.
The samples were removed, frozen, and concentrated by speedvac to 10 times. The
samples were subjected to protein estimation by microBCA assay kit (Pierce) according
to the manufacturer's instructions.
Trypsinization. Samples were further concentrated to 150 ul and reduced and alklyated
by addition of 2mM TCEP in 100 mM TEAB at 37C for 2 hours followed by addition of
5mM iodoacetamide in 100 mM TEAB at 37C for 2 hours. The samples were then
subjected to acetone precipitation by addition of 6 volumes of ice cold acetone and placed
at -20C overnight followed by centrifugation at 15,000 x g for 30 minutes at 4C. The
pelleted samples were resuspended in 25 ul of 50 mM TEAB containing 0.1% SDS.
Resuspended samples were subjected to protein estimation by microBCA assay. The
sequencing grade modified trypsin was resuspended in 50 mM TEAB at a concentration
of 0.lug/ul just prior to use (Promega). Trypsin was added to each sample at a ratio of
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1:37.5, trypsin to protein based on the first protein estimation by addition of 2/3 of the
trypsin amount followed two hours later by the last 1/3 of trypsin. To verify complete
trypsinization, sample set 2 was subjected to a second trypsinization at 1:75. Sample
volume is taken to 40 ul by addition of water and acetonitrile (to 10%). The samples
were incubated at 37C overnight and then speedvac'd to dryness. Samples were
resuspended in 500 mM TEAB, and 500 fmol of angiotensin I, 500 fmol of bradykinin,
and 500 fmnol of angiotensin II antipeptide were added to each sample as peptide internal
standards.
iTRAQ labeling. iTRAQ labeling was done according to manufacturer's instructions.
Briefly, 100 ug (sample set 1) and 75 ug (sample set 2) of peptides in 26 ul of 500 mM
TEAB from each of the 2 sets of four samples were taken (3.0 ml equiv. of control and
injury sample; 2.0 ml TNF-a sample; 1.5 ml of IL-1p) following the addition of peptide
standards for labeling. A set of iTRAQ labels was equilibrated at room temperature and
then diluted with 70 ul of ethanol. The label was vortexed for 1 minute and centrifuged
at 16,000 x g for 1 minute. iTRAQ reagent was added to each 100 ug sample of peptides
from sample set 1 (75 ug peptides for sample set 2; 114.1: untreated, 115.1: IL-1p, 116.1
TNF-a, 117.1: injury), and the sample was vortexed for 1 minute, sonicated for 5
minutes, centrifuged at 16,000 x g for 1 minute, and then allowed to incubate at room
temperature for 55 minutes. Following the reaction, samples were diluted to 200 ul total
with water and combined based on the volume equivalent of proteins - 1.5 ml for the first
sample set (200 ul IL-1 IP, 150 ul TNF-a, 100 ul of untreated and injury) and 1.0 ml
equivalent in the second sample set. Combined samples were dried down to
approximately 50 ul and combined with 1.0 ml of strong cation exchange buffer A (SCX
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buffer A: 10 mM Potassium Phosphate pH 2.8, 25% acetonitrile) and 1% phosphoric acid
to pH 3.5. Sample was further diluted with 3.0 ml of SCX buffer.
Strong cation exchange chromatography. An off-line 2D LC approach was taken
similar to that described by Peng et al.[68]. The combined sample was injected by 4.0 ml
sample loop onto a 2.1 mm X 100 mm strong cation exchange column (PolyLC) on an
Agilent 1100 HPLC equipped with a UV cell and microfraction collector. Sample was
injected on to the column at a flow rate of 250 ul/min for 20 minutes with 100% Bufer A
followed by a gradient from 0 to 40% buffer B (10 mM Phosphate buffer pH 2.8, 400
mM KCl, 25% acetonitrile) over the following 40 minutes and then from 40% B to 95%
B over 10 minutes holding at 95%B for five minutes before returning to the starting
conditions (total run time -80 minutes). The run was monitored by UV absorption at X =
214 nm to determine when the peptides eluted during the gradient. Fractions were
collected every 0.5 min (125 ul each) using an automated fraction collector. All fractions
from the void volume were diluted and rerun to verify that no peptide was lost due to
high salt and then discarded (plate 1). Approximately 90 fractions (plate 2) were
collected during the gradient elution of the peptides (as determined by UV absorption).
Fractions were transferred to 0.5 ml tubes and stored at -80C until use. Fractions were
then concentrated by speedvac and desalted by ziptip combining adjacent ziptip'd
fractions to obtain approximately 50 fractions for LC/MS/MS analysis.
LC/MS/MS. Desalted SCX fractions were injected by manual injection (Rheodyne,
manual injector with 0.5 ul internal loop) onto a 75 um ID x 160 mm column with 10 um
tip (New Objective) packed in house with Vydac protein/peptide C18 packing material
(5um particle size, 300 angstrom) as described previously [69]. Peptides were loaded at
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2% Buffer B (1.2% acetic acid in 90% acetonitrile; flow rate: 250 nl/min) for 12.5
minutes before elution on a 147.5 minute gradient from 2% to 40% B followed by a wash
out for 20 minutes from 40% to 60% B and held at 60% B for five minutes before
returning to 2% B over 15 minutes and equilibrating at 2% B for 60 minutes (Buffer A:
1.2% acetic acid in water). The LC is connected to a QStar, quadrupole time of flight
mass spectrometer (ABI) equipped with a nanospray source [70]. Data was acquired
through information dependent acquisition using Analyst 1.1 selecting for precursor ions
between m/z 400 and m/z 1600 with a charge state between two and four and which
exceeds 15 counts. The cycle time was 10 seconds and each cycle consisted of an MS
scan (m/z 400-1600) followed by 3 data dependent MS/MS scan (m/z 100-1600) with
ions excluded for 100 seconds after obtaining a single spectra. Data was collected for
over the entire 240 minute chromatographic run with peptides typically eluting between
60 and 180 minutes. Many of the fractions containing large number of peptides were run
twice and lumped together into the data set to improve analyses. All fractions from
sample set one were run prior to running sample set two.
Data analysis. Data was analyzed using both ProQuant 1.0 with ProGroup Report
(ABI) searching against the NCBInr (Genbank) bovine database assembled in December
2005 and the Genbank database release 153 with MS error set to +/- 0.25 Da and the
MS/MS error was set at +/- 0.20 Da. Allowed modifications were limited to iTRAQ
labeled tyrosine, oxidized methionine, and 1 missed trypsin cleavage. The spectra level
output was assembled by ProGroup report, and the report was imported into Excel and
sorted to remove all low confidence peptides (confidence < 90). Most of the peptides
above this criteria were deemed high quality matches by manual inspection (>97%; only
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-17/500 of the first viewed spectra did not have compelling matches). All peptides with
no signature ratios for quantitation or those with ratios of 0 or 9999 were discarded. The
resulting data were sorted according to protein and then by peptide sequence and were
imported into Matlab (Mathworks). Matlab scripts combined redundant spectra for each
peptide (including variable iTRAQ labeling and methionine oxidation) and excluded all
peptides with a ratio below 7 and an error of greater than 33%, which aided in improving
quantitation by eliminating some of the spectra with high error due to low signal
intensity. Ratios above 7 were left unmodified as high ratios are subject to higher errors
because of the mass spectrometer dynamic range limitations. The peptide list was then
combined into a protein list again calculating the means and the standard deviations of all
values. The data were normalized based on the geometric mean of the chondroitinase
ABC ratios as it was added to the sample in equal amounts for deglycosylation at the
beginning of the sample work-up to serve as an internal standard. All mathematical
manipulations were done in log space, so data are represented as geometric means and
the standard deviations are multiplicative and not additive (error factors). Histograms of
much of the data were constructed to view the underlying distributions. Overall, the data
displayed a normal distribution in log space as determined by Lilliefors test, a
modification of Komolgorov-Smirnov test for normality which does not require a fixed
mean or variance (Matlab). Exceptions to normality include distributions of proteins
whose fragments were differentially lost leading to multi-modal distributions (typically
bimodal). Thus, we conclude that the method gives rise to normally distributed data, and
testing for normality is both useful and important given its biological relevance to the
system. Based on the outcome of Lilliefor's test, either Student's t-test or Wilcoxan sign
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rank test both with Bonferroni correction for multiple comparisons was performed to
determine whether the protein amount was different with treatment compared to without
treatment (untreated control). Protein identifications were verified by Spectrum Mill
(Agilent). Proteins were subjected to manual validation (of both identification and
quantitation) of at least one peptide per protein For proteins identified by 4 or fewer
peptides, all peptides were evaluated for proper identity and adequate quantitation.
Protein identification is defined as identification of least 2 peptides from the protein with
a confidence of greater than 90%.
Clustering analysis. A final protein list was compiled from all proteins identified by 2
or more peptides from the first iTRAQ experiment (sample set 1) searched against the
bovine database and supplemented with proteins identified only in the second experiment
(sample set 2) as well as non-bovine proteins identified by Genbank search that represent
proteins not yet annotated in the bovine genome. This complete list was clustered using a
k-means clustering algorithm (Matlab statistics toolbox) of the log transformed mean
signature ion ratios for each protein. The K-means clustering algorithm partitions the
proteins into k clusters (defined by user) by iteratively minimizing the summed squared
Euclidean distances of each protein within the cluster to the cluster centroid over the
entire k clusters. The program was allowed to iterate as many as 1,000,000 times to
achieve a minimum given a set of starting values, and we allowed 500,000 replicates
beginning with k randomly chosen proteins to achieve the actual minimum for the
dataset. The proteins were clustered into between 4 and 25 clusters to determine both the
best fit (Silhouette plots) and a biologically useful number of clusters to interpret the
system. A student's t-test was performed to determine whether the clusters were
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significantly different from one another, and thus likely to describe unique biological
phenomena.
4.4 RESULTS
Normalization of data using an internal standard - Chondroitinase ABC correction.
Because protein amounts were expected and known to be different between the
samples, internal standard was used for ratio normalization. The chondroitin sulfate
lyase, Chondroitinase ABC, was used to deglycosylate the samples prior to labeling and
analysis, and it served as the internal standard as it was unlikely to be present or show
strong similarity to other proteins present in the sample. Table 1 provides data on the
chondroitinase ABC standard and the mean ratio values which were used for correction.
The second analytical duplicate appeared to suffer from some untreated (control) sample
loss in work-up which caused the average signature ion ratios to be around 2-2.5 rather
than the first duplicate sample set where all ratios were close to 1. Sample loss likely
occurred with acetone precipitation based on protein estimates taken after sample
concentration and after acetone precipitation.
The data was normalized by dividing the geometric mean of Chondroitinase ABC
signature ion ratios by the corresponding signature ion ratios for each peptide and protein.
This is equivalent to subtracting the Chondroitinase ABC signature ion ratios from the
corresponding signature ion ratios for each protein on the log transformed data. While a
more sophisticated normalization approach may have been used, this normalization was
sufficient to correct the data such that the ratios for the first analytical experiment and the
second analytical experiment were within 20%, which is sufficient to interpret biological
effects in these samples.
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Analytical duplicates - analytical variance and reproducibility. By performing
analytical replicates on average samples (samples combined from multiple explants from
multiple animals), we evaluate the average behavior of the cartilage explants to the
treatment, and we can test whether our method is sufficiently robust and reproducible for
further analysis of biological replicates where the variance is compose of both biological
variation and analytical variation. The protein data from the analytical duplicates were
compared by dividing the geometric mean of each signature ion ratio of each protein of
the first duplicate (ratio 1) by the geometric mean of the corresponding signature ion ratio
of each protein from the second analytical duplicate (ratio2). To simplify the
comparisons, only those proteins from the bovine-specific database with 2 peptides or
greater were compared using the accession number for protein identification. Figure 2
represents overlaid histograms comparing the all protein signature ion ratios represented
as log2 (ratio l/ratio2). In this histogram, the log transform of the ratio of signature ion
ratios should fall with a mean of zero, and the variance should be small suggesting good
repeatability/reproducibility in the values obtained. In this case, we noted that the
log2(ratiol/ratio2) values were shifted slightly off from zero with overall ratio mean+/-
standard deviation for 115:114 of 0.0536 of +/-0.4597; for 116:114 of 0.2471 +/- 0.5087,
and for 117:114 of 0.1368 +/- 0.4730. These values are similar to those obtained by
comparing the ProGroup protein Summary for each dataset (supplemental material).
The slight shift from a mean of zero represents a 4-19% error in quantitative agreement
between the two experiments and may be attributed to pipeting variation of the internal
standard. The variance around zero, represented as the standard deviation of the log
transformed data, is larger than reported by Keshamouni et al. [71], and analysis indicates
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that both the large ratio values and poor identification/outliers appear to contribute to the
variance (supplemental data). Thus, with manual validation of identification and
quantitation expect that this standard deviation may be closer to 0.35 for most proteins
with ratios less than 4.
To gain a better idea of how this error may potentially affect interpretations of the
results, we attempted to determine the consistency between the two data sets which we
define as both duplicate ratios showing the same change - both ratios greater than one or
both ratios less than one. Using this method, we obtained 1388 ratio values in agreement,
126 values that disagree (370 ratios that were not identified in both sets) representing
consistency of 90% between datasets. Manual inspection indicates that most of the
inconsistencies were the result of ratios of one or of close to one. The dataset from the
first analytical duplicate was used as the primary list, and data from second analytical
duplicate was added in the case where the protein was not found in the first sample or
where the protein had a better identification and quantitation score (more peptides
identified and signature ions were of sufficient intensity for good quantitation). In
addition, proteins identified by Genbank from non-bovine species were used to
supplement the protein list if the protein was not yet annotated in the bovine genome. All
inconsistent values were labeled so they could be tracked during further analysis. The
final protein list was subjected to manual validation of at least one peptide per protein
and secondary validation by Spectrum Mill. All proteins identified by less than 4
peptides were manually inspected for accurate quantitation. While statistical significance
has not been achieved for many of the proteins identified and quantified by only few
peptides, the data comparisons in figure 2 suggest that any ratio that is greater than two
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standard deviations of the log2(ratiol/ratio2) for the corresponding signature ion ratio
likely represents a reproducible finding.
Matrix degradation and synthesis in response to mechanical compression
and treatment with cytokines, IL-1p, TNF-a. Previous experiments have suggested
that loss of matrix proteins to the medium may represent new matrix synthesis, matrix
degradation or passive loss of components from the tissue. To explore the behavior of
matrix proteins, figure 3a is a graph of the 14 highest scoring matrix proteins being
released into the medium plotted as the log transformed mean ratio +/- SEM of over 40
peptides for each protein. Proteins such as collagen VI and fibronectin show an increase
in release to the medium while proteins like COMP, nucleobindin 1 and NG-2 show a
slight decrease compared to the control. While most of the proteins are showing a
statistically significant change the variance represented in this findings are within a single
experiment, and we suggest caution in interpreting findings suggesting less than a 40-
50% increase. To better characterize the anabolic state of the tissue, figure 3b is a graph
of collagen telopeptide relative quantitation for each of the fibrillar collagens. Collagen
telopeptides are cleaved following collagen triple helix formation, and thus the release of
the telopeptides to the medium should approximate new collagen synthesis. Based on
Figure 3b, a decrease in all fibrillar collagen synthesis is seen in response to cytokine
treatment (IL-l p and TNF-ca) and to a lesser extent mechanical compression injury
(p<0.01 for all collagen telopeptide in response to cytokine treatment; p<0.05 for
collagen type II and the 2 collagen XI subunits in response to mechanical compression;
table 2). A sharper decrease in collagen type I synthesis was seen with TNF-a compared
to IL- IP or mechanical injury (p<0.05; student's t-test with Bonferroni correction). A
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decrease in collagen synthesis is consistent with previous reports using other methods to
determine collagen production [72, 73].
As mentioned previously, proteins possessing multimodal distributions with
respect to its peptides are expected in this sample because of proteolytic degradation of
existing matrix proteins. Figure 3c is a graph describing the quantitation of each
globular domain of aggrecan based on the quantitation of each domain's peptide
constituents. While the second and third globular domain of aggrecan (G2 and G3) are
abundantly released to the medium in response to cytokine treatment (p <0.001 for G2
and G3 for both cytokine treatments; table 2), the aggrecan GI domain was not increased
and was actually significantly decreased with TNF-a treatment compared to untreated
(p<0.05 for GI with TNF-a treatment; table 2). These results indicate that aggrecan's G2
and G3 domains are separated from the GI domain, and the GI domain is retained in the
tissue longer than the G2 and G3 containing fragments. The decrease in GI release with
TNF-a treatment may also reflect a decrease in new proteoglycan synthesis which is seen
in response to cytokine treatment and mechanical injury (data not shown).
Matrix degradation occurs in response to cytokine treatment and mechanical
compression injury and is correlated with an increase in matrix metalloproteinase (MMP)
production. Figure 3d is a graph of the identified members of the matrix
metalloproteinase family and their response to IL-1 IP, TNF-a and injury treatment.
MMP-3 and MMP-13 are most dramatically elevated with all treatments (p<0.05 for both
proteases with all treatment except for MMP-13 with injury (p=0.057)). The only
protease to decrease, MMP-2 decreased significantly with mechanical injury; however a
concomitant increase in MMP-9 is seen suggesting a shift in gelatinase activity with
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mechanical injury (p<0.05 for both MMP-2 and MMP-9 with injury). P-values
indicating significant changes in MMP quantities with each treatment compared to
control are given in Table 3. Cytokine treatment and mechanical compression generally
caused an increase in MMP release to the medium which is likely the result of new
protease synthesis. A shift in the anabolic-catabolic axes can be seen with the decrease in
collagen c-terminal telopeptide production indicating a decrease in collagen synthesis
with treatments; the increase catabolic behavior as seen with aggrecan G2 and G3 domain
release to the medium; and the increase in MMP expression.
A targeted look at anabolic-catabolic shift. Before subjecting the data to
systems-level analyses, the data was reviewed to explore relevant anabolic and catabolic
pathways in an attempt to better understand the proteins released as systems rather than
focusing only on the primary effectors. Among the most striking class of proteins,
elevated in response to IL-1p, TNF-ca and to a lesser extent mechanical injury, were
proteins involved in innate immunity. Figure 4a is a graph describing the response
profile of proteins involved in innate immunity including complement proteins and LPS
binding proteins. Again, a number of the proteins are elevated both with cytokine
treatment and with injurious compression (asterisks indicate p<0.05 change over the
untreated sample. Complement factor B, C3, and CIr are significantly increased with all
treatments (IL-1p, TNF-a, injury) compared to untreated (p<0.05). Clq is significantly
increased with TNF-a and IL-1p and C1 inhibitor is increase with TNF-a and injury
(p<0.05). Proteins involved in LPS binding, LBP is elevated with IL-lb, and CD14 is
elevated with TNF-a and IL-Ip treatment compared to untreated (p<0.05). Lactoferrin,
serum amyloid A3 and chitinase 3 like 1 and 2 were also elevated with treatments
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(p<0.05 for all treatments and proteins except lactoferrin with injury). Cytokines and
chemokines are involved in modulating inflammation and recruiting immune cells were
also identified, and their profiles are shown in Figure 4b. While most of the cytokines
and chemokines are not statistically significant due to the low number of peptides
identified, the extent of their elevation compared to the error between analytical
duplicates suggest that these are real increases in protein release. The presence
particularly in response to IL- 1P and TNF-a treatment, suggests that cytokine and
chemokines may play a role in modulating the tissue inflammatory response as well as
the recruitment of inflammatory cells into the joint area in vivo. IL-6, CCL-2, CCL-20,
M-CSF and CXCL6 are all increased over five-fold with both IL-1 I6 and TNF-
treatments. IL-17B was the highest scoring of the cytokines, and it was significantly
elevated with IL-lJp treatment (p<0.05). The TGF-3 superfamily is involved in
modulating chondrocyte phenotype and enhancing cartilage matrix production. Figure
4c is a graph describing the response to of the TGF-p superfamily and its inhibitors.
While connective tissue growth factor, CTGF, is not a member of the TGF-p family, it is
known to be elevated in response to TGF-p and may be responsible for some of the well-
characterized TGF-p effect so it was included. TGF-p superfamily members inhibin beta
and CDMP-2 appear to be elevated with injury alone and injury and IL-1 P respectively
with a trend toward significance with inhibin beta with injury (p-0.1). TGF-p2 is largely
unchanged with treatments. The BMP inhibitors, chordin like 1 and chordin like 2 are
both decreased with all treatments (p<0.05) while gremlin is elevated with IL- 1p and
TNF-ax treatment. BMP-1, a C-collagen endopeptidase known to degrade chordin [74],
was elevated with all treatments as was LTBP-l S (p<0.05), and LTBP-2 was elevated
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only with IL-10 and TNF-ca treatment. Finally, CTGF is elevated with all treatments
(p<0.05) while HTRA1, IGF-BP7 and inhibin beta inhibitor, follistatin like protein 1, are
all unchanged with treatment.
As with the TGF-p superfamily of proteins, insulin-like growth factors (IGFs) and
their binding proteins enhance matrix production and are considered highly anabolic
factors for cartilage. Figure 4d describes the profile of IGF-II and the four IGF binding
proteins (IGF-BP) found in the tissue. IGF-II appears to be elevated roughly 2 fold with
injury; however it is not significant because of the limited number of peptides identified.
IGF-BP3 and IGF-BP5 are both elevated with all treatments (p<0.05 for both treatments
and all proteins except IGF-BP3 with injury where p<O.1). IGF-BP6 is also elevated
with IL-1p3 treatment (p<0.05), and IGF-BP4 is largely unchanged. Changes in IGF-BP
expression may suggest different amounts of free IGF-I or IGF-II are available for
signaling. Shifts in the catabolic-anabolic balance and shift in inflammation and
immunity responses are suggested by the changes in cytokine and chemokine production,
changes in IGF-BP and changes in the TGF-p biological pathway.
Projection Plots and principal component analysis (PCA). In addition to
focusing on specific classes of proteins, a systems-level analysis was also undertaken to
better understand the global protein response to the treatments. The validated final
protein list was subjected to principal component analysis. Figures 5a-d are projection
plots of the proteins represented by their responses to the three treatment conditions.
Principal component analysis of the data suggests that 75% of the covariance is described
by one principal component, and 97% is described by two principal components. The
existence of two major principal components suggests that at least two of the treatments
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cause similar protein behavior. This can be observed visually in Figure 5b where a
linear relationship is evident between the global protein response to IL-i p and TNF-a
with a Pearson product-moment correlation coefficient, R of 0.87 (R2 = 0.7575;
p<0.0001). In fact, the plot of cytokine: untreated vs. injury: untreated are also well
ordered, appearing almost Y-shaped (figures 5c-d). The Y-shape can be attributed to
four major subsets of proteins -- a subset of proteins that is decreased regardless of
treatment (stem of the Y), proteins whose amounts remain unchanged (junction) with
treatment, proteins that are elevated slightly with cytokines and largely with injury
(branch 1) and the other arm represents proteins which go up slightly with injury and
largely with cytokine treatment (branch 2). Thus, while two dimensions may be
sufficient to describe the protein data, we maintained the treated: untreated axes for k-
means clustering as it offers a greater visual understanding of the data.
K-means Clustering
K-means clustering was used to divide the proteins into six groups based on their
general proximity in space by minimizing the sum of the protein to centroid distances
within clusters over all the clusters. Six groups (clusters) are indicated by the different
colored and shaped icons for proteins (points) in the graphs in Figure 5. The clusters
were shown to be statistically different from one another at p<0.001, and the six clusters
represent a good biological fit for the data. Figure 6 is shows a graph of the cluster
centroid profiles represented as mean+/-SD, and the profiles are color-coded to match the
clusters shown in Figure 5. Six clusters divide each branch of the 'Y' into two clusters in
an attempt to understand biological differences between those proteins that respond very
strongly and those that respond more moderately to treatments.
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4.5 DISCUSSION
To compare and contrast the extracellular effects of cartilage mechanical injury
and treatment with inflammatory cytokines, TNF-a and IL-1p, to untreated cartilage,
cartilage medium from a 5 day culture was collected pooled and compared between
sample groups using iTRAQ labeling and 2D-LC/MS/MS analysis (Figure 1). The goal
of the experiment was to compare proteins lost from equal volumes of cartilage into equal
volumes of medium as a result of each treatment. Different amounts of proteins were
expected to be lost, so correction for sample loss during work-up was performed based on
an internal standard protein, chondroitinase ABC.
The LC/MS/MS analysis was done on duplicate samples to provide information
about the analytical variance and reproducibility of the method using an internal standard
protein for correction. Figure 2 and the supplemental data provide a detailed analysis
of the analytical duplicates and the source of variance (error) identified in this
experiment. Based on this analysis, we determine that the log2 (ratio l/ratio2) standard
deviation is roughly 0.5 suggesting 95% of the log2 (ratiol/ratio2) values were within a
factor of 2. We anticipate this to be a measure of the maximum error for the experiment
as the error is in part the result of poor identification/ poor quantification as well as large
mean ratio values due to the limited dynamic range of the instrument. To decrease error
caused by poor identification or quantitation, all proteins with 4 or fewer peptides were
manually validated considering both identification and quantitation. Proteins displaying
large ratios in at least one signature isotope ratio possess slightly larger errors in the
ratios. Mathematical outliers, defined as values 3 standard deviations away from the
mean, were not removed. Outliers appear to be the result of signature ions outside of the
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dynamic range of the detector, poor identifications, variable trypsinization, and/ or
variable labeling, so removal of outliers may improve quantitation and reproducibility.
The finalized protein list is organized by clusters and contains all ratios, SDs, peptide
numbers, Spectrum Mill identification information, manual validation notes, consistency
between the first and second analytical duplicate, and p values (supplemental data).
Overall, good reproducibility and consistency was observed using this method with
additional error resulting from proteins with very few peptides and proteins one or more
large ratios which we attempt to remedy by manual verification of protein identification
and quantitation.
As mentioned above, the samples exhibit some unusual properties that make data
interpretation more complex. First, as mentioned above, some proteins may exhibit
multimodal distributions due to loss of different domains of a protein at different rates
due to proteolytic processing and release from the tissue. Protein release may result from
new protein synthesis from proteolysis or from passive loss from the tissue due to an
increase in transport in part due to loss of aggrecan (proteoglycan effects on transport
[75]). The passive loss of proteins, due to an increase in transport from the tissue, should
possess ratio values similar to aggrecan especially if the proteins are not anchored to
other matrix constituents. This increase in transport does not mean that all proteins lost at
a rate less than or equal to aggrecan represent passive loss; it simply means that there is
additional complexity in interpreting the data. Mechanical compression injury may also
change transport due to damage to the collagen network; however, this change is likely to
be more subtle. At the same time, we chose a five day treatment because the aggrecan
curves begin to flatten out suggesting that we achieved a new equilibrium. Finally, the
-164-
cartilage was harvested from 2-3 week old calves, and the cartilage may represent both
chondroblastic and chondrocytic phenotypes rather than the chondrocytic phenotype
expected from older tissue. In other words, young cartilage is more biologically active
and still forming large amounts of matrix, particularly the collagen network. Thus, this
model may not completely recapture the behavior of normal adult cartilage. At the same
time, osteoarthritic cartilage is also known to exhibit some chondrobastic behavior, so
this model may possess some similarities and differences compared to behaviors seen in
OA cartilage. Ultimately, this is an observational experiment in which proteins lost to the
matrix may represent some aspect of the biology going on in the tissue, and this biology
may represent appropriate or inappropriate repair processes in response to the matrix
damaging stimuli.
Mechanical injury and inflammatory cytokines, TNF-a and IL- 1p, shift the
anabolic-catabolic balance in cartilage. This shift has been described in the literature in
response to cytokine treatment and in response to mechanical compression injury. For
example, IL- 1 and TNF-a are known to decrease collagen type II and type XI synthesis
while not dramatically affecting its breakdown early in response to treatment [72, 73, 76].
Over time, IL-1 may also enhance the production of collagen type I and type III subunits
although PGE2 is normally inhibits type I and type III collagen production in
chondrocyte with IL-1 treatment [72, 77]. While no direct study on the effects of
mechanical injury on collagen synthesis has been conducted, Lee et al., by real time RT-
PCR, showed very little change in type II collagen transcription which may imply that
mechanical injury does not alter collagen synthesis beyond its effects on cell death or that
the inhibition of collagen synthesis may be a post-transcriptional effect [53]. Kurz et al.
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showed an decrease in 3H-proline incorporation compared to free swell controls
following mechanical compression injury even when corrected for cell death [49].
Previous work by Sah et al. showed that approximately 80% of the proline incorporation
represents new collagen synthesis in this young bovine model [78], which taken together
with Kurz et al. suggests that there is likely a decrease in collagen synthesis with
mechanical compression injury [49]. Figure 3b is a graph of the C-terminal telopeptides
of the fibrillar collagens identified in the samples. The C-terminal telopeptides are
important for collagen fiber formation, and their release is indicative of new collagen
synthesis. Figure 3b suggests that there is a general decrease in collagen synthesis with
treatments (table 2 for p values). This decrease in collagen syntheses as described by
collagen c-terminal telopeptide release to the medium is consistent with previous reports
on collagen synthesis and represents an anti-anabolic shift in response to cytokine
treatment and mechanical injury.
In response to IL-l p and TNF-ca, aggrecan is rapidly degraded via the actions of
aggrecanases, ADAMTS4 and ADAMTS5. Aggrecan is bound via its GI domain and
proteoglycan link protein to hyaluronic acid which is in turn bound to the chondrocyte
cell surface through its interactions with CD44 (for review [79]). The proteolysis of
aggrecan by aggrecanases occurs at multiple positions along the core protein with the
most commonly characterized sites within the CS-rich region releasing aggrecan G3 or
within the interglobular domain between G2 causing the release of all but the GI
aggrecan fragment. The aggrecan G1 and proteoglycan link protein are known to
accumulate in cartilage with age [80]. Maroudas et al. measured the half life of aggrecan
GI and proteoglycan link protein to be approximately 25 years by aspartic acid
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racemization method [81]. More recently confocal microscopy work by Fosang et al.
showed that aggrecan GI-NITEGE fragments may be internalized [82], and Embry et al.
provided further evidence that this may be a hyaluronic acid-dependent event mediated
by CD44 [83]. The aggrecan GI and link protein, with their high binding affinity to
hyaluronic acid, may remain in the tissue and released more slowly with time or may be
turned over via cellular internalization. Figure 3e is this study describes aggrecan release
into the medium separated by globular domains. Aggrecan G2 and G3 domains are
increased 3-5 fold with IL-1p and TNF-ca respectively. However, aggrecan GI is
released at roughly the rate of the untreated explants suggesting that aggrecan GI is
retained in the tissue where it may be released more slowly or possibly internalized by
the chondrocytes. Aggrecan proteolysis with accompanying release of the aggrecan G2
and G3 domains and with evidence of aggrecan GI tissue retention is characteristic of the
catabolic behavior seen with IL-i 1P and TNF-ct treatment.
In response to IL-1$, TNF-a, and mechanical compression, chondrocytes produce
proteases which may mediate extracellular matrix degradation. In particular, the MMPs
have been implicated in the degradation of aggrecan, collagens, fibronectin, and COMP
[84-87]. MMP expression is important for matrix remodeling and turnover to insure
ECM integrity; however in response to pro-catabolic stimuli, the over expression of
MMPs can lead to matrix degradation that is not balanced by new matrix synthesis
yielding a negative equilibrium [88]. Figure 3d is a graphical representation of the
identified MMP expression profiles with each treatment. Using the mechanical injury
model described in this study, Lee et al. reported an increase in MMP- 1, MMP-9, MMP-
13 and MMP-3 gene expression 24 hours after compression injury compared to free swell
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controls [53]. In this study, a statistically significant increase in MMP-3 and MMP-9
protein release is observed with mechanical injury compared to untreated (free swell
controls) (p<0.05), and a trend towards and increase is seen for both MMP-1 and MMP-
13 compared to untreated (free swell controls; p-0.1) [53]. Other explant and
chondrocyte model systems have shown an increase in MMP-9 and MMP-13 expression
with TNF-a treatment [73, 89], and an increase in MMP-1, MMP-3, MMP-8, MMP-9,
and MMP-13 with IL-16 [87, 90-95]. In this study, MMP-1, MMP-3, MMP-9, and
MMP-13 are elevated with IL-l p compared to untreated controls while TNF-a treatment
results in an elevation of MMP-3, MMP-9 and MMP-13 relative to untreated controls
(p<0.05, table 3). The identification and response of the MMPs found in this study are
consistent with previous findings in this and other models for both cytokine treatment and
mechanical injury. An increase in matrix metalloproteinases in response to both cytokine
treatments and mechanical injury suggests a shift toward more pro-catabolic behavior of
the chondrocytes.
TNF-ct and IL-I P, both, play a role in the immune response and tissue damage
which has motivated the successful use of anti-TNF-a and anti-IL-I therapies in the
treatment of rheumatoid arthritis [31, 32]. By focusing on the effects of these cytokines
in an in vitro model, we hoped to better understand the contributions of the cytokines and
chondrocytes to immune response inflammation and tissue destruction. In trying to
understand the effects of both mechanical injury and inflammatory cytokine treatment,
we assumed that the tissue behavior should be appropriate to illicit both an immune
response and to initiate a repair process. Immune response and tissue repair is typified by
dermal wound healing where there exists a well-characterized balance of pro and anti-
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inflammatory factors and pro and anti-fibrotic factors which dictate both tissue protection
against infection and scarring or repair processes. Dermal wound healing is an
orchestrated systemic event; however cartilage, being avascular tissue, must mount an
attempt at repair on its own.
Thus, proteins involved in the innate immune response were evaluated including
complement factors and antimicrobials. Figure 4a is a graph showing the profiles of
some of the protein that may play a role in innate immunity. Complement factor B, C3,
and C Ir are significantly increased with all treatments, Cl q is significantly increased
with TNF-a and IL-1p, and Cl inhibitor is elevated with TNF-a and injury. While not
possible to determine the amount of protein present using this method, the coverage on
both factor B and C3 suggest that these proteins may be present in reasonably large
quantities. Factor B is involved in the activation of the complement alternative pathway
through its interactions with C3, while Cl is involved in the lectin binding and classical
complement pathways (for review of complement [96]). C3 is thought to initiate the
alternative complement cascade through interactions with and deposition onto
particulates such as LPS, yeast and plant polysaccharides, and virus particles [96].
Cartilage has been shown to produce factor B, and synovial cells produce complement
factors including factor B and C2 and C3 suggesting that complement is synthesized
within the joint particularly in inflammatory conditions [60, 97]. Skin fibroblasts have
been shown to increase production of complement C3 and factor B in response to IL-I
and TNF-ct [98]. Production of factor B rather than IGF-l in TNF-a stimulated
macrophages may be determined by the co-stimulation with IFN-p (IL-6) or IFN-
y representing a means by which TNF-a may contribute to both the immune response and
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early repair [99]. Mice deficient in factor B and complement C3 (B', C3-) both show an
increased resistance to arthritis in collagen induced arthritis mouse models [100, 101].
CD14 and LBP are both involved in the transfer of LPS to the MD2-TLR4 complex
required for cell signaling. However, elevation of these LPS handling proteins may also
inhibit LPS response (for review [102, 103]). Peptidoglycan recognition proteins,
PGRPs, are a class of peptidoglycan interacting proteins that may serve either as
bacteriostatic or antibacterial agents that may play important roles in phagocytosis,
cytokine response to microbes, and peptidoglycan degradation (for review [104]). In this
study, PGRP-L, but not PGRP, was elevated with TNF-a treatment which may suggest
that the tissue may be generating factors to break down pro-inflammatory peptidoglycans
rather than generating bactericidal factors. Hanayama et al. recently showed that milk fat
globule EGF factor 8 (MFG-E8) plays a critical role in the phagocytosis of apoptotic cells
by binding to phosphatidylserine on the surface of dead cells and forming a bridge
between the cell remains and the phagocyte [105]. This clearance of apoptotic cells may
be important in preventing autoimmune disease as a lupus like syndrome when
phosphatidylserine is masked by a dominant negative form of MGF-E8 [105, 106]. The
effect of mechanical injury on apoptosis has been well characterized in this model, and
we anticipate that approximately 30-40% of the cells may undergo apoptosis in response
to the injury protocol used [47, 107]. Coincidently, the decrease in MFG-E8 is
approximately 35% compared to the untreated control (figure 4a); this decrease may
represent a decrease in synthesis or possibly retention of MFG-E8 in the tissue through its
binding to apoptotic cells. Elevation of complement and LPS binding proteins
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particularly with cytokine treatment suggests that cartilage serves as an active participant
in the innate immune response against foreign pathogens.
In addition to elevation of the innate immune proteins, elevation of cytokines and
chemokines were also noted particularly in response to IL-1p and TNF-a treatment.
Three main families of chemokines exist based on structure and function, the CCL
family, the CXCL family, the CX3CL family and the XCL family (for review [108]).
The CCL family of chemokines, typified by macrophage chemotactic protein 1 (MCP-1),
serve as chemotactic factors for monocytes and macrophages. Chemokine receptors
often bind multiple chemokines, and they have been found on a diversity of cell types.
Cartilage has been shown to produced MCP-1 in response to IL-1, TNF-a, TGF-, LPS
and LIF [109]. Pulsatelli et al. showed that human OA, RA, and normal chondrocytes
produce IL-8, GRO-a, MCP-1 (CCL-2), MIP-la (CCL-3) and RANTES (CCL-5) in
response to IL-1 and TNF-a treatment [110]. Human chondrocytes also express
chemokine receptors including CCR1, CCR2, CCR3, CCR5, CXCR1, and CXCR2 [111].
Chemokines CCL-2, CCL-20, CCL-5, and CXCL6 were all identified with mean ratios
above 5 suggesting an increase in chemokine production with IL- 1 and TNF-a
treatment (Figure 4c). IL-i 7B was also elevated slightly with IL- 1 treatment and has
been previously identified in cartilage [112]. Cytokine like protein C17 has been
previously identified in cartilage [60], and CCL16 (small inducible cytokine A16) has
recently been identified in synovial tissue [113]. IL-6 and M-CSF are both known to be
elevated in cartilage with IL-I and TNF-a treatment [10, 114], and M-CSF has been
shown to increase CTGF expression suggesting that it may play a role in repair processes
[115]. To our knowledge, no prior work has been done exploring the effects of
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mechanical injury on the production of cytokines and chemokines that may play a role
immune cells recruitment and inflammation following injury. Unfortunately because of
the large differences seen with cytokine treatment, the elevation of cytokines and
chemokines are difficult to determine. In response to IL-1 IP and TNF-a treatment,
cartilage releases chemokines and cytokines which may modulate the inflammatory
processes and immune recruitment as well as begin to promote tissue repair.
The TGF-p gene superfamily and related biological pathways play a role in
cartilage phenotype determination, anabolic response, and more generally in wound
repair. The TGF-p gene superfamily is composed of TGF-P 1, 2, and 3 as well as the
activins/inhibins and the bone morphogenetic protein (BMP) family (for review [116]).
TGF-p1-3 are complexed with latent TGF-p binding proteins (LTBPs) for secretion.
TGF-p is released from these latent complexes through proteolytic cleavage MMP-2 or
MMP-9 or through interactions with thrombospondin 1 or avp6 integrin (for review
[117]). Early work on the effects of TGF-p on cartilage matrix synthesis and
chondrocyte dedifferentitation by Galera et al. indicate TGF-p has little effect on
chondrocyte dedifferentiation when cultured in monolayer with serum, and TGF-P may
decrease collagen synthesis in primary chondrocytes [118]. Luyten et al. compared the
effects of bone morphogenetic protein 4 (BMP-4), activin and TGF-$ Ion cell
proliferation and sulfate incorporation (as a measure of sGAG synthesis) [119]. This
study showed that BMP-4 and TGF-p 1, and to a lesser extent activin, promoted sulfate
incorporation indicating an increase in matrix production [119]. Since then, TGF-p as
well as the BMPs have become widely used in stimulating mesenchymal stem cell
differentiation towards a chondrocyte phenotype (for review[120]). TGF-p also plays a
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primary role in wound healing and fibrosis which is mediated in part through its elevation
of connective tissue growth factor (CTGF) expression, a member of the CCN family (for
review [121]). To support its role in cartilage repair, Nishida et al. showed injection of
CTGF into an implantable hydrogel enhanced new tissue growth following experimental
defect formation in a rat OA model [122]. In addition, ctgf- mice suffer from impaired
chondrocyte proliferation and inappropriate aggrecan and link protein deposition within
the cartilage matrix[123]. Work by Omoto et al. indicates that CTGF is expressed more
highly in OA cartilage than normal cartilage, and this expression is associated with
chondrocyte proliferation and possible changes in chondrocyte phenotype [122].
Transfection of mouse synovial membrane cells with CTGF resulted in fibrosis (as
determined by collagen type I expression and matrix deposition), an increase TGF-p, an
increase in matrix degrading enzymes, and cartilage damage [124].
Bone morphogenetic proteins were first identified as factors involved in
osteochondral differentiation, development, and phenotype maintenance (for review
[125]). BMP-2 and BMP-4 are found in developing and OA cartilage; however very
little is present in normal adult cartilage [126]. Bobacz et al. reports BMP-6 expression
in normal cartilage, and shows treatment of cartilage with BMP-6 enhances proteoglycan
synthesis [127]. IL-1p has been shown to increase BMP-2 expression in a
chondrosarcoma cell line and in human cartilage [128, 129]; however IL-l P also
suppresses the anabolic effects of BMP stimulation with the exception of BMP-7 [130-
132]. BMP activity is regulated by the BMP antagonists, DAN, gremlin, chordin, and
noggin. Studies focusing on the differential expression of BMP antagonists in human
normal versus OA cartilage and with cytokine treatment indicate that gremlin is
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decreased with both IL- 1p and TNF-a treatment, that follistatin is increased with TNF-a
treatment, and that chordin is unaffected by IL-l $ and TNF-Ca treatment [133, 134].
Activins are inhibin homodimers while inhibins are heterodimers, so in the
absence of other inhibins, it is likely that activin A is the biologically relevant signaling
molecule in response to injury. The presence of follistatin suggests a role for the
activin/inhibin family in cartilage, and Hermannson et al. reported an increase inhibin
beta A protein synthesis in OA cartilage compared to normal cartilage [60]. More
recently, this same group also reported inhibin beta expression by fine chopping of
cartilage as well as treatment with IL-I and TGF-p [135]. While activin A may play a
role in tissue repair as a member of the TGF-p superfamily of proteins, there is also
evidence that it may also serve as a pro-inflammatory molecule as it is released within
minutes following LPS or yeast stimulation and its production may be stimulated by
TNF-a and IL-i a (for review of activin A in systemic inflammation [136]).
Because of the important role the TGF-p superfamily of proteins and their
regulators play in cartilage maintenance, we chose to take a targeted look at the response
of these proteins to treatments. Figure 4c is a graph showing the behavior of TGF-p
family proteins, their inhibitors and their binding proteins. Only three TGF-p
superfamily members were identified, TGF-p2, inhibin beta, and CDMP-2. Inhibin beta
was shown to be elevated in response to injury with a trend towards significance (p-0. 1)
while follistatin like protein 1 was unchanged. TGF-p2 was not changed with treatment;
however, a large increase in LTBP-l S and LTBP-2 were noted which may suggest an
increase in TGF-p synthesis or activity. CDMP-2 shows signs of elevation with IL-1p
and injury though is not statistically significant. BMP antagonist gremlin was slightly
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elevated with IL-1IP and TNF-a treatment while the chordin like 1 and chordin like 2
were decreased with all treatments. These profiles are markedly different than those
described by Tardif et al. in human chondrocytes stimulated with TNF-a and IL-1IP [133,
134]. This difference may be species based difference, or it may represent differences in
cartilage/chondrocyte behavior with age and tissue maturation. No change was seen with
HTRA1, a serine protease, thought to play a role in modulating TGF-p signaling and was
reported to be elevated as much as 7 fold in OA cartilage explants [137]. CTGF is
elevated roughly 4-fold over the untreated sample with all treatments in this study
(p<0.05), and peptides from other CCN family members, WISP-3 and NOV were also
identified. CTGF may be elevated in cartilage by BMP-2, TGF-p, or M-CSF [115, 138].
The elevation of CTGF in this system may be mediated by M-CSF which is elevated with
cytokine treatment and possibly by inhibin which was elevated with injury. We
hypothesize that elevation of inhibin beta and CTGF may suggest signs of early tissue
repair processes. The TGF-p related biological pathways are responsive to treatment
with IL-1P, TNF-a and injurious mechanical compression, and these changes may be
important in mediating tissue repair.
In addition to the TGF-p related pathways, insulin-like growth factors (IGF-I and
IGF-II) are important in promoting anabolic activity in cartilage, and may play a role in
limiting tissue damage and promoting tissue repair. IGF-1 is produced in the liver under
the regulation of growth hormone, and it is typically bound to serum IGF binding
proteins (IGF-BPs; IGF-BP3 is the primary binding protein in serum) which increases it
half-life in the blood (for review [139]). IGF-1 has been shown to promote anabolic
behavior and inhibit catabolism in cartilage (for review [140]), and IGF binding proteins
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are found within the cartilage matrix and may regulate IGF- 1 stores and activity. IGF-
BP6 and IGF-BP2 are the primary IGF-BPs isolated from adult steer cartilage [141].
IGF-BP3, IGF-BP4 and IGF-BP5 are increased in human OA cartilage tissue, and IGF-
BP3 synthesis is increased in OA suggesting a role for IGF pathway in OA [142, 143].
At the same time, IGF-BP5 and IGF-BP3 may undergo proteolysis which eliminates its
bioactivity [144]. Cir and Cls have been implicated in the break down IGF-BP5 [145];
however, Zumbrunn et al. identified HTRA1 which possesses an IGF binding domain and
can act as an IGF-BP protease [146, 147]. More recently, IGF-BP3 and IGF-BP5 has
been shown to have IGF-independent activities, and IGF-BP3 may enhance apoptosis in
mesenchymal chondroprogenitor cells independent of IGF binding [148, 149]. Thus,
both IGF-l and IGF-2 may play an important role in maintaining cartilage catabolic
activity, and IGF-BPs play a primary role in transport, storage and modulating IGF
activity with IGF-BP3 possessing some IGF independent functions. Thus, figure 4d is a
graph showing the profiles of IGF-II and IGF-BPs identified in this study and their
relative quantitation with treatments. IGF-II is elevated slightly with mechanical injury,
and is likely produced locally within the tissue. IGF-BP3 and IGF-BP5 are elevated with
both cytokines and with injury compared to untreated controls while IGF-BP6 is only
elevated with IL-13 treatment (p<0.05) and IGF-BP4 is largely unchanged. The
elevation of IGF-BP6 may be the result of increased transport or proteolysis if it
represents the most abundant IGF-BP6 normally found in bovine cartilage [150]. IGF-
BP3 and IGF-BP5 are elevated sufficiently and in all conditions to suggest that they may
be newly synthesized. Because both IGF-BP3 and IGF-BP5 may have both IGF-
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dependent and IGF-independent activities, the elevation of these binding proteins is
difficult to interpret although it likely represents a shift in tissue response to IGF.
By looking specifically at biological pathways, we were able to see evidence of
increased catabolism, a decrease in anabolism, shifts in pathways regulating innate
immunity and inflammation and anabolic and phenotypic response. These observations
possess some similarities with normal wound healing with inflammation and innate
immunity important to protect the host against infection and with repair orchestrated
through TGF-p and IGF biological pathways. This analogy likely represents an
oversimplification of the events occurring; however it is helpful in organizing a more
targeted discussion of events before subjecting the data to a systems-level analysis.
To better understand the effects of IL-1p, TNF-a and injurious mechanical
compression at a more global level, we plotted each protein as points in three
dimensional space which represent each protein's response to each treatment (Figure 5a),
and they distributed in space almost as a plane which can be seen more readily in the 2D
projection plots (figures 5b-d). We were somewhat surprised by the linear response
observed in the cytokine: untreated conditional space. Looking at individual proteins,
differences between IL-l IP and TNF-a can be seen; however from a systems-level view,
the response of proteins to the cytokine is quite similar, and these similarities represented
well by a Pearson-product-moment correlation coefficient, R of 0.87 (R2 = 0.7575). The
behavior of proteins in cytokine: untreated vs. injury: untreated also possesses a great
deal of order, appearing almost 'Y'-shaped. The principal component analysis indicating
75% of the covariance is within a single principal component and 97% within 2 principal
components exemplifies this ordering. This 'Y' shaped behavior in protein response to
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cytokine treatment and to injury is consistent with known effects of each treatment. In
particular, both cytokine treatment and mechanical injury are known to decrease
proteoglycan and collagen synthesis as described above. In addition, mechanical injury
has been shown to cause cell death primarily by apoptosis, some matrix degradation
while cytokine treatment promotes an inflammatory response, cartilage matrix
degradation, and possibly some apoptosis. The projection of the proteins represented as
points based on the protein's response to treatment displays the overall similarities and
differences between treatments in this study.
To group the proteins according to their responses to treatment, we performed K-
means clustering. While four clusters may be sufficient to pull out proteins which are
largely represented as decreased with treatment, unchanged with treatments, increased
primarily with injury, and increased primarily with cytokine treatment, we chose six
clusters in hopes of teasing out more biological details of the system. Six clusters
separates those proteins that are moderately elevated (2-5 fold) from those that are more
dramatically elevated (7-10 fold) in response to cytokine treatment and injury treatment.
Figure 6 is a graph of the centroid profiles represented as mean +/- SD of proteins
present in the cluster in response to each treatment.
In dividing the data into six clusters, we hoped to gain further insight into cell
death in this model. In our SDS-PAGE-LC/MS/MS profiling, we identified intracellular
proteins released into the medium in response to the injurious mechanical compression.
In this study, we identified and quantified the release of a large number of intracellular
proteins that were elevated between 5 and 20 fold with mechanical injury compared to
untreated and elevated 2-4 fold with cytokine treatment compared to untreated samples.
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The release of intracellular proteins in response to injurious mechanical compression may
result from mechanical disruption of the cells or from loss of membrane integrity in cells
undergoing apoptosis. While unlikely to cause necrosis, cytokines, and TNF-a in
particular, may induce apoptosis in chondrocytes, so the increase in intracellular protein
release with TNF-a may be the result of apoptosis. Previous unpublished work suggests
that treatment with 100 ng/ml of TNF-a promotes apoptosis in as many as 10% of the
cells. IL-1 P, however, is not known to cause apoptosis in chondrocytes. TNF-a causes
only a moderate increase in intracellular proteins compared to IL-1 IP, and both cause
elevated intracellular proteins over the untreated samples. Another explanation for the
increase of intracellular proteins with cytokine treatment is that TNF-at and IL- 1P cause
an increase in transport through aggrecan degradation. This increase in transport may
cause the release of intracellular proteins from cells that were damaged during explant
harvesting. This alternative hypothesis is weak given the rapid release of actin post injury
compared to the length of the entire study and how few intracellular protein were found
in the medium of untreated explants in the gel based profiling study. In an attempt to
understand the leaking of intracellular contents suggesting loss of membrane integrity
and cell death, we looked more specifically at the protein differences between cluster 4
and cluster 6. In particular, we assumed that ER proteins are more likely to be released
with necrosis than apoptosis. Proteins from clusters 4 and 6 were sorted according to
different intracellular location and plotted based on the relative elevation with each
treatment (figure 7). While we noted a small but statistically significant increase (-40%)
in cytoplasmic and metabolic proteins compared to cytoskeletal proteins and ER proteins,
this trend was consistent across all treatments relative to the untreated sample, so no
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conclusions about the contributions of necrotic compared to apoptotic proteins can be
made. Mechanical injury and cytokines to a lesser extent cause an elevation in
intracellular proteins which may be due to mechanical cell lysis and apoptosis.
Among non-intracellular proteins identified as elevated with mechanical injury
(clusters 4 and 6) were CTGF, inhibin beta, semaphorin 3C, and proenkephalin.
Semaphorin 3C is known to play a role in axon guidance, repelling sympathetic nerve
fibers (for review[151]). Semaphorins are thought to signal, with the help of cell surface
neuropilins which signal through plexins and alter signaling through Rho-GTPases.
Neuropilin-2, identified in this study, also serve as co-receptors for VEGF 165 and
VEGF145 [152]. Mangasser-Stephan, et al. described the expression of Semaphorin 3C
(semaphorin E) expression in rheumatoid synovial cells and suggested that it may serve
an immunosuppressive role[153]. Miller et al. reported expression more recently again in
synovial cells and suggested that semaphorin 3C may be playing a role in inhibiting axon
growth of sympathetic nerves which may serve a pro-inflammatory role by decreasing
norepinephrine which may in turn lead to greater TNF-a production[154]. The presence
of both semaphorin 3C and its receptor neuropilin-2 suggest a role for semaphorin 3C
within the cartilage. The quantitation of both semaphorin 3C and neuropilin 2 is found
in Table 4. The expression is elevated between 3 and 5 fold with all treatments giving it
an expression pattern similar to CTGF. Thus, we hypothesize that semaphorin 3C may
play a role in either immuosuppression or early repair processes in the tissue; however
more work must be done to characterize the effects of semaphorin 3C in this model. In
addition to semaphorin 3C, we also noted the elevation of proenkephalin, which was
elevated only with mechanical compression injury. Proenkephalin is the precursor for
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enkephalins which are opioid-like peptides that serves as neurotransmitters in the brain.
Proenkephalin is abundantly expressed in bone and cartilage during organogenesis [155],
and Rosen et al hypothesize that the production of opioid peptides may play a role both in
tissue regeneration with injury and in pain control [156]. Consistent with its role in
organogenesis and repair, Villiger et al. showed chondrocyte proliferation correlated well
with proenkephalin gene expression [157]. TGF-p and PDGF stimulated cell
proliferation and proenkephalin release while retinoic acid and IL- 1f inhibited
production [157]. Taken together, proenkephalin may play a role in cartilage repair after
injury.
While many of the proteins elevated in response to cytokine treatment have
already been reviewed in the targeted analysis above, some additional proteins identified
with cytokine treatment included pleiotrophin and oncostatin M receptor. Pleiotrophin is
a very basic cytokine (pI 10.1) and protooncogene that has been implicated in tumor
transformation, apoptosis, angiogeneisis, and mitogenesis (for review[158]). Pleiotrophin
leads to such diverse responses by signaling through transmembrane receptor tyrosine
phosphatase (RPTP) p/y which modulates p-catenin signaling by disrupting beta-catenin
and E-cadherin association. p-catenin is an important member in the wnt signaling
pathway which signals by binding frizzled and inactivating GSK-3p which targets p-
catenin for degradation through phosphorylation (for review[159]). Pleiotrophin is found
in abundance in the resting zone of fetal epiphyseal but not in adult normal cartilage
[160]. Pleiotrophin and the wnt signaling pathway, more generally, are important in
osteoblast differentiation [160, 161]. Overexpression of pleiotrophin in transgenic mice
led to the expression of pleiotrophin in cartilage with poor bone-cartilage delineation and
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type I collagen production within the cartilage [162]. Pufe et al. recently described
pleiotrophin expression in the synovial tissue from rheumatoid arthritis patients, and
showed pleiotrophin expression was elevated with TNF-x treatment. This suggests that
pleiotrophin expression is increased with both IL-1p and TNF-a treatment. In addition to
pleiotrophin, we note that a number of secreted frizzled proteins, inhibitors of the wnt
signaling pathway were also present. Pleiotrophin represents a possible means of altering
p-catenin behavior which may impact wnt signaling. We thus suggest that pleiotrophin
may be involved in repair or possibly in dedifferentiation of cells with inflammatory
cytokine treatment.
In conclusion, we have used iTRAQ labeling and 2D-LC/MS/MS analysis of
proteins released from cartilage that was untreated, injuriously compressed, and treated
with cytokine IL-l p and TNF-a, and proteins involved with injury, immunity, and repair
processes were observed. Among the proteins involved in injury were intracellular
proteins which we believe were primarily released in response to mechanical cell
disruption; however the increase with cytokine treatment suggests that loss of membrane
integrity with apoptosis may also be occurring. Protein associated with immunity were
most pronounced with cytokine treatment with a increase in complement proteins factor
B, C3, Clr and Clq noted as well as proteins associated with LPS binding and LPS
response. Elevation of these proteins was accompanied by elevation of cytokines and
chemokines which include IL-6, CCL-20, CCL-2 and M-CSF which may play a role in
modulating inflammation and immune cell recruitment in vivo. Evidence of altered
anabolic pathways may suggest signs of repair. TGF-p superfamily members, TGF-p2,
inhibin beta, and CDMP-2 were identified. Inhibin beta was elevated with mechanical
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compression injury, LTBPs were elevated with cytokine treatment as well as a decrease
in BMP antagonist, chordin like 1 and chordin like 2. A release of different IGF binding
proteins may suggest a shift in IGF pathway with the potential to increase the
extracellular stores of the enzyme. Of note, both IGF-BP3 and IGF-BP5 may serve IGF-
independent functions and were shown to be elevated with all treatments. Finally, we
note an increase in CTGF, semaphorin 3C, proenkephalin, and possibly pleiotrophin as
proteins that may also play a role in tissue repair processes. In response to cytokine
treatment and mechanical injury, cartilage possesses some ability to repair damage as
long as the injury is not too severe and inflammation not too prolonged. The
observations of protein response in this study reflect tissue damage, immunity, and
potentially signs of repair. Understanding of these pathways and their effects on cartilage
may aid in identifying new therapeutic strategies to treat disease processes.
Acknowledgments. I thank to Dr. Forest White for his invaluable assistance with the
experimental design and mass spectrometry assistance. I thank Dr. Jimmy Flarakos for
his technical assistance with the offline 2D-LC/MS/MS experimental approach.
- 183 -
4.7 FIGURES
Figure 4.1
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Figure 1: Figure 1 is a schematic of 2D-LC/MS/MS data analysis process. Samples are first
deglycosylated with Chondroitinase ABC. The proteins are then subjected to reduction,
alkylation and trypsinization before labeling with the iTRAQ reagent. Each sample is labeled
with a reporter tag with a unique signature ion, and the samples are combined and subjected to
SCX chromatography and the fractions are analyzed by LC/MS/MS (QStar). Data is collected
and analyzed by ProQuant, and the assembled peptide list from ProGroup report is imported to
excel where low confidence peptides are removed as are peptides with incomplete quantitation.
The data is imported into matlab where the spectra are combined to peptide averages and then the
peptide averages are combined to get a protein level average with statistical analyses being done
using both t-tests and Wilcoxan tests with Bonferroni correction for multiple comparisons.
Finally, protein identifications are verified by a combination of Spectrum Mill and manual
validation prior to further analyses.
Table 4.1
Table 1
Expt Peptides 115:114 115 SD 116:114 116 SD 117:114 117 SD Normal
Itrag 65 1.29 1.30 0.995 1.22 1.23 1.19 Yes (3)
Itraq2 55 2.43 1.76 2.81 2.14 2.26 1.68 Yes(1)
Table 1: Chondroitinase ABC normalization statistics. Table I provides the
Chondroitinase ABC geometric mean signature ion ratios which were used to normalize
data. Normalization was performed by dividing all protein signature ion ratios by the
corresponding Chondroitinase ABC ratio. Some sample loss occurred with untreated
(m/z 114.1 labeled sample) which led to high correction values for the second set of
samples.
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Figure 4.2: Comparison of the first and second analytical duplicates
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Figure 2 Analytical variation and reproducibility. Figure 2a are overlaid
histograms comparing the mean protein ratios between the first analytical duplicate
and the second analytical duplicate after internal standard correction. The data are
plotted as log2(mean protein ratio experiment I / mean protein ratio experiment 2).
The mean log2(protein ratiol/protein ratio2) +/- SD for 115:114 is 0.0311 +/-0.5602
for 116:114 is -0.2371+/-0.5736 and for 117:114 is 0.1596 +/- 0.5435. Asforthe
inter-injection graphs, a mean of 0 is expected, and we see here an offset as high as
17% for the 116:114 ratio. The error described by the variance of the
log2(ratiol/ratio2) is in part dependent on error caused by large ratios and poor
identification/quantitation (supplemental data).
Figure 4.3: Matrix proteins Released
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Figure 3: Matrix Proteins and MMPs released to the medium. Figure 3a is a graph displaying
the behavior of the top 14 scoring matrix proteins. With the exception of nidogen and matrilin 1
with injury and nucleobindin 1 and COMP with TNF-alpha treatment, all changes are statistically
significant at p < 0.05. Caution should be used in interpreting statistical significance of finding that
represents less than a 50% increase. To better characterize the anabolic state of the system, Figure
3b is a graph of the C-terminal telopeptides of fibrillar collagens, col2A1, coll A1, coil A2,
col5A1, collAl, collA2. The release of these telopeptides may approximate the production of new
fibrillar collagens, and this data suggest that collagen synthesis is generally decreased with all
treatments. Figure 3c is a graph of aggrecan quantitation based on peptides from each globular
domain. Aggrecan is a proteoglycan that is rapidly proteolyzed in response to IL-Ibeta and TNF-
alpha treatment. The graph suggests that G2 and G3 are lost more readily than GI which is
consistent with known behavior of the proteoglycan. Figure 3d displays the response of MMP
identified in the medium with each treatment. All data is represented as mean +/- SEM of between
3 and 100 peptides.
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Figure 3d
Table 4.2
Table 2: p values for collagen C-terminal telopeptides and aggrecan globular
domain release
Condition CoI2A1 CollAl CoI11A2 CoI5A1 CoIlAl Col1A2 GI G2 G3
IL-1p:cont <0.005 <0.005 <0.005 <0.05 <0.005 <0.005 ns <0.005 <0.005
TNF-a:cont <0.005 <0.01 <0.005 <0.005 <0.005 <0.005 <0.05 <0.005 <0.005
Injury:cont <0.005 <0.05 <0.005 -0.6 -0.9 -0.3 ns -0.3 -0.3
Table 2 lists the p values of collagen C-terminal telopeptides and aggrecan globular
domains for statistical comparisons treatment and control using Student's t-test with
Bonferroni correction for multiple comparisons
Table 4.3
Table 3: p values for statistical significance in comparing treatment to untreated by
Student's t-test with correction for multiple comparisons
Protein p value p value p value
IL- 1:untreated TNF-a:untreated Injury:untreated
MMP-3 <0.001 <0.001 <0.001
MMP-2 0.004 0.02 <0.001
MMP-9 <0.001 <0.001 <0.001
MMP-13 0.009 0.027 0.057
TIMP-1 1.23 0.54 0.023
MMP-1 0.001 0.09 0.10
MMP-14 0.09 1.3 0.008
TIMP-2 0.36 5.4 <0.001
Table 3 lists the p values for statistical significance in comparison each treatment to the
untreated control by Student's t-test with Bonferroni correction for multiple comparisons.
All p values smaller than 0.001 are indicated as <0.001.
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Figure 4. Figure 4 are a set of graphs focusing on biological pathways to better understand the
effects of treatments. Figure 4a is a graph of proteins involved in innate immunity including
complements and antimicrobials. Figure 4b is showing the behavior of proteins involved in the
signaling of TGF-beta superfamily members and their inhibitors. Figure 4c is a set of cytokines
and chemokines and their production with each treatment. Figure 4d are the IGF binding
proteins. All data are plotted as the mean ratio value for each treatment +/- SEM with the
number of peptides ranging from 2 to 35. The asterisks indicate p<0.05 for significance of
treatment compared to control and the '+' indicates p<O.1 indicating a trend towards
significance. All statistical analyses were done by either Wilcoxan Sign rank or Student's test
with Bonferroni correction for multiple comparisons.
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Figure 5: Projection plot of proteins represented by the three treated: untreated ratio
conditions with colors representing the protein clusters defined by K-means
clustering. Figure 5a includes all three dimensions and appears almost planar in the
threedimensional condition space. Figures 5b-d represent the three 2D projections of
the data. Figure 5b has been fitted to a line with a slope of 0.8465, an intercept of
0.2152 and Pearson product moment correlation coefficient, R, of 0. 87, indicating a
robust and statistically significant relationship between the response of proteins to
TNF-alpha and to IL-ibeta (p<0.0001). Figure 5c-d proteins are arranged in a 'Y'
shaped pattern suggesting similarities and differences exist between the response to
cytokine treatment and injurious mechanical compression.
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Figure 6: Centroid profiles for the six clusters identified by K-means clustering. Data is
displayed as centroid mean +/- SD, and all clusters are significantly different from one
another (p<0.001). Each cluster contains between 42 and 156 proteins, and they
renresent the vroteins resoonse to the treatments.
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Figure 4.7
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Figure 7. Intracellular proteins released in response to treatment separated by intracellular
function or location. Mechanical injury, TNF-a and IL-l p causes a significant increase in the
release of intracellular proteins compared to the untreated control. A slight increase in the release
of cytoplasmic and metabolic proteins was seen compared to cytoskeletal and ER proteins. This
difference was consistent with all treatments. This difference in loss may reflect different modes
of cell death or normal differences in release rates for different intracellular components.
I . 5
Table 4.4: Other Potentially Relevant Regulators
Protein Name IL-1p: untreated TNF-a: untreated Injury: untreated
Semaphorin 3C 4.48 2.73 4.88
Neuropilin 2 1.83 2.34 1.03
Proenkephalin 2.5 1.39 29.9
Pleiotrophin 9.82 4.43 1.37
Frizzled related 1.81 1.77 0.83
protein
Secreted frizzled 1 2.3 1.9 1.13
sFRP4 3.6 2.5 1.4
PDGF-like 1.07 0.98 0.79
receptor
Angiopoeitin like 7 1.54 2.23 2.45
GAS6 0.74 0.64 0.61
Fibroleukin 2.13 2.34 1.03
APP 0.52 0.62 0.41
Table 4: Potentially relevant regulators. Table 4 is a list of some of the other potential
regulatory proteins identified in the samples and their relative quantitation.
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Chapter 5: Summay and Conclusions
The first objective of this thesis was to identify the effects of TNF-a and IL-1p--induced
nitric oxide as a mediator of cartilage tissue damage. A detailed analysis of the data presented in
Chapter 2 leads to the following conclusions:
* Nitric oxide may be partially responsible for TNF-a induced aggrecanase mediated
aggrecan degradation. In contrast, nitric oxide may protect against aggrecan degradation
in response to combined IL-l 1P and TNF-a--induced matrix degradation.
" Inhibiting nitric oxide production in response to TNF-a and Il-1 P treatment had no effect
on gene expression after 26 hours on a survey of 32 genes including matrix proteins,
proteases (including aggrecanases ADAMTS4 and ADAMTS5).
* The effect of nitric oxide on aggrecan degradation appears to be contextual - that is, it
may depend on the other signaling mechanisms in play and/or yet uncharacterized shifts
in protein expression.
* Nitric oxide may partially mediate inhibition of protein synthesis as determined by 3H-
proline incorporation. A partial reverse in cytokine-induced protein synthesis inhibition
is seen following the addition of L-NMA.
The second objective was to determine the effects of IL-i [P, TNF-a, and mechanical injury
on secreted factors, matrix degradation, and mechanisms of chondrocyte cell death using an
SDS-PAGE-LC/MS/MS protein profiling approach. Our main conclusions are:
* Mechanical injury may promote degradation of matrix proteins (this may result from
mechanical damage to the matrix or increased breakdown of newly synthesized matrix
components) - especially collagen VI, collagen II, COMP, and fibronectin.
* Mechanical injury causes an increase in the release of intracellular proteins. The release
of actin occurred primarily in the first 24 hours after injury, suggesting mechanical
compression injury may cause mechanical disruption of the chondrocyte cell membrane.
We hypothesize that this mechanical disruption occurs in the periphery of the 3mm-
diameter explants where the radial strain is highest. Previous work has implicated cell
death by apoptosis in the central region of the tissue that experiences pressurization with
high strain, high strain rate compression (strain 50%, strain rate 1 000/olsec).
I L-1P and TNF-a cause an increase in some acute phase proteins including acid-I-alpha
glycoprotein, haptoglobin, and serum amyloid A3.
The third objective of this study was to further quantify the effects of IL-i [p, TNF-a and
injury treatments using an isobaric labeling (iTRAQ) based 2D-LC/MS/MS approach to better
understand matrix degradation, cell death, immune response, and evidence of cell-mediated
repair processes. The main conclusions from these experiments were:
* Mechanical injury may release proteins that are important in promoting tissue repair by
serving as pro-anabolic stimuli -- Inhibin beta, proenkephalin, CTGF, CDMP-2, IGF-II,
and semaphorin 3C were all elevated to different degrees in response to mechanical
injury. BMP inihitors, chordin like and chordin like 2 were decreased, while inhibin
inhibitor, follistatin 1 was unchanged.
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* Mechanical injury and cytokine treatment may promote matrix degradation or matrix
remodeling through the production of MMPs (ADAMTS proteases were not identified) -
MMP- 1, MMP-13, MMP-9, and MMP3 were elevated with treatments and in most cases
the elevation was significant.
* Mechanical injury again showed evidence of intracellular protein release with proteins
elevated roughly 10 fold compared to untreated controls. Slight differences were seen
between the release of cytosolic and ER proteins; however this difference was not
sufficiently different to directly attribute release to a particular mechanism of cell death.
* Inflammatory cytokines, TNF-a and IL-l1P may also cause the release of intracellular
proteins compared to no treatment. The increase of intracellular protein release may
occur with apoptosis and cell leaking or the increase in intracellular protein release may
be the result of increased tissue transport that may enhance the loss of intracellular
proteins of cells dead prior to the start of the experiment.
* Inflammatory cytokine (IL-1 P and TNF-a) and mechanical injury may decrease collagen
synthesis (as evidenced by decrease in C-terminal telopeptide release)
* Inflammatory cytokines may promote aggrecan degradation as measured by sGAG
release, increases in NITEGE fragment release, by separation of GI from G2 and G3
domain regions by gel and 2D-LC/MS/MS analysis.
* IL-1IP and TNF-a may enhance the production of alternative pathway complement and
LPS surveillance proteins relative to untreated - complement factor B, C3, and Clr were
elevated
* Mechanical injury causes a slight increase in complement proteins and proteins involved
in innate immunity.
* IL-1P and TNF-a also increased the release of immune modulatory and immune
recruitment proteins including CCL2, CCL20, CXCL6, 1L-6 and M-CSF. IL-17B release
was increased with IL-IfP treatment and CCL-5 appeared elevated with TNF-a treatment.
* Potential catabolic proteins such as CTGF, pleiotrophin, and semaphorin 3C were also
elevated possibly suggesting tissue repair.
Future Work
Current experiments suggest some similarities and some differences between mechanical
compression injury and treatment with inflammatory cytokines, TNF-a and IL-1p. In addition,
previous work in the lab has indicated that combination of cytokines, IL-IfP and TNF-a, and
injury may have additive effects on decreases in synthesis and nitric oxide production and
synergistic effects with respect to sGAG release. These effects of the combination of treatments
will be further characterized by conducting a second systems level analysis using the iTRAQ-
LC/MS/MS approach of chapter three and comparing cytokine and injury in combination to each
cytokine alone. While these in vitro models cannot directly recapture in vivo effects ofjoint
injury, they provide information on the anabolic and catabolic changes that may occur in vivo
and may lead to greater understanding the disease.
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Appendix A.1 In-gel Digestion Protocol
1. Excision of protein bands from polyacrylamide gels
a. Wash gel 2 with ddH20 ten minutes each
b. Excise the band of interest. Cut as close to the protein band as possible to
reduce the amount of "background" gel. Cut into 1mm x 1mm cubesand
place in 0.65 ml tube (do not crush or clog pipet tips)
2. Washing gel pieces
a. Wash the gel pieces with -400 ul of water, 15 min.
b. Wash with water/MeCN 1:1, 15 min (vortex) (200 ul + 200 ul is a good
volume for all subsequent wash steps)
c. Remove liquid, add MeCN to cover gel pieces (vortex)
d. After pieces shrink and turn sticky white, remove MeCN
e. Rehydrate in 100 mM NH4HCO3 (AMBIC) (vortex) AMBIC =
ammonium bicarbonate
f. After 5 min, add equal volume of MeCN (to get 1:1 ratio) (vortex)
g. Incubate 15 minutes then remove solvent
h. Dry down in speed vac
3. Reduction and alkylation (200 ul is sufficient for TCEP and iodoacetamide steps)
a. Rehydrate in I mg/ml TCEP in 100 mM AMIBIC
b. Incubate at RT for 10 min (vortex)
c. Remove solvent, replace with same volume of 55 mM (10 mg/ml)
iodoacetamide in 100 mM AMBIC
d. Incubate 45 minutes at room temp in the dark
e. Remove solvent
f Wash with Ambic and MeCN as in step 2e.
g. All the Coomassie blue stain should be removed at this time. If residual
Coomassie still remains, repeat wash with AMIBIC/MeCN (1:1) until
removed
h. Gel pieces should be dried completely in speed vac
4. In-gel Digestion
a. Dilute 20 ug of Promega sequencing grade modified trypsin in 200 ul of
50 mM AMBIC (0.1 ug/ul) (trypsin solution)
b. Dilute trypsin solution 1:10 in 50 mM AMBIC (10 ng/ul trypsin solution)
c. Add 60 ul of 10 ng/ul trypsin solution to gel pieces and leave on ice for 1
hour.
d. Incubate at 37*C overnight
5. Extraction of Peptides (never let the supernatant go dry, just concentrate (-10 ul))
a. Add 20 ul of formic acid to gel pieces (this stops trypsin reaction)
b. Vortex 10 mins (sonicating 30 min is a very good idea instead of
vortexing).
c. Remove supematant and concentrate it in the speed vac
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d. The following steps are optional but may enhance peptide recovery
1. Add 200 ul 100 mM AMBIC, sonicate 30 min, and add
supernatant to the supernatant you are currently drying in the speed
vac
ii. Add 0.1% trifluroacetic acid (TFA) in water, sonicate, speed vac
supernatant (as in step i)
iii. Add 0.1% TFA in water/MeCN (1:1), sonicate, speedvac
supernatant (2 times)
6. Sample desalting
a. Use Millipore Reverse-Phase ZipTip
i. Follow instructions included with ZipTips, briefly
1. Wet tip with 0.1% TFA in 50% MeCN
2. Equilibrate with 0.1% TFA in water (5 x 10 ul)
3. Load sample onto tip (20 x 10 ul)
4. Wash with 0.1% TFA, 5% MeOH in water (5 x 10 ul)
5. Elute with 0.1% TFA in 50-60% MeCN (10 ul)
6. You may speed vac the desalted sample to concentrate but
don't dry
7. RP-LC/MS/MS
a. New Objective 75 um ID with 10 um tip capillary packed with Vydac C18
300A, 5 um particle size using a pressure bomb to ~I6cm.
b. Manual injector equipped with 0.5 ul loop
c. LC architecture
i. Tubing is 50 um with the exception of the split line after
connectors and should be -32 cm of 20 um tubing
ii. Flow rate is typically between 4-7 ul/min depending on column
(for a -250 nl/min flow through the column)
d. Buffer system:
i. Buffer A -- 1.2% Acetic Acid (v/v) in water
ii. Buffer B - 1.2% Acetic Acid in 90% ACN, 8.8% water (v/v/v)
e. LC Gradients for nano-LC/MS/MS (optimal approach)
1. 2% B to 40% B in 2-2.5 hours
ii. 40% to 60% in 10 minutes
iii. Hold at 60% for 10 minutes
iv. Re-equilibrate to 2% over -2 hours
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Appendix A.2 - Two-dimensional Gel Electrophoresis of cartilage medium samples.
Following the initial SDS-PAGE-LC/MS/MS profiling experiments and work, we
considered both iTRAQ and DIGE-2D-PAGE. Although we decided to pursue the
iTRAQ route in part because of the significant number of differences between the
samples, I did develop a reasonably reliable method to get two-dimensional gels for
comparison. In order to get clean 2D gels (spots and not smears), we performed
deglycosylation with three enzymes - Chondroitinase ABC, Keratanase II, and PNGase
F. This supplement will begin with a detailed working protocol for experiments
followed by some silver stained gels and some DIGE-2D-PAGE experiments done using
an imager being developed by Millenium Pharmaceuticals through Dr. Mustafa Unlu, a
former research scientist for CSBi. Dr. Unlu contributed to this work by teaching me
how to run 2D-PAGE, and Debby Pheasant assisted with putting together the 2D gel
protocol when we were learning together.
Medium samples were the result of a five-day treatment of 40-50 ml of cartilage in 2.0 ml
of medium with a 10% medium removal and 10% supplementation every 24 hours.
Deglycosylases: Chondroitinase ABC and Keratanase II were purchase from Seikagaku;
PNGase F was purchased from New England Biolabs
Proteasefree Chondroitinase ABC: 2U + 200 ul water - 5 ul aliquots at -80C
Keratanase 11: 0.1 U + 200 ul water - 5 ul aliquots at -80C
PNGase in glycerol: use 2.5 ul / 2.0 mls store in -20C
Sample dialysis and deglycosylation. Samples were deglycosylated in 7.5 kDa cutoff
dialysis cassette (Pierce) in a similar fashion to the SDS-PAGE protocol
Dialysis Buffer: 10 mM Tris Acetate pH 7.8, 80 mM Sodium Chloride, 3 mM EDTA
To a 2.0 ml aliquot of medium, 5 ul of Chondroitinase ABC and 5 ul Keratanase
II was added and the sample dialyzed for 12 hours. 2.5 ul PNGase F added followed by
further dialysis for another 12-24 hours. The dialysis was done at 37C in buffer in 100-
1000 fold excess during deglycosylation. The buffer was then changed to water for
another 2 x 12 hours in water at room temperature - it can be difficult to keep proteins in
solution as deglycosylation generally decreases protein solubility - transferring the
proteins to 4C may enhance chance of precipitates forming.
The pH of deglycosylation/dialysis buffer is near optimal for Chondroitinase ABC
(pH 8.0), but a bit far from the optimal pH for Keratanase II. However based on previous
experiments, this protocol was sufficient for deglycosylation (Chondrotin sulfate is likely
the largest sugar component in the sample).
Following dialysis in water, protein solutions were collected and dried by
speedvac. The dried samples were reconstituted in 75u of lysis buffer (see below for 2D
gel details).
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Before Getting Started: 2D gel BUFFER STOCKS
Stock Solutions Needed
1 MDTT
1 M Na HEPES, pH 8.5
x M Tris HCl, pH 6.8
10 % SDS (in ddH20)
87% glycerol stock
Lysis Buffer (Sample Buffer)
Recipe for 50 ml to be aliquotted and stored at -80C
6 M Urea 18.0 g
Make up to 40 ml with ddH20 and dissolve urea
2 M Thiourea 7.6 g
Dissolve mixture
10 mM DTT 500 ul of 1 M DTT stock
2% CHAPS 1.0 g
Dissolve
10 mM NaHEPES, pH 8.5 500 ul of 1 M HEPES stock
Add water to 50 ml. At this point keep it cold to prevent urea breakdown.
Aliquot into 1.0-1.5 ml aliquots and store at -80C
Rehydration Buffer
Recipe for 20 ml of Rehydration Buffer
6 M Urea 7.2 g
Make up to about 15 ml and dissolve urea
2 M Thiourea 3.0 g
Dissolve
2 mM Acetic Acid 2.7 ul Glacial Acetic Acid (17 M)
Add
1% ASB-14 or 2% Chaps (depending on protein mix)
(ASB- 14 is better for membrane proteins)
Add water to 20 ml
Reducing agent
2-4 mM Tributylphosphine 1:50 or 1:100 from 200 mM TBP (Biorad)
or
10 mM DTT
trace bromophenol blue
Store at 4C.
200 ul of 1M DTT stock
Add
1:200 IPG buffer (containing ampholytes) at are added just prior to use.
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Equilibration Buffer
Recipe for 100 ml Equilibration Buffer.
125 mM Tris HCl 25 ml Tris HCl stock, pH 6.8
1% SDS (2% if DIGE) 10 or 20 ml of 10% SDS stock
8.7% glycerol 10 ml 87% glycerol stock
Store at 4C or room temp
2-4 mM TBP is added to Equilibration Buffer to make Equilibration buffer 1,
2% lodoacetamide and trace of bromophenol blue is added to make
equilibration buffer 2. Add just prior to use.
ISOELECTRIC FOCUSING
Rehydrating strips
1. The Amersham strips are stored at -20*. Bring them to room temperature before
opening the package to prevent condensation from forming on them.
2. Immobiline DryStrips can be purchased from Amersham Biosciences (GE).
Either 11cm or 13cm Immobiline DryStrips can be used in conjunction with the
Criterion gel boxes. If you are using 13 cm strips, you will need to cut off the
plastic tabs on the edge. Most of protocol is based on 11/13 cm Immobiline
DryStrip 3-11 NL. If using other strips, it may be useful to check recommended
IPG buffer/ rehydration amounts.
3. Prepare Rehydration Buffer. For 11 cm strips, Combine 200 ul rehydration buffer
+ 1 ul of IPG buffer / strip; for 13 cm - 250 ul + 1.25 ul IPG buffer. For other
strip lengths, follow the manufacturer directions. Generally speaking, for the 3-11
NL (non-linear) add 0.5% IPG buffer (ampholytes) to rehydration buffer. Store
remaining opened IPG buffer at 4C; return unused rehydration buffer to 4C as
well. Add the Rehydration buffer to the rehydration tray spreading out the buffer
over most of the length of the IPG strip.
4. Level the preswelling tray, then add the appropriate volume of buffer to each lane
(200 ul for 11 cm strip), loading it all at one end. Remove the strip from its
package, noting that the gel is on the side whose writing you can't read. Flex the
strip slightly to release the thin protective plastic from the gel and remove that.
There is a 5 mm space at each end of the strip, which has no gel on it so it's safe
to grab the strip there. Lay the strip on the buffer gel-side down being careful
that no bubbles are trapped under the gel. Once the gel strip is placed on the
buffer, slide the strip back and forth to be sure that everything is evened out.
5. Close the lid on the preswelling tray and place it into a Ziploc bag containing two
wet paper towels. This will retard evaporation of the buffer. Seal the bag and
leave it on the bench overnight. Gels will swell to 0.5 mm thickness.
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Sample preparation
If you are using cup loading, you are limited to approximately 100 ul and 100 ug of
protein. If you need to go higher (with regards to protein amount or volume, consider
loading during the rehydration step).
1. Dry down 10-100 ug protein in a Speed-Vac overnight to remove volatile buffer
components.
2. Add IPG buffer (ampholytes) to LB at 2ul per 100 ul of LB just prior to
resuspending the samples. If you are DIGE dyes, do NOT add IPG buffer until
AFTER labeling sample.
3. Resuspend sample in 20-100 ul Lysis Buffer (LB).
Running the focusing
1. Level the Multiphor II. Clean the white tray and align it correctly on the electrode
plate. Add 108 ml light mineral oil over all 12 lanes even if only running a few.
2. Place the gel strips into the center lanes, gel side up. Put the + end at the top with
the end of the plastic just below the center hole in the tray. Be sure strip is
centered within the lane and completely covered with oil. Center strips between
indentation within the well.
3. Pre-wet the wicks on a plastic surface using 150 ul high-quality water/wick. Use
two wicks per gel strip. (The wicks prevent salts and excess proteins from
reaching the electrodes as well as providing enough water to prevent
electroendosmosis.)
4. At the top of the strip, place the wick so that it touches the feet of the cup, and at
the bottom, place it so that it is over some of the gel. Place the wicks at both ends
of the gel such that the wick contacts the end of the gel. Submerge the wick the
wicks in the mineral oil. The wicks should cover the + signs at the anode.
5. Place the sample cups over the gel (on the + side of the gel) just in contact with
the wicks.
6. Load sample (>20ul and <100ul) in each cup, placing the pipette tip under the
surface of the oil as you deliver sample.
7. Place the top electrode with diagonal lines toward you so that it contacts both the
wicks and the gold cathode plate at the outside edges. Snap it into place with the
knobs at the sides. Place the bottom electrode similarly, having it contact the
anode plate.
8. Close the lid and enter your protocol. A sample protocol (for 11 cm 3-11 NL
strips) is shown below:
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a. No rehydration time (since that was already done)
b. Temp. to 20*C and current to 50 uA per strip
c. Step, 500 V, 2 hour (goes to 500 V immediately)
d. Grad, 1000 V, 2 hour (ramps up to 1000 V over 1 hour)
e. Grad, 6000 V, 2 hours
f. Step, 6000 V, 30 min
13 cm can be taken to 8000 V and held for 30 min. See accompanying Immobiline
Drystrip booklet (comes with the gels) for more protocol information.
9. Press Edit and give the file a name.
10. To begin the focusing run, hit Start twice. At 500 V, you should see some
number of uA which means that current is moving through the gel. Seeing 0 uA
would indicate trouble - you are not making a connection - go back and make
sure that salt bridges/ wicks are contacting gels and electrode for example. Note
that while you are running in voltage controlled setting, the machine limits the
current to 50 uA, so you may be current limited at least initially in runs. As
focusing progresses, the uA should go down allowing voltage to go up. If current
only allows a very small voltage, that would indicate that your samples have too
much salt in them. Next time desalt sample. If you desperately need this data,
consider changing salt bridges possibly repeatedly to pull salt out of system.
Ideally, everything should be fine and you should be able to approach if not reach
the upper voltage limit.
11. Toward the end of the run, prepare two Equilibration Buffers, 7 ml each for each
strip. Make one batch with DTT and one with iodoacetamide.
12. When the run is over, record the total Vh before turning off the machine.
13. Pull each strip out of the oil and blot excess oil off the back of it onto a paper
towel. Curl the strip around the inside edge of a small Petri dish, gel side in. Add
7 ml of the DTT containing equilibration buffer and shake gently at RT for 15
mm.
14. Pour out the DTT -equilibration buffer and rinse the gel strip briefly with water to
remove the DTT. Add 7 ml of the equilibration buffer containing 2%
iodoacetamide and shake gently at RT for 15 min. At this point, the gel strip
could be frozen at -80* for running later.
15. Meanwhile, set up the 2 "d dimension SDS gel and rinse its top surface off with
water. All experiments were performed on Criterion pre-cast Tris-HCl gel second
dimensions which allowed the use of 11 or 13 cm strips (BioRad). Add the gel
strip into the slot with the + end at the left. Orient the strip so that its plastic is
against the back wall of the slot and the gel is facing forward into the air. Be sure
the strip is in contact with the top of the SDS gel down its entire length - it is
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important to avoid air bubbles! Add molten agarose (with bromphenol blue and
0.1% SDS) to just cover the gel on the strip and remove any bubbles, which might
occur. Label the face plate of the SDS gel with the sample name.
16. Run the 2 nd dimension gel at 20 mA/gel for approximately 3 hours and stain with
Coomassie blue or Silver Stain.
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Appendix B.1 Additional Cytokine + L-NMA experiments
The purpose of Figure B.1.1 is to determine whether addition of L-NMA altered collagen
degradation. Medium from five day experiment was partially deglycosylated as
described in the methods of chapter 2, and it was then subjected to Western blotting for
collagen using a monoclonal antibody specific for collagen type II (Neomarkers).
Figure B.1.1
Figure B.1.1: Western Blot of collagen type II (arrow indicates C-terminal fibril
fragment while upper band is indicative of full-length collagen
Based on this blot, there is little or no additional collagen degradation with cytokine
treatment and no effect with L-NMA. This is consistent with the literature in that
collagen degradation occurs after aggrecan release.
Because differences in fibronectin release were seen with injury, we also decided to look
at the effects of cytokine treatment on fibronectin. Figure B.1.2 is a Western blot
probing for fibronectin and fibronectin breakdown and indicates the cytokine treatment
causes and increase in fibronectin release and in fibronectin breakdown
Fivnre R.1.2
IL-1 IL-1 TNF TNF CON CON MW
NMA NMA NMA
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Appendix B.2: Additional Cytokine + injury experiments and Data
To determine the overall nitric oxide (NO) production for the experiment, NO end
product, nitrite, was measured on the five-day medium. Based on previous cytokine data,
nitrite should represent about 50% of the total nitric oxide end products. Figure B.2.1 is
a graph of the nitric oxide production with cytokine, TNF-a and IL-10, treatment and
mechanical injury plotted as mean +/- SEM for 2-3 sets of explants per animal from five
animals respectively.
Figure B.2.1
Cytokine (TNF-a and IL-Ib) and Mechanical Injury
Induced Nitric Oxide Production (five day
accumulation of Nitrite)
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Cytokine treatment alone but not injury alone is sufficient to elevate nitric oxide
production 3-5 fold over control (p<0.01; Student's t-test with Bonferromi correction for
multiple comparisons). The combination of injury with TNF-a led to an elevation of
nitric oxide production above that of the TNF-a treated alone while IL-lIP in combination
with injury decreased nitric oxide compared to IL-1 IP alone.
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To monitor the effects of the cytokine and injury treatments in these studies,
sGAG loss was also monitored using the medium collected every 24 hours for each set of
explants over the five day time course. Figure B.2.2 describes the effects of IL-1P and
TNF-a in combination with injury on sGAG release over the five-day time course. Data
is represented as mean +/- SEM for five (TNF-a), six (IL-ip), or 11 (injury and control)
animals with 2-3 sets of 4 explants per animal. The double asterisks indicate a
significant difference between TNF-a and TNF-a plus injury at all times points except
24 hours (p<0.01; Student's t-Test with Bonferroni correction for multiple comparisons)
while the single asterisk indicates differences compared to control (p<0.01; Student's t-
test with Bonferroni correction for multiple comparisons). Mechanical compression
injury showed a small, but significant increase in sGAG loss to the medium at the 24
hour time point (p<0.05). No difference was seen between IL-lp and IL-lp plus injury
(p >0.5 at all points).
Figure B.2.2
sGAG release to medium in response to injurious
mechanical compression and cytokine (IL-1p and TNF
cl) treatment
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In addition, a dramatic increase in sGAG release with TNF-a in combination with
injury compared to TNF-a alone; however, the synergy was not seen with IL- IP in
combination with injury. While no signaling differences have been delineated between
IL-1P and IL-la, this is one possible explanation for the differences. While the effects of
IL-1 in combination with injury were not significant, the effects of TNF-c in
combination with injury caused a large and significant increase in sGAG release to the
medium compared to TNF-a alone.
-219-
The differences nitric oxide and sGAG release in IL-lp and TNF-a response in
combination with injury represent additional differences between the effects of these
cytokines. Nitric oxide product differences mirror the sGAG release for TNF-a and
TNF-a with injury in which sGAG release is elevated with nitric oxide production. In
the cytokine-NMA study described in Chapter 2, nitric oxide seems to stimulate sGAG
loss with TNF-a treatment as indicated by a decrease in sGAG loss with L-NMA. The
data above in combination with the cytokine-NMA study of chapter 2 beg the question
of whether the increase in sGAG production seen with injury is driving the increase in
sGAG release. In addition, the TNF-c-induced increase in sGAG release with nitric
oxide is the exact opposite effect as that seen with IL-1p and TNF-a in combination. In
the above data, a decrease in nitric oxide was seen with IL-Ip in combination with injury
relative to IL-l p alone. This is accompanied by very little change in sGAG release with
IL- Ip and injury in combination. At the very least, this data further supports the different
mechanism by which IL-Ip and TNF-a alter cell behavior and the use nitric oxide as a
signaling molecule.
Further characterizations of the cytokine-injury experiments were performed by
measuring 3H-proline and 35S-sulfate incorporation on the day six following the five-day
treatment. While this incorporation rate may be artificially decreased with cytokine
treatment due to an increase in transport, radiolabel incorporation provides an estimate of
biosynthesis rates for the tissue. Figure B.2.3 is the radiolabel incorporation data for day
six following the five-day treatment. The data is represented as mean +1- SEM for five or
six different animals and 2-3 explant sets per animal.
Figure B.2.3
Biosynthesis: Sulfate and Proline Incorporation
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The asterisks represent a significant decrease in incorporation rate relative to the control
(p<0.01 for all treatments by Student's t-Test with Bonferroni correction for multiple
comparisons). The '+' indicates a significant decrease in incorporation rates in the
combination treatment relative to cytokine treatment alone or injury alone (p<0.01;
Student's t-Test with correction for multiple comparisons).
To determine changes in MMP activity in the medium, zymograms were
performed of the medium. Figures B.2.4 are representative zymograms from five-day
accumulated medium. Figure B.2.4a is a gelatin zymogram with treatment conditions
labeled below. The lower doublet represents MMP-2 and is found in all conditions while
the upper band is likely indicative of MMP-9 activity, which is more pronounced with
TNF-a and TNF-a and injury combination treatment though increased with injury as
well. Figure B.2.4b is a casein zymogram showing MIP-3 activity, which is weak in
all samples although small amounts of activity may be seen with TNF-a, injury, and
TNF-a and injury combination treatment.
Figure B.2.4
injury TNF+inj TNF-a control std
std control TNF-a TNF+inj injury
Figure B.2.5 is a casein zymogram of the five day accumulated medium from an
il-I-injury experiment. MMP-3 activity is increased most dramatically with IL-1P
treatment, no additional increase is seen with IIL-1P and injury in combination, and very
little activity is seen with injury in comparison.
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Figure B.2.5
injury IL-1p+inj IL-1f control std
Because changes in mechanical properties with injury suggest damage to the
collagen framework, we probed collagen type II fragments in the medium by Western
blot to determine whether the damage is accompanied by collagen degradation. Figures
B.2.6 are collagen western blots of medium from cytokine-injury experiments. In both
blots, a -30 kDa band can be seen with all treatments; however it is more pronounced
with injury with not additional increase in intensity with injury and cytokine in
combination. Based on the size of the fragment, this band may correspond to the
collagenase cleavage fragment, which is shown in the blot on the right. These findings
are similar to those of Thibault et al. [JOR, 2002] and Chen et al., [JOR, 2003] and the
increase in potential collagenase cleavage fragment likely results from mechanical
denaturation of the collagen fibril with secondary collagenase (MMP) cleavage.
Figures B.2.6
26 3kD
COL2+MMP13 COL2 COL1 Injury lNJ+ILIb IL-10 control
430 kD
injury hj+TNF TNF- control
To look at global differences in the proteins released into the medium, we performed
SDS-PAGE with silver staining. Figure B.2.7 is a silver-stained gel of IL-lb-injury
treatment in duplicate with one set at 100 ul and the other at 250 ul.
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Figure B.2.7
Std con ill iI-inj inj std con ill if-inj inj
A number of differences can be readily seen between conditions by SDS-PAGE. iTRAQ
based analysis of medium from IL-1-injury and TNF-injury experiments are currently
underway and may begin to explain some of these differences. The conditions across the
bottom of the gel are as follows: std- MW standard; Con - control; ill - IL-1p; il-inj -
IL-Ip and injury; inj - injury.
Additional survey experiments and results include an anti-actin blot of medium
from a TNF-a-injury experiment. Approximately 100 ul of medium from each condition
(untreated, tnf-a, tnf-a+injury, and injury) was probed for by anti-actin antibody (Figure
B.2.8). This blot was only done with medium from one experiment, so conclusions
would be premature. However, this result is worth at least verifying as it may imply that
TNF-a treatment may alter amount of actin release or at least the proteolytic degradation
of actin that has been released. This result may make more sense when the iTRAQ
experiment is complete. It may also be worthwhile to repeat this experiment to verify its
reproducibility. This blot is being included because it may provide insight into
experiments currently being performed.
Figure B.2.8
Injury tnf+inj tnf-a control std
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The aggrecan GI blot from a TNF-injury experiment also only performed once however
it is worth at least noting the effects of the combination treatment on G1 fragments in the
medium (Figure B.2.9).
Inj t-inj tnf cont std
Aggrecan G1- Blot: Inj-injury, t-inj-TNF-a + injury, tnf-TNF-a, cont- control, std--
standard
The aggrecan GI -immunoblot above was performed as an sGAG controlled
experiment - equal volumes of sGAG are loaded per condition. TNF-a and TNF-a with
injury both have a sharp band around 75 kDa, which may represent the aggrecanase
cleavage fragments of G1. A small increase is seen with injury compared to untreated
samples. This suggests that TNF-x and injury in combination cause a greater increase in
aggrecan GI fragments then TNF-a, which is greater than injury, which is greater than
the untreated. If all G1 fragments are identified with equal intensity, then it seems that
there is more G1 released per sGAG with injury and control than there is with TNF-a
treatment or with TNF-a and injury together. This is consistent with the iTRAQ results
for aggrecan release by globular domain with cytokine treatment.
Because we recognized the possibility that a number of other MMPs in addition to
MMP-3 could contribute to the clearing by casein gel zymography, we wished to verify
the MMIP-3 activity. Thus, below is an MMP-3 immunoblot for the IL-1-injury
experiment (Figure B.2.10). We chose the IL-1p experiment because IL-1p causes a
significant increase in MMP-3. I believe this was 100-150 ul of medium. This result
confirms MMP-3 protein expression with injury. The effects of injury in combination
with IL- IP appear limited.
Figure B.2.10
Inj il-inj ill cont std
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Finally, a blot for MMP-9 was done to confirm its presence with TNF-a and with
injury. The MMP-9 antibody did cross-react with MMP-2; however it did give a band at
around 90 kDa that corresponds in appropriate intensity with the gelatin zymograms
suggesting that is able to detect MMP-9 (Figure B.2. 11).
Figure B.2.11
: con TNF T+I inj M1M9P-2
Ant-MMP-9 Blot - Std: standard, con: control (untreated), TNF: TNF-a, T+I: TNF-a
and injury, inj: injury, MMP-2: matrix metalloproteinase 2
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Appendix B.3: 2D-PAGE results.
Below are some representative 2D PAGE results from various medium types.
Figure B.3.1 is a 2D-PAGE gel of untreated medium in 4-15% second dimension
gradient gel stained with Silver Snap 2 silver stain (Pierce); The streaking is likely due to
insufficient deglycosylation and desalting as this represents one of the first gels with only
chondroitinase ABC and Keratanase II used at low concentration. All subsequent gels
will be 8-16% second dimension gels. Note that the anode is on the left and the cathode
is on the right - gel dimensions are approximately 14 cm x 7-8 cms.
Similar to the Figure B.3.1 above, Figure B.3.2a-b is a picture of a 2D-PAGE gel of
NMA only treated sample deglycosylated as described above, run out on an 8-16% gel
and silver-stained. (Control-NMA sample should be similar to the control only; however
the control-NMA was used because more medium samples were available).
Figure B.3.2a
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Figure B.3.2 is a silver-stained gel with an 8-16% second dimension of medium from
IL1P and TNF-a combination treatment. This represents the most complicated of the
samples that were run with respect to the number of spots observed on the gel.
Fivure B.3.2b
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Once the method was sufficiently developed and verified, some DIGE labeling was used
to compare IL-I medium samples to I-1 and NMA medium samples as well as untreated
samples with NMA only samples. Figure B.3.3 is a set of gels comparisons of IL-I and
untreated with or without NMA. Some spots were picked, but this project was not
followed up on.
While the DIGE method with the described work-up is capable of providing
reproducible results, the sample complexity makes this method very labor intensive
because identification takes place at the mass spectrometry level and in-gel digestion of
each spot is necessary for peptide-based protein identification. In addition, most software
attempts to normalize based on the assumption that you are always comparing equal
amounts of protein - this represents an equal volume experiment, and it may be
somewhat difficult to normalize based an internal standard. The DIGE method is ideal
for a set of experiments in which the differences expected are small and the samples are
protein controlled. The lab doing the experiments should have access to appropriate
imaging and spot-picking technologies, and automated in-gel digestion machinery as well
as a MALDI interface may provide further benefit.
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Appendix BA: iTRAQ Supplemental Information and Data analysis
Because the samples represent proteins released into an equal volume of medium
from an equal volume of cartilage, protein amounts were expected to be and known to be
different. In addition, the sample work-up was somewhat lengthier and more
complicated than many, and thus, it may represent a source of error prior to sample
labeling and analysis. Therefore, it was not prudent to accept ProQuant sample
normalization or to assume no normalization at all. Thus, we chose to use the
deglycosylase, chondrotinase ABC, as the internal standard which was added in equal
amounts at the beginning of sample work-up. Table B.4.1 provides data on the
chondrotinase ABC standard and the mean ratio values which were used for correction.
Correction was performed simply by dividing each protein's iTRAQ signature ion ratios
by the mean chondroitinase ABC signature ion ratios. Figures B.4.1 a-f are the
histograms for the chondroitinase ABC peptides for each of the signature ion ratios and
for the analytical duplicates. While a more sophisticated normalization approach may
have been use, this normalization was sufficient to correct the data such that the ratios for
the first analytical experiment and the second analytical experiment were within 20%,
which is small compared to most differences seen in this experiment.
Table B.4.1
Expt Peptides 115:114 115 SD 116:114 116 SD 117:114 117 SD Normal
Itraql 65 1.29 1.30 0.995 1.22 1.23 1.19 Yes (3)
Itraq2 55 2.43 1.76 2.81 2.14 2.26 1.68 Yes(1)
Itraq2 median 115 - 2.21; Median 116 - 2.55; Median 117 - 2.15
Itraql median 115 - 1.28; Median 116 - 0.9716; Median 117 - 1.2349
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Figure B.4.1a-f
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Histograms of Chondroitinase ABC peptides in logz space. Figure B.4.1 is a set of histograms representing the
ratio values for the Chondroitinase ABC peptides in log 2 space. The top panel represents data from the first
experiment and the bottom panel the data from the second experiment. The peptide distributions for the first
duplicate experiment due pass Lilliefor's test for normality while only the 117: 114 ratio experiment 2 qualifies.
The mean values were used as correction factors in this experiment, and this may account for up to a 10% error
based on the mean to median difference. The statistics for the ratio corrections are given in Table I above.
Because the samples being compared in this experiment represent samples which
vary in amount of protein (by a factor of 2), in post-translational modifications
(particularly glycosylation and proteolysis), and in proteins present (ratios from 0.1 to
100), understanding the limits of quantitation and reproducibility is key to interpreting
the data. Thus, we chose to take a systematic look at the protein level quantitation
reproducibility in a number of placing starting with reproducibility between inj ections. A
number of the SCX fractions were sufficiently complex that we chose to inject them in
duplicate to increase coverage of proteins present in the sample. This data on duplicate
injections provided sufficient data to look at interinjection variance as a source of error in
the data. Approximately 20 fractions were subjected to duplicate injection, so the data
was divided into first injection files and second injection files, and the data was subjected
to the treatment described in the data analysis section. Briefly, all spectra with no
quantitation or with uninterpretable quantitation (0 or 9999) and with an identification
confidence less than 90 were removed. Redundant spectra were averaged to generate a
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non-redundant peptide list which was then averaged to generate a final protein list. Using
protein accession number, the protein list from the first injection and the second injection
were compared as the ratio of the first injection mean isotope ratio to the second injection
mean isotope ratio.
To generate symmetry for values greater than one and values less than one, the
data were log transformed. Thus, if the data matched perfectly, log transformed ratios
would all equal 0, and since the data are prone to a number of small error sources, we can
expect a normal distribution with a mean of 0 and the variance would provide a
numerical estimate of the reproducibility between injections. Duplicate analysis of the
same set of SCX samples led to the identification of an addition 72 proteins with a score
greater than 3. Figures B.4.2 are the histograms for the first and second injection
datasets for the first analytical duplicate. The data represent 316 proteins with an
original ProQuant score of 3 or higher in both datasets. The data generally appear to be
normally distributed with the 116:114 and 117:114 ratios looking slightly offset from
zero with a mean of -0. 1416 and -0.1936 respectively which represent as much as a 15%
error. The variance was larger than expected with a standard deviation of approximately
0.4 for all ratios indicating that 95% of the data fall between ratio of 0.6 and 1.7. In this
experiment, the geometric mean of each treated to untreated ratio is 2 or greater, so while
this error must be dealt with appropriately, the error is unlikely to impact the results from
this experiment.
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Figure B.4.2 Interinjection variation in quantitation at a protein leveL Figure 2 are the histograms
for the three signature ion ratios (m/z 115:114 (a), m/z 116:114 (b), m/z 117:114(c)). The distributions
generally appear normal with mean +/- SD for each isotope ratio are -0.0504 +/-0.4208, -0.1416+/-
0.3874, -0.1973 +/- 0.3997 for the 115:114, 116:114, and 117:114 ratios respectively. The slight shift
in mean and slightly large standard deviation may be in part due to proteins with one or more large
ratios. This data represents 316 proteins with original ProQuant scores of greater than 3 in both
datasets
At the same time, understanding the source of the error might aid in the
experimental interpretations. Thus, one possible explanation for the interinjection
variance is that many of the ratios were much larger than one, so quantitation may be
limited by the dynamic range of the detector. To get a better feel for the impact of large
ratios on the variance of the data, we decided to look only at those proteins in which all
ratios were less than 10 and then all ratios that had means up to 50 which is likely outside
the dynamic range of the mass spectrometer detector. Figure B.4.3 is a plot of the mean
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ratio of dataset 1 versus the log2(ratiol/ratio2) with Figure B.4.3a representing only
proteins with all ratios less than 10 and Figure B.4.3b representing all proteins with
ratios less than 50. If the large ratio values were a cause of error, the data spread for the
10g2 (ratiol/ratio2) would appear to widen out as mean ratio values became increasingly
large. This is seen to some extent in both figure B.4.3A and B.4.3B. To provide further
support for the additional error associated with large ratios, we computed the average and
variance based on the ratio size. When only proteins with all ratios between 0.25 and 4
were included, the standard deviation dropped to between 0.2 and 0.25 which is
consistent with previous reports. When proteins with ratios between 0.1 and 10 were
included, then the variance increased to between 0.30 and 0.35, and then to around 0.40
when all proteins were included. While large ratios (meaning one or more than one
signature ion peak is greater than the other ones) are unlikely the cause of all
interinjection error, it appears that large ratio values may contribute some to the variation
seen between injections. This effect of large ratios likely results from the limited
dynamic range of the detector compared to the range of the proteins within the sample.
All interinjection variation analyses were done prior to normalization of chondroitinase
ABC internal standard.
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Figure R4.3 the effects of the ratio mean on the reproducibility between experiments.
Figure 3 is a plot log2(ratiol/ratio2) values obtained in figure 2 versus the sample 1 ratio for
each protein and signature ion ratio. There is some additional spreading of the data with larger
ratios, so the effects of large ratios on quantitation is one source contributing to interinjection
variation.
Analytical Variation
The analytical duplicates are susceptible to variation, which includes inter-
injection variation as well as errors from sample collection and work-up not corrected by
the chondroitinase ABC, and errors associated with the use of an internal standard
(pipeting error of standard, inappropriate normalization method). Thus, a similar
approach is taken to the chondrotinase ABC normalized data. Quantitaton data for all
proteins with an original ProQuant score greater than 2 were used for comparison.
Figure B.4.4a-c are the histograms displaying the distributions of the log2(ratiol/ratio2)
values this time comparing the first analytical duplicate (ratiol) and the second analytical
duplicate (ratio2) for each of the signature ion ratios. Again, the data is expected to be
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normally distributed centered at zero with a variance being small compared to the
average ratio value. As seen with the inter-injection variation, a slight shift from zero is
noted with the mean +/- SD for the 115:114, 116:114and 117:114 of 0.0346+/-0.4861,
0.2364 +/- 0.5505, 0.1327 +/- 0.5139. The shift in the mean suggests as much as a 20%
error and is similar to that seen with the interinjection variation. This shift may be
properly attributed to an error in internal standard normalization; however this shift is
similar to that seen with the intrasample variation which cannot be explained by this.
Because this shift is small compared to the differences seen in this data, we will consider
this error when making conclusion about the data. Finally, the standard deviations are
slightly larger (as much as ~0. 15) than those seen with the interinjection variation which
should be expected unless unless the mass spectrometer is the greatest source of error in
the measurement. Thus, this additional error may be the result improper normalization,
variation in extent of deglycosylation, trypsinization, or labeling which are not
completely accounted for with normalization used. In addition, false identifications may
account for some of the error in quantitations as we are expecting a false identification
rate of approximately 3% at a peptide level. One additional source of error for the
116:114 ratios may be error in the signature ion quantitation due to interference of an ion
intensity occasionally seen around m/z 116.06; this error is usually not seen with the
other isotope ratios, and it is likely to be a error that should be consistent throughout the
experiment.
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Figure B.4.4: Comparison of analytical duplicates. Figure 4a-c are frequency plots of
log2(ratio /ratio2) for each signature ion ratio (115:114 (a), 116:114 (b), 117:114 (c)). The mean
SID for each ratio are as follows - 115:114 0.0346 +/- 0.4861, 16:114 0.2361 +/-. 0 .1327
0.5130.
However, a closer look again at large ratios as well as identification certainty was
made. First, as before Figure B.4.5 is a plot of the log2(ratiol/ratio2) versus the mean
ratio 1 values to determine whether the variance again showed some dependence on ratio.
While it is likely that most of this type of variance is accounted for in the interinj ection
variation, the large correction values for the second duplicate may contribute to some
additional variance. Again, there does appear to be some contribution of ratio size to the
variance; however, it does not appear to be the only cause of variance in the data.
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Figure R4.5: The effects of large ratios on analytical variation. Figure 5 is a set of plots of the
log2 (ratiolIlratio2) versus the mean ratio 1 for all proteins with ratios less than 10 (a) and less than 50 (b). 'x'
represents 115: 114 ratios; 4'represents 1 16: 114 ratios; and '*' represents 117: 114 ratios.
Another important source of variance is false protein identifications or
quantitation outliers which will be most pronounced in proteins with very little peptide
data. In the case of false identifications, the variance should decrease if the criteria for
protein identification were increased. Thus, we chose to compare the distributions
generated from data with 2 or more peptides, 3 or more peptides, or 4 or more peptides.
If poor identification is the problem, we would expect the variance to decrease as more
peptides were required for identification (and thus more peptides used for quantitation
which would decrease the effect of a single outlier). Table 2 displays the mean and
standard deviation data from comparing log2 (ratiol/ratio2) the two analytical duplicates
including proteins identified by 2 peptides or more, 3 peptides or more, or 4 peptides or
more. The change in variance ranged from 0.06 to 0.09 when increasing identification
criteria from 2 peptides to 3 peptides. This suggests that false identifications or outliers
in quantitation may account for roughly /2 the increase in variance seen between the
interinjection variance and the analytical duplicate variances. The effects of false
identification/false quantitation also appear to mask the initial effects of the large ratios in
analytical variation. The impact of large ratios becomes more clear once the data from
less than 2 or 3 peptides has been removed (contributes again between 0.06 and 0.09 or
so to the variation). It appears that poor protein identification and large ratios may both
contribute to the variance in comparing both analytical duplicates.
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Identification Mean SD Mean SD Mean SD
cutoff 115:114 115:114 116:114 116:114 117:114 117:114
2 peptides 0.0346 0.4861 0.2364 0.5506 0.1327 0.5130
3 peptides 0.0538 0.4266 0.2435 0.4833 0.1237 0.4207
4 peptides 0.0647 0.4233 0.2609 0.4642 0.1268 0.3958
Table R4.2: Contributions of false identifications or outliers in quantitation. Table 2 provides the mean
and standard deviation (of log2 transformed data) for the log2 (ratio l/ratio2) comparison between the first and
second analytical duplicates. The variance appears to decrease substantially when increasing the identification
criteria from 2 peptides to three peptides suggesting that false identifications may be contributing to the
analytical variance comparing the analytical duplicates.
The analysis above suggests that secondary verification of protein identification
and possibly peptide identification as well as manual validation may be important for
data in which the quantitation is based on only 2 or 3 peptides. Thus, all data will be
verified by Spectrum Mill, and at least one peptide per protein will be manually validated
to improve accuracy of the data. In addition, for proteins identified and quantified by
four or fewer peptides, all spectra will be verified manually. Errors caused by large ratios
(one or a couple signature ions much larger than the others) may alter interpretation of all
the ratios for that protein. Thus, we anticipate we can decrease the overall error in the
experiment through manual validation and secondary validation of the data; however
large ratios will have larger intrinsic errors.
Comparison of Matlab Scripts to ProQuant and ProGroup Protein Summary
As a means of verifying our chosen quantitation method, we compared our results
to those of ProQuant and ProGroup protein report. Figure B.4.6 is the histograms for
each of the signature ion ratios. The mean +/- SD for each ratio are as follows - 115:114:
0.0752+/- 0.4505, 116:114: 0.1440 +/- 0.4450, 117:114: 0.1791 +/- 0.6012. While some
differences in the data were noted, the consistency (both data sets in agreement about
whether the value is above or below 1) was approximately 92%. These values seem
reasonable given the slightly different approaches to the data. (Also ProQuant protein
summary is based on a 20% confidence limit, so there may be more intrinsic error due to
false identification of peptides.
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Figure B.4.6: Comparison of Matlab scripts to ProGroup Protein Summary.
Figure 6a-c are histograms of the log2(ratio l/ratio2) as a measure of error for each of
the signature ion ratios.
The ProGroup protein summary from the first and second analytical duplicate was
also compared as described above. Figure B.4.7 is a set of histograms representing the
signature ion ratios. The mean +/- SD for each of the curves were 115:114, 0.0362 +/-
0.5787; 116:114, 0.1926 +/- 0.6705; 117:114, 0.1383+/-0.5552. Overall, there is not a
dramatic difference between the output of the Matlab scripts and the ProGroup protein
summary with the exception of a slight decrease in the variance seen with the Matlab
scripts. Similar to that found with the Matlab scripts, the data was approximately 90%
consistent in the outcomes.
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Figure B.4.7: ProGroup protein summary comparison for the analytical duplicates. Figure
7a-c are the histograms for the three signature ion ratios used for quantitation, 115: 114 (a),
116: 114 (b), 117: 114 (c).
Appendix C.1: Protein List from SDS-PAGE-LC/MS/MS with
Spectrum Mill (Agilent) identification
Table C. 1 on the following page provide information on proteins identified from the
SDS-LC-MS/MS analysis by Spectrum Mill Proteomics Software (Agilent). Table I
provides information that was used for the samples comparisons made in Chapter 3.
Column 1: untreated (control):
Row 1: Number of spectra
Row 2: Summed peptide ion intensity for each protein
Column 2: IL-1
Row 1:
Row 2:
Column 3: TNF-a
Row 1:
Row 2:
Column 4: Injury
Number of spectra
Summed peptide ion intensity for each protein
Number of spectra
Summed peptide ion intensity for each protein
Row 1: Number of spectra
Row 2: Summed peptide ion intensity
Protein MW: Protein molecular weight (kDa)
Protein p1: Protein isoelectric point
Species: Animal species of matched protein sequences
Accession: Database accession number
% coverage: The percent coverage of protein
Peptides: Number of peptide identified
Score: Summed score based on peak ions matched and uniqueness
Protein name: Name of protein identified
Function: Categorical function of protein identified
Location: Normal location of protein identified
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GAsEt04 324e.04 SA4aa04 $24E404 19334. familians 243.45
0 a e 0 Bos extracellular matrix protein i isoform I precursor isoform i ECM structure ECM
000.0000 sA2E+0 00E4 00E. 0 63427.9 6.5 taurus .QQ .g 13 241.3 30
11 0 1 1e Bo Transforming growth factor-beta induced protein IG-13 pr cell matrix interactions ECM
4A.E+04 0E400 428E+04 8nE44 81444.6 6.36 taunt 15 239.5 Up
1 0 0 24 -o actinin, alpha 4 isoform 11 cytoskeleton cytoplasm
iuE 02 500E+00 0.0E+00 I teIOsE 108355.6 5.29 tauru 7 14 233.4 40
a 1 0 BO glucose regulated protein 58kD PDI ER
ouse1100 ejis + tOtso tAs0 o 58929 ___82 tauru 14 224.E _.
t 63 4 25 BOS serine (or cysteine) proteinase inhibitor, clade G (Cl inhibite protease inihibitor (complemei secreted
7AU.04 sass+0s usises a.1e"D 517235 8.19 taurus 12 215.7' A2
2 4 12 3r Bos vimentin cytoskeleton cytoplasm
1.716e03 0me+04 e.1se04 4.0s00 53877.1 5.21 taurus 14 214.6 43
0 0 a 0 Homo KRT13 protein contaminant - cytoskeletal cytoplasm
0.0E1+00 nOE+00 G-ra06 0AWE.00 51061.3 4.95 sapies 7 6 13 213.4 44
0 4 2 3Bo LOC612571 protein metabolism cytoplasm
0.00E00 32E04 2.E+03 2 ASE40s 81428 8.62 tauns 7358728 31 14 21 45
28 38 so Bos keratin 4 isofonn 9 contaminant - cytoskeletal cytoplasm
122E+0 4.16E40s 0.2E+06 110331_5 54 taunjt 7 _ 13 211.8_ 48
39 Fibromodulin ECM structure ECM
430379 5.5 taurus 10 211.5 A1
12 t1 2 w os Lumican ECM structure ECM
1flnE+ 401E+0 2.9104 sAe0oE 38758.2 5.9 taurus 1 12 211.2 4j
39 24 24 3 -90-S PIS protein PME
3,01&0_ 601004 4.130.00+O 404800 23743. 9.33 taunts 7428832A 49 1 205." 50 ________________________ ___________ ________
0 1 7 6BgCollagen alpha I(IX) chain precursor, partial ECM structure ECM
3A39+0t $3e+" 1.02E05 0.22M3e 99493 8.75 taunts 7 1 201.32 a ____________________
t2 ts o u Boo Collagen, type 1, alpha I ECM structure ECM
1231E00 1 B10.Oe 4.16E004 50E4CA 139939.2 5.81 taunt, 75750 11 103.72 .Jj ______________________
o 1 Bo Melanotransferrin precursor (CD228 antigen) transport membrane
3.09+04 770E00 473E04 2204 80694.8 5.53 tauru 78gC7g5 12 188.96 U)
0 2 1 a B UDP-glucose pyrophosphorytase 2 metabolism cytoplasm
. 4E4E00a .2Xaoo a1eoos 56903.5 7.6 tauru 43678 27 12 188.87 54
14 7 2- B serine (or cysteine) proteinase inhibitor, clade A (alpha-lant protease Inhibitor secreted
12000 1346+05 U111041 421es05 46104.2 6.0! tauru 1 W 12 187.67 *50 1 0 12 Bos cytoskeleton-associated protein 4 cytoskeleton cytoplasm
0.00E+00 4ME+03 0 .00E+00 2oE+0s 80352.5 6.36 taunus 76619051 20 11 181.65 56
01 27 41 a os cytokeratin Vib contaminant? - cytoskeleton cytoplasm
1,1E+05 321E+9% 4J4e+06 G0e4 54848.5 5.0 taurus d Q 11 180.6 57
t2 10 28 32 Mmecan precursor (Osteoglycin) osteoinductive factor ECM structure ECM
9.245+04 120E50 157E00s 2ABE0s 34209.7 5.43 BOVIN 12 37 10 176.6 j*
2 5 a U Bos annexin 5 cell matrix interactions membrane
1obo lo" 0.72e03 120*000 36089 4.8 tauru _ 6 10 173.02 ___
a 1 e 11 os Triosephosphate isomerase metabolism cytoplasm
0.00S00 2A1902 s4004 220E400 26689.6 6.5 tauru 7426782 49 10 163.55 60
0 2 to 11 Bos lactate dehydrogenase A metabolism cytoplasm
0.0000 31E+04 3.10E+04 2E045 36597.8 8.1 tauru 278 CS55 3 10 159.6 g
a It B collagen, type 1, alpha 2 ECM structure ECM
9.80E+04 11E+00 2.72E+04 17 1E40 129064.2 9.23 taun 27806254 8 10 157.51 62
0 1o 0 0 Bos Haptoglobin precursor isoform 4 transport secreted0.00E+00 320E40 3203+04 00E+00 44859.4 7.83 taunt 70 g f 7 11 153.07 Jj
O 0 0 10 Bo Protein disulfide-isomerase AS precursor PDI ER
000E00 000E00 0.000000 10050 48514.9 4.91 taurus 76021 31 9 152.5 M64_
Is 4 4 t0 Bos AE binding protein I cell matrix interactions -unkni ECM
0000.04 2270+04 1.4004 0200004 82366.3 4.7 taurus 27 M7 J AI 10 152.4d *jQ cytoplasm
0 0 t 12 Bo5 peroxiredoxini redox cytoplasm
0.00E00 6.76E404 4.010+04 2-00 22209.7 8.5 taunts 20 -1 U 10 151.5 _Q
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1 * is 0 Bos Apolipoprotein E lipid regulation secreted
6.2E0*55 6.1E+O4 241E+4 ME0 36039.1 5.67 tauns 7 4 9 150.1 67
a 0 12 Bos 90-kDa heat shock protein alpha chaperone cytoplasm
005E+u0 0ZE+s 40.0E4 I Si05 84731.2 4.9 taurus 14 10 147.09 Se
a 2 a 21 Bos 78 kDa glucose-regulated protein precursor (GRP 78) (BiP) ( chaperone ER
ss0.+ . ISE+04 t 00t 0 Aae 61243 4.7 tauru 14 236 261
0 2 2 isBog Phosphoglycerate kinase I metabolisma cytoplasm
OAE+00 3s.0 2403E+4 1.esees 44537.9 BAE taurus A2(JZ 2 9 146.10 IQ
o ar 11 Bo matrilin 3 ECM structure ECM
8.1&04 3Mes s.106005 t.0se 60882.3 7.8 taurus 6 19 a 145.43 1J
a 0 2: 0 Momo Keratin 4 contaminant -cytoskeleton cytoplasm
s00E+00 Ma0EW0 2.AE+0 t a0E0 57285.5 6.25 spi 2776921 17 9 144.52 72
12 0 3 is 0 follistatin-like I signal negative secreted
1.02e+06 26E515 i11+06 3mews 34856.6 5AG taurus 10 141.54
20 7 22 1 agen alpha 11) caan precursor ECM structureEC
1.se+06 6EeS49e . 6 1375405 100000 9.64 tauru 3Q $$ 7 231.12 74
9 23 13 1 Bos Unknown (protein for IMAGE:7942574) contaminant-ribonuclease secreted
4.10, 2.+0 .0ee806 I.e-0e 22766.5 9.74 tauuS { 7 138.64 M
0 0 o 13 Bos Tumor rejection antigen (gp86) I chaperone ER
0.00E+00 OA000 0.0E+0 M661104 92427.2 4.7e tauns DZ75 § _U 10 137.01 Q0 3 9 23 1s beta-actin cytoskeleton cytoplasm
u.tE+00 ASE+05 $YOE+#4 seeaos 4167. 5.36 taurus 2265531 3 9 133.15 1. I
4 2 2 24 B dermatan sulfate proteoglycan 3 ECM structure ECM
22E+04 7A2E+03 *.2E+03 4275555 36687.9 4.76 taurus 278052 28 6 131.7 78
0 0 21 0Ho tumor necrosis factor contaminant-cytokine secreted
0.00E+00 40E+00 4.1+06 D4050E0 25644.5 6.4 sapien O S4 11 156.0. 19
0 0 10 Bog Protein disulfide-isomerase A4 precursor (Protein ERp-72) PD] ER
.+t 00E+00 e.+ .s6e" 72468.4 4.90 taurus 768j62g 1j 9 129.71 Q
a a 2 13 Bos procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 isoform PTM ER
4.0E+03 1 400+50 S.Wee0s 1 .21104 68587.5 6.14 taurus 1 j 8 124.3 j1 1
7 3 3 Bos decorin ECM structure ECM
7.7E+64 1ASEW 4.70E!4 5AE404 39879.3 8.72 taurus MI 7 25 8 121. Jj
a 0 2 * 9oS PREDICTED: similar to keratin, hair, basic, i contaminant - cytoskeletal cytoplasm0.00E+00 O E+00 4.7E405 63i2E4 53989.5 5.42 tauntu 76617 16 9 120.6
S 30 20 4 frIzzled-related protein signal-negatve/positive secreted/membrans
422E+04 225+0 2.0E+505 e77E404 362342 8.75 tauru 2780662 26 7 119.5 85
4 0 3 2 Bo WOE8 protein cell matrix interactions secreted
3.61E+04 622E+04 2245+04 tfSE403 47862.6 6.8 tauru 8 119.31 M$
0 4 7 0 B vascular coB adhesion molecule I cell matrix interactions membrane
.. Do,0 C414 esleiso0 CnescO 81368.7 5.3 taunt 7Jjj j 7 117.59 j
0 a 1 i0 Thioredoxin domain containing protein5 precursor (Endopl PI0.00E+00015t 1 es 6499"4 38672 6.2 taunt 7 7 117.41A E+_0
0 a epsilon isoform of 14.3-3 protein signal cytoplasm
0.00E+00 623+2 14- 7405104 281741 4.61 ,oElodyte 32 6 117.81,30E404
o 22 12 0 1 Serum eayloid A 3 innate Immunity- lipidreulM secreted
sOsE+00 3 Me5 I 0400 1 147697 935 tau+ 17 40 8 116.7
2 13 2 13 alpha 2 type VI collagen isoform Ca precursor isoform 1 ECM structure 1CM
1ME0 I insist 32Ei06 I MEW 97178 5.53 tatr 8 114.
a 4 2 4 BgEMILIN I precursor (Elastin microfibril anterfaceloca-ted pro ECM structureEC1.6304 11SE+04 1.9E+4a 2JsE 108881 5.2 taunt 8 114.74
i i240. 7 PI 111 U Trypsin precureor contaminant proteas 
secreted
15 6 a 6 EGF-like repeats and discoldin I-like domains-containing pn c~ell matrix interactions 8C
1.421+05 1.160405 9.04+60 015104 49753.1 8 taunt 7 5 12 188.11 49_
0 0 Is 2 annesin AB membrane assocatec
5.0E+0 045E+00 2.05+4 254 36787 53 taunt 2780631 25 7 107. 95
Ir 10 20 4 - Collagen alpha 1011) chain precursor isoform 2 ECM structure
221E+05 2255655 1)9546 2A404 138850.1 63 taunt 7A2 7 1075
6 2 a 2 MNretinol-binding protein 4, plasma precursor transport secreted
3.9E+04 isse404 1.2104 2.206s4 41081 104 taunts 2 6 107,11 JZ
2 4 1 7 Collagen-biinding protein 2 precursor (Colligin 2) chaperone ER
2.2e+03 640E4 1126 4 8E403 801 t 1657.. .01 tours 66311 2 6 07.4 2
O is01' 0 Unknw (protein for MC:1 28004) - lipocalan tasport secreted
0.2E+00 124E+0 .s16E+ 400 23182 561 taunts 6 16541 __
2 Is 3 2 Bog Neutrophil gelatinase-associatel lipocalin precursor (NGAL transport secreted
1.1+04 234E+0 2 0 2.72104 42342 98 taunt 7 J9 8 104.83 ___
2 5 0 Bo complement component 1, q subcomponent, beta polypepti, Innate immunity secreted
2100+04 a.7604 1.025106 5055 239 5 tut ~ ~ 0. 2L ______________
e 0 11B Al
Pa4 plonsoro4. i oeane 7.3) signablim cytoplasm
050.4 OssaO 2814 12e40 146839 93 taurut 7 ,JjQt 4 6 11.7 90 _____________________
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1e n 10 M B Fibulin-5 precursor (FIBL-6) signal secreted
17WE+t 2.0E+06 124E+05 14.4 32629.8 5.9 taurus 7 101.02 1Q
0 2 10 Bo calreticulin chaperone ER
s.00Ean E+00 2.76004 3saE's, 48038.7 4.31 taurus 8 100.42 104
4 a 4 0 Bo Procollagen C-proteinase enhancer protein precursor (PCP PTM ER
1asE+04 3.-4E04 2me,94 0wE0 48211.2 8.13 taurus 1j 99.21 JM
1 5 2 Bo acid phosphatase-like 2 PTM secreted
3.E+4£ 0ABE+63 1.110" 2.77E,04 41503.1 8.6 taurus 7 * 6 97.1 0
a e e so 14-3-3 protein theta (14-3-3 protein tau) signal cytoplasm
a.00e+0w 3.2e+o4 3ASmEH 1.23E45 50743.1 8.2E tauru 766301 15 6 96.84 107
o 4 4 0 8O platelet-derved growth factor receptor-like protein signal membranelsecreted
1oE+04 .2KE04 e . 5E+06 OsE4OO 41820 8.84 tauru 7836968 24 6 95.13 108
a 17 17 17 Bo Histone H2B 291B DNA architecture nucleus
3A0E+4I 2.92E+04 1A%6I 2W7E% 18354.5 10.62 taurus f j 1 6 95.06 109
6 5 3 2 Bos alpha I type XVI collagen precursor ECM structure ECM
5.0nE04 1U0E+04 2.16004 3.Es03 121440.4 7.84 laurus 1 9 1 7 108.1 M _.
o a 2 0 Bos complement component 1, q subcomponent, alpha polypep innate immunity secreted
s.IE+0 e.2ks04 1E504 CapE-go 25802.2 9.11 taurus 2 58 32 5 91.22 111
3 6 8 3 chondromodulin Il signal secreted
2IEe+04 2.175E+0 1.90E405 2A0E404 14547.9 9.25 bovine 751347 49 6 90.67 112
1 0 a $ Bos Unknown (protein for MGC:127630) metabolism cytoplasm
3.314.#3 0.0E+00 1.1e6E0 2A1E415 17316.2 7.70 taurus 4 44 6 89.80 J14
0 0 a 0 Pan PREDICTED: annexin I transport - exocytosis membrane associate
aisOEaw cOsACEa 5oe. 33+4 OososI0 58876 5.86 trogiodyte 55111 1* 5 88.85
7 12 a 5 SOS0 Tissue inhibitor of mettaloproteinase 2 protease inhibitor secreted
3.6E404 225+06 32504 1ATE406 24371.4 7.44 tauru 4 47 6 109.1s JJ6
3 r Bog Serine protease H-IRAI 
precursor (LS6) protease secreted
.e1o 4954 321:w44 3m5"4 55970.7 8.7 lauras j 5 8. __5 86A 6 I
o 7 0 o nei 2tasot-eoyoi ebaeassociatec
0awE'0 0.00e+40 1.110464 3J5E'a4 38612.3 6.92 taurus 2297 5 86.30 jj_ _ _
2 23 2 Bos secreted modular calcium-binding protein 2 ECM structure e
1 .504 2305+0 1.03E+Se ME1J04 33343.2 9.32 taurus 9 4 86.21 j_0 0 1 4 Bos phosphoglycerate mutase metabolism cytoplasm
.00E+0. 0 OE+00 3Mea3 034E404 28852.1 8.6 taurus 7740421 33 5 85.88 120
0 0 0 BUS N----acetylmuramoy d.-alanine amidase precursor (Peptidogy innate immunity secreted
oiAw Io 055*E+o 2005044 oososo 77245 .3 l 5 _84.74 __jQ
a 0 0 1 Basanei transport - exocytasis membrane associatec
aw0E+, 505E+00 4.5wE40 235E40a 38992 6.34 taurus 9 5 .17 6 84.59 1=.
6 a 16 6 Bo collagen triple helix repeat containing I ECM structure ECM
1.1AE+6 2.16E00 5 x,0us'se 227E406 26176.1 8.5 taurus Ij 5 84.24 12A
a 0 a 5 B0s FK506 binding protein 9 rotamase ER
a0E+00 0.00E+0 0 0+ .24E404 63535.4 4.92 taurus 7Q815Q1 1J 6 84.02 ZjQ
0 1 0 2 Bo EGF-containing fibulin-like extracellular matrix protein 2 pre ECM structure ECM
3E.+04 1.1ee+04 we.0 e28z03 49515 4.8C taurus 57457 15 5 82.69 12&
a s 0 0 Bo lactofemn innate immunity - iron transpo secreted0.00E+001 +004 OAE+00 a.O0E400 78168 8.7E taurus 482g 7 5 82.46 127
U 4 Is 2 Bos casein alpha-SI transport secreted
ssE+Ou 3-0E+04 2r.E+04 1.2E406 24529.1 4.9E taurus 30744 4 81.98 128
0 0 a 5 Rab GOP dissociation inhibitor beta (Rab GDI beta) signal cytoplasm
O.E+Ow u.O0E+w OtSE+ 2,05sE4 50512.4 6.0, BOVIN ja 5 80.33 122
a 2 1 4 Bos Profilin 1 cytoskeleton cytoplasm
0M0E00 I.49E+04 4.3E+3 I.5E404 15057.5 8.4( taurus 4 5 80.07 j).
s 12 1s 12 B0S germinal histone H4 gene DNA architecture nucleus
2.155+04 1.1e+0s 1.22E+0 72T404 35525.3 10. tauru 7QQ34272 1 4 79.7 1
0 0 1 1 Bos plasminogen activator inhibitor protease inhibitor secreted
0.+00 aME+e ie.E03 425404 45371.5 5.9( taurus WQ1 j 5 78.14 _ ))
4 2 2 0 Bos Carbohydrate sulfotransferase 11 (Chondroitin 4-0-sulfotrar PTM golgi
2.19+06 2.01e+0" S.rE+03 OE400 62118.1 9.7 taurus 76609724 13 5 78.14 134 1
o1 1 7 3 Bos Unknown (protein for MGC:1 37015) contaminant- rilboncuelease secreted
1.5E06 1.050+0 6.42E+04 1ASE404 17003.6 9.0 tauru J 5 77.88
o a 1- Parkinson disease (autosomal recessive, early onset)(9 metabolism colas
0.00E+00 I 500E+00 9BE2 4.17E404 20035.4 6.84 laurus 6275 5 77.74 1)j
0 4 0 a BOS Unknown (protein for MGC:127526) metabolism cytoplasm
0.0E.0 e*2+04 0.00e+0 63e44 47328.4 6.3 tauru UW45 ij 5 77.0 43
0 2 5 4 Bs anglopoletin-ike 7 signal secreted
0A*E+00 4.1E+03 1.33E40 5.73E04 39456.8 7.55 lauru 624051 14 1 4 77.01 138 1
0 5 2 0 BO CD14 anfigen innate immunity - signal membranelsecreted0.00E+00 4E5+04 2.30E04 aoE"Oa 39681 5.37 tauru 13 4 76.79 _,}0"" 0 Complement component 1, r subcomponent inat"ei"m"m"y-complement secreted
0005uE+0 1iE+05 I .0E0 50W0E0 44557.7 5.76 tauru 7435413 13 4 76.3 140 1 _
5 4 B0 Cytokine-like protein C17 precursor signal secreted
5.0E+04I 4.77E+04 4E+04 I ioE 156325 7.6 tauru 037 5 75.94 141
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2 0 2 protein 8 (alpha) signal secreted
4.7E+44 1.50E+4 taeE+00 170EM4 75133.1 5.29 taurU gQE 6 74. 14
1 2 3 0 Bo retinoic acid receptor responder (tazarotene induced) 2 isof unknown secreted
1.E403 -2.01E04 70eO03 o0oE+00 18357.3 8.96 tauru 76jI1 42 4 713.42h
0 0 2 5 Bte PRDX2 protein redox cytoplasm
0.0E+0 IO0E40 22E+0 43104 21946.1 5.30 tauru2 4 72. 6 J4_
12 10 0 15 so H3 histone, family 2 isoform 2 DNA architecture nucleus
ese+4 10"a 1.35e. 213E005 37765 11.A tauru 1 5 71.64 14
0 0 L 0 Bo7 PRtEDICTED: similar to Complement C3 precursor isoform 2 Innate immunity - complement secreted
_.00E+00 .00E+00 3.1__E_4_ O.E400 187315.2 6A1 tauru 7 4 5 70.11 146
4 1 0 0 Bol cystatin EIM protease inhibitor cytoplasm?
1.28E+4 3.2E403 0.oE+00 0aE.00 16356 7.63 taurui 6109791 46 4 68.73 147
0 4 2 1 Bol plasminogen activator inhibitor type 1, member 2 protease inhibitor secreted
0.00E+ " 10E+04 1 0E554 321E40 43877. 9.56 tauru 2 2 4 68 "L4
3 2 2 3 BoE oligosaccharidebinding protein innate immunity secreted
3.1E04 2.1e04 1.12014 2.14014 21063.2 9.59 taurui 1955042 23 4 67.85 149
2 4 4 801 tissue Inhibitor of metalloproteinase i protease Inhibitor secreted
1ev.4 7.231+04 06E+04 4M50E04 23031.7 8.A6 taurm 6 25 4 67.5 M.
1 1 2 Bo reticulocalbin 3, EF-hand calcium binding domain chaperone ER
S.7E02 11.s6e+02 4A1+03 5.0+04 29798.7 4.62 taur 7664211- 18 4 66.8 152
0 0 3 2 so Phosphatidylethanolamine binding protein metabolism cytoplasm
.00 000 OME0v 1*E+04 1.16E+04 21004.9 7.73 tauru 74359 2 4 66.6
0 0 0 Homo keratin 16 contaminant - cytoskeletal cytoplasm
0,00E+00 0.00E+0 1AE+04 -1E+04 51268.1 4.98 sapien 11 4 66.5 154
a 0 0 8 Cartilage intermediate layer protein 2 precursor (CILP-2) ECM structure ECM
1.10104 IME4 030E+0 QA0E00 131227.5 8.77 tauru 7821011 5 4 66.24 ij.
O 0 0 4 Bo NADP-dependent malic enzyme (NADP4VE) (Malic enzyme I metabolism cytoplasm
0.00E+00 0.00E.0 00E+05 *2E103 53048.5 6.29 tauru g 4 65.2e IN
0 4 3 0 Bo Unknown (protein for IMA GE:7989842) transport secreted
0.00E00D 1.09406 1.22E+04 0E45100 17684.4 6.32 tauru 56o 21 4 64.28 
__5_1 2 0 7 Proactivator polypeptide precursor [Contains: Saposin A (Pi other lysosome
3.0EvS2 2.3E404 020E+00 ijE404 58120.9 5.13 BOVW 138789 11 4 63.27 159
0 0 0 e Bo elongation factor I alpha translation cytoplasm
O.E400 00E400 0.00E+00 6015E04 34378.9 9.22 taur __ _ __22 4 62.33 M_ _
0 0 0 4 Bo23 nucleolin-related protein isoform 9 DNA architecture nucleus
20E+00 0.0E40 0A0E+00 6,9404 79731.2 4.5 taur 7 4 5 62.1 161
2 2 0 3 lysyl oxidase-like 3 precursor PTM ECM
esAE4 e ? 5*53.W OW100 2 A9104 82977.8 65 taurum 4 62.01
a 0 0 0 Bas Unknown (protein for MGC:133714) metabolism cytoplasm
0+00S6 .00E. .vEO00 218E04 37685.5 7.03 tauru 4 61.82 163
0 0 1 BNE Glutathione S4ransferase M1 redox cytoplasm
.0E+0 0.00e40 0eE+03 023+04 25635 6.91 taur ) g .. 24 4 61.64 194
O 0 0 2 Bo. growth arrest-specIfic 6 signal secreted
2.4E+44 00E+00 0 .00E+00 3.79E403 64589.1 5.8 taums 76532 7 4 60.66 165
S 21 4 1 Bo% melanoma inhibitory activity signal secreted
1.1E+06 41E405 1A06SE 6AsE10 14353.6 7.65 tOuru 33 3 60.01 __
0 0 0 5 Boo Unknown (protein for MGC:1 27305) translation cytoplasm
02000 0.00E+00 OIE+00 2AG0b+4 95368.7 6.41 taum 7 4 5 59.38 17
0 3 1 2 Boe anti-oxidant protein 2 (non-selenium glutathione peroxidase redox cytoplasm
0.00E+00 0.17E010 320231 4,70+04 25067.1 6 tauru 4 58.96 .... I
4 2 7 2 Boa Insulin-like growth factor binding protein 7 precursor (IGFBI signal secreted
0A0K14 1AE+04 4*2E+4 .10E104 14247.2 5.5 taurus 7 Jj 3 58.8 J-j
4 0 0 0 B Apollpoproteln Al lipid transport secreted
O.10603 0.00+00 0A0E+00 0A0E+00 30276.5 5.71 Ovum 74282 17 4 58.81 1.9
0 0 o0 PREDICTED: similar to Moesin (Membrane-organizing exten cytoskeleton cytoplasm
o0toE+o0 0*0E+00 0.00E+00 3.00E+04 04355.4 5.98 Ovumu 7665954E 7 4 58.21 172 _______________________ ___________
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e $ 3 0 scrapie responsive protein I unknown secreted
1E.+. 7J2E+04 1.20E OsE+00 14340 8. tourus 34 4 58. *jI
2 2 3 1 Be angiogenin signal - ribonuclease secreted
1.03E4 S302 2.74E40 9aiE03 18450. 9.53 tauru 7 4 57.83 174
2 4 a 7 Homo qulescin Q6 Isoform a variant unknown cytoplasm
1.160-0 7*455e 2WEs5e 1 2___#04 83173._ 9.1 e n 4 .. k 5 95.370 2 1 0 Boe Bone morphogenetic protein i precursor (BWNP) (Procollag PTM-protease secreted
0mE., M.13e.00E.7E 3E+03 0AE00 111838.2 7.28 tauru 7 j 3 57.04 170
0 s 0 muscle endopin 1a protease inhibitor cytoplasm
0.00E+00 0.0E+00 -. 70E44 OAOEI+00 46285.2 5.67 tauru 4 1 4 568.7 177
1 2 4 a -EHypothetical protein LOC525716 8,100IfCaBP cytoplasm?
4.02E+82 4ME 1A0E+04 e1E+4 10666 4.57 tauru 73587372 40 3 56.71 178
0 1 2 4 B0 CTSS protein protease cytoplasmisecreted
5455545 13440 2W5 3 M04 se 36719.5 5.57 taurna 14Q 3 55.91 _
1 4 3 2 Sol PREDICTED: similar to Extracellular superoxide dismutase I redox secreted
1.77E+04 ImE+04 1A6E+0 323E4 27390.2 6.59 tauru- 78680741 J 3 55.34 1
0 5 0 1 BO. connective tissue growth factor precursor signal secreted
0.00O 3.3304 0E+0s 32E03 37924.5 8.20 tauru 1 3 54.71 1_1
3 3 1 5 om Lysyl hydroxylase, precursor PTM ER
1.4E+4 S.t5E+04 2.4E404 3.25+04 83596.7 6.47 sapien 16741721 5 3 54.42 182
a a 0 BoT Collagen alpha 2(IX) chain precursor ECM structure ECM
1.01E+ I 118E405 0oE+00 I 00E+00 64963 9.23 taun 7$6 86 3 54.12 183
1 1I 3 a B0E secreted modular calcium-binding protein I ECM structure ECM
3.2SE+03 -i.E+06 75.4+ ussE+00 14997.2 8.53 tauru 7ZJA911 A 3 53.09 1 4
3 s 6 0 Bo Complement Clq subcomponent, C chain precursor isoforn innate immunity- complement secreted
4.3E+44 1.53E+06 55E+04 OaE+00 28997A 9.16 tauru i 3 52.94 JJ8
0 2 a 0 Bt secreted frizzled-related protein I signal secreted
0.00E+0 4.32E04 1.004 sAsE+00 34763.1 9.05 tauna 7 JA 3 52.5 I880 0 3 2 Bo SOD1 protein redox cytoplasm
u.u0E 00 5ADE+00 6.71e02 IME04 15682.6 5.85 tauru 358854 41 4 51.41 187
S 15 1 BI matrix Gla protein cell matrix interactions ECM
32.71+4 457E403 6EE04 G,6Ee3 12217 9.27 tauru 2780727 24 3 50.63 188
00 4 Cathepsin D precursor isoform 3 protease lysosome
.0E+0 12E40 040E+00 221E44 45385.6 7.56 tauru 7 9 4 50.02 _
4 1 S 2 B Extracellular matrix protein 2 precursor (Matrix glycoprotein ECM secreted
15E+3 ME+0 5ME+03 3.1E+03 54027 9.93 tauru 1 3 49.94
0 1 3 6 Bos Unknown (protein for MGC:133720) metabolismAransport cytoplasm
.E+0 2.0E+03 3.71E+04 2AE490 21401.7 4.8 auruE A18721 3 49.9 e.1
0 0 0 a Bas alpha glucosidase I alpha subunit isoform 2 metabolism cytoplasm
u.uuE+00 .0E+u0 oA0E+00 1.15E*04 111465 6.19 tauru 3 49.57 I
1 0 3 0B secreted modular calcium-binding protein 2 ECM structure ECM
.ssee3 eOeE+04 24W+04 uA.o00u 65538.7 8.94 tauru _05 [_ 3 48.51 1M)
0 3 2 0 Bo cartilage C-type lectin signal secreted
0.00E+00 1.22E+04 1.42E+4 020E+00 22215.7 9.04 tauru 2780714 20 3 47.9 194
2 0 3 6 B =77 6.5 innate immunity -complement secreted
12E+05 044E+00 457E4" 425E404 20493.9 7.58 tauru 28 20 3 4716 MQ0 1 0 4 B0 Reticulocalbin-1 precursor, partial chaperone ER
0.00+00 .2Eu2 ustE+00 AI7E+03 33602.1 4.65 taurus 7 J 3 47.14 iS_
0 0 4 0 Homo esophagin contaminant - keratinocyte dil cytoplasm
0.00E+00 0CE+00 45E+04 0+090 18183.1 8.8 sapien, 21j729; 1j 4 45.84 JZ
2 1 1 0 Rats Cocoacrisp protein protease inhibitor? secreted
1.04e+4 e.73E+02 3Ae+03 .e0u0 56974.9 7.93 nolvegicu 6449 3 45.E ly@
0 0 0 4 K50 binding protein 10 precursor (Peptidyl-proly cis-tran rotamase ER
0E+m 0.00E+00 0.00!+00 1.63E+04 64512. 5.68 tauna 7 9 3 45.51 19_
0 0 0 4 1 Ribosomal protein, large P2 translation cytoplasm
u.OE+00 0.00E+00 0E+00 1M2E+04 11702.1 4.5 tauru 8257175 40 3 45.5 200
4 1 3 t Bo- lamini alpha 4 precursor cell matrix interactions ECM
1.74E+03 4.03E+03 3A4E+03 0eE+00 192346.3 7 tauna 78 J3 -6 6 84.9 92
0 0 Bo PREDICTED: hypothetical protein XP_602993; HA binding tI ECM structure ECM
1.0re04 0mE+00 0.00E+00 usE0 72898.2 4.6 tauru 7 3 44.7 _92
0 2 0 0 B fibrillin 2 precursor ECM structure ECM
o.0esse s.1E903 sAsE+00 mee00 162937 4.85 tauru_ __ __ __ 2 44.1E_2Q0Bo Gremlin-1 precursor (Cysteine knot superfamily 1, BP ante singal secreted
0.00E.0 siSE0 se.2E0 uO 00 16292.3 9.68 tauna 7662733 27 3 43.74 204
0 0 1 2 Bo Hypothetical protein LOCS36182; malate dehydrogenase metabolic cytoplasm
00E+00 0E+00 1.72E+03 73E+03 36438.4 6.16 tauru 743 6 14 3 43.7 M
3 0 0 B T casein alpha-32 transport - Calcium phosphate secreted
1.69E+ 0.00E+00 2.98E+0 OME+00 26018.6 8.5 auna Q j 42.2 27B_9_UI
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L .4p TNF-a Injury Proin Protein pl species accession c peptides score group # Function Locations(Control) MIN_ ____ ___ ___ coverage _ ___Protein NAME0 e e o Ran GTPase-activating protein I signal cytoplasm
Canis
0t0E+0 1.04E0 ealE+04 E 142453.3 5A6 familiaris Zgw 2 41.3
0 0 0 3 -transketolase metabolism cytoplasm
status 0.0;4" Itt-3 93W23 67906. tauru 3_ _ _ 41.2
2 0 3 1 procollagen-lysine. 2-oxoglutarate 5-dioxygenase 3 precurs PTM ER
1.06E+a 0AE+00 323E+4 1sE404 86469.6 5.62 laurua j27 2 39.11 =1
C 4 0 0 vanin I precursor signal membrane
asteus 0.0020 M sttu se-e 56947 5.31 taua* 2 38.45 2n I
7 . 2 _ _3 Fructos_4btphosphate aldolase A (Muscle-type aldolase) is metabolism cytoplasm
staEO 0a.Eu QaiE+0 2MEV4 39436.3 SA5 tauru z=V'U l i 3 38.13 _
4 1 11 6 Bo prostaglandin H2 0-isomerase transport membrane
3.87ee4 I.22e504 2.1?e+0s sME404 21229.3 6A3 tauru 2707521 11 2 36.13 AI_
0 1 0 Bo Collagen alpha (IX) chain precursor, partial ECM structure ECM
.4E+ 0iE+0c 3.19e+4a 0ADE+0 26967.6 8.76 tauru 766.47 .11 3 36.02 p15
0 a 2 2 Bo GS'Pi protein redox cytoplasm
0.00E+00 0.00E+00 4YE43 e.7E 03 23613.3 6.89 taurae 74268 19 2 35.92 216
0 0 1 2 RaItu transaldolase metabolism cytoplasm
5.WE500E 0.0E+00 024E+02 222E+03 37476.3 6.57 nrvegj 2 35.77 gif
1 0 1 0 6o C1q and tumor necrosis factor related protein 3 isoforn b is signal secreted
IMeu3 ai0+ 31E+0m 0=Es 34953.3 6.67 tauru 7 7 2 35. 71Q
4 0 1 0 - Amylold beta A4 protein precursor (APP) (ABPP) signal membrane
i.re+04 0.00E+0$e s.2s0 sEa 63986.1 4.73 taurua 660764 -a 2 35.03 2190 0 0 2 Can Cofilln-I (Cofilin, non-muscle Isoform) cytoskeleton cytoplasm
a.00E+00 0.00E+00 s.aE+00 7.19403 23481.6 8.92 familiads 73946791 12 2 34.71 220
0 0 0 4 Bo tubulin, alpha I cytoskeleton cytoplasm
a.00E+00 ta E+tau aa0E+0 10rE e4 51290.3 4.96 tauru 7 2 34.51 221
0 Bo cystatn C (amyloid angiopathy and cerebral hemorrhage) protease inhibitor secreted
saE+00 IAE+03 utsE+0 0e0E+00 16265 9.23 tauru 27679 30 2 34.42 g
0 0 0 2 Bo endoplasmic reticulum protein 29 precursor chaperone ER
.ta+00 ..0s E+00 s 3E404 28806.2 5.63 taura ......L 2 34 _aJ
0 0 3 Bo serine (or cysteine) proteinase inhibitor, clade B (ovalbumin protease inhibitor secreted
0.00E6-0 t.oE+ 3.1sem 1.701+4 42560.9 5A4 tauru 27807517 5 2 33.72 24
0 1 2 3 PPIA protein PTM ER
0.00E+0a AessE+0 se+0s ase03 17869.5 8.34 taura 2 33.5 g
2 1 0 o Chordin-like protein 2 precursor (Chordin-related protein 2) signal secreted
1.22E+04 136e+04 ta0E+00 OaE+00 80199. 8.9 laura 5 2 33.4 =
0 0 a Cani platelet-activating factor acetylhydrolase, isoform lb, beta s cytoskeleton cytoplasm
Ota.0E .taE+ OutEus 2.2YE-04 63827.5 7.66 familiadsi 7395510 4 2 33.35 2270 2 1 0 Bo nterleukin-47B precursor (IL-17) (Interleukin-92) (rL-20) is signal secreted
stat0 1E+04 6.4E+o sE400 24932.3 947 lauru 7 J3 1 2 33.31 2200 3 0 0 Bo hypothetical protein LOC512242 Innate immunity - lipid binding secreted
s.00E+00 3 S2E+04 taE+00 ta0E+00 53698.3 6.61 tauru 8457 4 2 33.29 2M
1 3 0 Macrofibril-associated glycoprotein 4 precursor cytoskeleton cytoplasm
8.65+04 S03 2.13E+04 saE+00 28558.3 5.09 BOVIN p * 2 32.85 g
0 0 1 2 Bo Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) metabolism cytoplasm
staE+00 .taEu 12SE+3 a.70E3 24575.5 6A4 tauru fjAW 1j 2 32.810 2 0 0 Bo matrix metalloproteinase i protease secreted
0.o0E00 119E+04 a .0E+00 tau E+00 53354.3 5.97 tauru 278QQ54t g 2 32.77 *J
4 1 2 0 alpha I type XV collagen precursor ECM structure ECM
1ANE04 4.22M+63 isA9E+04 0A0E+00 21825.1 7.73. tar 75igg 12 2 32.55 )
0 0 0 2 Dihydropyrimidinase-related protein 2 (DRP-2) (Neural-spec metabolism cytoplasm
osE+00 0.0E+00 stuE+00 IAE+04 62277.9 5.95 BOVIN }) 2n 4 2 32.31 2)_0 0 a 2 B-0 heat shock protein, alpha-crystallin-related, B6 chaperone ER
.tuE+00 statu0 0E+00 I lE+04 21044.1 9;4 tauru 044g i 2 32.1E 3
2 Bi TIP120 protein isoform 3 translation cytoplasm
statu status sttu lTt's 122998 560 laura 78M 7 2 1 31.99 2M..
0 4 Bo. Ras GTPase-activatingflke protein IQI2API (p185) isoforus I signal cytoplasm
t.0E+ o.tatus sta+ 423ee63 157942.8 5.61 taura j 2 31.77 J)Z
0 0 a 3 BO liver glycogen phosphorylase Isoform 6 metabolism cytoplasm
staE+00 0.00E+0 stE+u .15E+03 98258.3 6. tauru 768278); 2 2 31.40 1 2 0 Bo beta-2-microglobulin immunity -MHC class I beta cl membrane
0.00E+ 3.30E+t2 rIe+3 siEs00 13676.7 7.79 tauru 413866 33 2 31.3 239
0 0 0 - Protein CutA precursor (Brain acetytcholinesterase putatlive other membrane
stuE+00 O.a0E+00 ta0E00 st2E+03 18976.2 8.64 BOVIN 286494 23 2 31. _49
1 1 u Bo von Willebrand factor A domain-related protein isoform 1; % ECM structure ECM
status 2 A2E+03 3E+ OEa 52047.5 8.93 tauru A , 2 31.0 2_L1.
2 1 2 a Angiogenon-2 signal secreted
0e+03 32E+3 t2E+03 suE400 14522.4 9.97 BOVIN 2)QQ561 24 2 30.2 - __g
0 0 0 4 Bo beta tubulin cytoskeleton cytoplasm
status0 o.us seus 8.Ese03 49937.3 4.78 taura 5M4 1 **j 2 301 A I _
S 3 plakoglobin signal cytoplasm
.0E+000E+00 tus 1 6E+ 1.ire+3 81821.3 5.76 laura 2))01 3 2 29.9E , __________
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untreated Protein Proteinpi species accession c peptides score group# Function Locations
(Control) ______ _____ijur_ coverage ____Protein NAME
3 2 a Sas complement Cis innate immunity -complement secreted
omE+A0 M SE e6E+04 000 78101. 4.76 scrola JQ{Q 2 2 29.9 gJi
0 2 0 0 Homo polyubiquitin catabolism cytoplasm
OeE+0 1.26 ee A omE* A0oa 68723.4 713 sapien 13D41 2 29.56 24
1 2 a 0 Bos Nimnick disease, type C2 metabolism lysosome
Me." I.Me0a sAQs . 0Ass0e 16e84_0. 8. tauru s 1 IQ 2 29.28 EE
5 2 0 6 -040 4 o alpha 3typeIX collagen ECM structure ECM
IAe.4 IJaE*0 24e34 .17e4 72972.2 8.74 tauru 766131 3 2 29.24 249 plasm
0 0 a a BS Ribosomal protein, large, PO translation cytoplasm
a0e.+00 aE+00 ae+0 1.es. 34400.8 5.72 tauru 7 2 29.12 25
0 2 a Mus 5Tryl0-like trypsinogen protease secreted
ME+00 a24e.. eA.E+Oo aOM 26531.2 4.82 musculus 5109230: 15 2 28.77 251
0 3 a Boe CEGP1 protein cel matrix Interactions secreted
aMEe0 eAE+00 2.105404 eE00 85142.8 5.91 taurus 76634 3 2 1 28.73 252
0 2 1 1 - om megakaryocyte stimulating factor; MSF ECM structure ECM
0.E+.0 432E0 15 E I 200E+02 151091.9 9.53 sapiens 1572721 2 2 28.6 253 _______cytoplasm
0 o o 3 Homo ribosomal protein 812 translation cytoplasm
eae. M rseav arssac emEaSS 14598.1 6A2 sapiens 2 28.5 5
a a 2 BSUnknown (protein for MGC:128488) ; glulathione S transfers rdox cytoplasm
0ae00 45 1aO. ao00 1 M+"4 28727.2 5.6 taurus 2 27.63 .5Q
0 2 0 0 an interleukin 1, beta proprotein; preinterleukin I beta; catabo signal secreted
vasea i et re . owa 5432. 8. r G~2 alectin-3 cell metrix Interactions EC
0r a+ +04 .0E+00 . 14"E+4 27646.2 8.87 taurus 7666865E 9 2 26.95 257.
I 0 1 2 - os heat shock 27kDa protein I cytoskeleton cytoplasm
ar0o+as .0e+0r.se +04we. aeaE* 22679.4 5.77 laurus 71}4 12, 2 26.94 5
O 0 o A 2 B ca umenin isoform 2 isoform 2 PTM ER/secreted
o.Es.. .0E+a. aE... 1.12E404 37747.6 4.44 tauru 7 2 26.9 3..0 a a a Ba MYLS protein lipid transport lysosome
OAs..0I AO ra.oa aE.. AoE404 16961.2 4.A a ur 2 28.83 2
a 0 2 Bas Protein transport protein Sec23A (SEC23-related protein A) seaesidle trelficking cytoplasm
erse+00 aEeo.. omsr 4.101103 86976.3 8.8 taurus 7§147421 2 26.70 .. i.
3 a 0 Rattus PREDICTED: similarto RIKEN cONA 4933437K13; similar to radox cytoplasm
1.2E+ a.00 VaME+00 0.00E+00 77979.2 6.37 norv'cu 2 25.5 2,Q _
a a 2 a 0a LMNA protein contaminant? - cytoskeleton cytoplasm
ea.0+0 .E+00 10 0.00E+00 65122 6.5 tauru 7435471E 4 2 25.33 264
0 a 1 7Can prolyl 4-hydroxylase, beta subunit
aO0E+00 aOa s.12E+3 2A1E4 57417.2 4.8 famlars 739474 1 22.5 2_6 .
S aRattu microfibril-associated glycoprotein I
o.as0+0 arE+00 e9rE+0s 5.00E 23840.2 5.1 norvegicu 71M 4 1 22.2 2W
1 1 1 1 Ba caseinkappa
tASE+02 122E+04 222E+03 2ASE403 21269.5 6.2G tauru 1 21.22 2Bg0 0 Bo granulocyte chemotactic protein-2 precursor
O0E+00 3.E+03 OME0o OaDE400 11588.9 9.4 tauru 1146459 n 1 20.94 273
1 2 2 0 Rattus similar to RIKEN cDNA C130099A20
a.E+03 ice o S2A2004 .0sE4s 0 54958.7 8.95 novegi 4 1 20.91 2Y
S 2 os filamin A interacting protein I
A0E0 .a+0 TEr 03 sa a eOE400 114886.4 8.2e taurus 7062541 1 2 20.84 275
1 0 aOS vitrin
ar+..0 72Esa 0.00E4Wa a.00E.00 70872.9 8.97 taurus 1 20.82 27-
a 2 t t unnamedprotein product
Mus
tr0E+00 236E+04 .0E+00 o.0E+00 68733 5.7 musculus 741375Q5 1 20.29
a 3 2 Bo fibrillin I
oraE+0 aOaE+00 5.22E+03 eAe.s 312253.4 4.82 tauru 2780663' 0 1 20.27 279
0 0 2 - .OS milklysozyme
ersE+00 OsE+00 AaE+04 awE+00 16782.6 9.92 taurus 510243 1 1 20.25 _ lJJ
0 a 0 1 Tumor protein, translationally-controlled I
BOE
trE+0. omE+a. aE+r ME46 19581.4 4.84 taurus 7435648 8 1 20.23 281
a a 1 ISO Rho GDP dissociation inhibitor (GDI) alpha
0E E*00 Ura E+a 4. 6Eas 23421.5 5.12 tauru 1 286037 gj1 1 20.14 2M__
a 5 Pan PREDICTD: similar to 60 acidic ribosomal protem P1
raE+0 1 0.0E0 0swa sEao3 11688.3 4.77 troglodyte M "11[ 4 1 20.1 283 0
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Appendix C.2: Protein list of iTRAQ-2D-LC/MS/MS with ProQuant
(ABI): Protein identification relative Quantitation and p values sorted
by K-means Clustering
Table C.2 is the protein list for experiments and data described in chapter 4
including the protein identification, quantitation for each treatment relative to the
untreated sample, and significance values.
Column 1: Order: Final Protein number
Column 2: Protein Name: Name of protein
Column 3: Protein #: Protein number
Column 4: Score: 10 s***) is the p value for the protein ID (ProGroup score)
Column 5: Score 2: 10 "("') is the adjusted p value for protein ID (matlab scripts)
Column 6: Mass Coverage: Summed peptide molecular weight for each protein
Column 7: outliers: 0 indicate no outliers for all signature ion ratios; I indicates
presence of outliers in one or more signature ion ratios
Column 8: pvalue 115: p value for 115:114 ratios based on Wilcoxan Rank-sum or
Student's t-Test with Bonferroni correction for multiple comparisons
Column 9: pvalue 116: p value for 116:114 ratios based on Wilcoxan Rank-sum or
Student's t-Test with Bonferroni correction for multiple comparisons
Column 10: pvalue 117: p value for 117:114 ratios based on Wilcoxan Rank-sum or
Student's t-Test with Bonferroni correction for multiple comparisons
Column 11: 115: 114: Geometric mean for 115:114 ratios
Column 12: SD: error factor for the 115:114 ratio (SD of log transformed ratio)
Column 13: 116: 114: Geometric mean for 116:114 ratios
Column 14: SD: error factor for 116:114 ratios (SD of log transformed ratio)
Column 15: 117: 114: Geometric mean for 117:114 ratios
Column 16: SD: error factor for 117:114 ratios (SD of log transformed ratio)
Column 17: Accession: database accession number
Column 18: Sig 115: Consistency - Analytical duplicate agreement for 115:114 ratio
- greater than 1 or less than 1 (3 indicates agreement, 1 indicates found in
1 sample, 0 indicates disagreement
Column 19: Sig 116: Analytical duplicate agreement for 116:114 ratio -- greater than
1 or less than 1 (3 indicates agreement, 1 indicates found in 1 sample, 0
indicates disagreement
Column 20: Sig 117: Analytical duplicate agreement for 117:114 ratio -- greater than
1 or less than 1 (3 indicates agreement, 1 indicates found in 1 sample, 0
indicates disagreement
Column 21: SM-ID: Spectrum Mill verification of protein identification (yes/no)
Column 22: coverage: Spectrum Mill coverage of protein
Column 23: manual: Manual validation of identification and quantitation
Column 24: Idexer: Sorting indexer from K-means clustering (6 clusters)
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Thesi _CH4traqsupplemrenprotins _ortad
order Protein Name p
22 PREDICTED: aimilar to Gelaolln precursor (Actin-depolyrnorzing factor) (ADF) (Brevin) (AGE
27 collagen, type 1, apha 2
2 matrix moetalloproleinase 2 (72KD type IV collagenaae)
35 PREDICTED: similar to procolagan, type I, alpha 1 looflnn 1 ; PREDICTED: similar to proco
53 PREDICTED: similar to xylosyltraneberase I
58 PREDICTED: similar to CD109
66 werted protein, acidic, cystelne-rich (osteoneolin] [Bo  taurus]
70 AE bidTng protein 1
75 PREDICTED: simltr to Transforming grwth ator-beta induced protein IG-H3 precursor (Br
80 PREDICTED: similar to alpha type XI colagen loorm A preproprotein, partial
91 protein S (alpha)
100 PREDICTED: similar to Chordln4ke protein ) precursor (Neourain) (Vntroptin), partial
110 PREDICTED: similar to Carbohydrate ulfotransfoerase I (Chondroifin 4-D-sulfotranokeaa
131 PREDICTED: similar to alpha 1 type XVI collegen precursor
144 malanoroa Inhhibity activRy
151 PREDICTED: shiniler to Collagen alpha I(V) chain precursor
152 PREDICTED: similar to Calsyntenin-1 precursor
155 PREDICTED: similar to EGF-Ilkse repeats and discokln I-tke domainscontaining protein 3, p
172 PREDICTED: similar to gowth anest-apclfic 6
182 PREDICTED: similar to Insuln-lke growth factor binding protein 7 (predicted). partial
18$ PREDICTED: similar to carbohydrate (chondrollin 6) ullotransterase 3
191 PREDICTED: similar to Chordindta protein 2 protcrnor (Chordirolated protein 2) (Breast h
199 PREDICTED: slmilar to procolagen. type V, alpha 2
203 PREDICTED: similar to Amylold beta A4 protein precursor (APP) (ABPP) (Alohelmers diease
200 PREDICTED: similar to retinol-nding protein 4, piaama precursor
214 PREDICTED: similar to Colagen alpha 2(IX) chain precursor
222 PREDICTED: similar to procolagen, type V. alpha 1
224 PREDICTED: aimilar to screpe responsive protein 1
266 PREDICTED: similar to glypican I precursor, partial
268 PREDICTED: hypothetical protein XP..602993
268 chondromoduln I precursor teulocyte cell-derived cherolaxin 1) (Boa taurus]
281 PREDICTED: similar to Angiotensinogan precursor
303 PREDICTED: dnar to Chordin precursor
304 PREDICTED: similar to Immunoglobulin superfandly containing leucine-rich repeat sotorm 4
325 microllbrilar-aaaocated protein 2
328 PREDICTED: inir to Alpha-mannosidcae I (Mannosyl-olgosacchadde 1,3-1,6-alpha-man
333 PREDICTED: aimiler to SPARC-related modular calclum binding protein 1
334 PREDICTED: aimnltr o cooacrip, partial
340 PREDICTED: smilar to actonuclenode pyrophosphatacclphosphodiecterae 2 (autotaxin)
348 PREDICTED: aimilar to UDP-GtcA:bElaGal bets-1,3-N-acotytgtucoswminyransfoerase 7
352 PREDICTED: similar to microibritar-assoated protein 4
408 PREDICTED: similar to chondrolin bete1,4 N-acetylgalactomminyltanaterase
441 PREDICTED: srmilar to fucosyltararnsfese i t (alpha (1,3) lucosyltranelerse)
476 PREDICTED: similar to pleoin domain contining 2 precursor
407 PREDICTED: clmilar to UDP-N-acetyl-alha-D-galacioccmine:poypepide N-ecetylgalactoa
521 PREDICTED: similar to isthmin 1
532 PREDICTED: similar to Ciqandhmor rtorosis factorr eted pmoten 3isoform b oeform 2:
551 PREDICTED: simier to pleas glutamate carboxypepdase
68 PREDICTED: eimilar to Fib oblast growth fador receptor 3precursor (FGFR-3) (Heperin-biro
61 PREDICTED: similar to C1q and tumor necrosis actor elated protein 2, partial
2 PREDICTED: similar to Bosement membrane-spedlic heparan sulfate proteoglycan core pro
3 PREDICTED: similar to alpha I type XI colagen long Ioform precursor loorm I ; PREDIC
5 thrombospondin6 PREDICTED: simlar to melanoma-assocated chndmiin sultate proteoglycan 4
12 PREDICTED: similar to Nhlogen-2 precursor (NID-2) (Ostonldogen)
14 PREDICTED: ciiltr to colegen, type XI, alpha 2 isoorm I proproprotein
15 PREDICTED: aimilar to Cartlage matin protein precursor (Matrilln-1)
16 PREDICTED: similar to nucleobindin 1 ioflon I
19 PREDICTED: similar to Cartilage oligomeri motrix protein precursor (COMP) isofom I ; PR
20 PREDICTED: similar to Cartilage intermediate layer protein 2 precursor (CILP-2)
30 cartilage ining protein 1
31 procolagen-ysine, 2-oxoglutamte 5-dloxygenace pr cursor
39 PREDICTED: similar to Laminin alpha-4 chain precursor, patial
40 biglycon
41 pepidyptyl somerase B
52 PREDICTED: similar to Colagen alpha 1(111) chain precursor Icotorm 1; PREDICTED: imiba
54 PREDICTED: simniar to throrbospondin 4 precursor isoform 3
55 erine (or cysteine) protenaoe Inhiblior, clade A (alpha-lantiproteinaa, antirypsin). momer
56 foilstatin-ke 1
68 DCN protein
61 apolupoprotein E
72 PREDICTED: similar to Annexin AS (Annexin V) (Lipocortin V) (Endonexin 11) (Calphobindin I
73 PREDICTED: similar to Colagen alpha 1(IX) chain precursor, partial
75 PREDICTED: similar to Procolagen C-proteinase enhancer protein precursor (PCPE) (Type
77 PREDICTED: similar to Extrceelular matix protein 2 precursor (Matrix glycoprotein SCt/ECI
82 PREDICTED: similar to Colagen-biding protein 2 precursor (Collgin 2) (Rhaumatoid erthrtl
84 PREDICTED: simiar to add phosphalese-like 285 PREDICTED: Somilar to Serine proteseo HTRA) precuruor (L56)
92 PREDICTED: similar to Fiblan-5 precursor (FIBL-5) (Devealoprental arteries and neural cres
93 serIne (or cyaleine) protlnase inhibitor, dade G (Cl inhibitor), member 1, (angloedema, hen
94 lumican
96 PREDICTED: similar to yyl oxidaoe-ik 3 precursor
97 PREDICTED: nilar to Low-denty lipoprotein receplor-related protein ) precursor (LRP) (A
101 PREDICTED: similar to procotagen-lysin,. 2-oxoglularate 5-dioxygenase 2 isoform a precun
102 PREDICTED: similar to Lysyl oxklace homolog 2precursor (Lyayl oxldasedika protein 2) (Lys
103 ibrromodulln
104 milk t globule-EGF fador 8 protein
105 PREDICTED: similar to Melanobsoferrin precursor (Melanorma-asocated antigen p97) (Cr
III PREDICTED: imilar to EGF-cntaining tuin-le extracollar matrix protein 2 precursor (F
112 PREDICTED: similar to Nucleobindin 2 precursor (DNA-binding protein NEFA) (Gastric canc
rotein #core peptides score2 masscov oulliers pvat 116 pval 11 pval) 1)5:1)4 BD 116:114 11 117:1)4 0 Aoceaatarclg 118 eIght sIgh?
22 0028 3 59967 47021 0 1 03E-00 1 27E-05 0.074832 070013 1.1728 056723 1.28)5 1058 1.4278 76&25353 3 3
47.915
56.092
51.285
36.046
41.137
44.461
33.046
28.046
52
25.523
23.699
21.523
23.666
18
17.097
15.614
15
23.046
14.569
13.39
12.569
16.921
12
16.398
Is
12
9.0458
9.5229
13.046
8.7959
7.0458
7.0458
6
6.920
4.5686
5.5229
6
4
3.5229
3.3979
3.0969
3
6
3
173.19
154.59
138.01
101.98
83.933
68.444
73.137
73.523
66
53.569
5.798
53.092
52.535
40.967
41.489
34
40.046
43.62
35.614
41.046
35
33.188
32.395
39
27.046
34.921
22.319
26.046
28.569
26.854
25.489
27.523
24.535
30.046
28.62
27.14
28.921
24
25.541
23.398
22.444
43412
48456
4360
3186
39750
48133
29716
22794
48150
20242
22197
15511
21448
19750
14173
12109
14167
13120
19477
13419
14337
1500
16614
057.6
14419
17637
10541
9012.5
9152.6
14143
9131.6
7188
6129.5
6390.3
67115
4280.2
8101.8
5097.6
5308.
4378.2
3513.9
6644.4
2741.5
3107.7
3425.9
2491.3
3451.9
4061.6
3254.9
156900
140470
114210
68251
86319
57100
63168
668
64263
43867
503
48065
47213
37963
34624
26109
34532
42546
30136
35092
300
28853
28018
30201
2475
29359
2198
23734
21571
24299
20052
24469
24742
26500
26052
23821
25436
19680
20511
19609
23009
1 0.000298 1.33E-09 0.12126 0.4052
1 0.003627 0.021477 2.91E-14 05
0 0.005763 207E-12 0.44871 075417
0 0.003214 0.000619 0.000931 08634
0 1.04E-06 1.56E-05 0.043117 080248
0 7.25E-12 2.8E-09 3.32E-12 0487
0 7.45E-05 0.003016 0.013527 054535
0 0.013824 0.001541 0.000497 077270
0 0.001314 0.00712 6.38E-07 050205
0 3.87E-0 664E-06 8.26E-0 0.39242
0 0.00099 0.001574 0.001519 0.5392
0 0.23438 1.3945 0.001072 082515
0 1.95 0.041343 2.92E-06 1)228
0 0.0026 0.1527 0.00206 0.5289
0 0.001141 0.007011 0.61002 0.4025
0 0.000393 0.00255 0.001368 225
0 772E-06 002343 248E-06 0300
0 0.30997 0.05528 0.065354 0742
0 4E-09 7,18E-05 5.11iE-06 0.7019
0 0.20145 0.049794 0.4867 07197
0 0.00015 0.000317 8.12E-06 02
0 0.040912 0.00464 0.62355 08)384
0 0.001734 0.006592 0.04675 o13
0 0.00115 0.1875 0.1875 070458
0 1.5 0.03620 0.807 078018
0 1.2188 1.1719 0.9438 068747
0 0.000409 0.002915 0.1875 04474
0 011103 0.095198 0.052257 0.553
0 0.012267 0.054972 0.057297 0286
0 0.014637 0.036234 1.2188 04442
0 0.1481 0.073461 1.5064 0253
0 0.025004 0.37997 0.19276 04677)
0 4.5291 1.3965 0.0138 0 71
0 0.44442 2.6655 0.07864 054715
0 0.43023 2.8327 0.1474 0058
0 2.2952 1.5052 0.95616 07235
0 0.12701 0.6131 0.059257 0205
0 0.45792 0.72618 0.047058 054165
0 0.2739 1.9671 0.66925 0.4673
0 0.045052 0,029063 0.1622 0200
0 0.11296 1.9873 0.19966 066771
0 0.90723 0,92364 2.0227 08
0 1.2366 2.7765 0.23089 081)57
0 0.1024 0.53537 6 003458
0 4.9397 1.1934 0.28272 092068
S05491 0.99 0.17857 035929
0 6 6 6 047984
0 0.32907 0.19542 0.26874 0.681
0 6 5.9084 034116
1 2.79-09 1.56E-18 2.82E-13 13739
1 3.88E-14 7.16E-14 2.83E-15 10625
1 1.34E-06 5.18E-08 0.007771 12272
0 4.676-05 2.539 0.007091 07478
0 3.46E-07 1.85E-10 0.87984 I.259
1 0.02941 01607 2.9491 17601
0 436E-10 2.59E-09 3.8529 13822
1 4.07E-08 0.87787 2.52E-08 071148
1 0.00221 0.20534 0.000705 0.05M
1 1.07E-05 1.24E-08 0.01239 13
0 0.000685 0.001252 0.022754 1.011
0 4.502 0.000175 0.14762 10135
0 3.74E-0 1.28E-09 2.44E-07 13
0 4.69E-06 4.26E-07 0.001062 059584
1 6.53E-07 2.52E-08 1.2E-12 1.0374
0 0.23571 1.9208 0.020749 1.1851
0 0.23291 2.0175 0.030686 1.347
0 1.3249 0.022795 0.19727 1.067
0 0.01408 0.53751 1.11E-05 12W
0 4.4475 0001474 022383 097051
0 0.029119 0.019961 4.44E-05 12488
0 1.4629 0,011321 0.004185 11292
0 3.71E-08 3.93E-07 0.003595 062877
1 1.3926 0.048075 0.21917 05380
0 0.004233 0.002232 17747 1.612
0 1.3149 4.926 2.5203 106
0 0.032559 1.4376 4.78E06 119)
0 0.63526 4.59E-05 5.89E-05 0375
1 4.0725 0.12156 0.090454 10019
0 3.8656 3.471 4.74E-05 087379
0 0.79695 7.89E-08 0.000952 0854
0 0.096376 0.01082 7.56E-06 1312
0 0.00299 0.001465 0.34913 13157
0 0.44395 1.4582 1.8792 11349
0 1.27 0.005698 5.20E-1 1076
0 0.024902 0.005048 0.88147 12389
1 2.0824 0.8915 0.11214 110
0 0.021583 0.002513 0.003752 1203
S0.001505 7.15E-08 1.04E-06 1.264
0 0.68901 4.1046 0.000305 087787
0 000D4302 0.2153 0.007907 1.2271
1.5711 0.40372
1.2397 0.87414
1.5737 0.45)19
1.3185 0.51990
1.3 0.6744
1.3156 0.596
1.311 0.84616
1.3083 0.72692
2.0142 0.0)747
1.2121 0.40086
1.3537 0.847)5
1.75 0.87451
1.5029 08052
1.3088 09)44
1.2259 070219
1.2935 4431.2495 04085
1.4325 0835)
11044 05385
1.423 072400
1.742B 01828
1.4396 04832
1.3254 00)675
1.119 08)30
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2.3314 070202
1.1767 04)552
1.3663 00443
1.4796 025588
1.5349 003)
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1.5642 01)
1.431 0941
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1 0.5024)
2.127 0.17035
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1.347 1)9
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2. 13629
1.248 126
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1.278 142551.38 1075
1.7621 0907381.4442 119M
1.4934 05418
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1 00)4
1.7633 0)1624
1 Or
1.266 080402
1.2396 122541.2570 093357
1.4013 029
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Thesi,CH4_itraqsupplmet_proins_sorted
order ProtainlName
114 oteoglycin (osleoinductive factor, mnmec.n)
117 peptidylglydne alphamidating monooxygenase
124 PREDICTED: similar to platlet-drived growth factor receptor-lke protein
126 PREDICTED: similar to EMLIN I precursor (Elastin tmirofibdl interface-located protein 1) (E
127 PREDICTED: similartoms t In 4.iofonn2 precursor
126 PREDICTED: similarto CG12002-PA, loform A/ similar to NCAM
133 sOsue Inhibitor of mtteloproteinase 2
137 PREDICTED: sioar to Cathepsin Dprecursor Isoorm 2; PREDICTED: similar to Cathepai
140 trombospondin 2
147 dermatan sulfate proteoglycan 3
148 annexin I
159 peptidoglycan recognition protein
160 cathapsin L
161 PREDICTED: similar to Olfactomedn-like protein 3 precursor (HNOEL-ISo) (h0LF44)
165 mannosidase, alpha, class 28, member 1
175 PREDICTED: similar to Nidogen precursor (Entactin) iso/orm 2; PREDICTED: similar to Nid
177 tieu. Inhibitor of metalloprolinasa I (erythrold potentiating activity, colagenas Inhibitor)
181 legumain
184 PREDICTED: similar to signal peptide. CUB domain, EGF-Nke 3
195 PREDICTED: Oiiear to cal growth regulator with EF hand domain I
196 PREDICTED: similar to fbufin I isoorm C precursor Ssorm 2; PREDICTED: similar to bbu
200 PREDICTED: i r to a"ha 1 type XI collgen sonbrm 6 preproprotein, partial
204 PREDICTED: similar to Stem call growth factor precursor (Lymphocyte secreted C-type Sctl
206 PREDICTED: similar o secreted modular calcium-binding protein 2
210 PREDICTED: smlasr to Peptidy y cis-tras Isomerase C (PPlase) (Rotmase) (Cycloph
212 fibillin 1
215 keatin 10 (spIdermolytct hyperkratols)
216 PREDICTED: simlar to Extrsoelular superoxide tinulse ICIu-Zn] precursor (EC-SOD) ISo
218 PREDICTED: slmilar to refinoic add replor responder (tazarotene iduced) 2 Sorm 2
225 PREDICTED: similar to von willebrand factor A omin-related protein isoborm 1
226 PREDICTED: similar to keratin I Iso/orm 2 ; PREDICTED: simiar to keratin I Soson 7 : PR
227 angiogrin
228 PREDICTED: similar to secreted! modular calcium-binding proten 1
234 protaglandin H2 D-somerase
243 PREDICTED: simlar to T7H6.5
245 PREDICTED: similar to mannosidase, alpha, ds 2A, member I
247 PREDICTED: similar to dermastan 4 sullotranserose 1
254 PREDICTED: similar o Cytokne-ike protein CI7 precursor
255 PREDICTED: iilar to colagen triple helix repeat containing 1
259 PREDICTED: similar to pha-N-acetylgalactosaminldase precursor (Alph-galadtooidase 8
294 PREDICTED: similar to ilbuln 2 precusor, isoforn a
271 PREDICTED: similar to mannoe receptor, C type 2
288 '-nucleoliase, edo (CD73)
300 cyalatin E/M
305 PREDICTED: simlar to Colagen alpha 1(Vil) chain precursor (Long-chain colagen) (IC ad
310 PREDICTED: similar to integrin, beta-lke 1(Wih EGF-Ilke r peat domains)
311 PREDICTED: silare o prolyl 4-hydroxylase, alpha If subun isoform 2 precursor iSoform 2
314 PREDICTED: almilar to transforming growth factor, beta 2 isoonrm 2: PREDICTED: almilar
319 carboxypsptidase X
335 PREDICTED: s/Oar to complement factor I
353 PREDICTED: similar to Cathpain F precuror isoforn 3 ; PREDICTED: similar to Cathepsi
355 PREDICTED: similar lto seread odular calcium-bindsng protein I
360 PREDICTED: silaru to hyaluronan d proteoglycan link protein 3 (predicted)
361 matrix Ga protein
363 |yy oxidase
366 PREDICTED: smiar to Annxin AS (Annexin VI) (Upsoftin VI) (P68) (P70) (Protein 111) (Ch
374 PREDICTED: Similar to Tetrnectin precursor (1N) (Ptesminogen-lingia 4 bindig protein)
377 PREDICTED: sioilar to alph  1type XV Collagen precursor
379 glutarinyl-peptde cyclotransferase (glutaminyl cyclas)
394 PREDICTED: aimilr to Angiopoletin-related protein 2 precursor (Angiopoefln-ike 2) isos/f
401 PREDICTED: similar to Beta-hexosamindlase alpha chain precursor (N-Soetyl-beta-glucoa
404 pead basic amino add cleaving enzyme [furin, membrane associated receptor prolein) [Bo
406 insun-glt growsh fador bncing poten 4
429 PREDICTED: ahmilar to semaphorin 6D Isoform I precursor
433 PREDICTED: similar to Neogenin precuror, pertial
445 slalylansferase ST3GaI-VI
446 PREDICTED: similar to Collagen alpha 1 (XVIl) chain (Bullous pamphlgoid antigen 2) (180 k
450 PREDICTED: almilar to esophageal cancer elated gne 4 protein
455 ATP6IPI protein
475 PREDICTED: ilmilar to Beta-1,4-galcosybtransfaerase 4 (Bela-1,4-GalTase 4) (Bela4Gal-T
483 PREDICTED: similar to Biolnidase precursor
485 PREDICTED: similar to eclonucleollde pyrophosphatase/phosphodiesteraas 1. p tial
500 PREDICTED: similar to Latent ansforming growth factor beta boindig protein 3 precursor)
514 mannosdase, beta A, lysosomal
523 PREDICTED: similar to Polential carboxypeptklae-like protein X2 precursor
546 PREDICTED: simlar to Thrombosponde-3 precursor Isoform 1 ; PREDICTED: similar to Th
617 type IIA procollagen
627 Chandrorinasse ABC
629 PREDICTED: imlar to CIq and tuor necrosis factor related protein 5 isosorm 2 ; PREDIC
I PREDICTED: ilmilar to alpha 3 type VI colagen isolorm precusor isoform 1
4 PREDICTED: similar to Fibronectin precursor (FN) (Cokl-insoluble globulin) (CIG) Sofrm I
8 PREDICTED: similar to Collagen alpha 1(VI) chain precursor loform I
9 aggroean I
10 PREDICTED: similar to Tenacin precursor (TN) (Hexabrachion) (Cytotactin) (Neuronectin)
36 PREDICTED: similar to matrlin 3 precursor
44 PREDICTED: similar to Bone morphogenelc potein I precursor (BMP-1) (Prooolgen C-p
49 PREDICTED: similar to alpha 2 type VI colgen Ssoerm 2C2@ precursor isoorm 1
57 chondreadherin
71 clusrin
81 ploaminogen activrlor Inhibitor type 1, member 2
88 vernican
protein # score peptides score2 masscovoutlers pval116 pvaI16 pval117 115:114 SD IIB:114 SD
114 22.71 10 20 14090 0 3.5739 0.6094 0.5703 094004 14268 080304
117 22.15 11 20.444 1927 0 0.29883 0.018314 4.6070 10591 1.2808 05200
124 21.18 11 20.699 19263 0 0.24577 2.5255 0.006644 10705 10946 0B7B8B
126 21.17 10 20 15730 0 0.33897 0.B0915 2.7133 12613 13908 1254 1
127 21.02 13 23.014 17448 0 0.001465 5.89E-05 37077 1656 13809 16054
128 20.67 9 17.523 15630 0 0.003462 0.000467 0.15766 16373 i3089 rB207
133 20.23 12 22.092 17705 0 0.36339 5.458 7.48E-07 11204 1.2161 12758
n 137 19.77 10 19 16748 0 4.5042 1.2237 9.39E-07 096752 13003 093695
140 18.96 11 20.523 17126 0 4.0167 1.7947 0.000187 09661 1301 10913
147 18.58 11 21 20375 0 2.6883 0.10099 0.023438 0.9471 1.1004 0B342B
148 18.57 9 17.523 15492 0 0.007052 2.7371 0.025018 1.6940 1.328 11097
159 17.05 9 17.046 14550 0 0.001263 0.001495 0.68436 14762 12013 06600
160 13.92 7 13.046 13072 0 3.4405 0.14725 7.5E-05 1.0033 12094 12B33
161 16.91 9 16.268 14158 0 0.000968 4.024 0.023430 10072 12213 1034
165 16.47 8 15.046 11960 0 0.89063 0.20129 0.001557 12768 14001 12969
175 15.64 8 15.523 14548 0 0.098042 0.003718 4.9207 14135 13606 163
177 15.39 9 17.699 19843 0 1.2305 0.5377 0.02343 11961 14761 1.243
1i 15.06 9 15.063 12874 0 0.2953 0.25262 0.00067 071707 10369 073201
184 14.86 7 13 13733 0 0.007918 0.054657 0.5626 1694 12116 12974
195 14 7 14 16326 0 2.9362 3.1289 4.75 11207 10059 10804
0 196 14 14 27.046 24151 0 0.006655 0.000732 0.018065 12144 11979 1309
200 13.57 9 16.046 14006 0 0.29781 0.002246 0.25354 17531 20727 07126
1 204 13.23 7 12.046 10582 0 5.1909 2.4375 0.027232 09724 14873 061
208 12.97 7 12.569 10910 0 4.8279 5.625 0.017805 I.0821 22420 096727
210 12.85 9 16.444 12527 0 0.057266 0.17019 0.31638 1.3329 1260 12748
212 12.8 6 11 10377 0 043154 0.16672 1.2968 1039 14770 19471
215 12.37 7 12.046 9523.2 0 0.006738 0.098356 3.8752 070716 11702 003838
f 216 12.36 6 12 9139.6 0 0.14999 0.44221 0.025418 11822 11384 1104
218 12.14 7 14 12094 0 0.09375 0.000612 0.020897 17333 1275 10636
225 12 B 12 13361 0 1.6133 1.5441 0.32406 12091 1.436 1.162
1 226 11.66 6 II 8663.4 0 5.6392 0.88943 5.4340 1.0231 2022 102
227 11.54 5 10 7422.6 0 0.040463 1.5093 0.31404 17581 12779 11381
228 11.52 6 11.523 9972.6 0 1.7923 0.22075 0.0292509 0948 11194 0780
234 11.06 6 10.444 8665.5 0 0.1875 0.3557 0.1875 07762 12147 174
243 10.59 5 10 8512.3 0 0.63614 0.39676 3.75 13816 13835 1294
245 10.39 6 10 10307 0 0.32812 4.4594 2.3332 072633 13847 097301
247 10.27 5 10 7547.9 0 3.863 0.93634 0.16646 10348 11658 1114
254 10 5 10 9374.6 0 3.412S 1.683 3.7283 11148 14703 10605
255 10 5 10 7351 0 0.375 0.014479 0.075993 12637 12024 14109
259 9.97 5 9.0458 7322.8 0 0.54167 0.22967 0.002449 12913 12631 13386
264 9.67 5 9.220 86202 6 061947 0.1307 3.0093 1396 130 13651
271 9.3 5 9.0456 7294.6 0 2.9367 5.483 2.0349 11186 13831 1024
288 8.45 5 8.0915 80204 0 4.2417 0.58531 0.022791 1.0269 11371 11729
300 8.13 4 8 9477.4 0 027281 0.035671 0.25402 06900 1201 063707i 305 B 4 B 6499.8 0 0.12673 0.31714 2.9626 12396 11014 2.310
310 7.63 4 7.0458 6164.2 0 3.48805 5.0591 0.031875 0.9M 14438 10242
311 7.53 3 5.3979 3970.2 0 0.64658 0.17964 0.3625 14397 12035 126
c 314 7.51 3 5.0458 4174.1 0 1.7678 2.8985 3.8963 1364 14924 12143
319 7.33 4 7 6177.4 0 5.0854 2.0188 3.9269 1085 14348 062489
335 6.88 4 6.5686 7082.9 0 3.8375 0.92635 1.6542 12213 19643 1063
n 353 6.15 3 6 3837.1 0 5.0567 0.10885 0.19414 099023 10784 1.2453
355 6.14 3 6 4244.1 0 3.1156 2.3867 1.2734 066 12703 080966
360 6 4 B 6087.5 0 0.69416 5.4448 1.9678 1434 1389 1024
361 6 5 10 8241.1 0 3.75 0.375 32727 099148 100 13271
363 6 3 6 4367.8 0 0.064634 0.04771 4.1033 19426 10941 062602
368 6 3 6 4516.6 0 5.3821 6 1.9977 097016 12436 00627
374 6 3 6 5796.1 0 1.6775 0.64792 2.6109 16376 1768 11296
377 5.87 3 5.5229 4874.8 0 0.7910 5.2579 0.26309 1207 11737 1014
379 5.86 3 5.5229 5151.7 0 1.5156 1.9006 3.3943 12721 13890 1166
m 384 5.68 3 5.0458 4525.1 0 3.3292 3.2889 1.7324 1113 13018 10767
n 401 5.08 3 4.4437 4746.5 0 2.049 6 0.19581 16169 1470 10953
a 404 5.05 2 3.0458 4729.3 0 1.631 6 0.55834 17260 1431 08
406 5 3 5 53676 0 3494 2.830 5.1751 12 109 070674
429 4.33 2 4 3823 0 2.0243 1.1284 1.5387 088787 11038 10008
433 4.28 2 4 3475.1 0 1.243 0.25289 3.53508 13289 11403 101
445 4.11 2 3.5229 3343.9 0 0.38632 0.29525 4.8657 1.7169 10807 1023
C 446 4.04 2 3.3979 3127.5 0 1.015 1.3784 2.6171 17222 1232 060
450 4 2 4 27406 0 3.7546 3.6678 2.4262 076744 17037 071392
455 4 2 4 4222.4 0 2.8427 6 0.35868 080411 13283 099463
4 475 4 2 4 42685 0 0.63965 0.75841 3.3763 16005 1119 16961
483 4 2 4 3020.7 0 0.26006 2.1551 14599 063315 10178 076046
485 4 3.69 7.3979 6153.3 0 5.7652 0.9775 0.6775 1038 1157 1.0007
L 500 3.7 5 7.4949 8408.8 0 2.625 1.9704 0,52818 12499 16M 1.4974
514 349 2 3 326.6 0 3.3319 2417 3.4557 11896 13399 06843
523 3.31 2 3 2877.6 0 5.3813 3.8201 1.9322 097129 128 10662
r, 548 3 5 9 8023.4 0 3.6344 1.8994 2.7529 10061 125M 1102
1 105.66 58 112.15 104530 0 4.7774 1.83E-07 0.36899 10049 27417 008162
3 91.83 50 97.444 101060 0 3.1046 5.8757 4.1086 097060 12983 09662
1 566 2.66 1 2 1917.1 0 6 6 6 17348 I 1096
1 207.94 107 207.68 170540 1 5.27E-18 1.35E-15 5.69E-17 2.1418 1.3616 1.35W
3 4 149.44 81 104.93 148410 1 6.89E-14 1A6E-09 9.73E-14 2.587 1.3301 1.26
8 93.86 59 111.85 101310 1 3.78E-10 8E-10 1.67E-09 2.7414 1.53 1.9244
9 93.47 61 117.23 117440 0 1.21E-10 5.01E-07 0.006772 .2010 1.8843 202
10 86.63 47 92.523 85529 1 3.57E-26 4.36E-23 0.026206 34419 14110 30211
36 47.7 27 52 48784 0 2.6E-13 4.59E-10 3.8461 304 14833 21116
r 44 40.81 21 39.614 31714 1 1.42E-14 3.93E-11 7.35E-05 80221 14874 40243
49 38.2 23 42.967 40490 0 2.7E-09 7.92E-07 1.81E-08 22131 14348 16686
57 36.2 20 37.796 33238 0 3.62E-09 5.01E-06 0.6564 2.2459 1.3461 1.476
71 31.97 17 33.046 31086 0 2.72E-13 0.001758 0.45M66 2.0374 1.1281 3.1776
81 27.07 14 27.097 20805 1 2E-06 0.000732 2.58E-05 1.6726 1.2201 1.6042
as 26.43 17 30.313 20088 1 2.3E-05 4.87E-12 2.3403 1.6014 1.271 2.2621
117:114 SD Accesslorsig 116 sIg116 sig117 SM-ID
.2963 1.122 1.2156 2706829 0 3 3 yes
.1847 1.0248 1.307 278060 3 3 0 yes
1.0915 0.79418 1.1674 7665663 0 3 3 yes
.4819 0.8525 1.85 61845535 3 3 3 yes1.2645 0.98177 1.1383 76633782 3 3 0 no
1.2169 1.244 1.2723 7661898 3 3 3 yes
1.9881 1.8042 1.1871 27806163 0 0 3 yes1.1655 3.6959 1.3313 76858406 0 0 3 yes1.2671 1.4211 1.1771 28875793 3 0 0 no
1.2162 2.1942 1.386 27805823 0 3 3 yes
1.4133 1.3862 1.2477 25461193 3 3 3 yes
1.1949 1.1073 1.186 27808640 3 3 0 yes
1.2476 2.0075 1.1518 27608673 3 0 3 yes
1.2644 2.3859 1.4155 61611393 3 0 3 yes
1.3205 2.4754 14601 31341666 3 3 3 yes
1.2669 0.975 1.3543 766149 3 3 3 yes
1.3349 1.909 1.3954 27806161 3 0 3 yes
1.4718 2.1491 1.381 2780655 3 3 3 yes
1.1673 0.92131 1.1295 765501 3 3 3 yes
1.3751 1.0033 1.1632 7682967 0 0 0 yes1.2578 0.79345 1.2687 76617190 3 3 3 yes
1.1891 1.526 1.691 76674654 3 3 3 no
1.4449 0.8579 1.0806 76642160 3 3 3 yes
1.675 0.69117 1.2252 7660599 3 0 3 yes
1.3136 1.3654 1.5087 76622682 3 3 3 yes
10554 0M963 1.1817 27808637 3 3 3 yes
1.1518 1.0228 1.1315 27805977 3 3 3 no
1.1134 1.293 1.1352 7680741 3 3 3 yes
11396 0.78765 1.1453 7616163 3 3 3 yes1.3783 1.3106 1.3024 76637679 3 3 3 yes
1.7973 0.98926 1.2358 76617876 3 0 0 yes
1.2429 1.3546 1.282 27800923 3 3 3 yes
1.2327 0.7023 1.1579 76669311 3 3 3 yes
1.7473 0.72266 1.4173 27807521 3 0 3 yes1.2326 1.0294 1.5892 76264 3 3 3 no
1.2136 0.9027 1.249 76524022 3 3 3 yes
1.1496 0.7415 1.218776627567 0 0 3 yes1.1688 1.1012 1.4867 76620378 3 3 3 yes
1.1194 1.4193 1.19986 76834746 3 3 3 yes1.2397 1.9693 1.1496 76616903 3 3 3 yes
1.1597 11463 1.431 7664536 1 1 1 yes
1.5861 0.87239 1.3251 76646205 3 3 3 yes
1.1433 1.9155 1.1718 27806507 0 0 3 yes
1.1423 1.3765 1.2065 61097917 3 3 3 yes1.7174 1.0796 1.2178 76649216 3 3 3 yes1.248 2.0173 1.2121 7661183 1 1 1 yes
1.0736 2.9895 1.637 622268 3 0 3 yes1.4626 1.16 1.637876670067 3 0 0 yes
1.4017 0.88054 1.6717 6271399 3 3 3 yes
1.4217 1.706 1.666 76619404 1 1 1 yes
1.0089 1.8496 1.217 7658024 3 0 3 no
1.4117 0.78623 1.259 76659309 3 3 3 yes
1.4555 0.64845 1.3288 7647007 3 0 3 yes
1.3811 0.77556 2.3663 27807275 3 0 3 yes1.1022 0.90385 1.45 27806857 3 3 0 Ye
1 1.5660 1.4419 76623595 3 3 3 yes
1.0786 0.89463 1.2205 61819239 0 0 3 yes
1.1732 080582 1.044 76624759 3 3 3 yes
1.223 1.142 14011 29135303 3 3 3 yes1.1958 1.1257 1.1541 7663040 3 3 3 yes
1 3188 1.0662 76626683 3 3 3 yes
1 2.379 1.1977 27808495 0 3 0 yes
1.5755 1.0516 1.3834 27807009 0 3 0 yes
1.1909 0.65917 1.2855 76627892 3 0 3 no1.0421 0.8696 1.3001 7672111 1 1 1 yes1.0474 0.91159 1.339 072137 1 1 1 yes
1.1112 1.2321 12720 76654900 3 3 3 yes
1.9759 2.5603 2.664476629599 3 3 3 yes
1 0.75048 1.039 26461231 1 1 1 yes1.166 1.086 .1529 7863 1 1 1 yes
1.2777 1.1065 1.0592 76671919 3 3 3 yes
1.3391 1.321 1.2849 76500000 0 3 0 yes
2.217 1.2201 1.219 61640215 0 3 3 yes
1.506 0.84487 1.3544 27805995 1 1 1 yes
1.2004 0.77551 1.2204 768193 0 0 3 yes
1.3209 0.8972 1.3446 78812138 0 0 3 no
15833 0.8398 2.191 gqi10947027
1.2352 0.96883 1.2049 gJ|5938742; gi3991938; gil3406155; gil1607541
1 1.1626 1 76635366 3 3 3 yes
1.3366 1.6062 1.4487 76614736 3 3 3 yes
1.3212 1.6875 1.3007 76610128 3 3 3 yes
1.353 2.0466 1.3333 7667061 3 3 3 yes
2.1569 0.92602 1.186 27806761 3 3 3 yes
14443 1.1767 1.398 7625295 3 3 0 yes
14054 1.0241 1.2867 76630143 3 3 3 yes
1.567 1.7489 1.5599 76624630 3 3 3 yes
1.344 2.0827 1.3982 7607764 3 3 3 yes
1.2616 1.1368 1.3999 27806697 3 0 0 yes
1.1396 1.0772 1.1755 2780607 3 3 3 yes
1.4742 16027 1.2641 27807207 3 3 3 yes
1.1812 1.0664 1.3498 30794358 3 3 0 yes
coverage manual Indexer ki
31 yes 2
17 yes 2
34yes 2
11 yes 2
yes 2
10 yes 2
24 yes 2
23 yes 2
yes 2
44yes 2
8yes 2
yes 2
31 yes 2
I8 yes 2
11 yes 2
eyes 2
30yes 2
1B yes 2
11 yes 2
32 yes 2
6yes 2
yes 2
27 yes 2
9yes 2
6 yes 2
3ys 2
yes 2
32yes 2
45 yes 2
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8 yes 2
a2 yes 2
45 yes 2
I8 yes 2
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4 yes/poor quant 2
6yes 2
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16 yes/poorquant 2
25 yes 2
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yes 2
4yes 2Byes 2
4 yes/poor quard 2
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Thes_CH4_traq_supplement_proteins_sorted
order Protein Name proteins score peptldes score 2 maos con otter. pet pvet 116 peal 117 116:114 SD 116:114 D 117:114 80 Actesslcreig lit 019116 sig117 814D0S PREDICTED: simiar lo germinalhison H4gene; PREDICTED: si rterteinl histone 105 23.62 20 38.523 31972 0 1.26 6.27E-10 0.531 1.9211 1.2717 1.007 1.2561 1.20 1.2104 618247 3 3 3yesIStPREDICTED simir to rmli-preusor (CytImeko erfm8eiy 18upIRantagnist 11 3i 2.05 10 20 21637 0 B.5SE-OS 3.960-05 5.902 1.9048 1.2214 l.64e 1.1248 1.901 1.1534 6186323 3 3 3yes120 PREDICTED: similartoLamnb gas n-I chainprecursor(Lainin e2chain) patial 120 22 11 21.222 20122 0 0011719 0000232 074312 19279 1n3o6 22236 1.43 1.208 1.44947, B6M75 3 3 Oc123 PREDICTED: similar tHtoreH262911PEDICTEDsilrtottistomtH191B;pRI 123 21.39 12 21.053 14594 0 110-09 217E-10 120E.08 21625 11292 20611 11039 2.2365 1.1717 76612878 3 3  ye129 PREDICTED: similar to Histons e (Amiy 2Ioolom2 129 2084 11 19541 153 0 00559 0000748 0050131 25568 1649 21221 15112 2.2856 1.445 76612880 3 3 m143 PREDICTED: similar to Fibroleuin precursor (Fibrinogen-ike protein 2) (pT49) Isolom 1 143 1873 8 18523 14544 0 000017 0000143 54609 21304 12062 23364 12401 1.0278 1.3109618802 3 3 yes145 cyanoge bromide 145 1869 9 17398 14378 0 00400 I.4929 0016549 28349 22984 078817 15952 2.1553 1.7172 47584048 3 yes156 donaln)Iectn, superfamily member l(cartilage-derived) 19 17.39 9 17.046 13804 0 517E-05 0000190 0004954 2955 13851 17482 12172 1.4848 1.2564 2767147 3 3 0y163 PREDICTED: similar to CEGPI protein 163 18.66 8 16 13667 0 0046675 6.35S 32081 13916 12028 2791 12971 0.3191 1.357 76830840 3 3 yes169 call-dedved chemoxln 2 169 18.27 9 17.046 13497 0 1290O 00223 38232 21314 12081 1 77 124 1.036 1.2172 2780683 3 3 Open171 tizzled-related prot in 171 18 8 16 12979 0 022218 023438 14107 18148 2084 17889 16734 0.83488 1.4821 278062 3 3 pee192 angiopoitin41ke 7 192 14.00 8 I5MS 14248 0 0007987 0000206 173E-06 15368 13673 22258 12859 2.45 11456248004 3 3 ye193 hemoglobin, gamma 193 14 7 14 11665 0 0020797 3685-05 0001786 13726 1187 38348 12784 1.578 1.1749 62460484 3 3 m21 PREDICTED: similar to CruopsmieOne proensotmIPREDCTED:simiarttroi 18 13.78 7 13.046 11726 0 0.37 0.04686 0.1979 20466 1814 165 14274 1.3513 1.2672766677 3 3 201 PREDICTED:*tr to Corniplasnprecursorormedase) 86itrr 2;PREICTED: aim 201 13.42 7 12.523 11672 0 0.014544 0.159S4 0.087845 2.8506 1.5766 1.654 1.487 1.956 1.5236 76607845 3 3 Sync205 RAB7, member RAS ncogen family 205 122 8 12 1169 0 0.17044 0.006912 0.001376 1 536 1412 20449 1.301 1.6700 1.143278084 3 3 3pec213 PREDICTED: tlar to neuroplin 2 lobrm 3 precursor ooform 4 ; PREDICTED: sinilr to n 213 12.43 8 11.046 7934.8 0 0.0010 3.030S 0.87721 18262 11901 29162 11356 0.83486 1.2832 7680302 3 3 pee217 PREDICTEDiilartoerted oulrmbc indhgprotein2 217 12.29 6 12 10759 0 7.00CE07 0.1875 0.13148 51798 1084 3467 12152 1.184 1.121 78660084 3 3 3ye237 screted fizzled-related protein 1 237 10.81 5 10 8037.7 0 0.01045 0.00879 1.5117 22781 12907 18494 1.18 1.1358 1.23732780136 3 3 yeo241 alpha-2-HS-glycoprotein 241 10.84 5 10 7329.8 0 0000218 o023836 008716 53187 1204 1 8602 12821 2.0881 1.500227601 3 3 3yes251 PREDICTED: simnlar to proteogyan 4 251 10.14 5 IS 7968.3 0 0000656 010295 0010115 29952 15941 16446 12301 3.297 12459 768018 3 3 yes257 PREDICTED: similar to Complement Cq subcomponent, C chain precursor isoorm 1 ; PRE 257 10 5 10 7855.1 0 0001861 0007325 17248 23468 11784 1956 12015 0.86913 1.291676811607 3 3 yes262 PREDICTED: similar to Histone H11.4 (H VAR.2) (H1e), partial 262 9.63 5 9.2676128.4 0 0013282 0039729 020584 30868 14384 18484 13917 1.398 1.416676651042 3 3 3ye263 PREDICTED: imtlar to collagen, type XXVII, alpha 1 263 9.71 4 8 588.1 0 0015729 003859 502 2033 11846 1827 1.195 0.91612 1.35297625260 3 3 yes267 PREDICTED: similar to PDZ domain containing 6 267 9.52 6 11.623 12228 0 0012090008703 004076 21078 11687 18765 11481 1.1849 1.088678221 3 3 Open279 PREDICTED: similar lo Procollagen C-ndopeptidase enhancer 2 precursor (Procoagen CC 279 8.8 8 9.8144 8262.6 0 0003606 0010122 048175 25804 13003 2.1409 13978 1.483 1.5544 7688418 3 3 yee280 PREDICTED: hemoglobin alpha chain ifom 2; PREDICTED: sinar to alpha 2 goAin- P 280 8.9 4 7.5=9 8 0 34634 001228 23785 12073 163 373 15748 1.1318 1.251 752523 3 3 3ys287 beta-2-mlcroglobulin 267 8.45 4 8 7037.8 0 0085642 0014481 01153 32248 15772 48384 13997 1.8447 1.1268413883 3 3 3yea
294 PREDICTED: similar to olfletomedin-ie 2B 294 618 4 75229 85823 0 000217 0005483 02001 54148 12039 53627 12887 2.086 1.4817 78612610 1 1 m99 PREDICTED:iiartIteieukinIn78 precuso QLI 70) (Cyoote proteincyo) (No 288 8.13 6 9.0408 9487.5 0 003331 0.19152 1.898 327861 159671 2.0722 1.8324 1.1778 1.4539 7682670 3 3 3pyea308 PREDICTED: similar to inteuin-17grotfacrtrbnngproten 6o l 306 787 3 5.0458 41481 0 00012C9 1y2159 2y1- 3k249 10297 1.961 1.89 1.099 1.15236168355 3 0 O 2e9313 PREDICTED: similar to inu313 752 4 7529 8916c5 0 02277 0o1n55 21757 1806 13862 2591 14426 0.85804 1.25767785 3 ee318 PREDICTED: *ier to Laminin beta- chain precursor (Laminin B1 chain), partial 318 735 4 70458 54232 5 021927 533181 071611 17903 1361 2288 1.59 1.28 1.206 7615137 3 3 yes321 PREDICTED: similar to mannosdea, alpha, class 1A, member 1, partial 321 73 5 90459 70028 0 000158 0256 0000965 2038 11392 1.2089 11633 1.8532 1.118578674188 3 3 pee331 PREDICTED: similar to csroma eon derNed factor 4 331 696 3 6 56301 0 02008 016551 021664 23361 13178 18272 I 1937 1.8872 1.2539 76637700 3 3 m332 PREDICTED: similar to complement component 1, q subcomponent, bela polypeptide precuo 332 62 4 68208 84825 0 0035275 0058344 012758 23042 13674 20491 12753 0.8235 1.081576611613 3 3 Opec341 PREDICTED: similar to thmmbospondin repat containing I isoforn 1 341 848 3 50459 51488 0 0067081 027336 20362 84456 14829 34737 16159 2.0173 28558 76612850 3 3 pec342 nrat mclloptnan 14(membronc-1merted) 343 845 3 6 43639 0 0093255 m l3923 08975 22218 1.117 21043 21392 1.442 1.04827801 3 3 3d e345 PREDICTED: similar to polypepaide N-acatylgalacosanmiylransferase 2 345 036 4 8.5688 86231 0 23802 067332 37067 17267 24528 1.8085 14567 1.0838 1.3307 788906 1 1 I pea350 PREDICTED: similar to alpha 3 type IX collgen 350 822 3 6 57852 0 2088 90730 21982 2.693 45206 09755 15317 2.028 2.80 7666312 3 3 yes378 PREDICTED: simnar to ApoIlpoproain D precursor (Apo-D) (ApOD) 378 5.7 4 752268038 0 0011968 048918 001436 39387 1306 17225 15117 2.3809 1.1879766018 3 3 m386 transcobalamin II 386 587 2 35229 29117 0 078201 11806 33858 3537 14351 2845 1888 1.1779 1.3241276 3 3 3yes394 PREDICTED: similar to meotorin, gl o dirferentiation reglor-lke 394 5.52 2 4 3103.6 0 084338 08339 11322 69248 18397 3889 1368 2441 1.4703 76845380 3 3 pe412 Niemann-Plok disease, t C2 412 4.7 2 3 384.9 0 016132 082569 023929 32332 10726 13382 1.096 21921 1.108527808881 3 3 yes417 PREDICTED: similar to Calhepsin L precursor (Major excreted protein) (MEP) 417 4.82 2 4 3982.2 0 18778 20073 35479 49248 33436 36781 28058 1.7001 2.725961867538 3 3 lee418 H2A2As bmltonemesitrZ;PREDICTED:elrterto family, memberVisit 418 4.6 2 4 2748.8 0 10197 02617 035884 35854 16386 316 10839 24387 1.1254278773 3 yes19 PREDICTED: similar to Pedloin preoursor (PNs) (Olooblast-specilic factor 2) (OSF-2), parth 419 4.6 2 4 363 0 056708 12927 04568 3218 1280 1.4924 12209 3.3349 1.24967663330 3 3 yes4 20 PREDICTED: similar to mnVes incrblcoeA prersiP36 ror(P3bco a 4.4 2 4 3217.9 0 050312 13271 0.271 13673 1.004 1.78 1.331 21744 1.082 81878717 3 3 3yes4 2 PREDICTED: similar to Gal Inducil pcytllne Ilprecursor 426 4.23 2 4 3924.1 0 034773 045487 35878 1852 1-0602 1129 1.118 1.077 1.1776 78642911 3 3 ye431 PREDCTED:eter to aet.3 indgpotenprecusor(Ltn gtersterrtig sol 431 4.26 2 4 2633.4 0 0.63786 0.58341 0.10882 1.7521 1.1432 2.1678 1.1834 2.0038 1.0267 768545574 3 3 3pyec435 PREDICTED: similartofibroblastgrowt factorreceptor I ieom5prsccsor981cm3; PR a 4.24 2 4 3122.9 0 1081 0341 46271 26781 1r4c09 4.465 1.85 1.1754 2p0957 76O981 3 3 3 pee447 PREDICTED: tiar to ERGIC-53 protein precursor (ER-Golgi Intermediate compaortment 53 447 4.03 3 3.0468 3102.8 0 0.32941 0.23143 1.0232 17817 10732 23831 10773 1.5081 1.172976652230 3 3 Open458 PREDICTED: similar to Dipsptidyl-peptidasa I precursor (DPP-l) (DPPI) (Cahepsin C) (Cath 458 4 2 4 3738.9 0 2.0213 1.327 1.383 20143 1.784 20921 14584 28867 1.8087 78656863 3 3 pea463 gycoprotein-4-bret-glaciosyoransferae 2 463 4 2 4 268.4 0 0.11608 0.29582 0.15674 32482 10518 22085 15939 21081 I.053429135321 3 3 3m46M PREDICTED: similar to Syndecan-4 precursor phigycn) (SYND4) (Ryudocan core Prot 46 4 2 4 597 0 0.352 0.74 8 3.8677 1.529 2477 1.291 0.519 1 763377 3 3 e491 S00calciumr bining protein A12 (calgranulin C) 491 4 2 4 2624.5 0 0.021177 29171 1.001 2 8 1.009 1.1588 1.3155 1.643 1.219427807183 3 3 pe507 PREDICTED: tiar to Complement factor D precursor (C3 convertase activator) (Proprdin 507 252 2 3.5M 3151.1 0 a 8 6 3.3821 I 1.5178 I 1.3 1 81882363 3 1 1 96510 chemokine (C-X.Cmot)igand6(granulcytechemotaclcprotein2) 510 3.52 2 3.5229 28801 0 0.56539 0.84451 048187 73566 15206 27888 1.387 21767 1.14672780833 1 1 yes512 PREDICTED: similar to Secreted fizzled-related protein 4 precursor (SFRP-4) (Frizzled prote 512 3.52 2 25239 3401.9 0 0.070311 0.42881 0.032159 3805 1.034 2.4939 11561 1.4082 1.0041 768 1 1 I yen520 PREDICTED: ilar to Pentraxin-related protein PTX3 precursor (Pentaxin-related protein P 520 24 2 3.3979 3124.9 0 0.93377 0.4808 8 35898 15897 52072 1.327 0.93353 1 7687843 3 3 pen525 PREDICTED:similarto5T4eoncoealtrophoblastglycoprotein 525 23 2 3.301 1834.8 0 17372 088317 27383 20832 18812 23157 12395 1,111 1.2403 782454 I 1 I no540 Inler-alpha-typsin I hibitor (ptmtern HC) figt 0 3.05 2 3.0458 3088.4 0 t.4021 1.0876 59503 23587 15839 30686 1 5801 1.0057 1.8567 2780743 3 3 0 yes58 PREDICTED: esingarto CSVgrnoan B (Migration Intilletory lactor-reteted protein 14) (MRP-IZ 378 5.1 3 5.0989 4042.5 0 0.1854 0.70881 0.012489 5.33 1.8336 2.3982 1.7747 2.2597 1.08666 61677405 1 1 yes570 PREDICTED: almilar to ondroitin polymerizing factor 408 427 2 3.048 20185 0 8 6 6 1.812 1 2.227 1 1.479 1 76610721 I 1 1 yes575 PREDICTED: slar to IAA1822 protein 424 4 2 4 25636 0 040503 10657 34743 24003 11408 126 11102 1.0818 1.1152 768472 I I yee580 ndothel protein C receptor 439 4 2 4 27107 0 17067 2898 58571 22248 17192 16889 20161 0.96738 1.38492780603 3 3 yes618 dystroglycon 19g 8.92 4 8 7777.8 0 003677 0004756 013318 16313 12754 2356 11304 1B0 I.2508gi(2893448 99621 fioluin; Sequence 11 from patent US 5981483; Sequence 8 fmm patent US 5821227 244 8.26 3 5.3979 48123 0 0044103 038838 12391 5.484 12734 18811 121,8 1.7561 1.8871 g11344:81110058432:8116004708 m07 PREDICTED: similar to WNT1 inducible sipgan pathway protein 3 precursor (WISP-3) 595 6.86 3 6 4526.6 0 12454 031535 8 39111 198 40206 11771 0.836 1 7662568 3 3 311 procolagan-pcline,2-ogIularafte4-dioxygennae 11 75.44 42 78679 84542 0 0.000001 220-16 9.880-08 1.0283 13102 17596 1.2735 6.8191 1.4874 27606601 3 3 3 pen17 PREDICTED: similar to cytonkeleton-assoclated protein 4 17 831 33 83967 6982 0 1.7105 2.280-13 3.21E-28 23887 19026 21782 13327 10.211 1.3927 7619065 3 3 yes18 onst 18 8089 33 64 56049 0 1.6611 4.16-15 5.650-22 1920 13 32208 14881 7.36 1.9384 270686 3 3 3yen
23 PREDICTED: similar toLamn awlgmin) Itm2 23 5296 28 488 45158 0 a8lph14 228E-18 4.90-05 2.381 131 3.6026 1.324 5.033 1.4233 76612308 3 3 3pn 24 glucose rgulated protein58IkD 24 4877 27 5362 46919 0 216E-10 278E-09 3.36E-05 20752 14348 18836 1.4593 11.148 1.867827809 3 3 3yes33 PREDICTED: ilear to Moesin (Membrane-orgenizing seenaon spite protein), partial 33 4431 25 44025 37278 0 5.530-8 2.63E-lI 1.03E-14 1.5359 1.2947 20800 I 3388 3.8403 1.426 70616391 3 3 3m37 PREDICTED: similar to Filarin8eroiafcamn)pAd ~n1( rtein) a 37 4619 22 40535 38423 0 4.81E-07 8.36E-07 278011 21906 15485 2386 15667 4.4442 1.814 7(- a7F t 3 3 3 ye38 PREDICTED: sitar to 78 kWe 9ucose-regulated protein precursor (GRP 78) (Immunoglobu 38 4578 38 68313 62411 0 3.330-10 8.820-13 4.366-24 1.5432 1.3138 I897 1.3769 8.2872 1.5114 78820567 3 3 3 pen46 heat shock 70 kD opmtein a 46 3801 22 43012 36108 0 1.120-07 3.870-08 0.000182 25488 15733 30162 17396 8.3729 20115 27809926 3 3 3 yen50 PREDICTED: ier te Ribosome-binding protein I (Ribosome r ceptor protein) (mRRp) 50 3778 20 35229 30009 0 1.380-0 0.097 8.276-08 I.9506 1.2833 1.7425 1.5176 5.0704 1.93 76632458 3 3 3 pen62 tumor rejection antigen (gp96) 1 62 337 18 39589 23963 0 2810-07 1.78E-07 1.36E-12 18472 1254 21447 1.3068 8.2182 t.4214 27807283 3 3 3yes64 PREDICTED: *ier to AHNAK nucloprotein isobrm 1 64 351 17 31488 29634 0 0.03862 0.002197 3.080-08 20551 20133 21582 2083 6.8047 2828976680 3 3 3yen67 calreticulin 67 3239 17 31.365 26831 0 0.0044 7.45E-06 1.28E-13 16397 14703 21585 15254 10.595 1.46M827806723 3 3 yes68 aci, beta 68 3231 18 20048 31560 0 0.001179 2560-0 1.470-14 19918 11925 22018 1.302 8.32D5 1.3861 2780765 3 3 3 pen87 PREDICTED: sir to alphawocotalphasubunform2 87 2551 12 20915 18448 0 0.000281 4.310-OS 1.730-08 18589 1309 18384 13051 4.7907 1.3741 7857688 3 3 3f 288 armeoin A2 88 2652 13 28 22733 0 0.011718 0.00019 5.820-07 1529 14743 18120 1.249 2474 1.4238 2767288 3 yes90 vlin 2 9 26.15 22 39.581 34710 1 0.000185 40-08 2730-12 18773 1.3331 1.9432 14243 3.5988 1.5036 27 31 3 3 3yes95 PREDICTED: similar to Fructose-blphosphale akeolose A (Muscle-type 99ism2: 95 25.61 13 24.046 21404 0 0000232 8220 3250-07 28231 1828 355932 17152 7.3126 1.830 7653611 3 3 3m96 PREDICTED: similar to glyceraldehyde3-phosphate d hydrogens isofm 2; PREDICTEI 96 20.4 13 25.38 21978 0 895-07 7620-07 1280-08 19132 12248 24482 13417 9524 1.6727816518 3 3 3ye107 heat shocokm70kD Protein l 107 24 17 33.052 25388 0 0.022 020016 2 4430-07 128562 1283 2065 1.82- 6.2754 2.295540254806 3 e
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order Protein Nme protein # score peptides ocore 2 mass cov outlors plalII pvalllS pvalllT 115:114 80 116:114 SD 117:114 60 AccssaorolglI6 s111 .9117 6*40
116 PREDICTED: simier to Prolyl 4-hydroxylas alpha-I aubunl precursor (4-PH alpha-1) (Proc 116 22.24 11 21.523 18890 0 0.00301 0.000236 3.4007 1.5731 1.3112 1.668 1240 60708 1.212 76666 3 3 3500
119 PREDICTED: similar to FKOS binding protein 9 119 22 11 21.523 16426 0 0.000136 0.001357 0011719 1072 42200 17244 13248 8.O09 18211 766153o1 3 3 3yes
121 PREDICTED: similar to tubulin, beta 5 Iobrm 4; PREDICTED: simler to tubulin, bobe 5ISO 121 21.98 10 20 16069 0 0.068604 0.010907 1.65E-06 23814 17489 24178 17846 90642 1666700 58 3 3 35ye
125 PREDICTED: imar to Thioredoxin domain containing protein 5 prowro (Thioredoxin-like 125 21.17 13 24.569 22070 0 6.E-06 2.02E-08 1.42E-10 48882 1231 25748 13039 tori t.43487007683 3 3 3 yes
132 oukaryollo translation ongation factor apha 1 132 20.24 9 16.092 14473 0 0.040875 0.040876 1.470-05 26257 17708 26613 18311 4000 17966 682967 3 3 3yes
135 PREDICTED: similar to semaphorin 3C 135 20.07 11 18.569 17820 0 2.13E-07 0.270-05 3.580-07 44828 13192 27332 1.3037 48784 1.26 76610006 3 3 3500
136 PREDICTED: similar to liver glycogen phosphorylase Isoorm 7 ; PREDICTED: lmr to live 136 19.9 10 17.137 15393 0 0.011719 0.023436 0.023438 20722 10208 28641 101 601 24748 7682705 3 3 3yes
136 protein Idnase C substrate OOK-H 138 19.44 11 19.012 18191 0 0660-05 8010-09 2810-07 21083 13230 27007 13148 10692 17162 413877 3 3 3yes
139 Rho GDP dissociation inhibior (GDI) a"lh 139 1927 9 17.523 13630 0 510-06 3.7E-07 1110-0 22308 12732 32612 12088 8437 42413 2603774 3 3 3yes
141 PREDICTED: siilar to Rb GDP dsocation Inhibitor beta (Rob GDI beta) (GDI-2) lIoform 141 18.92 10 17.137 15969 0 01194 007467 0000172 2102 20408 274 2344 77034 23022 76328 3 3 3s
142 PREDICTED: similar to FKOO binding protein 10 precursor (Peptidy-prolyl cl-trana isomers 142 18.76 9 16 14618 0 0000801 0030293 1480-07 10931 12917 10905 14603 12020 1429470460 3 3 35
153 pemxfredoxin 1 153 17.53 9 10.569 11083 00023 0023438 0420-10 25583 11232 20858 1138 77025 115032780081 3 3 319
164 PREDICTED: simmer to actinin, alpha 1 164 16.62 18 34.092 29154 0 0006 1020-08 32909 18083 18893 25497 10403 56681 18035766106 3 3 30n
167 PREDICTED: simlar to Galoctin-3 (Galciose-speciic lcin 3) (Mac-2 antigen) (g-bidig 167 16.3 8 48 12370 0 0000882 0001763 29E-06 23742 1304 20046 10108 8.3384 1.407768618 3 3 34ye
170 PREDICTED: smilartoltropomyoin 3aoorm2Isoornn 3; PREDICTED: simar to mropomyc 170 16.16 8 14.62 12127 0 0022373 0040875 0048875 4881 14002 27045 14671 8.4013 1O0 706207 3 3 1ye
176 PREDICTED- similar lo alurmenin precursor isolrm 4; PREDICTED: similar to calumenin p 176 15.52 8 15.523 12374 0 0017799 002008 23200 15591 I 320 1396 12425 3.7044 1.332 76015719 3 0 350e
179 PREDICTED: similar to Glucose--phosphate isomeras (GP) (Phosphoglucos i merase) 179 15.21 7 12.523 12411 0 012030 0030834 908-05 19534 14682 31334 178 90053 1.00770540989 3 3 3yes
183 cathopuin B 183 14.92 8 14.921 15081 0 0013107 0086018 000204 1884 14829 10471 14615 3.8384 1898 2760671 3 3 3500
188 coflin I (non-musclh) 188 14.47 7 14 8867.7 0 01870 008375 00875 2288 17308 3551I 7268 7.7107 2.394 02751777 3 3 3cn
189 PREDICTED: drmar to nucleophomarn t isoform l 189 1426 7 13.523 8918.1 0 0487000083 0010-08 24592 12308 20718 12626 .086 128007026542 3 3 3yes?
197 PREDICTED: similar to archain isoorm 2; PREDICTED. similar to archain iobofrm 1 ; PRED 197 13.87 0 12 9767 0 0040855 01483 0000833 2023 14763 20877 18891 87088 21411 70039416 3 3 3yes
206 solnderin 206 13.03 8 12.887 11997 0 008378 00024 0000194 21487 10863 33483 16744 75129 1.794 276041 3 3 3yes
230 PREDICTED: *ir to calmodulin 1; PREDICTED: similar to calkoduln 1 230 11.37 7 12.444 13079 0 0010207 0000004 0000045 4684 1406 28479 13706 0.305 17402 70064 3 3 3 yes
231 tyroslne 3-monooxygenaAeryptophan 54nonooxygenaso activation protein, epsilon p lypep 231 11.26 8 17.046 13701 0 0000341 7700-06 010-06 20746 13284 2978 12806 72042 15048 2780047 3 3 3501
239 PREDICTED: simmler lo ruiocalbin 3, EF-hand calcum binding domain 239 10.71 5 9.3979 94027 0 0274480040882 9 -06 12021 1148 8 11489 81032 10839 7042117 0 3 3y
240 peroxredoxin 2 240 10.66 5 10 10284 0 022787 018271 0000318 24509 10671 33397 10899 9068 132072707408 3 3 3yes
242 PREDICTED: similar to ubiequtln C oform 11 ; PREDICTED: *mir to ubiin C loolm 1' 242 10.63 6 10.048 907 0 0.000438 00004 0.1876 2.20 4817 3.0429 1.287 4.544 13353 7608714 3 3 30y7s
244 PREDICTED: lmilar to myosin, heavy polypepide 9, non-musclo, partial 244 10.5 6 10.268 9578.3 0 01870 04875 000208 1048 120 25953 1339 32180 1240476333 3 3 3yes
250 tyrooine 3-monooxtygenaseryptophan Sno ooxygenase activation protein, gamma polypep 250 10.14 6 15.046 11326 0 047E-05 1060-05 8810-06 21918 12158 30706 I.282 8708 15109 27607401 3 3 35y0
252 GDP dissociation i hibitor 1 252 10.14 9 16.092 14227 0 018201 0088618 0000781 1.8755 2.381 2204 20884 0617 22062 2760647 3 3 3yes
253 PREDICTED: similar to Lamin B1 253 10.05 6 10.046 9205.1 0 0.875 0.1875 0.000249 34288 27433 48470 2.6455 43337 11941 78008 3 3 3yes
250 hilordoxin 256 40 7 13 11665 0 4.879 0.65625 0.081388 22011 4035 33359 40028 7.5001 468827806783 3 3 3yes
270 PREDICTED: imlr to WD-peat protein I (Acin Interacting proteln 1) (AIP) (NORI-1) 270 9.3 5 9 8730.6 0 0.65224 0.05786 0.020084 15130 1822 27414 18237 57243 18675 76020344 3 3 3oye
272 PREDICTED: mler to Cysttin B (Liver thiol proteinase Inhibitor) (CP-B) (Stalin B) 272 9.27 5 9.0450 8171 0 014226 0005087 0000381 10263 13119 23843 120 44900 121476038 3 3 300
273 peroxredoxin 4 273 9.09 8 14.824 13903 0 008376 008375 0000454 23337 10303 2478 18328 60500 4744227806085 3 3 3yes
274 PREDICTED: simear to endopasmic reiculum protein 29 precursor 274 9.05 5 9.0468 7375.9 0 021589 040492 000181 149702 18289 2.6213 17307 12810 15805700331 3 3 3yos
282 PREDICTED: alr to Reficulocalbin-1 precursor. partial 282 8.64 4 8 6637.6 0 031848 017 0002397 12882 14855 12799 11318 43097 148047672684 0 0 3yes
283 hepatome-derived growth factor (high-mobilty group pmtein 41k) 283 8.84 4 8 761.8 0 0046039 014588 0037071 20496 13042 2.8959 18546 10145 19002 20461297 3 3 3509
285 PREDICTED: similar to Reticulocalbin-2 precursor (Calcium-binding protein ERC-55) (Taipo 285 8.62 4 8 099i8 0 027874 04530 000387 18357 1285 17520 1166 8.005 1.3100 70047200 3 3 3501
291 PREDICTED: similar to Purmycin-seonive aminopopidase (PSA) isorm 2; PREDICTED 291 8.3 4 7.5229 6430.5 0 07850 047481 022049 181 18018 24148 19611 5132 248177 40 3 3 3s
292 ribosomal protein Lio0 292 8.26 4 8 6765.1 0 0018375 0017548 0.002274 30153 1172 24804 12246 12010 13190 027547 3 3 3yes
296 PREDICTED: imier to srinellhronine protein kinase MASK partial 296 8.15 4 6 88834 0 0039070 14025 0033299 18124 11912 17448 17713 1502 292463778370 3 3 393.
29O PREDICTED: similar to Filamin A (Alpha.lilmin) (Fiamin 1) (Endothelial cin-binding protei 298 8.14 5 9.529 8435 0 0064 0000172 0002771 19427 44304 28178 13232 4717 13806705841 3 3 3ys
301 PREDICTED: similar to cytoplanic bete-actin isoform 1 ; PREDICTED: simiar to cytoplasm 301 8 12 24 24085 0 1.80-06 1870-06 4290-0 20748 13208 23048 12707 94620 14298 7645442 3 3 3500
315 PREDICTED: similar to Phosphoacetylglucosamine us (PAGM) (Acetylglucosmine phc 315 7.5 4 7.0458 6445.9 0 027530 008487 0020 2012 15285 22447 43788 02804 153067635467 3 3 3yes
316 heal shock 27kDa protein 1 316 7.4 3 0 5496.2 0 018017 25651 0047208 16044 11583 15029 20433 14021 100447137405 3 3 3y
320 PREDICTED: imilar to Proteasome subunit alpha type 6 (Proleasaome ol chain) (Macrophl 320 7.3 4 7.301 6103.7 0 003133 078142 0009784 13775 1064 499 15844 02085 13861 704409 3 3 3 ye
324 wuperole dismulae 1, soluble; PREDICTED: similar to Superoxide dimutase 324 7.13 3 6 5039.6 0 03642 048206 015292 30198 40459 3000 17702 72972 17500 27607109 3 3 3yes
327rbosomal protin 12 327 7.05 4 7.0458 92024 0 081492 0360 502483 22231 17878 29801 18670 10485 18081 02461011 3 3 3622.
330 heat shock 10kDa protein 1 (chaperonin 10) 330 6.95 3 6 4080.3 0 18820 11882 08565 16105 17504 23810 22185 44657 302102780 7 0 0 30n
337 PREDICTED: umflar to F-acin capping protein alpha-1 subunt (CapZ alpha-1) Isoorm 1 ; P 337 8.76 3 6 5430.9 0 1 483 6 070832 1987 1.367 33439 1 7061 10821 01021581 1 1 400
343 PREDICTED: simnar to Transtional endoplasmic reliwtm ATPase (TER ATPas) (15S Mgt 343 6.38 3 5.3979 5271.1 0 235 8 027803 31328 2.9449 1.9795 1 02158 2298 76024455 3 3 300
344 PREDICTED: similar to lune prollne-enriched proteoglyan(eprecan) isofor 3: PRED 344 6.30 3 5.0458 5166.4 0 02288 0022 009211 1785 11844 744 1117 47585 14031 7672344 0 3 3ys
347 UDP-lucose dehydrogenase 347 6.33 3 6 6035.9 0 11046 20502 005181 25442 14612 2524 10729 58242 13304278038 1 1 1500
354 hat Shock 70 kD protein 3 354 6.14 12 23.523 20510 0 0000136 3470-05 1920-07 26087 13995 27972 14621 75505 1.7394138 1 1 1
358 PREDICTED: similar to MIR-Irteracting aeposin-like protein precursor (Transmembrans prol 358 6.12 3 6 5172.9 0 057325 047246 0001504 1906 12143 48072 44152 s,8s8 1408881813820 3 3 3501
369 PREDICTED: similar to Leukotrione A-4 hydrola.s (LTA-4 hydrolase) (Leukonree A(4) hydn 369 6 3 5 5323 0 8 8 020347 11747 1 1.5383 1 85214 20811 70017 3 3 3yes
370 chlorkde intraceflular channel 1 370 a 3 6 4329.3 0 18238 1.481 0080400 26224 1.893 23352 10231 82924 1409902751070 3 3 3400
373 gelsolin-like capping protein 373 8 3 6 5807.1 0 0835 02504 0068881 12629 11980 1723 12198 32378 12472304024 I I 1500
380 PREDICTED: similar to Tumor neois factor receptor superfatly member I1 precursor ( 380 5.84 3 5.048 4694.5 0 039267 015070 0 8 2830 15247 17261 1087 4216 12927703463 3 0 35
385 PREDICTED: Simr to NGNG-dimthylarginine dimothylaminohydrose 1 (Dmethlarginn 385 5.68 3 5.3979 4636.6 0 031183 002152 0010733 18381 43128 30809 11248 14092 12929701343 3 3 3ye
387 PREDICTED: slmilar to sploing factor, arginine/seine-rich I (ASF/SF2) 387 5.61 3 5.0458 4394.2 0 026 032450 022339 23347 13776 2844 15704 8798 2112378471 3 3 3500
388 prosapooln 388 5.59 2 4 3007.6 0 09559 000702 018094 14823 11948 15704 1108 2298 1083327800447 3 3 3yes
390 PREDICTED: similar to Proteasome subunit apha type 3 (Proleasome component C8) (Mac 390 5.54 3 5.3979 5293.3 0 8 15109 052982 1.80 1 42124 2337 85802 327147027984 3 0 3501
397 ARP3 (acin-rlated protein 3. yeast) horolog 397 5.4 3 5.3979 5776 0 10407 018729 0087526 23506 17438 25358 1338685141 14871 27800339 1 1 488
399 PREDICTED: similar to Heterogeneous nuclear ribonucloprolen G ohRNP G) (RNA-bindin 399 5.33 3 4.0915 4078.2 0 01077 044384 02432 20448 10566 25818 110 060 142 76701 3 3 3
400 aminotranogerase 1]{glueamic-oxloeeotioc ranaminase 1. soluble [BoStaourus 400 5.26 3 5 5463.1 0 0003 074452 031761 19703 15403 2523 48386 70441 233072135299 3 3 34.
400 myoin, ligt popkle S, alkel, smooth muscle and ronomuscle 409 4.82 2 4 2197.1 0 083517 044149 034312 21831 12798 28352 4178 82323 12775 28401487 3 3 3ro
414 PREDICTED: iilar to Thloredoxin domain containing protein 4precursor (Endoplasnic ret 414 4.64 2 4 3157.6 0 0 0 0 1704 1 482 4 4435 1 76816554 3 3 3yes
415 PREDICTED: similar to vesicle amine tnsport protein 1 homolog (T califorica) isoform 3; I 415 4.64 2 4 3302.6 0 1.3687 07997 0.1349 12157 1108 3433 1 63310 1066277120 1 1 y
426 PREDICTED: similar to 1-phosphalkiyfirnolol-4,5-olphosphate phosphodlesterase drlsa ( 426 4.34 2 4 3584.7 0 8 0 0.30482 202 1 23412 1 08055 4244378298 3 3 300
430 PREDICTED: sir to FK506 binding prolein 14 precursor (Peptidyl-prolyl cis-trans isomer 430 4.33 2 4 3516 0 0 1.4401 0.38829 12947 1 12704 14434 60976 1264670615304 4 4 4 yes
436 tyrosin 3-monooxygonasatrypophan 5 -monooxygense activailon protein, beta polypepicd 436 4.2 9 16.569 12285 0 206-05 2720-06 0.023438 2.0029 1.2123 30727 1.2577 6213 I.4412 27807403 3 3 300
449 PREDICTED: similar to Bitoncional 3-phosphoedmnosine 5-phosphosutate synetthase 2 (F 449 4 2 4 4180 0 a 0 0114 1.834407 1 2103503 1 8380 1 70074566 1 1 1 501
450 lWin, galactosidebinding, soluble, I (gacln 1) 456 4 2 4 3975 0 13374 038882 040768 18206 14008 28402 1832 74748 14091241189 2 3 3yes
450 PREDICTED: similar to D-dopfchrome teutomerase (Phenylpyrovate tautomermse 1) 459 4 2 4 2402.4 0 025204 0 420 4906 10621 40403 1 75815 268187038463 3 3 3yes
462 S100oadicium-binding protein Al0 462 4 2 4 3909.3 0 1278 017862 00847 18077 43392 23004 1096 68584 15145 27607173 3 3 3no
464 thymosin beta 4 464 4 2 4 2799.4 0 4480 001083 010032 14049 1807 10312 11023 14123 11771 50073141 3 3 3yes
467 PREDICTED: similarto Calgizzrin (S100 calcium-bincing protein A11) (SOOC protein) (MLI 467 4 2 4 3023.4 0 0 0 0.938 15386 1 22612 1 78458 24721 76612913 3 3 3500
487 PREDICTED: eimilar to issue specifc transplantation antigen P358 487 4 2 4 2970.4 0 1324 4072 014288 30401 47685 25804 20474 87992 11217 70634088 1 1 1508
490 PREDICTED: similar to SWAP-70 protein, partial 490 4 2 4 3008.3 0 0067 067752 073847 31036 1.3089 2.5582 1.208 95271 488007035779 1 1 1 no
503 protein O-ficosyltronserase 1 503 3.6 2 3 3507.8 0 0 0 079741 12391 4 28230 1 10435 2019308 7 1 1 Iyes
519 PREDICTED: silartoqubkii-ougalingenzyme E2N (homologousto yeast UBC13) Io 519 3.4 2 3.3979 4328.5 0 10442 003027 08479 17214 12403 29754 12959 77324 18103 78047540 3 3 3506
550 PREDICTED: siiar to RAB1, member RAS oncogens famiy Isofon 4; PREDICTED: im 550 3 2 3 3468.1 0 42312 40792 017009 1646 4266 22374 40430 90551 114667029047 3 3 30n
555 PREDICTED: similar to hi4gi-moblEy group box 2 isoform 23: PREDICTED: similar to hig 555 7.65 4 7.0465812 0 1948 14726 0081202 1 2 17246 18 13189 0493 26427241297 3 3 3
556 inhllon btea A 633 6.58 4 6.4437 6131.6 0 5964 33488 0088372 1006 21782 1482 2001 1oa 25296270848 1 1 3yes
562 PREDICTED: similar to Plasminogen actvator Inhibior I RNAbiding protein (PAI RNA4i 316 7.05 4 7.0468 5714.2 0 030488 007507 00066 243 46 17741 14402 81186 131027025300 1 4 1 yes
564 PREDICTED: similar to heterogeneous nuclear dbonudeoprotaen C leeform b isoonn 6o; PR 348 6 3 5.3979 4639.8 0 14229 1374 078472 25612 26545 20037 20374 6383 3.75276627027 1 1 100
569 PREDICTED: samr to 14.3-3 protein thote (14-3-3 protein tau) (14-3.3 prteln T-ceN) (HS1 392 4.66 7 13.523 9824.4 0 002932 007611 0002646 2042 18088 31882 17235 88341 2288 70301 1 1 400
573 PREDICTED: simler to actin related protein 2/3 complex, subunit 4 415 4.12 2 4 2564.5 0 0 03284 045279 16969 1 25725 1124 70376 1123 76648493 1 I 1081
5790PREDICTED: similar to CGII1577-PA 436 4 2 4 3190.2 0 0 0 0.081276 18209 1 30000 1 40113 10721 01800884 1 4 10
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593 PREDICTED: similar to Testican-I Precursor (SPOCK protein). partial
608 PREDICTED: sier to SEC31-like 1lotbrm 2
619 plectin 7 ; plectin 5; placin 3; plectin II ; plocsn ; plectin 10; plectin 4; plectin 9; pectin
7 albumin
13 PREDICTED: Siilar to Complement factor B precursor (C3/C5 converoso)
25 PREDICTED: similar to Complement C3 precursor Isoform 1
26 PREDICTED: similar to Stromelysin-1 precursor (Matirk metloproteinose-3) (MMP-3) (Tram
29 PREDICTED: oimilar to chinese 3-like I isobrm 2
32 PREDICTED: similar to Complement Cir subcomponent precursor (Complement componen
34 PREDICTED: similar to extracellular metrix protein I isofbrm I precursor isolrm 14; PRED
59 PREDICTED: similar to Haptoglobin precursor otorm 4
69 Uerum myloid A 3
83 mtrix metalloproteinase 9 (gelanmie 8, 92kD matri metalloproteinase 9 (gelatiase B. 9
115 vascular cel adhesion molecule I
122 PREDICTED: simlar to Insulin-like growth fator binding protein 51solorm 1 ; PREDICTED::
134 lactoforrin pacotransferin][Bo tourus)154 matrix metalloproteinuae 13 (olleonae 3)
162 PREDICTED: slatr to Chiliness 3-ike protein 2 precursor (YKL-39) (Chondrocyte protein 3
166 secreted phlocphoprotoin 1
173 PREDICTED: similar to latent mnsfonng groth fador beta bindng protein I istform LTSI
178 plelorophin [liepadn binding growth factor 8, neoute growth-promoting factor 11 [Bos taurus]
186 latent transformirng growth factor bets binding protein 2 (NOTE:redeinton ofsymbol)
219 vanin I precuror
221 matrix meilloproteinase 1
232 Insuat-like gowth factor binding protein 3
235 PREDICTED: similr to lipopolyseccharido-bnding protein precursor isoforn 1 ; PREDICTEl
258 CD14antigen
307 PREDICTED: similar to Alphai-1-aid glycoprotein I precursor (AGP 1) (Orosomucold 1)(OM
346 PREDICTED: similar to N-acetyimurmoyl-L-elanine amile precursor (Peplidoglycan reco
348 PREDICTED: eimilar to Putative serum e yloid A-3 protein
392 superoxide dimitase 2, mitochondriall
451 PREDICTED: similar to ICOS ligand precursor (87 homolog 2) (B7-H2) (87-lIke protein GCf5
452 CD44enn8ige (homing funcdion end lodin blood group sytem] [Boeturs]
453 PREDICTED: similar to onostatin M receplor, partial
454 chmoldne (C-C mot) Oigand 20
492 chemoidne (C-C motftIlg5nd
515 colony simlatIng factor 1 (macrophage)
522 chemolnoe (C-C motift)gand 2
529 Inledeouln 6(Interfeon, beta 2)
541 sphs-2-plamin inhibitor
633 PREDICTED: similar to chemoldne (C-X3-C moot) ligand 1, partil
42 PREDICTED: similar to Pyruvote inase, isozymes MI/M2 (Pyruvute kinse muscle leozyme
43 PREDICTED: simlar to phosphoglycerate inase I blon 3; PREDICTED: similar to phosl
45 PREDICTED: imiler to Prolein disulkie-somerase A4 preocursor (Protein ERp-72) (ERp72)
47 heat srock 90kD protein 1, alpha
51 trlosephosphate isomerase
63 UDP-glucos pyrophosphoryleas 2
65 PREDICTED: emilar to nucleolln-related protein bsoform 8; PREDICTED: similar to nudeoli
741alede dhydrogenum A
76 PREDICTED: similar to tranalolese I borm 1
79 rinetalmilse86 PREDiCTED: oiar to phocphogiycorete mulasr 1 ikoe a Isoor 6; PREDICTED: similar t
106 tyrosine 3-monooxygenaseryptophan 5-monooxygenase aclivation protein. zeta polypeptid
108 enoisse 1
113 PREDICTED: similar to Protein disullideleomerse A6 precursor (Thioredoxin domain conta
130 Parkinson disease (aulomoal recessive, ady onset) 7
146 PREDICTED: sdimlar to Tuuln alph-2 cho (Alpha-tubit 2) oform 8; PREDICTED: in
148 PREDICTED: similar to Heterogeneous nuclear ribonucleoprotles A26u1 (hnRNP A2 / hnR
157 ani-oxidant protein 2 (noo-eniooum gluathlone peroxidose, acidic celcium-independent pho
158 PREDICTED: similar to Calhepin H precursor
168 ll dehydrogeneB 
174 PREDICTED: similar to heterogeneous nuclear ribonucleoprotein D isoiorm b isotorn 13 ; P
186 PREDICTED: silmlar lo Alcohol dehydrogenase [NADP+] (Aldehyde r ductso) (Ado-keto r
190 serne (or cysteine) proteingse Inibior, clods B (ovalbumin), member 6
194 annexin AB
202 PREDICTED: lmolar toPhosphatidylethanolamine-binding protein (PE8P) (Protatic binding
207 connective Issue gmwth factor
211 PREDICTED: similar to Matte dehydrogesree, cytoplaomic isoflor 1
220 PREDICTED: similar to Fascin (Singed-ake protein) (55 kDa actin bundling proteIn) (p55) iso
223 high-iobilky group box 1
229 isocitrate dehydrgenase I (NADP+). solublo
233 PREDICTED: almier to serine (or cyeeine) protelinse inhibitor, dodo 8 (ovalbumin), mmbo
238 glusathloos 84ransferse M1
248 PREDICTED: similar to popidplprolyl bomerase A storm I borm 1 ; PREDICTED: elmte
248 PREDICTED: similar to glyoxolse 1
26 PREDICTED: similar to eukaryic translation i illn factor 4A, isloform 1 isofor 20; PRE
275 profilln
278 PREDICTED: similar to Elongation factor 1-gamma (EF-1-gamma) (eEF-IB gamma) isform
278 PREDICTED: simrdarto Stress-nduced-phosphoprotein 1 (STi) (H4c70/Hap90-organizing p
284 PREDICTED: eielar to ubiqpilin-aciating enzyme El isolbrn 2; PREDICTED: similar lo ut
286 riboaomal protein, large, PO
293 PREDICTED: similar to Alcohol dehydrogones class Ill ti chain (Guothione-dependent to
295 PREDICTED: similar to NADP-dependent mlic enzyme (NADP-ME) (Malic enzyme 1)
297 PREDICTED: similar to SPUF protein precursor (Secreted protein of unonown fmncion)
302 PREDICTED: asmilar to SH3 domain binding glutamic acid-rich protein like 3 Isoliors 2 ; PRE
306 PREDICTED: similar to heat shock 70kD protein binding protein boflorm 6; PREDICTED: min
309 lamini receptor 1(ribosoml protein SA, 67 kDA)
312 gluthone S-ransfrm pi
317 PREDICTED: similar to Spiing factor, prolne-ond glmine-rich (Polypyrimidine tract-bindh
322 PREDICTED: silar to Stathmiln (Phosphoprotein p19) (ppI9) (Oncoprotein 18) (OpI8) (Leu
336 PREDICTED: similar to Phosphoglucomutuoe I (Glucos pbosphomulase 1) (PGM 1). pares
protein # score peptides score 2 massov outliers pval 116 pal 116 pval 117 116:114 SD 116:114 60 117:114 80
471 3.52 2 3.5229 2123.7 0 0.8624 0.65664 0.18089 1.9204 1.1825 2.2116 1.2152 11.452 1
579 2.6 1 2 1447.7 0 6 6 6 1.7568 1 2.502 1 11.671
206 8.27 3 5.3979 4739.8 0 0.57463 0.3089 0.48091 2.0239 1.1632 3.0224 1.1352 4.9873 2
7 96.49 52 102.44 96672 0 3.365E-27 1.44E-32 1.79E-09 138 2.2347 43.125 2.481 2.4791 2
13 75.08 35 68.745 60606 1 5.31E-17 2.65E-15 0.000673 27.733 3.2067 24.001 3.514 2.6215
25 55.54 29 53.405 47320 0 9.55E-18 7.64E-20 0.023691 7.7038 1.6996 12.93 1.7432 1.215
26 52.84 30 58.046 44259 0 3.52E-17 3.88E-13 5.63E-13 28.033 2.485 7.7705 2.1675 .792 2
29 51.94 34 65.319 61405 0 1.11E-26 5.62E-21 3.38E-10 27.915 1.7561 13.279 1.815 3.4717 2
1 32 49.23 24 48 43922 0 4.39E-15 3.2E-14 2.72E45 17.424 1.9464 9.583 1.7849 31791 1
1 34 46.62 29 49489 50817 0 4.96E-05 1.56E-13 0.000163 26.937 2.2552 12.071 2.1767 2.6722 2
59 36.03 18 34.589 2752 0 2.5E-08 4.3E-07 0.011921 42.035 4.2707 17.256 3.8335 3.4082 3
69 32.19 20 37.569 2809 0 4.05E-13 9.37E-12 0.002989 34.317 2.2797 22.488 2.3733 2.7865 2
2 83 26.75 14 26.092 23947 0 2.02E-07 4.31E-09 0.00014 5.5758 1.7464 6.8015 1.574 1.9693 1
115 22.36 12 21.569 19319 0 2.15E-05 2.33E-05 0.021812 15.135 2.6794 25.63 2.8245 3.5165 1
1 122 21.35 10 20 16040 0 8.13E-06 3.78E-06 0.040525 4.7706 1.4446 7.1549 1.6594 2.223 1
134 20.11 10 20 16103 0 7.59E-06 9.09E-05 0.010457 17.533 2.2259 8.4221 2.2077 1.8144 1
154 11.52 5 10 9438.5 0 0.009601 0.027022 0.057845 36.035 2.868 19.221 3.1497 4.1771 1
162 16.66 8 16 13218 0 1.35E-06 7.62E-06 0.002529 36.035 1.6774 14.19 1.6369 2.218 1
168 16.33 8 16 15227 0 0.0119 0.046875 0.046875 21.672 3.4218 18.165 2.9584 18.777
173 15.76 17 29.967 29750 0 3.34E-07 2.42E-07 0.02316 8.4893 2.5296 7.2501 2.3157 1.8371 2
178 15.23 8 14.569 11570 0 1.14E-06 9.65E-0 0.036897 9.8194 1.3796 4.4331 1.3316 1.3697 1
186 14.72 7 13.046 10573 0 0.005294 0.0330 0.29026 10.281 2.7465 3.9275 2.3595 1.3695 1
219 12.14 6 11.523 9701.9 0 0.001091 0.004265 0.01554 21.035 2.1295 5.7239 1.7821 3.0505 1
221 12.13 7 10.717 11364 0 0.001136 0.09936 0.099695 11.257 2.242 5.1186 1.9145 2.601 1
232 11.25 5 10 7849 0 0.001723 0.004905 0.10359 8.8309 1.5066 6.0226 1.2915 5A864 2
' 235 11.05 6 11.046 11006 0 0.002D99 0.25837 6 44.095 2.9386 11.746 2.4977 2.4186
259 9.97 5 9.5229 7257 0 0.020509 0.025368 0.64504 12.08 2.5042 12.036 2.5832 4.0657 2307 7.68 4 7.0458 5378.8 0 0.17749 0.19308 1.852 35.891 6.2221 36.859 6.7026 3.1889 4
S 346 6.34 3 6 59565 0 0.60686 0.18647 2.0648 3.2954 2.0412 19.7 2.5396 1.8686 2349 6.28 11 21 15136 0 1.52E-07 5.22E-07 0.065925 30.296 2.0741 17.03 11.992 2.2204 2
392 5.52 3 5.5229 4137 0 0.0679 0.058386 0.024124 12.342 1.5952 16.954 1.6277 6.1812 1
451 4 2 4 2344.2 0 0.2047 0.25208 3.5176 7.5746 1.16 9.7155 1.2376 0.90017 1
452 4 3 6 4540.6 0 0.003789 0.02438 040004 7.9181 1.0029 10.579 1.0219 1.7514 1
453 4 2 4 3644 0 0.14057 0.28116 0.12327 10.656 1.1311 14.529 1.3219 7.9623 1
454 4 2 4 2401.3 0 0.3385 0.26072 6 57.062 1.7801 11.83 1.2698 1.0699
492 4 2 4 3425.8 0 2.4277 1.2394 2.5787 2.6593 2.7743 33.736 5.3323 2.682 3
515 3.44 2 3.0458 2527.5 0 1.2052 1.1586 6 9.2933 2.7986 16.5 3.4504 1.396
522 3.39 2 3.0458 3060.6 0 0.5464 0.73141 1.5822 7.163 1.4934 8.1491 1.7774 2.6496 1
529 3.22 2 3.2218 3525.2 0 0.29186 0.24311 6 125.52 1.6874 26.379 1.3431 1
541 3.05 2 3.0458 2446.5 0 0.23683 0.42677 1.9454 15.428 1.2715 12.545 14838 4.3999 3
574 2.64 2 2 2054.6 0 6 6 8 5.252B 1 7.5261 1 3.1734
42 41.56 20 38.143 35708 0 0.001758 3.36E-07 3.15E-10 3.8482 1.8837 5.2343 1.9499 13.88 2
: 43 41.45 22 40.66 34191 0 1.87E-08 8.27E-11 2.01E-15 3.1415 1.8688 4.311 1.5826 17.103 1
i 45 39.83 20 37.489 34307 0 0001179 1.14E-08 3.79E-13 2.1654 1.51 3.0406 1 .06 12.221 1
47 36.6 20 37.967 33941 0 1.1E-09 2E-11 2.64E-14 3.9242 1.5945 5.117 1.5493 12448 151 3761 19 37.097 30762 0 1.06E-10 2.36E-14 1.12E-14 2.9952 1.3639 4.5134 1.3144 9.9139 1
63 33.81 17 32 27938 0 0.001009 0.001465 0.001758 3.0746 2.3549 3.1054 1.7927 14.252 26 32.89 16 30.559 23611 0 2.27E-10 6.49E-1I 4.6E-14 4.1137 1.3995 6.1708 1.4864 22.201
74 30.25 16 28.535 23252 0 9.12E-09 2.25E-09 0.002627 2.7646 1.3691 3.8254 1.4548 11.131 1
76 27.86 14 26.62 19426 0 8.56E-06 3.87E-07 0.005732 3.0923 1.6404 4.4179 1.664 17.262 179 27.17 14 25.523 23238 0 1.9E-06 5.53E-07 1.75E-09 3.9754 1.5518 5.9828 1.6553 14894 186 26.57 15 28.569 29874 0 9.21E-07 1.31E-08 1.24E-12 3.0427 1.5079 4.0101 1432 12.356 1106 24.01 12 23.046 18300 0 3.71E-06 3.62E-08 5.53E-09 2.36 1.3432 3.5355 1.316 9.5453 1109 23.69 11 21.046 19284 0 7.6E-05 0.058594 3.35E-05 4.2717 1.8349 3.4549 2.4551 9.4742 2i 113 23.09 10 20 18120 0 0.008166 0.004487 3.58E-05 4.9315 2.7127 5.6337 2.6714 15.588 2
130 20.52 11 20.523 17520 0 0.002799 0.000202 9.99E-07 2.9185 1.849 4.8472 1.9303 14.892 2146 18.83 10 19.398 1881 0 0.007919 0.002081 0.023438 2.5775 1.6816 3.005 1.6189 12.588 1
1 149 18.31 9 17.699 15650 0 0.023436 0.000268 0.001011 3.1215 2.1902 3.0399 1.4217 13.985 3157 17.33 8 15.222 11913 0 0.003934 2.34E-05 2.74E-05 2.8028 1.4146 42395 1.1776 11.568 1
156 17.17 8 15.046 12222 0 0.001851 0.000998 3.43E-06 2.93 1.4785 3.2288 1.4533 14.536 1
16 16.29 12 21.012 17690 0 2.66E-0 1.43E-05 7.1E-09 2.4717 1.2989 3.3208 1.3837 11.808f 174 15.68 6 15.523 13640 0 0.003456 0.00076 2.28E-05 6.2452 2.0813 8.7929 1.9356 21.385 1180 15.17 8 14.097 10520 0 0.000597 7.11E-05 3.95E-06 2.5434 1.3122 3.96897 1.4286 11.856 1
190 14.22 7 13.046 13705 0 0.00877 0.022379 0.00816 2.6905 1.4676 4.1319 1.9733 8.5335194 14 7 14 10267 0 0.001238 0.000237 6.37E-05 2.9963 1.4389 5.537 1.5273 5.5473 1202 13.29 7 13.046 13058 0 5.54E-05 7.82E-05 5.86E-06 3.1749 1.2491 4.4369 1.3557 12.705 1207 13 7 13 10899 0 0.00098 009375 0.001782 5.9987 1.7675 4.3546 1.5698 5.7014 1
211 12.81 5 9.3979 9274 0 0.051518 0.011623 0.000554 2.5965 1.3628 4.8755 1.6318 15.895 1220 12.13 6 11.301 8583.8 0 0.006765 0.001296 0.000179 2.7107 1.440 4.4201 14656 9.7856 1
223 12 5 10 9245.6 0 0.015485 0.015447 0.00085 3.3754 1.2968 4.4589 1.3759 9.5795 1229 11.38 6 11.046 9252 0 0.08799 0.049048 0.00235 3.0437 1.8308 4.3718 2.3452 11.187 2
233 11.16 5 9.0458 8717.2 0 0.00421 0.002986 0.00033 31448 1.3117 3.9541 1.1827 9.7674 1
238 10.78 6 12 9563 0 0.16268 0.16933 0.01558 3.2492 1.7895 4.7354 2.181 12.066 2248 10.22 6 12 6467.6 0 0.025396 0.040333 0.013582 3.2854 1.7984 3.8159 2.0911 7.3083 2249 10.18 5 9.5229 7840.4 0 0.043425 0.01169 0.00637 2.9344 1.6109 3.4113 1.4621 12.242 11 265 9.66 5 9.5229 8533.8 0 0.09825 0.02549 0.001008 3.0692 1.5822 4.3522 1.1812 21.322 1
275 9.08 5 9.0456 8707 0 0.002312 0.003113 0.003096 2.8729 1.1257 3.4875 1.1676 8.7527 1276 9.05 5 9.0456 8354.7 0 0.053392 0.04406 0.375 3.1411 1.7118 4.9751 2.0412 12.177 1278 9.04 4 7.5229 6454.8 0 0.10931 0.091345 0.26236 2.9163 1.2880 4.645 1.8517 10.596 4
284 0.62 4 8 7811 0 2.4031 0.90238 0.045399 2.4553 2.5207 44043 3.087 13.093 2286 8.57 5 8.568 7386.9 0 0.2395 0.1708 0.004531 3.7306 2.6674 5.3567 3.029 20.735 2293 8.25 4 7.0458 4798.5 0 0.58491 0.34822 0.13224 2.5106 2.1664 3.6876 2.3924 10.414 2295 8.15 4 8 7841.6 0 0.016298 0.00252 0.000785 3.7509 1.3486 5.828 1.3551 20436 1297 8.14 4 9 8243 0 0.061118 0.043642 0.10307 6.5042 2.0431 4.0788 1.5373 8.7758 2302 8 5 10 8279.3 0 0.01294 0.00664 3.65E-05 2.8956 1.2382 5.0679 1.2968 17.044 1306 7.98 3 6 4216.4 0 0.45196 0.34472 0.11277 3.1269 1.7771 4.5437 1.9292 10.674 1309 7.65 4 7.0458 580.1 0 0.15562 0.064695 4.89E-05 3.7201 14532 3.7499 1.3164 23.86
312 7.52 4 7.5229 8402.8 0 0.021242 0.025482 0021654 34071 1.339 4468 14633 9.1752 1317 7.4 4 7.3979 60266 0 0.001584 0.004624 0.008769 5.2679 1.1785 7.3776 1.3274 15.578 1322 7.28 3 6 3929.2 0 0.076918 0051102 0.067625 5.1903 1.355 6.6967 1.3579 6.135 1336 6.84 3 5.5229 4741.7 0 0.11988 0.36937 0.1897 3.3568 1.3512 4.3019 1.9305 11.596 2
Acc-asorsig 118 sig16 elg17 SM4D
.1775 27806687 1 1 1 yes
1 76680545 3 3 3 yes
.3147 g440649920 gi40849916; gil4064980; gil4no
.0395 30794280 3 3 3 yes
2.913 78650936 3 3 3 yes
1.447 76622034 3 3 3 yes
.0838 61863538 3 3 3 yes
.0121 78836770 3 3 3 yes
.6894 76616391 3 3 3 yes
.3007 76612740 3 3 3 yes
.7166 7640813 3 3 3 yes
.5288 38568869 3 3 3 yes
.4069 27807437 3 3 3 yes
,8201 41386707 3 3 3 yes
.9377 76610359 3 3 3 yes
.474130794292 3 3 3yes
.6212 2780999 3 3 3 yes
.4335 76613223 3 3 3 yes
3.059 27806401 3 3 3 yes
.0401 76629029 3 3 3 yes
.2587 27806813 3 3 3 yes
.3451 27805991 3 3 3 yes
.6463 66792902 3 3 3 yes
.4817 27808541 3 3 3 yes
.0343 27807007 3 3 3 yes
1 76633538 3 3 3 yes
.3826 41386760 3 3 3 yes
.4081 76625309 3 3 3 yes
.4049 76821288 3 3 3 yes
.0687 76691305 3 3 3 no
.2222 41529822 3 3 3 yes
.2161 76608986 3 3 0 yes
.0889 27806703 3 3 3 yes
.0994 78846489 3 3 3 yes
1 27808273 3 3 3 yes
.0557 28461277 0 3 00o
1 27806879 3 3 0 yes
.8171 2710671 3 3 3yes
1 27808867 1 1 1 yes
.222427807209 1 1 1yes
1 7682274 3 3 3 yes
.1582 762669 3 3 3 yes
.8049 76679981 3 3 3 yes
.763 76616203 3 3 3 yes
.6585 60592792 3 3 3 yes
.4698 6188856 3 3 3 yes
.1232 41386780 3 3 3 yes
1.509 76682888 3 3 3 yes
.491727806559 3 3 3yes
.7346 76658485 3 3 3 yes121 81491841 2 3 3 ys
.4399 76654685 3 3 3 yes
.5055 27807367 3 3 3 yes
.3559 27806645 3 3 3 yes
.5188 76630220 3 3 3 yes
.024 62751849 3 3 3 yes
.7519 76618145 3 3 3 yes
.3139 76892749 3 3 3 yes
.5194 27807167 3 3 3 yes
.5586 76647098 3 3 3 yes
1.585 27806561 3 3 3no
.9515 7620256 3 3 3 yes
.5179 7680510 3 3 3 no
2.266 27807517 3 3 3 yes
.4019 278317 3 3 3 yes
.3968 7638068 3 3 3 yes
.8524 2780677 3 3 3 yes
.4769 61856478 3 3 3 o
A7M5 76854327 3 3 3 yes
.3934 41386729 3 3 3 yes
.0231 30794318 3 3 3 yes
3255 76651280 3 3 3 yes
.2988 28461273 3 3 3 yes
.3395 76626930 3 3 3 yes
.9854 76650162 3 3 3 yes
.7911 76643173 3 3 3 yes
.301 2751593 3 3 3 yes
.5715 7665731 3 3 3 yes
.0752 76657889 3 3 3 p
.2207 79655770 3 3 3 o
.0789 60592767 3 3 3 yes
.9157 76892146 3 3 3 no
.2659 7625476 3 3 3 yes
.0755 7683120 1 1 1 yes
.2233 76611225 3 3 3 p
.7768 76617020 3 3 3 no
1.103 27805951 3 3 3 yes
.7011 29135329 3 3 3yes
.6213 76614612 3 3 3 yes
.3999 76611374 3 3 3 p
.1541 76614007 3 3 3 yee
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ThesisCH4.aq_supplementJroteins_sorted
order Prten eName protein acorn peptidee scame2 maacsvolera poaill poal1i1 pvall7 115:114 SD 116:114 SID 117:114 SD Accestoreall sighs sigT SM-ID
339 eukaryotic translation elongallon factor I beta 2 339 6.62 3 6 4651.6 5 0.29362 0.9870 0.011037 34306 1.6332 4.3967 1.38M 12962 1.2099 62450566 3 3 3 yes
357 PREDICTED: similar to Dihydropydmidirnas-related protein 2 (DRP-2) (Turned on after divia 357 612 6 12 10634 0 0.032186 0002632 0.000606 22231 1.6172 3696 I 4777 9.8134 1.5111 7664847 3 3 yes359 PREDICTED: simlarto Ca -2caalytc eubuni (Caaio-2 large s996n6) (Caiom-cohal 309 806 3 03979 46679 0 0.36915 0.20306 0.34009 41324 18956 43802 1209 0ubuni 2.1(ain74 76636 1 I l ye(
362 nucloside-dilphosphate anasNBR.A; nuclicside-dphosphat wasw NR-B; PREDICTE 362 8 3 6 4899 0 0.06 0.00769 0.00096 27769 1.0726 40832 1.093 14.372 1.096 6I5 3 3 3 ye
367 peroxiredoin 5 precursor 367 8 3 8 6876.6 0 083101 06898 031427 806 4607 60984 30819 12.708 2.3618 27807445 3 3 yes381 PREDICTED: similar to Protein transport protin SeOC23A (SEC23-reated protein A) Isoform 381 6.81 3 0.229 5235.1 0 6 6 6011284 31422 1 36376 1 9.16 1.2488 76647464 1 I yes362 fusion. derived from t(12;16) malignant iposarcoma 382 6.72 3 6.3979 5729 0 0007675 0.37366 0.077329 34937 1.0807 32736 11788 13.728 1.6812 3780887 3 3 3 ye
383 endoplasmic reoulum thloredoxin superfamily member, 18 kW 383 6.71 3 6.3879 6064 0 0.74821 0.0287 0030978 39634 1.3664 36264 I.3382 16.557 1.3343 82758 3 3 3 yes391 PREDICTED: similar to haloacid dehalogenas-ike hydrmse domain containing 2 isoform 3 391 0.62 3 6.6228 3778.2 0 018241 0.3613 0033072 33264 14498 37139 18016 13.306 1.37 76614 3 3 0393 PREDICTED: elmilar to Hypoxanthire-guanine phosphorbosytuensbrase (HGPRT) (HGPRI 393 6.52 2 4 3167 0 6 8 0074386 34383 1 6.6304 1 12.677 1.0732 76871371 3 3 56
395 PREDICTED: almir to CG1532-PA Isolorm 3: PREDICTED: similar to CG1532-PA soform 395 5.6 2 4 3001.7 0 037139 0091707 018633 27428 11493 3584 15443 13748 1.1972 788457 3 3 08398 rbosomal protein, large P2 396 64 3 6.3979 60.1 0 03604 0023492 0000225 38236 1209 066 10152 19.187 1.031837807523 3 3 3yes390 PREDICTED: sinlar to Ras GTPase-activating-lke protein IOGAP (p195) isobrm 1 398 6.39 3 6 68.8 0 009743 026318 0.3281 43181 13684 34123 11376 7.6514 2.34877848939 3 3 3ye
405 C19erf10-Uke 405 5 3 6 3931.3 0 0083237 004257 6002865 21213 11877 31397 1634 18798 111264756474 3 3 o
407 PREDICTED: similar to 8-phosphoglucomnte dehydrogenem, decarboxylating 407 5 3 6 6176.8 0 032018 0.5004 610303 32569 1.Ci 3891 2.0081 9818 1880 7687482 3 3 no411 epslon subunit ofcoatomer proteln complex 411 418 2 3.58 4109.3 0 8 6 636983 35524 1 49035 1 13619 1.4301 298312 3 3 ye
416 PREDICTED: slhrto Nucleosome asserbly protein 1-ke 1 (NAP-1 related prmtin) (hNRI 416 4.63 2 4 3863.1 0 8 8 011064 28707 1 41432 1 16493 11188 7617371 I 1 1 yes423 polyprilmlbne tract binding protein 1 423 4.4 2 4 2951.6 0 10569 08786 016449 36496 16931 819 18288 11432 11827806103 3 3 yes424 plasminogen activator inhibitor-1 424 4.35 2 4 2834.8 0 6 1.3985 0992 11818 1 97794 34433 1628 28261 27800497 3 3 yes427 tumor protein, trandationay-controld 1 427 4.33 2 3.0469 3526 5 0296 649494 021849 2818 11261 3986 290 12109 1221962177184 3 3 e432 dbosomal protein L12 432 4.29 2 4 3105.9 0 6 65083 29491 1 33782 1 11786 10917440019 1 1 lye.438 plablet-acvating factor acetyydroeee, isoorm lbbeob subunit (3kD) 438 4.14 2 4 3324.9 0 8 6 8 30171 1 39009 1 14804 1 2780193 3 3 3o439 famesyl dphosphate synthase 439 4.14 2 4 416.2 0 11884 070349 067932 33093 17218 49358 15219 13182 .740339136293 3 yes448 gial fibdllary acidlo protein 448 4 4 8 8917 0 025627 0032707 001199 28927 18707 32047 1.1326 9696 155692984921 3 3 ye472 PREDICTED: similar to Mathloni- (MT.-) (Metallothionsin 2A) 472 4 2 4 2182 0 082766 0766 06 26812 27882 2281 24915 6863 235 7664668 I I n478 PREDICTED: similar to retinoblestaome binding protein 7 isolorm 1 ; PREDICTED: similar to 1 478 4 2 4 297 0 10231 049019 045206 4068 17132 47749 134 1147 16176 7865872 1 1 lye.488 PREDICTED: similar to Actin-related protein 2/3 complex subunit 3 (ARP2/3 complex 21 kDa 482 4 236.3 0 0.2376 008619 0.1936 34799 1.112 30164 10412 9.874 1182661892 3 3 n493 PREDICTED: similartogluMathlone-S-tanslerase, mu 5 isobrm 2; PREDICTED: similartog 493 3.99 3 6.0458 3739 0 045669 040049 03264 27841 161 36149 18086 10953 2291761309 3 3 ye502 lftty acid binding protein 5 502 387 2 304 21421 0 0785 1143 046688 271 13429 37404 17772 97333 148492705805 3 3 yea508 PREDICTED: catilage-deived morphogenetic protein 2 668 362 2 36329 3403 0 I.7669 6 2-0807 19002 7.664 14369 1 12749 8886 76634671 1 1 1 ye500 PREDICTED: simiar to Proleasome subunit alpha type 4 (Proteasome component C9) (Mac 509 352 2 35229 30697 0 042695 0.2688 0.2484 2.3992 I.149 28117 11036 12.056 I.2977 618638 1 1 1 no511 poly(rC) binding potein 1 511 362 2 35229 3406 0 011183 040344 026484 396 0871 569 12978 18513 13216 62751650 1 I 108526 proenkephailn 526 652 3 66229 3433 0 8 6 0190 2C 1 I.393 1 29806 2697527906489 3 3 ye527 deIhllacindepolymerkzngfactor) 627 325 3 46198 37840 0 0027084 001238 0027C 266 .1163 3702 1. 086 11141 I.3279 62751673 1 1 yes534 clahrin, light polypeptide B (light chain B) 534 306 2 30458 29133 0 10497 089862 02011 28197 5116 38081 1.666 8.172 1.307927805873 3 1yes545 thomdoxin redudtase 1 545 305 2 30458 30919 0 6 6 035977 3C2 1 493 1 13.7 1418277129 1 I lye.547 PREDICTED: mlar toaldhddehydrogentsembllaooe ;PREITsmito 646 306 2 20458 26866 0 023703 0018193 010033 31766 11069 3y42t4 1.0063 1 1.10497611741 1 1 ee?5 7 PREDICTED:elar oukowtio tranlatiornitiaon actor4A2 Isofon2; PRDICTED:e 6 47 3 6 85229 81647.4 0 6.375 0,003006 0.00166 3.4078 1.9665 4.1234 1.1897 20.223 1.736876607308 3 3 3 yes563 PREDICTED: similr to Chloride Intracellular channel protein 4 (mc3w5/mICZLc) 329 644 3 96229 54939 0 063798 060434 021777 30017 9659 33991 99 8.9071 2.1001 7669766 1 1 08567 PREDICTED: similarto TAFISRNApolymemse II, TATA box binding protein (TBP).assodiat 379 608 2 4 22791 0 066764 033473 00930 61079 15021 43176 11983 27.627 1.12017642871 1 1 08572 bucenlaur 413 414 2 4 3139.6 0 01396 088717 63515 49231 10817 41719 6126 16047 1.273727807389 1 1 lye592 PREDICTED: similar to dehydrogenasereductase (SODR family) member 6 loform 2; PRED 46 3.2 2 3.629 2121.2 0 019726 021876 007973 37542 I.1015 44559 11284 15.487 1.0906 7864180 1 1 yes604 PREDICTED: similar to Heterogeneous nuclear ribonucloprotein A1 (Helix-destabilzng prol 563 7.4 5 9.3979 78.4 0 091094 038 0080439 29202 37111 4291 35007 9.1461 3.291 7860 3 3 3 ye611 eaianyleisnas, 1. soluble 626 2.32 5 10 81.9 0 017026 0040117 0015791 37275 24021 37025 17629 91007 2.143 618886 3 3 ye834 PREDICTED: similarto SET protein (Phosphatae 2A Inhibitor I2PP2A) (I.2PP2A) (Temoplate 681 2.49 2 4 2846.6 0 1.2772 I.3987 0.35325 2.9056 1.6989 3.2924 1.967 11.667 1.3785 78830603 3 3 3
coverage m nual Indexer k@
12 yes 6
14 yes 6
4 bad quant 6
31 yes 6
10 yes? 6
7 yes/very poor quan 6
3 yes 6
13 yes 6
12 yes 6
15 yes/ poor quant 6
yes 6
40 yes 6
l yes 8
yes 8
yad poor quant 0
20 6
6 yes 6
9 yes 6
4 yes 6
? Gp96? ye 6
15 yes 6
yes 6
yes 6
8 yes 6
yeapoor quart 6
2 ye/poor quart 6
4ps 66yes 6
24 yes 6
ayss 8
yes 6
yes 6
3 yes 6
3 yes 6
13 yes 6
6 yes 6
9 yes 6
I8 yes 6
yes 6
ye/ poor quant 6
4 yes 6
B yes 8
34 yes - bad peptide 6
13 yes 6
yes 
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Appendix C.3: ADAMTS4 and ADAMTS5 blots and SDS-PAGE-
LC/MS/MS of 3 week chondrocyte-agarose cultures treated with TNF-a
The following ADAMTS4 and ADAMTS5 blots are 3 agarose cultures that I did in
Spring 2003 and they were primarily done so that I could learn 3D culture techniques and
clearly not for the purpose of trying to find an aggrecanase. There are 3 sets of cultures
on the gels: Set 1 were cultured only about 1 week prior to treatment and then treated for
24 hours TNF-ca +/-NMA (order: Control, Control-NMA, TNF-a, TNF-ai-NMA); Set 2
were cultured 2-3 weeks initially in FBS for first ~2 medium changes and then with ITS.
They were treated with TNF-ax for 36 hours (order: control, TNF-a); Set 3 were cultured
about 7 weeks in FBS and were overgrown routinely with fibroblastoid cells. They were
treated with TNF-ax for 48 hours (order: control, TNF-c). All these agarose sets were
treated with approximately 100 ng/ml of TNF-ca (in retrospect this concentration is way
too high!). There is approximately 50 ug protein/well from a detergent lysis of agarose
cultures (I don't believe that I still have the medium samples from these experiments).
Anti-ADAMTS4 blot - This blot was done under very mild washing conditions and
antibody concentration at 1:1000, so there is a chance of non-specific binding
AT4, C CN T TN
AT4, set1 set 2 set
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Anti-ADAMTS5. Information about the blot conditions and gel order are same as
above. Only one band was seen, and I need to rule out secondary binding since there is a
similar band in the ADAMTS4 blot.
Additional work trying to identify ADAMTS4 and ADAMTS5 in the medium and from
detergent extracts of explants samples from the cytokine + NMA experiment did not
yield positive results. Below is a anti-ADAMTS5 blot of the medium. A faint band is
visible at a molecular weight of roughly 200 kDa which was present in all conditions, but
no additional bands were identified. The left lane bands indicate the recombinant
ADAMTS5 protein.
- 254 -
ADAMTS5 TNF-a TNF-NMA cont con-NMA IL-1 IL-INMA 
cont con-NMA
The blot below is an anti-ADAMTS4 blot of the medium. Again there is a slight bad
around 200 kDa or so but no bands are readily apparent in the -80 kDa region which is
the expected MW of ADAMTS4. The lane on the left is the recombinant ADAMTS4
protein.
ADAMTS4 TNF T-NMA cont c-NMA IL-I I-NMA cont con-NMA
No additional bands were found in the detergent lysis of the explants.
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Table C.3 SDS-PAGE-LC/MS/MS analysis of detergent lyses of three
week chondrocyte cultures in agarose after 36 hour TNF-a treatment
Table C.3 is the Spectrum Mill protein summary for the SDS-PAGE-LC/MS/MS analysis
of 3 week chondrocyte cultures treated with TNF-a for 36 hours.
Column 1: GroupNum:
Column 2: Numspec.:
Column 3: Uniquepep:
Column 4: Uniquescore:
Column 5: % Coverage:
Column 6: TotalInstensity:
Column 7: MW:
Column 8: pI:
Column 9: species:
Column 10: Database:
Column 11: Accession:
Column 12: Protein Name:
Protein number
Number of spectra
Number of unique peptides
Score based on unique peptide identifications
percentage of protein amino acid sequence found
summed peptide ion intensity for each protein
protein molecular weight
protein isoelectric point
animal species
Protein database
database accession number
name of the protein
The purpose for this experiment was to attempt to validate the ADAMTS4 bands that
were identified by Western blotting. While there is ADAMTS4 present in the list, it is
the result of carry-over from the positive control (ADAMTS4 recombinant protein). The
intersesting findings in the list are iNOS, transcription factors such as STAT3, matrix
proteins, innate immune proteins that were also identified in cartilage explants (supports
new protein synthesis as the cause the release of innate immune proteins from explants),
caspases (suggesting possible apoptosis with TNF-a treatment). In addition to the above
findings that are primarily the result of TNF-a treatment, the increase in mitochondrial
proteins was also noted which were not found with injury to explants in which a number
of intracellular protein types were released. This may suggest a change in phenotype of
the chondrocytes (and attempt to deal with the oxygen tension) or it may simply be that
the mitochondrial proteins are not readily released with injury).
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groupNun numSpeci unique peptidescoreUnique % coverage totalintensity mw
1 151 46 776.81 71 2.03E+06 69
2 54 50 743.49 23 8.02E+04 341
3 222 39 724.38 68 2.70E+06
4 72 37 621.31 45 9.80E+05 84
5 47 42 602.51 23 9.04E+04 229
6 68 35 591.15 64 8.61E+05 56
7 51 36 560.26 58 5.75E+05 64
8 34 33 539.2 50 4.96E+05 80
9 37 30 498.43 48 6.74E+05 71
10 33 29 498.22 41 4.58E+05 84
11 34 34 492.62 19 3.88E+04 279
12 43 28 465.74 43 3.94E+05 72
13 84 28 465.69 41 1.04E+06 80
14 166 26 464.26 61 2.09E+06 47
15 99 26 456.39 72 1.60E+06 44
16 114 25 434.81 65 1.10E+06 38
17 68 28 432.04 51 1.06E+06 57
18 33 27 428.85 28 5.81E+04 157
19 30 29 427.52 17 5.13E+04 269
20 42 26 427.4 39 5.18E+05 80
21 56 27 424.55 40 2.97E+05 95
22 52 28 420.25 57 5.09E+05 53
23 54 25 413.13 62 7.64E+05 39
24 94 23 400.88 68 1.12E+06 47
25 50 21 391.15 51 5.54E+05 56
26 64 23 388.54 60 4.82E+05 38
27 27 22 387.98 47 2.57E+05
28 27 22 365.27 51 3.30E+05 60
29 67 23 362.13 65 6.62E+05 39
30 72 19 359.34 53 7.56E+05 46
31 48 22 358.37 58 5.65E+05 48
32 94 21 356.06 51 1.19E+06
33 57 22 349.18 60 5.73E+05 36
34 19 19 349.02 47 3.25E+05 62
35 47 21 348.26 48 6.09E+05 56
36 27 20 346.81 40 3.14E+05 67
37 30 21 344.2 31 9.19E+04 108
38 87 21 342.97 61 1.16E+06 43
39 38 23 338.93 30 1.09E+05 102
40 22 21 333.1 48 2.69E+05 55
41 82 21 332.68 60 7.01E+05 36
42 36 19 328.95 32 1.73E+05 89
43 27 21 327.94 37 2.94E+05 76
44 21 21 324.39 39 1.40E+05
45 55 18 311.5 51 5.92E+05 40
46 66 19 297.92 27 3.95E+05
47 21 21 297.87 16 3.06E+04 211
48 23 19 296.21 30 1.79E+05 8
49 23 18 294.5 50 2.55E+05
50 69 18 291.74 54 5.98E+05 36
51 19 17 289.8 27 1.69E+05 86
52 34 16 284.95 45 3.86E+05 48
323.9
601.4
61428
731.2
100.4
929.9
355.4
352.5
239.9
084.2
440.9
498.4
731.1
326.4
537.9
612.3
265.9
942.8
669.4
694.8
368.7
677.1
143.3
830.1
283.8
897.8
75537
977.9
436.3
506.9
038.7
48452
787.3
277.9
903.5
906.2
8355.6
3765.9
2207.4
5136.6
6088.1
9330.3
6758.3
65291
0287.E
66067
706.5
1492.5
35885
6597.8
185.4
8075.6
pi species
5.82 Bos taurus
6.08 Bos taurus
8.62 Bos taurus
4.93 Bos taurus
5.44 Bos taurus
6.23 Bos taurus
5.98 Bos taurus
6.36 Bos taurus
5.49 BOVIN
5.86 Bos taurus
5.53 Bos taurus
4.96 Bos taurus
5.54 Bos taurus
6.38 Bos taurus
8.48 Bos taurus
6.92 Bos taurus
4.8 Bos taurus
5.61 Bos taurus
database
NCBlnr
NCBlnr
NCBnr
NCBlnr
NCBlnr
NCBlnr
NCBnr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBlnr
NCBlnr
NCBlnr
NCBlnr
NCBnr
NCBInr
NCBlnr
5.75 Homo sapieiNCBlnr
5.53 Bos taurus
6.41 Bos taurus
5.21 Bos taurus
4.72 Bos taurus
4.8 Bos taurus
5.15 Bos taurus
6.44 Bos taurus
5.09 Bos taurus
5.71 Bos taurus
8.45 Bos taurus
9.01 Bos taurus
4.31 Bos taurus
4.97 Bos taurus
5.3 Bos taurus
5.95 BOVIN
7.69 Bos taurus
7.56 Bos taurus
5.29 Bos taurus
8.87 Bos taurus
6.29 Bos taurus
7.51 Bos taurus
4.94 Bos taurus
5.14 Bos taurus
8.41 Bos taurus
5.03 Bos taurus
7.93 Bos taurus
8.15 Homo sapi
4.88 Bos taurus
6.34 Bos taurus
5.54 Bos taurus
8.12 Bos taurus
6.64 Bos taurus
6.1 Bos taurus
NCBlnr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBlnr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
el NCBInr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
accession Protein name
30794280 albumin
76614728 PREDICTED: similar to alpha 3 type VI collagen isoform 1 precursor isoform
73587283 LOC512571 protein
34392343 90-kDa heat shock protein alpha
27807325 myosin, heavy polypeptide 10, non-muscle
27805905 glucose regulated protein 58kD
76659545 Villin 2
76619055 PREDICTED: similar to cytoskeleton-associated protein 4
123644 Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8)
76623595 annexin VI
76648768 filamin A
76616203 protein disulfide isomerase related protein
74356373 Hypothetical protein LOC535077
74354056 enolase 1
74353972 Phosphoglycerate kinase 1
27807289 annexin A2
27806501 procollagen-proline, 2-oxoglutarate 4-dioxygenase
76646935 PREDICTED: similar to Ras GTPase-activating-like protein IQGAP1 (p195) is
16753233 talin 1
76607158 PREDICTED: similar to Melanotransferrin precursor (Melanoma-associated a
74353984 Unknown (protein for MGC:127305)
27806785 vimentin
76630567 heat shock 70kDa protein 5
76650558 beta tubulin
28461221 ATP synthase, H+ transporting, mitochondrial F1 complex, beta subunit
74 annexin I
76617127 PREDICTED: similar to CG1550-PA isoform 2
76644268 LOC511913 protein
76653617 ALDOC protein
76636117 PREDICTED: similar to Collagen-binding protein 2 precursor (Colligin 2) (Rhe
27806723 calreticulin
76618161 Tubulin alpha-2 chain (Alpha-tubulin 2) (Alpha-tubulin isotype M-alpha-2)
27806317 annexin A8
3122018 Dihydropyrimidinase-related protein 2 (DRP-2) (Neural-specific protein NSP6(
41386780 UDP-glucose pyrophosphorylase 2
50844503 transketolase
76641275 PREDICTED: similar to actinin, alpha 4 isoform 11
76636770 chitinase 3-like 1
33332343 hexokinase 1
27806365 UDP-glucose dehydrogenase
73586525 annexin 5
73586667 Hypothetical protein LOC507345
76629806 glutamine fructose aminotransferase
79153525 Hypothetical protein LOC535321
27805853 cartilage linking protein 1
17318569 keratin 1
76625295 PREDICTED: similar to Tenascin precursor (TN) (Hexabrachion) (Cytotactin)
73586669 Hypothetical protein LOC510075
48374083 annexin A4
27806559 lactate dehydrogenase A
76647458 PREDICTED: similar to Protein transport protein Sec23A (SEC23-related prot
73586966 Hypothetical protein LOC505323
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groupNun numSpecl unique peptide scoreUnique % coverage totalintensity mw
284.01
282.85
279.9
275.39
273.69
272.33
266.95
266.6
265.68
265.51
265.4
264.98
263.57
262.87
262.76
262.04
260.13
258.93
258.53
251.48
250.78
244.98
242.87
241.35
241.15
236.36
234.95
234.68
233.7
232.1
228.7
227.7
222.07
219.95
219.93
218.54
216.44
215.62
214.22
213.75
213.56
212.72
212.43
211.18
209.08
204.92
203.79
203.3
202.36
201.67
199.52
199.41
4.33E+05
1.90E+05
2.01E+05
3.30E+05
1.77E+05
2.71 E+05
3.05E+05
1.42E+05
1.40E+05
1.96E+06
1.76E+05
2.11E+05
1.94E+05
5.17E+04
5.75E+04
1.61 E+06
2.92E+05
1.54E+05
4.81 E+05
1.83E+05
1.36E+06
1.68E+05
1.18E+05
1.14E+05
2.01 E+05
1.35E+05
2.12E+05
1.59E+05
1.67E+05
5.06E+05
1.42E+05
1.61E+05
5.29E+04
1.20E+05
1.95E+05
2.51 E+05
4.12E+05
1.34E+05
4.48E+04
2.41 E+05
1.79E+05
4.41E+04
2.10E+05
3.55E+05
1.89E+05
1.61 E+05
8.01 E+04
1.85E+05
1.17E+05
2.04E+05
1.56E+04
1.15E+05
59719.9
87124.2
61631.6
50512.4
79321.8
56709.1
51019.5
73742
85357.8
41676
79992.9
54982.7
64828.6
111465
98258.3
24638.1
62871
87797.3
246478.3
83173.1
35868.3
68782.9
94091.4
50824.4
55761.4
46759.6
50743.9
55872
53048.5
47502.2
83564.7
36617.3
83190.4
58605.4
48850.6
49414.8
48514.9
22393.2
102892.1
37588.6
81398.7
97400.3
54216
22209.7
33602.1
62086.1
29032.8
54414.8
63427.9
70954.7
274556
55575.6
pi species
9.21 Bos taurus
5.8 Bos taurus
8.03 Bos taurus
6.02 BOVIN
8.8 Bos taurus
7.54 BOVIN
5.14 Bos taurus
5.97 Bos taurus
8.08 Bos taurus
5.36 Bos taurus
5 Bos taurus
5.11 Bos taurus
6.65 Bos taurus
6.19 Bos taurus
6.34 Bos taurus
8.69 BOVIN
7.33 Bos taurus
6.86 Bos taurus
4.16 Bos taurus
5.14 Bos taurus
8.51 Bos taurus
6.15 Bos taurus
5.55 Bos taurus
8.96 Bos taurus
7.13 Bos taurus
6.13 Bos taurus
8.28 Bos taurus
5.83 Bos taurus
6.29 Bos taurus
6.81 Bos taurus
6.13 Bos taurus
6.8 Bos taurus
8.32 Bos taurus
5.85 Bos taurus
4.64 Bos taurus
9.14 Bos taurus
4.91 Bos taurus
5.98 Bos taurus
5.48 Bos taurus
4.56 Bos taurus
5.3 Bos taurus
5.31 Bos taurus
7.56 Bos taurus
8.59 Bos taurus
4.65 Bos taurus
6.24 Bos taurus
4.75 Bos taurus
5.36 Bos taurus
6.5 Bos taurus
6.37 Bos taurus
6.23 Bos taurus
5.68 Bos taurus
database
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBinr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
accession Protein name
102 H(+)-transporting ATP synthase
76661128 PREDICTED: similar to Signal transducer and activator of transcription 1-alph
74354891 Glutamate dehydrogenase 1, mitochondrial precursor (GDH)
13638229 Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate
76659038 PREDICTED: similar to acyl-CoA synthetase long-chain family member 4 isof
118502 Aldehyde dehydrogenase, mitochondrial precursor (ALDH class 2) (ALDHI) (/
74354615 Heterogeneous nuclear ribonucleoprotein K
73586960 Heat shock 70kDa protein 9B (mortalin-2)
27806769 aconitase 2, mitochondrial
22655316 beta-actin
76637003 Calpain-2 catalytic subunit (Calpain-2 large subunit) (Calcium-activated neutr
76641931 PREDICTED: similar to nucleobindin 1 isoform 3
76656655 PREDICTED: similar to Prolyl 4-hydroxylase alpha-1 subunit precursor (4-PH
76657688 PREDICTED: similar to alpha glucosidase II alpha subunit isoform 2
76627633 alpha-1,4-glucan orthophosphate glycosyl transferase
1174380 Superoxide dismutase [Mn], mitochondrial precursor
73587307 Unknown (protein for MGC:127793)
76654528 PREDICTED: similar to pyrroline-5-carboxylate synthetase isoform 1 isoform
37953324 aggrecan
76672350 PREDICTED: similar to leprecan 1 isoform 1
73587299 Glyceraldehyde-3-phosphate dehydrogenase
76633782 PREDICTED: similar to matrilin 4 isoform 2 precursor
76640328 PREDICTED: similar to vacuolar protein sorting 35 isoform 2
430 isocitrate dehydrogenase (NADP+)
73586529 LOC514939 protein
74354744 Isocitrate dehydrogenase 1 (NADP+), soluble
76630316 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein,
76670156 glycyl-tran synthetase
76625476 PREDICTED: similar to NADP-dependent malic enzyme (NADP-ME) (Malic e
41386719 milk fat globule-EGF factor 8 protein
27806477 procollagen-lysine, 2-oxoglutarate 5-dioxygenase precursor
73586501 Unknown (protein for MGC:126928)
76650936 PREDICTED: similar to Complement factor B precursor (C3/C5 convertase)
27806419 seryl-tRNA synthetase
74268096 Hypothetical protein LOC517087
76674779 PREDICTED: similar to phosphoglucomutase 1
76630218 PREDICTED: similar to Protein disulfide-isomerase A6 precursor (Thioredoxir
74354863 heat shock 27kDa protein 1
76644640 PREDICTED: similar to Puromycin-sensitive aminopeptidase (PSA) isoform 2
76615717 PREDICTED: similar to calumenin precursor isoform 3
41386707 vascular cell adhesion molecule 1
83405754 Coatomer protein complex, subunit gamma 2
78 annexin XI
59858511 peroxiredoxin 1
76672694 PREDICTED: similar to Reticulocalbin-1 precursor, partial
24251217 I-caldesmon
79153472 tropomyosin 1 alpha chain
61863538 MMP-3
76612740 PREDICTED: similar to extracellular matrix protein 1 isoform 1 precursor isofc
74268037 Hypothetical protein LOC504439
38425281 fatty acid synthase
410689 leucine aminopeptidase
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groupNun numSpecl unique peptidescoreUnique % coverage totalintensity mw
105 15 12 198.37 44 1.47E+05 38
106 19 12 197.37 32 1.99E+05 46
107 17 12 196.89 54 1.31E+05 28
108 14 13 195.9 25 1.39E+05 58
109 16 12 195.76 29 2.1OE+05 54
110 14 13 195.58 23 1.35E+05 63
111 12 12 195.42 18 9.37E+04 87
112 18 12 195.35 40 1.49E+05 44
113 13 13 193.64 8 1.65E+04 234
114 13 12 192.5 18 2.96E+04 107
115 11 11 190.13 58 1.42E+05 24
116 12 12 187.41 18 3.59E+04 117
117 11 11 187.09 36 7.62E+04 42
118 14 12 186.22 43 1.26E+05 29
119 11 11 185.62 26 1.07E+05 6C
120 13 12 184.47 18 8.71E+04 82
121 13 12 183.59 22 1.01E+05 82
122 16 12 183.13 31 1.62E+05
123 13 12 183.07 19 9.37E+04 89
124 38 11 182.21 33 2.31E+05 39
125 27 11 181.27 22 1.97E+05 51
126 32 12 181.12 30 1.61E+05 44
127 29 11 180.96 21 1.56E+05 5E
128 12 11 180.96 42 6.88E+04 33
129 11 11 178.7 21 1.27E+05 6(
130 15 11 178.5 62 1.65E+05 2C
131 12 10 178.15 54 1.72E+05 31
132 14 10 177.26 43 2.53E+05 31
133 13 11 176.62 17 8.81E+04 81
134 42 11 176.59 25 1.72E+05 6
135 12 12 176.35 27 1.16E+05 53
136 11 11 175.46 19 7.24E+04 7
137 14 12 174.9 19 8.40E+04 5
138 11 10 173.48 20 8.74E+04 6
139 19 11 173.38 21 2.19E+05 5
140 11 10 173.33 29 1.13E+05 5
141 13 11 172.98 29 9.05E+04 51
142 17 12 167.98 15 2.78E+04 1
143 14 10 166.85 18 1.32E+05 8
144 12 10 166.09 43 1.05E+05 2
145 11 11 164.42 17 6.30E+04
146 11 9 162.48 45 9.35E+04 2
147 12 11 161.41 9 2.71E+04 19
148 12 11 160.57 18 8.69E+04 6
149 16 11 160.16 14 3.39E+04 28
150 20 9 160.1 37 1.61E+05 3
151 11 10 159.62 33 4.78E+04
152 10 9 159.13 40 1.11E+05 2
153 11 11 158.58 15 2.92E+04 9
154 19 10 158.08 27 1.08E+05
155 20 9 157.91 50 1.54E+05 2
156 15 10 157.51 46 1.32E+05 3
351.7
104.2
727.2
109.7
785.7
535.4
643.7
791.5
747.7
736.6
566.1
945.6
866.6
9174.1
0586.3
032.1
2414.6
42236
9073.3
9879.3
1114.2
4859.4
9527.9
3646.9
0151.6
0035.4
1375.1
5143.1
5058.1
2064.6
9870.7
8120.9
7162.5
3085.7
1091.8
3812.3
7956.5
22998
4354.8
8663.2
83249
5302.9
1589.7
2482.3
8270.8
5668.7
33253
8852.1
8924.3
43514
1946.1
)839.8
pi species
8.09 Bos taurus
6.05 Bos taurus
5.6 Bos taurus
5.89 Bos taurus
6.55 Bos taurus
4.92 Bos taurus
6.44 Bos taurus
8.73 Bos taurus
5.79 Bos taurus
5.81 Bos taurus
5.55 Bos taurus
5.46 Bos taurus
5.44 Bos taurus
database
NCBlnr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBlnr
NCBInr
NCBInr
NCBInr
4.63 Pan troglody NCBInr
6.38 Bos taurus NCBInr
5.09 Bos taurus NCBlnr
6.81 Bos taurus NCBlnr
5.71 Bos taurus NCBInr
7.1 Bos taurus NCBInr
8.72 Bos taurus NCBlnr
5.73 Bos taurus NCBInr
7.83 Bos taurus NCBInr
5.17 Homo sapiel NCBlnr
9.95 Bos taurus NCBInr
4.36 Bos taurus NCBlnr
6.84 Bos taurus NCBInr
5.29 Bos taurus NCBInr
5.75 Bos taurus NCBlnr
6.91 Bos taurus NCBInr
5.14 Homo sapiei NCBlnr
5.76 Bos taurus
8.73 Bos taurus
5.45 Bos taurus
6.44 Bos taurus
4.44 Bos taurus
5.49 Bos taurus
6.32 Bos taurus
5.66 Bos taurus
5.67 Bos taurus
5.78 Bos taurus
9.17 Bos taurus
7.69 Bos taurus
5.48 Bos taurus
6.08 Bos taurus
5.83 Bos taurus
8.82 Bos taurus
5.66 Bos taurus
6.68 Bos taurus
5.45 Bos taurus
8.67 Bos taurus
5.36 Bos taurus
8.82 Bos taurus
NCBlnr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBlnr
NCBnr
NCBlnr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
accession Protein name
74354951 GNB2L1 protein
27806941 serine (or cysteine) proteinase inhibitor, clade A (alpha-1antiproteinase, antitr
73587123 chloride channel protein p64H1
76635420 PREDICTED: similar to archain isoform 3
75773587 Fascin homolog 1, actin-bundling protein
76615361 PREDICTED: similar to FK506 binding protein 9
75948195 Hypothetical protein LOC514586
76649531 PREDICTED: similar to transmembrane protein 43
76661429 PREDICTED: similar to Myofelin (Fer-1-like protein 3) isoform 3
76635618 PREDICTED: similar to coatomer protein complex, subunit beta isoform 3
76614007 PREDICTED: similar to Phosphoglucomutase 1 (Glucose phosphomutase 1)
76655772 ubiquitin-activating emzyme El
74354268 26S proteasome p40.5 subunit
55644755 14-3-3 protein epsilon isoform transcript variant 1
74354953 T-complex protein 1, gamma subunit (TCP-1-gamma) (CCT-gamma)
74268113 dipeptidyl peptidase Ill isoform 1
76666079 PREDICTED: similar to DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 isoform 2
76651280 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 6
76648296 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase delta 1 (Phospho
54660107 decorin
27806907 clusterin
76640813 haptoglobin
28317 Keratin, type I cytoskeletal 10 (Cytokeratin-10) (CK-10) (Keratin-10) (K1O)
76616406 PREDICTED: similar to B-cell receptor-associated protein 37 isoform 1
74356454 Protein kinase C substrate 80K-H
62751849 Parkinson disease (autosomal recessive, early onset) 7
76688665 PREDICTED: similar to Bifunctional 3-phosphoadenosine 5-phosphosulfate s-
73586870 NP protein
76684810 PREDICTED: similar to tumor necrosis factor, alpha-induced protein 2
55956899 keratin 9
76635779 PREDICTED: similar to SWAP-70 protein, partial
506 lactotransferrin
76658345 Hematopoietic cell-specific Lyn substrate 1
285642 5'-nucleotidase precursor
76690221 calnexin
74354933 WARS protein
75773567 Hypothetical protein LOC521540
76661740 PREDICTED: similar to TIP120 protein isoform 3
76630432 PREDICTED: similar to niban protein isoform 1
66792738 hypothetical protein LOC510041
74268185 FGF-2 binding protein
76610134 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclo-
27806689 clathrin, heavy polypeptide (Hc)
78369310 hypothetical protein LOC617109
76657613 AHNAK nucleoprotein isoform 1
81674781 malate dehydrogenase 2, mitochondrial
76643555 PREDICTED: similar to CG1532-PA isoform 1
77404217 similar to phosphoglycerate mutase
74267681 Major vault protein
74353843 GALE protein
74353992 PRDX2 protein
73586892 Voltage-dependent anion channel 1
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groupNun numSpect unique peptide scoreUnique % coverage totalIntensity mw
155.57
155.21
154.83
154.74
154.29
150.93
150.84
150.2
149.67
148.46
148.21
147.41
146.91
146.37
145.96
145.74
145.69
145.62
145.11
144.87
144.47
144.1
143.31
142.13
141.33
138.46
137.5
137.4
137.09
136.57
136.36
136.23
135.31
134.87
134.31
133.36
133.13
132.18
132.16
130.9
130.42
129.61
129.43
128.82
126.29
122.3
122.07
122.04
120.68
120.32
119.33
118.72
1.28E+05
1.75E+05
1.71E+05
2.39E+05
1.41 E+05
1.39E+05
8.16E+04
3.90E+05
3.21 E+05
7.28E+04
9.57E+04
1.67E+05
7.07E+05
5.43E+04
1.17E+05
1.25E+05
7.53E+04
7.43E+04
1.93E+05
1.65E+05
5.72E+04
7.53E+04
7.82E+04
2.06E+05
7.84E+04
4.19E+04
1.58E+04
2.18E+05
9.02E+04
5.13E+04
1.10E+05
1.30E+05
5.45E+04
9.27E+04
1.01 E+05
8.69E+04
1.48E+05
1.84E+05
5.48E+04
1.19E+05
6.03E+04
6.47E+04
8.81E+04
6.19E+04
5.84E+04
6.OOE+04
9.47E+04
5.39E+04
6.70E+04
6.56E+04
7.72E+04
4.71 E+04
37328.7
40773.4
38672.8
49753.1
46836.4
43683
91506.5
23613.3
43037.9
46285.8
58596.5
50419.4
34378.9
29585.8
38484.7
31619.7
21623.8
70649.5
38419
34613.4
47150.7
21664.1
61471.3
27646.2
37685.5
22426.6
136063.2
54848.5
36438.4
56285
64427.6
32884.3
57210.7
59950.5
24152.9
60206.8
69020.9
41170.6
46413.1
29798.7
26992
41571.8
47513.8
83112.9
55605.8
57475.6
25101.7
59290.6
73257.3
52240.7
50170.3
68917.3
p1 species
5.41 Bos taurus
7.68 Bos taurus
6.28 Bos taurus
8.48 Bos taurus
5.13 Bos taurus
9.59 Bos taurus
6.36 Bos taurus
6.89 Bos taurus
5.57 Bos taurus
5.35 Bos taurus
6.69 Bos taurus
6.31 Bos taurus
9.22 Bos taurus
6.15 Bos taurus
6.49 Bos taurus
7.47 Bos taurus
5.99 Bos taurus
8.74 Bos taurus
5.26 Bos taurus
4.71 Bos taurus
7.46 Bos taurus
8.4 Bos taurus
6.08 Bos taurus
8.87 Bos taurus
7.03 Bos taurus
8.4 Bos taurus
8.62 Bos taurus
5.05 Bos taurus
6.16 Bos taurus
5.93 Bos taurus
5.56 Bos taurus
4.8 Bos taurus
8.81 Bos taurus
5.86 Bos taurus
8.05 Bos taurus
5.8 Bos taurus
database
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
8.92 Pan troglody NCBInr
6.46 Bos taurus
7.09 Bos taurus
4.62 Bos taurus
5.17 Bos taurus
6.15 Bos taurus
9.19 Bos taurus
6.7 Bos taurus
7.62 Bos taurus
6.18 Bos taurus
6.6 Bos taurus
9.04 Bos taurus
6.71 Bos taurus
6.01 Bos taurus
6.44 Bos taurus
5.69 Bos taurus
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
accession Protein name
76649136 guanine nucleotide binding protein (G protein), alpha stimulating activity polyp
76617076 NADH-cytochrome b5 reductase (B5R) (Diaphorase-1) (Cytochrome b5 reduc
76676583 PREDICTED: similar to Thioredoxin domain containing protein 5 precursor (T
76661652 PREDICTED: similar to EGF-like repeats and discoidin I-like domains-contain
74354589 Thioredoxin domain containing 4 (endoplasmic reticulum)
10834556 proline arginine-rich end leucine-rich repeat protein
76672651 PREDICTED: similar to phosphofructokinase, platelet isoform 12
74268086 GSTP1 protein
74356334 Fibromodulin
76608670 PREDICTED: similar to glucan (1,4-alpha-), branching enzyme 1 (glycogen bi
76622660 PREDICTED: similar to antiquitin
76657631 PREDICTED: similar to Elongation factor 1-gamma (EF-1-gamma) (eEF-1B g
2293575 elongation factor 1 alpha
74354782 Hypothetical protein LOC515503
76620254 PREDICTED: similar to Heterogeneous nuclear ribonucleoprotein DO (hnRNF
62177148 voltage-dependent anion channel 2
76649594 PREDICTED: similar to Dolichyl-diphosphool igosaccharide--protein glycosyltr
74267810 ACADVL protein
27806751 alpha-2-HS-glycoprotein
77567785 Secreted protein, acidic, cysteine-rich [osteonectin]
37962708 phosphoribosylaminoimidazole carboxylase
61888850 adenylate kinase 1, soluble
76620344 PREDICTED: similar to WD-repeat protein 1 (Actin interacting protein 1) (AIP
76668658 PREDICTED: similar to Galectin-3 (Galactose-specific lectin 3) (Mac-2 antige
83638723 transaldolase 1
61888874 transgelin 2
76643113 PREDICTED: similar to Nitric oxide synthase, inducible (NOS, type II) (Inducil
479 cytokeratin Vib
74354869 Hypothetical protein LOC535182
76631190 PREDICTED: similar to UDP-N-acteylglucosamine pyrophosphorylase 1, like
76649693 PREDICTED: similar to FK506 binding protein 10 precursor (Peptidyl-prolyl ci
73587277 Laminin receptor 1 (ribosomal protein SA, 67 kDA)
76644716 PREDICTED: similar to proteasome (prosome, macropain) 26S subunit, non-,
76625467 PREDICTED: similar to Phosphoacetylglucosamine mutase (PAGM) (Acetylgi
76671596 PREDICTED: similar to Bifunctional 3-phosphoadenosine 5-phosphosulfate s
81673561 t-complex protein 4a
55624160 EGF-like repeats and discoidin I-like domains-containing protein 3
76626357 PREDICTED: similar to Acetyl-CoA acetyltransferase, cytosolic (Cytosolic ace
184 aspartate aminotransferase
76642117 PREDICTED: similar to reticulocalbin 3, EF-hand calcium binding domain
74268283 Chloride intracellular channel 1
84708845 Unknown (protein for MGC:133898)
415324 aspartate aminotransferase
81674209 STAT3 protein
74268173 Serine hydroxymethyltransferase 2 (mitochondrial)
73586876 Hypothetical protein LOC505313
76649600 PREDICTED: similar to Dolichyl-diphosphooligosaccharide--protein glycosyltr
76634481 PREDICTED: similar to Cytochrome P450 7B1 (Oxysterol 7-alpha-hydroxylas
76622127 PREDICTED: similar to KH-type splicing regulatory protein (FUSE binding prc
76643080 PREDICTED: similar to 26S proteasome non-ATPase regulatory subunit 11 (
76649598 PREDICTED: similar to Dolichyl-diphosphooligosaccharide--protein glycosyltr
75773506 Eukaryotic translation initiation factor 4B
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groupNun numSpecl unique peptide scoreUnique % coverage totalintensity mw
117.62
117.21
117.18
116.74
116.24
115.26
114.26
114.23
113.24
113.17
112.69
112.66
112.57
111.4
111.15
110.53
110.51
110.2
110.15
109.61
109.58
108.2
107.97
107.94
107.78
106.58
106.51
106.51
106.18
105.97
105.5
103.88
103.85
102.6
101.89
101.66
101.65
101.27
100.77
100.6
98.95
97.93
97.76
97.03
96.57
96.08
95.99
95.86
95.14
94.35
94.09
93.89
6.53E+04
5.32E+04
3.87E+04
5.27E+04
8.85E+04
3.26E+04
8.70E+04
3.03E+04
5.96E+04
3.37E+04
6.11E+04
4.77E+04
1.24E+04
1.78E+04
6.44E+04
9.89E+04
7.75E+04
4.12E+04
5.97E+04
5.44E+04
5.89E+04
1.30E+05
6.65E+04
3.77E+04
5.30E+04
6.26E+04
3.83E+04
1.39E+05
6.55E+04
4.20E+04
5.15E+04
6.12E+04
6.78E+04
6.87E+03
4.62E+04
4.96E+04
5.18E+04
6.34E+04
5.92E+04
5.19E+04
4.09E+04
6.41 E+04
5.27E+04
3.94E+04
7.05E+04
4.33E+04
5.82E+04
4.96E+04
5.19E+04
3.88E+04
3.71 E+04
7.20E+04
56451.9
26604.1
138850.1
97227.8
66153.3
22959.1
71705
33072.2
68475.7
29820.3
31157.8
28727.3
41590.3
125099.6
51272.9
38624.7
16702
56135.4
39216.1
29772.7
58206.8
41445.1
60882.3
34349.2
112885.4
75217.1
31235.5
46182.2
38221.9
56240.2
26879.6
55311.6
21183.5
307583.1
31308.3
29945.1
22612.1
39837.7
49784.1
38756.6
50680.2
19581.4
45797.3
37429.9
24804.9
22409
19987.8
73413.6
23544
47362.7
18692.6
34879.6
pi species database
6.47 Bos taurus NCBInr
4.7 Bos taurus NCBInr
6.39 Bos taurus NCBlnr
4.68 Bos taurus NCBInr
6.05 Bos taurus NCBInr
9.86 Bos taurus NCBInr
6.42 Homo sapiel NCBInr
9.34 Bos taurus NCBInr
5.42 Bos taurus NCBInr
5.57 Homo sapiel NCBInr
5.67 BOVIN
9.31 Bos taurus
6.83 Bos taurus
6.61 Bos taurus
7.16 Bos taurus
5.64 Bos taurus
4.65 Bos taurus
5.01 Bos taurus
9.26 Bos taurus
5.65 Bos taurus
7.01 Bos taurus
5.22 Bos taurus
7.88 Bos taurus
6.84 Bos taurus
5.14 Bos taurus
7.12 Bos taurus
10.25 Bos taurus
5.32 Mus musculi
6.33 Bos taurus
6.23 Bos taurus
3.88 Bos taurus
8.36 Bos taurus
5.73 Bos taurus
7.99 Bos taurus
4.9 Bos taurus
9.75 Bos taurus
6.73 BOVIN
6.14 Bos taurus
9.29 Bos taurus
5.93 Bos taurus
8.77 HUMAN
4.84 Bos taurus
7.64 Bos taurus
8.97 Bos taurus
4.51 Bos taurus
6.22 Bos taurus
5.88 Bos taurus
7.03 Bos taurus
6.39 Bos taurus
4.4 Bos taurus
5.99 Bos taurus
9.58 Bos taurus
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accession Protein name
78042498 phosphoglycerate dehydrogenase
28461287 hepatoma-derived growth factor (high-mobility group protein 1-like)
76609270 PREDICTED: similar to Collagen alpha 1(III) chain precursor isoform 2
76644624 PREDICTED: similar to karyopherin beta 1 isoform 2
76619715 PREDICTED: similar to phosphoglucomutase 2
28189605 similar to ribosomal protein S3
25058739 ALB protein
76632116 mitochondrial F1-ATPase gamma-subunit
75775489 ATPase, H+ transporting, lysosomal (vacuolar proton pump), alpha polypeptic
46360168 prohibitin
47117864 NG,NG-dimethylarginine dimethylaminohydrolase 1 (Dimethylargininase 1) (C
74354583 Unknown (protein for MGC:127664)
60650302 biglycan preproprotein
76660845 PREDICTED: similar to SEC31-like 1 isoform 2
74267948 CAP, adenylate cyclase-associated protein 1
76608399 PREDICTED: similar to Pyridoxal kinase (Pyridoxine kinase)
76676187 PREDICTED: similar to calnexin
76617087 PREDICTED: similar to protein kinase C and casein kinase substrate in neurc
61832036 PREDICTED: similar to IKK interacting protein isoform 2 isoform 1
73587049 Unknown (protein for MGC:128392)
83406133 Hypothetical protein LOC613336
76617010 PREDICTED: similar to heat shock 70kD protein binding protein isoform 2
76630143 PREDICTED: similar to matrilin 3 precursor
75948237 Hypothetical protein LOC540838
76607529 PREDICTED: similar to proteasome 26S non-ATPase subunit 2
76620042 PREDICTED: similar to Lysosome membrane protein I (LIMP 1l) (Scavenger
74267604 Ribosomal protein S2
74139596 Eif4al protein
76617802 PREDICTED: similar to Poly(rC)-binding protein 2 (Alpha-CP2) (Putative hete
76634377 PREDICTED: similar to carbonic anhydrase VIII
61857708 PREDICTED: similar to acidic (leucine-rich) nuclear phosphoprotein 32 family
76622496 PREDICTED: similar to Vesicular integral-membrane protein VIP36 precursor
76656657 PREDICTED: similar to Prolyl 4-hydroxylase alpha-1 subunit precursor (4-PH
76639293 PREDICTED: similar to GCN1 general control of amino-acid synthesis 1-like-
74267652 Hypothetical protein LOC540984
74267633 Ribosomal protein S3A
121664 Glutathione peroxidase 1 (GSHPx-1) (GPx-1) (Cellular glutathione peroxidasE
82571797 Similar to GDP-mannose pyrophosphorylase B isoform 2
76635122 PREDICTED: similar to Acetyl-CoA acetyltransferase, mitochondrial precurso
74354899 Lumican
67472677 septin 7
74356483 Tumor protein, translationally-controlled 1
76626483 proteasome chain p42
76662781 PREDICTED: similar to Heterogeneous nuclear ribonucleoproteins A2/B1 (hn
62460568 eukaryotic translation elongation factor 1 beta 2
74354052 Hypothetical protein LOC517171
42564199 ferritin light polypeptide
78042544 galactosidase, beta 1
74354082 Hypothetical protein LOC509970
76617377 PREDICTED: similar to Nucleosome assembly protein 1-like 1 (NAP-1 relatec
74356487 ATP synthase, H+ transporting, mitochondrial F complex, subunit d
77736103 hypothetical protein LOC532659
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groupNun numSpeci unique peptidescoreUnique % coverage totalIntensity mw
93.71
93.36
93.28
92.98
92.08
92
91.08
91.06
90.41
90.16
89.37
89.27
89.21
87.82
87.77
87.36
87.12
86.68
86.38
85.57
85.15
84.96
84.44
84.33
83.36
82.84
82.29
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81.45
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81.28
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80.16
79.99
79.54
79.37
79.31
79.12
78.54
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78.41
78.35
78.21
77.96
77.93
77.69
77.69
77.49
77.27
77.16
75.62
1.OOE+05
6.69E+04
1.13E+05
3.34E+04
4.94E+04
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3.uOE+04
3.86E+04
2.88E+04
1,87E+04
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2.03E+05
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4.59E+04
5.58E+04
1.78E+04
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4.39E+04
9.30E+03
2.45E+04
4.14E+04
3.79E+04
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6.57E+04
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1.97E+04
5.20E+04
4.66E+04
4.58E+04
53451.4
38876.4
60825.3
56309.9
66921.2
47638.3
26918.6
24469.7
23466.7
75769
44334.1
26689.6
80578.3
46535
51723.5
119794.6
46208.3
28609.5
21623.2
131429
141875.1
56704.8
27379.8
68587.5
26496.9
32979.2
22264.8
33856
40140
31581.2
107529.4
26246.2
35569.7
30914.2
34173.7
44773.8
26661.9
86231.8
40147.2
40976
48927.4
531958.1
59070.7
34400.8
36754.3
46417.5
48862.8
33194.6
24577.4
63572.1
41375.9
55559.3
pi species database
5.49 Bos taurus NCBInr
6.17 Bos taurus NCBlnr
8.7 Bos taurus NCBInr
8.72 Bos taurus NCBInr
6.76 Canis famili NCBInr
5.88 Bos taurus NCBInr
5.09 Bos taurus NCBlnr
6.12 Bos taurus NCBlnr
8.64 Bos taurus NCBInr
6.73 Bos taurus NCBInr
8.32 Bos taurus NCBlnr
6.45 Bos taurus NCBInr
5.67 Bos taurus NCBInr
8.09 Bos taurus NCBInr
6.19 Bos taurus NCBInr
5.54 Bos taurus NCBInr
6.37 Bos taurus NCBInr
6.96 Bos taurus NCBInr
4.5 Bos taurus NCBInr
6.42 Bos taurus NCBlnr
6.82 Canis familiz NCBlnr
6.89 Bos taurus
5.31 Bos taurus
6.14 Bos taurus
8.27 Bos taurus
5.57 Bos taurus
6.2 Bos taurus
9.62 Bos taurus
9.39 Bos taurus
4.98 Bos taurus
4.85 Bos taurus
8.26 Bos taurus
8.32 Bos taurus
7.18 Bos taurus
6.52 Bos taurus
7.64 Bos taurus
6.82 Bos taurus
5.25 Bos taurus
10.09 Bos taurus
8.69 Bos taurus
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
5.14 Canis famili NCBInr
6.01 Bos taurus NCBInr
5.12 Bos taurus NCBInr
5.72 Bos taurus NCBInr
6.28 Bos taurus NCBInr
7.15 Bos taurus NCBInr
5.44 Sus scrofa NCBInr
5.39 Bos taurus NCBinr
9.52 Bos taurus NCBlnr
6.87 Canis famili NCBInr
6.5 Bos taurus NCBInr
5.64 Bos taurus NCBInr
accession Protein name
76656527 PREDICTED: similar to annexin VII isoform 2 isoform 4
30466254 gelsolin-like capping protein
76617862 keratin 5
76644089 PREDICTED: similar to aldehyde dehydrogenase 3A2 isoform 1 isoform 2
73964981 MLL septin-like fusion protein MSF-A
75773598 S-adenosylhomocysteine hydrolase
76637711 PREDICTED: similar to EF hand domain containing 2 isoform 2
83405346 RAB25, member RAS oncogene family
77736431 hypothetical protein LOC613749
76623789 PREDICTED: similar to arginyl-tRNA synthetase isoform 5
73586687 Hypothetical protein LOC508324
74267824 Triosephosphate isomerase
473522 adseverin
756 Sjogren syndrome antigen B (autoantigen La)
27807349 serine (or cysteine) proteinase inhibitor, clade G (Cl inhibitor), member 1, (an
76623926 PREDICTED: similar to leucyl/cystinyl aminopeptidase isoform 1
76610535 PREDICTED: similar to GDP-mannose pyrophosphorylase A isoform 2
81673887 Similar to proteasome (prosome, macropain) subunit, beta type 5
76658622 membrane steroid binding protein
76623638 PREDICTED: similar to Protein transport protein Sec24D (SEC24-related proi
55742776 alpha 1 type If collagen
76611743 PREDICTED: similar to aldehyde dehydrogenase 9A1 isoform 2
74267960 Proteasome activator subunit 2
76607976 PREDICTED: similar to procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 is
217606 adenylate kinase 2A
74354976 Capping protein (actin filament) muscle Z-Iine, alpha 2
76613178 PREDICTED: similar to Rho-related GTP-binding protein RhoC (Silica-induce
76655832 PREDICTED: similar to cytidylate kinase
27807185 solute carrier family 25 (mitochondrial carrier
76670238 PREDICTED: similar to Thioredoxin domain containing protein 1 precursor (T
79153667 Vesicle docking protein p115
83638719 MGC133525 protein
28603704 APEX nuclease (multifunctional DNA repair enzyme) 1
76610491 PREDICTED: similar to Aflatoxin B1 aldehyde reductase member 2 (AFB1-AF
74353940 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1
61816796 PREDICTED: similar to Putative GTP-binding protein PTDO04 isoform 1
74355014 Dehydrogenase/reductase (SDR family) member 6
76653005 PREDICTED: similar to CG1486-PA, isoform A
76648962 PREDICTED: similar to Y55F3AM.10
74355044 Actin related protein 2/3 complex, subunit 1 B, 41 kDa
73947624 Proteasome 26S ATPase subunit 4
76647908 PREDICTED: similar to dynein, cytoplasmic, heavy polypeptide 1 isoform 3
76627692 PREDICTED: similar to Sorting nexin-1 isoform 1
74353873 Ribosomal protein, large, PO
73586789 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Mov34 homl
74268328 Argininosuccinate synthetase
47523464 oligosaccharyltransferase OST48
74353962 Chaperonin containing TCP1, subunit 5 (epsilon)
76631901 PREDICTED: similar to prohibitin
73984196 Actr3 protein
28461209 mitogen-activated protein kinase 1
74353841 Hypothetical protein LOC507327
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313 7 5 75.47 10 2.46E+04 74
314 5 5 75.4 9 3.57E+04 72
315 7 4 75.35 4 7.79E+04 95
316 5 5 75.06 21 1.74E+04 33
317 6 5 75.04 17 3.70E+04 32
318 6 6 74.6 8 3.18E+04 71
319 5 5 74.45 6 3.46E+04 83
320 6 5 74,31 18 3.68E+04 39
321 6 6 74.16 8 i.05E+04 106
322 5 5 73.66 12 4.23E+04 44
323 118 4 73.51 25 1.79E+06 24
324 6 5 73.33 12 3.53E+04 51
325 5 5 73.14 19 1.73E+04 28
326 8 4 72.96 13 9.67E+04
327 5 5 72.81 17 3.20E+04 29
328 6 4 72.75 12 3.26E+04 56
329 5 5 72.37 22 2.87E+04 31
330 6 4 72.29 19 5.13E+04 26
331 6 5 71.64 12 4.52E+04 49
332 5 5 71.34 23 2.19E+04 28
333 8 5 71.32 33 4.99E+04 17
334 6 6 71.29 7 5.81E+04 71
335 5 5 71.23 11 2.96E+04
336 5 5 71.19 8 1.03E+04 101
337 5 4 70.78 12 3.84E+04 37
338 4 4 70.36 7 2.42E+04 80
339 6 4 70.21 11 5.20E+04 42
340 5 4 69.27 8 2.52E+04 67
341 4 4 69.09 12 2.43E+04 61
342 8 5 68.98 5 1.48E+04 108
343 5 4 68.95 15 3.22E+04 39
344 5 5 68.75 13 1.83E+04 44
345 7 5 68.72 26 4.83E+04
346 4 4 68.24 7 2.35E+04 71
347 4 4 68.17 8 1.97E+04 85
348 7 4 67.72 6 3.51E+04 73
349 5 5 67.52 13 2.18E+04 42
350 4 4 67.15 9 3.35E+04
351 5 5 67.12 9 2.85E+04
352 5 5 67.11 8 2.33E+04 66
353 5 5 66.22 16 1.98E+04 38
354 4 4 65.98 9 2.36E+04 55
355 5 5 65.89 8 8.68E+03 104
356 5 4 65.88 9 2.85E+04 46
357 6 4 65.48 12 3.57E+04 45
358 5 5 65.48 3 4.15E+03 193
359 9 4 65.24 5 6.67E+04 86
360 5 4 65.24 18 2.33E+04 28
361 7 4 64.61 8 4.57E+04 48
362 4 4 64.42 15 2.16E+04 37
363 5 5 64.34 6 1.01E+04 119
364 4 4 64.3 14 1.68E+04 41
728.6
944.1
686.3
741.5
877.6
321.3
990.8
668.1
548.7
911.5
409.6
036.9
821.8
31721
595.9
170.9
256.4
409.7
212.8
718.6
504.3
462.9
60368
836.4
391.2
641.9
840.7
818.2
657.5
697.3
677.4
968.8
20161
006.3
157.9
334.7
579.1
53959
60107
993.8
803.9
524.4
323.3
691.2
653.4
115.8
925.2
195.4
964.6
187.1
789.8
919.7
pi species database
9.31 Bos taurus NCBInr
7.55 BOVIN NCBInr
9.93 Pan troglody NCBlnr
6.01 Bos taurus
9.82 Bos taurus
6.32 Bos taurus
8.48 Bos taurus
6.76 Bos taurus
5.25 Bos taurus
6.1 Bos taurus
7 PIG
6.13 Bos taurus
9.42 Bos taurus
4.41 Bos taurus
10.16 Bos taurus
5.2 Bos taurus
7.1 Bos taurus
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBlnr
8.51 Pan troglody NCBInr
5.87 Bos taurus
8.91 Bos taurus
8.91 Bos taurus
8.67 Bos taurus
5.68 Bos taurus
7.08 Bos taurus
5.6 Bos taurus
5.56 Bos taurus
6.03 Bos taurus
6.39 Bos taurus
5.47 Bos taurus
5.24 Bos taurus
7.46 Bos taurus
8.76 Bos taurus
5.09 Bos taurus
6.41 Bos taurus
8.19 Bos taurus
5.46 Bos taurus
6.84 Bos taurus
5.22 Bos taurus
7.1 Bos taurus
8.24 Bos taurus
9.17 Bos taurus
8.76 Bos taurus
8.46 Bos taurus
7.51 Bos taurus
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBlnr
8.23 Homo sapiei NCBInr
5 Mus musculi NCBlnr
8.91 Bos taurus NCBInr
7.15 Bos taurus NCBInr
5.44 Bos taurus NCBInr
5.84 Bos taurus NCBInr
6.83 Bos taurus NCBInr
10.33 Bos taurus NCBInr
accession Protein name
76619804 PREDICTED: similar to Signal recognition particle 72 kDa protein (SRP72) is(
51338770 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial pre
55631158 YWHAZ protein
1838956 capping protein, beta3 isoform
32189336 solute carrier family 25 member 6
74354788 Hypothetical protein LOC509624
76638695 PREDICTED: similar to acetoacetyl-CoA synthetase, partial
27807161 isocitrate dehydrogenase 3 (NAD+) alpha
76610871 PREDICTED: similar to proteasome 26S non-ATPase subunit 1 isoform 8
76648164 PREDICTED: similar to Cartilage-associated protein precursor, partial
136429 Trypsin precursor
74354958 PSMC2 protein
84490369 ATP synthase, H+ transporting, mitochondrial FO complex, subunit b, isoform
76668091 Myristoylated alanine-rich C-kinase substrate (MARCKS) (ACAMP-81)
61835740 40S ribosomal protein S4
76625333 PREDICTED: similar to 26S proteasome non-ATPase regulatory subunit 5 (2(
75948233 PRDX3 protein
55639371 RAN protein
59858331 proteasome 26S ATPase subunit 1
74356381 Shwachman-Bodian-Diamond syndrome
76607963 PREDICTED: similar to procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 is
76652230 PREDICTED: similar to ERGIC-53 protein precursor (ER-Golgi intermediate c
76626675 PREDICTED: similar to Beta-hexosaminidase alpha chain precursor (N-acety
76628078 PREDICTED: similar to C-1-tetrahydrofolate synthase, cytoplasmic (Cl-THF 
814 Guanine nucleotide-binding protein G(I)/G(S)/G(T) beta subunit 2 (Transducir
27807495 prolyl oligopeptidase
76671278 PREDICTED: similar to vesicle amine transport protein 1 isoform 1
76613409 LOC512486 protein
76657953 PREDICTED: similar to atlastin-like isoform 3
76667061 PREDICTED: similar to Collagen alpha 1(VI) chain precursor isoform 1
73586689 Hypothetical protein LOC505515
76633465 PREDICTED: similar to Microtubule-associated protein RP/EB family membe
76629651 GTP binding protein Rabla
76607778 PREDICTED: similar to Lanosterol synthase (Oxidosqualene-lanosterol cycle
76628858 PREDICTED: similar to Mannosyl-oligosaccharide glucosidase (Processing A
76619718 PREDICTED: hypothetical protein XP_598213, partial
76639219 PREDICTED: similar to Protein KIAA0152 precursor
76651799 PREDICTED: similar to Ubiquitin carboxyl-terminal hydrolase 14 (Ubiquitin thi
76628891 PREDICTED: similar to T-complex protein 1, eta subunit (TCP-1 -eta) (CCT-e
76611461 PREDICTED: similar to heterogeneous nuclear ribonucleoprotein R isoform 2
76617606 Heterogeneous nuclear ribonucleoprotein Al (Helix-destabilizing protein) (Sin
76640954 PREDICTED: similar to Xaa-Pro dipeptidase (X-Pro dipeptidase) (Proline dipE
76624106 PREDICTED: similar to Iron-responsive element binding protein 1 (IRE-BP 1)
75773452 Hypothetical protein LOC537713
976227 26S proteasome subunit p45
30420885 collagen type XIV
76622337 PREDICTED: similar to Septin-8
27806083 peroxiredoxin 3
74353855 HLA-B-associated transcript 1
74356397 Hypothetical protein LOC538829
79158721 ATP citrate lyase
76666230 PREDICTED: similar to 40S ribosomal protein S7 (S8)
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groupNun numSpeci unique peptidescoreUnique % coverage totalintensity mw
365 4 3 64.1 38 3.51E+04 15
366 4 4 63.34 17 2.35E+04 33
367 5 5 63.26 22 2.15E+04
368 4 4 63.23 13 1.88E+04 34
369 4 4 62.92 19 1.38E+04
370 8 4 62.88 15 9.01E+04 36
371 4 4 62.65 6 1.86E+04 86
372 7 4 62.63 6 6.92E+04 72
373 4 4 62.56 14 4.14E+04 22
374 4 4 62.27 14 2.02E+04
375 5 4 62.07 16 3.09E+04 34
376 6 4 62 9 4.39E+04 51
377 5 4 62 8 3.29E+04 5
378 4 4 61.93 18 2.53E+04 31
379 4 4 61.7 7 1.99E+04 83
380 4 4 61.38 20 1.91E+04 31
381 5 4 61.34 12 3.88E+04 4(
382 5 4 61.28 7 4.66E+04 7(
383 4 4 60.52 10 1.67E+04 4
384 4 4 60.5 34 2.48E+04 1
385 3 3 60.05 11 2.11E+04 4
386 4 4 59.9 12 3.96E+04 41
387 4 4 59.88 6 2.09E+04 71
388 5 4 59.84 8 3.05E+04 4
389 4 4 59.12 15 2.63E+04 3
390 4 4 58.93 9 1.50E+04 7
391 11 4 58.57 10 7.16E+04 4
392 3 3 58.2 10 1.83E+04 4
393 6 4 58.14 11 3.18E+04 4
394 5 3 57.72 6 3.57E+04 6
395 4 4 56.94 2 1.82E+03 23
396 7 5 56.91 6 6.46E+03 9
397 6 3 56.85 5 9.04E+04 8
398 4 4 56.76 14 2.79E+04 3
399 4 4 56.76 8 2.02E+04 7
400 3 3 56.67 9 2.26E+04 6
401 6 4 56.4 12 4.1OE+04 3
402 3 3 56.32 21 2.02E+04 1
403 3 3 56.06 7 2.54E+04 6
404 4 4 55.7 3 3.69E+03 19
405 4 4 55.64 8 3.07E+04 6
406 5 4 55.3 13 2.03E+04
407 5 4 55.12 3 2.04E+04 11
408 4 4 55.03 7 1.77E+04 5
409 4 4 54.93 5 7.93E+03 12
410 3 3 54.61 20 2.16E+04 3
411 4 4 54.21 2 3.07E+03 25
412 7 4 53.86 10 4.26E+04 3
413 4 3 53.8 7 2.05E+04 6
414 3 3 53.75 46 2.80E+04
415 5 4 53.59 4 2.22E+04 10
416 4 3 53.54 11 2.71E+04 5
136.3
192.8
33454
172.1
25656
385.1
558.4
341.8
2474.7
29511
4025.2
1251.1
3284.8
5425.3
9686.8
1548.1
0217.7
0539.3
0620.5
6384.9
8148.8
1061.7
1710.8
9718.7
4335.9
0798.4
0001.9
7897.6
5894.6
7915.6
7106.1
0280.5
1390.6
7730.7
6683.2
0682.2
7526.1
3737.7
1981.1
8221.9
8742.2
35403
3018.4
5488.8
1587.6
2035.3
4778.7
4856.6
2135.1
9985.6
0494.8
4723.9
pI species
6.41 Bos taurus
6.16 Bos taurus
7.73 Bos taurus
9.89 Bos taurus
6.45 Bos taurus
5.18 Bos taurus
6.45 Bos taurus
8.68 Bos taurus
9.26 Bos taurus
database
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBlnr
NCBlnr
7.58 Macaca fasc NCBInr
4.1 Bos taurus NCBlnr
6.33 Bos taurus NCBlnr
6.93 Bos taurus NCBInr
8.35 Bos taurus NCBlnr
6.01 Bos taurus NCBInr
6.5 Bos taurus NCBInr
6.48 Bos taurus NCBlnr
6.3 Bos taurus NCBInr
6.12 Bos taurus NCBlnr
9.25 Bos taurus NCBInr
8.8 Bos taurus NCBlnr
5.79 Bos taurus NCBInr
7.49 Bos taurus NCBlnr
5.26 Bos taurus NCBlnr
8.4 Bos taurus NCBlnr
5.41 Bos taurus NCBlnr
6.42 Bos taurus NCBInr
5.01 Bos taurus NCBlnr
5.03 Bos taurus NCBlnr
8.95 Bos taurus NCBlnr
8.61 Bos taurus NCBInr
8.6 Bos taurus NCBInr
5.38 Pan troglody NCBInr
5.36 Bos taurus NCBlnr
5.37 Bos taurus NCBInr
6.35 Bos taurus NCBlnr
6.66 Homo sapiei NCBInr
8.25 Bos taurus
6.36 Bos taurus
5.84 Bos taurus
5.15 Bos taurus
8.34 Bos taurus
9.2 Bos taurus
8.59 Bos taurus
5.64 Bos taurus
6.82 Bos taurus
5.33 Bos taurus
5.46 Bos taurus
4.9 Bos taurus
5.52 Bos taurus
4.86 Bos taurus
6.07 BOVIN
NCBlnr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBlnr
NCBlnr
NCBInr
NCBlnr
accession Protein name
76691672 PREDICTED: similar to 5-aminoimidazole-4-carboxamide ribonucleotide form
75775302 Hypothetical protein LOC507313
62460606 pyrroline-5-carboxylate reductase family, member 2
32 2-oxoglutarate carrier
76613071 Glutathione S-transferase M1
76691116 eukaryotic translation initiation factor Eif4a2
76645272 PREDICTED: similar to N-ethylmaleimide-sensitive factor isoform 4
76661938 PREDICTED: similar to UV excision repair protein RAD23 homolog B (hHR22
82571590 Similar to FK506 binding protein 11 precursor (Peptidyl-prolyl cis-trans isomel
67967814 Proteasome (prosome, macropain) subunit, alpha type 4
76612860 PREDICTED: similar to acidic (leucine-rich) nuclear phosphoprotein 32 family
76620649 PREDICTED: similar to Heterogeneous nuclear ribonucleoprotein H (hnRNP 1
76672944 PREDICTED: similar to solute carrier family 25 member 24 isoform 1 isoform
74267964 PDZ and LIM domain 4
76625842 PREDICTED: similar to Protein KIAA0776 isoform 1
76631393 PREDICTED: similar to esterase D/formylglutathione hydrolase isoform 5
61886357 PREDICTED: similar to N-acetyineuraminic acid phosphate synthase isoform
76634024 PREDICTED: similar to eukaryotic translation elongation factor 1 delta isoforn
27806463 peptidylprolyl isomerase D
76613864 PREDICTED: similar to ER-Golgi intermediate compartment 32 kDa protein (I
73586962 Ubiquinol-cytochrome c reductase core protein II
76629739 PREDICTED: similar to actin-related protein 2, partial
76619562 PREDICTED: similar to Phenylalanyl-tRNA synthetase beta chain (Phenylala
76635541 PREDICTED: similar to Nucleobindin 2 precursor (DNA-binding protein NEFA
78042500 hypothetical protein LOC505126
76659016 Lymphocyte cytosolic protein 1 (L-plastin)
27806703 CD44 antigen [homing function and Indian blood group system]
76620664 PREDICTED: sequestosome 1 isoform 1
76662827 PREDICTED: similar to transmembrane emp24 protein transport domain cont
76636495 LOC508448 protein
76625277 PREDICTED: similar to Proteasome-associated protein ECM29 homolog (Ecr
31982399 a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin t'
55632315 PREDICTED: heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)
76655900 PREDICTED: similar to SPFH domain protein 2 precursor
76675970 PREDICTED: similar to nuclear receptor binding protein
62751751 EH-domain containing 1
460771 hnRNP-E1
76662308 PREDICTED: similar to 3-oxoacid CoA transferase 1, partial
76652215 PREDICTED: similar to Asparaginyl-tRNA synthetase, cytoplasmic (Asparagil
76627770 PREDICTED: similar to talin 2
76652904 PREDICTED: similar to G1 to S phase transition 1
4097831 zeta-crystallin
31341666 mannosidase, alpha, class 2B, member 1
76619545 PREDICTED: similar to Enigma homolog (Enigma-like PDZ and LIM domains
76672887 PREDICTED: similar to exportin 1, CRM1 homolog
62460502 hypothetical protein LOC512526
76662196 PREDICTED: similar to melanoma-associated chondroitin sulfate proteoglyca
62988316 follistatin-like 1
76617192 PREDICTED: similar to fibulin 1 isoform C precursor isoform 3
76691670 PREDICTED: similar to 5-aminoimidazole-4-carboxamide ribonucleotide form
76621399 PREDICTED: similar to transportin 2 (importin 3, karyopherin beta 2b) isoforrr
3915188 Thioredoxin reductase 1, cytoplasmic (TR) (TR1)
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53.45
53.3
53.17
53.16
53.13
52.85
52.42
52.36
52.31
52.17
52.09
52.03
51.53
51.4
51.29
51.27
51
50.65
50.64
50.55
50.51
50.17
50.15
50.04
49.96
49.9
49.8
49.25
49.2
49.02
49.01
48.99
48.76
48.7
48.47
48.4
48.07
48.07
47.96
47.87
47.8
47.67
47.64
47.6
47.45
47.37
47.24
47.23
46.97
46.95
46.92
46.79
4.42E+03
4.50E+04
1.05E+04
1.58E+04
1.98E+04
1.27E+04
2.22E+04
1.60E+04
2.67E+04
3.55E+04
2.72E+04
2.03E+04
1.82E+04
1.68E+04
1.34E+04
2.68E+04
1.32E+04
2.89E+04
1.94E+04
2.63E+04
2.17E+04
6.97E+04
5.58E+03
3.49E+04
2.39E+04
1.68E+04
1.15E+04
1.55E+04
2.51E+04
6.17E+03
2.64E+04
2.18E+04
2.38E+04
2.23E+04
3.77E+03
2.80E+04
2.21 E+04
2.93E+04
6.95E+04
1.40E+04
2.51E+04
3.64E+04
1.80E+04
1.95E+04
1.99E+04
2.85E+04
2.38E+04
4.13E+04
1.48E+04
1.80E+04
1.32E+04
1.01E+04
111915.1
78539.6
32541.8
21245.4
27368.8
83352.3
18154.7
24306.1
49851.7
37013.7
79933.6
66464.5
23712.6
23370
28405.3
23349.7
76837.5
81837
64408.8
29716.8
48971.6
47457.9
28666.8
65626.6
36730.9
31023.2
61178.6
14894.1
36167
74787
46560.9
21424
37171.2
34577.3
22661.1
70671.3
53052.9
27842.6
56822.3
33643.9
84116.3
22201.6
36784.5
37088.2
56576.1
22132.5
61146.2
28806.2
176804.7
71930.3
36719.5
22964.6
pi species database
4.85 Bos taurus NCBInr
6.39 Mus musculiNCBlnr
10.89 Bos taurus
5.66 Bos taurus
4.71 Bos taurus
6.64 Bos taurus
4.96 Bos taurus
8.26 Bos taurus
6.13 Bos taurus
6.1 Bos taurus
8.37 Bos taurus
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
8.51 Mus musculi NCBInr
4.95 Bos taurus NCBInr
4.51 Bos taurus NCBInr
5.19 Bos taurus NCBInr
9.91 Bos taurus NCBInr
6,61 Bos taurus NCBInr
5.93 Homo sapiei NCBlnr
9.34 Bos taurus NCBInr
6.01 Bos taurus NCBInr
5.41 Bos taurus NCBlnr
5.61 Bos taurus NCBInr
10.85 Bos taurus NCBlnr
6.87 Pan troglody NCBlnr
7.05 Bos taurus
9.04 Bos taurus
5.83 Bos taurus
5.3 Bos taurus
9.41 Bos taurus
9.49 Bos taurus
5.34 Bos taurus
7.52 Bos taurus
6.75 Bos taurus
5.23 Bos taurus
9.39 Bos taurus
9.51 Bos taurus
7.02 Bos taurus
4.58 Bos taurus
8.82 Bos taurus
5.85 Bos taurus
5.96 Bos taurus
9.36 Bos taurus
7.65 Bos taurus
5.56 Bos taurus
5.66 Bos taurus
6.58 Bos taurus
7.07 Bos taurus
5.63 Bos taurus
6.53 Bos taurus
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
6.52 Pan troglody NCBInr
5.57 Bos taurus NCBInr
9.76 Homo sapiei NCBInr
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accession Protein name
27806553 microtubule-associated protein 4
13183789 glutamine: fructose-6-phosphate amidotransferase 1 muscle isoform GFAT11N
76631260 Histone H1.1
76669166 PREDICTED: similar to Copine-3 (Copine 111), partial
74356321 Hypothetical protein LOC505637
76619239 PREDICTED: similar to dynamin 1-like isoform 2
81294317 Hypothetical protein LOC517857
74267846 GrpE-like 1, mitochondrial
76610199 LOC506562 protein
76630782 PREDICTED: similar to protein phosphatase 2A, regulatory subunit B isoform
76678705 PREDICTED: similar to protein kinase C, delta isoform 3
50510663 PREDICTED: glutaminase isoform 5
74354306 Hypothetical protein LOC533251
74354935 Hypothetical protein LOC513312
61553092 proteasome alpha 3 subunit isoform 1
27806307 mitochondrial ATP synthase, 0 subunit
27806089 protein kinase, C alpha
28466983 leprecan-like 2
76689356 PREDICTED: similar to septin 5
76669942 type XI collagen alpha 1 chain
76681614 LOC504752 protein
76675550 PREDICTED: similar to actin-related protein 3-beta
74267715 Ribosomal protein S6
55615936 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclof
76655159 PREDICTED: similar to caspase 7 isoform delta
73587441 NAD(P)H dehydrogenase, quinone 1
76648277 PREDICTED: similar to EPM2A-interacting protein 1 (Laforin-interacting prote
76650162 PREDICTED: similar to glyoxalase 1
78045537 hypothetical protein LOC509983
76637153 PREDICTED: similar to heterogeneous nuclear ribonucleoprotein U isoform b
76616903 alpha-N-acetylgalactosaminidase precursor
74353868 Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding prc
76673628 PREDICTED: similar to Ribose-phosphate pyrophosphokinase I (Phosphoribc
73587111 Leucine zipper transcription factor-like 1
76681980 PREDICTED: similar to Latent transforming growth factor beta binding proteir
74268035 Poly(A) binding protein, cytoplasmic 1
76645357 PREDICTED: similar to 26S proteasome non-ATPase regulatory subunit 12 (
76685000 PREDICTED: hypothetical protein XP_588946, partial
76631182 PREDICTED: similar to Ectonucleoside triphosphate diphosphohydrolase 2 (1'
76615466 PREDICTED: similar to Biliverdin reductase A precursor (Biliverdin-IX alpha-r,
76620459 PREDICTED: similar to Leucine zipper-EF-hand containing transmembrane p
76633366 PREDICTED: similar to Copine-1 (Copine 1) isoform 1
30794344 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1
76633362 PREDICTED: similar to Copine-1 (Copine 1) isoform 9
297129 H+-ATPase non-catalytic subunit B
74354774 Biliverdin reductase B (flavin reductase (NADPH))
76659718 PREDICTED: similar to ribosomal protein S6 kinase polypeptide 3, partial
76639231 PREDICTED: similar to endoplasmic reticulum protein 29 precursor
76649917 collagen type XI alpha 2
55616117 PREDICTED: tubulin, alpha 1
73586701 CTSB protein
62897773 ribosomal protein S5 variant
groupNun numSpecl unique peptidescoreUnique % coverage totalintensity mw
46.67
46.63
46.52
46.47
46.36
46.28
46.22
46.2
45.78
45.6
45.29
44.91
44.68
44.65
44.58
44.4
44.06
43.63
43.57
43.56
43.41
43.3
43.28
43
42.8
42.78
42.7
42.65
42.49
42.41
41.98
41.87
41.72
41.09
41.08
41.06
40.89
40.85
40.74
40.52
40.52
40.3
40.23
40.11
40.09
39.84
39.43
39.2
39.08
39.05
39.03
6.04E+03
2.48E+03
1.50E+04
2.25E+04
1.31 E+04
2.07E+04
1.49E+04
1.77E+04
1.34E+04
2.38E+04
3.53E+04
1.58E+04
2.10E+04
1.09E+04
1.39E+04
6.50E+03
2.11E+04
1.57E+04
1.89E+04
3.26E+04
9.54E+03
1.59E+04
1.92E+04
2.12E+03
1.78E+04
7.73E+03
2.29E+04
6.72E+03
3.20E+04
7.86E+03
1.81E+04
2.22E+04
1.29E+04
1.64E+04
2.98E+04
1.56E+04
2.32E+04
1.39E+04
1.61 E+04
1.64E+04
1.80E+04
2.29E+04
7.37E+03
1.05E+04
1.52E+04
1.25E+04
2.12E+04
1.93E+04
3.27E+04
3.31 E+04
1.46E+04
6.80E+03
25015.6
292118.3
74425.2
20504.7
70068.6
43244.7
42497.4
27298.5
77865
52655.7
66727.3
44976.7
57105.5
26155.4
36965,4
56297.6
23208
32844.4
44294.3
59609.8
30025.8
51946.8
25849.1
92368.7
36746.8
101989.6
45533.6
158004.5
33328.3
23610.8
78733.3
51529.6
46285.2
49368.3
24529.1
32453.7
35723
47991.2
42791.7
38964.7
34503.3
25542.2
59659.5
69164.6
129064.2
28929.8
52804.6
59190.2
38400.2
45385.6
42880.8
69136.6
pl species
7.94 Bos taurus
5.52 Bos taurus
8.49 Bos taurus
6.74 Bos taurus
5.63 Bos taurus
8.57 Bos taurus
8.85 Bos taurus
7.76 Bos taurus
6.37 Bos taurus
5.6 Bos taurus
5.93 Bos taurus
6.58 Bos taurus
9.22 Bos taurus
7.7 Bos taurus
6.52 Bos taurus
8.16 Bos taurus
7.84 Bos taurus
5.27 BOVIN
5.05 Bos taurus
5.4 Bos taurus
10.61 Bos taurus
8.81 Bos taurus
9.39 Bos taurus
5.47 Bos taurus
9.02 Bos taurus
6.74 Bos taurus
5.54 Bos taurus
9.35 Bos taurus
5.34 Bos taurus
6.44 Bos taurus
6.05 Bos taurus
5.31 Bos taurus
5.67 Bos taurus
8.72 Bos taurus
4.98 Bos taurus
9.14 Bos taurus
5.5 Bos taurus
8.98 Bos taurus
database
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
8.06 Canis familiz NCBInr
5.13 Bos taurus NCBInr
5.11 Bos taurus NCBInr
4.9 Bos taurus NCBInr
5.6 Canis familiE NCBInr
5.92 Bos taurus
9.23 Bos taurus
4.82 Bos taurus
6.26 Bos taurus
5.32 Bos taurus
5.34 Bos taurus
7.58 Bos taurus
5.64 Bos taurus
5.5 Bos taurus
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
accession Protein name
899229 thrombospondin-1
76659571 PREDICTED: similar to ubiquitin specific protease 9, X-linked isoform 1 isofor
76631992 PREDICTED: similar to Carnitine 0-palmitoyltransferase I1, mitochondrial pre(
83638644 Similar to ADP-ribosylation factor-like 3
76655054 PREDICTED: similar to X-prolyl aminopeptidase (aminopeptidase P) 1, solubl
76613223 PREDICTED: similar to Chitinase 3-like protein 2 precursor (YKL-39) (Chondr
76632784 LOC613338 protein
74267997 transmembrane emp24 protein transport domain containing 9
83405734 LOC511200 protein
73586898 Hypothetical protein LOC512626
73586515 Eukaryotic translation initiation factor 3, subunit 6 interacting protein
76654829 LOC514371 protein
17298537 polypyrimidine-tract binding protein
74355022 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E isoform 1
76668080 PREDICTED: similar to N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase pre
76607166 PREDICTED: similar to ectonucleotide pyrophosphatase/phosphodiesterase
76614885 PREDICTED: similar to high-mobility group box 2, partial
585322 Inorganic pyrophosphatase (Pyrophosphate phospho-hydrolase) (PPase)
73586582 Hypothetical protein LOC527201
73586947 Chaperonin containing TCP1, subunit 8 (theta)
61886865 PREDICTED: similar to 60S ribosomal protein L7a
76618666 citrate synthase
76627860 PREDICTED: similar to Electron transfer flavoprotein alpha-subunit, mitochon
76636780 PREDICTED: similar to Plasma membrane calcium-transporting ATPase 4 (P
76654464 PREDICTED: similar to Short chain 3-hydroxyacyl-CoA dehydrogenase, mito<
30523262 100 kDa coactivator
74354034 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 6
76632456 PREDICTED: similar to Ribosome-binding protein 1 (Ribosome receptor protE
73587257 Hypothetical protein LOC521254
84579874 hypothetical protein LOC616503
76658374 PREDICTED: similar to cysteinyl-tRNA synthetase isoform b
74354621 Hypothetical protein LOC508535
62946669 muscle endopin 1a
27806759 adipose differentiation-related protein
30794348 casein alpha-Si
76651922 PREDICTED: similar to vesicle-associated membrane protein-associated proi
76631732 PREDICTED: similar to Potassium channel tetramerisation domain containing
74354968 CNP protein
73949258 Purine-rich element binding protein A
76611318 PREDICTED: similar to nuclear distribution gene C homolog (A. nidulans) isol
28603812 epsilon subunit of coatomer protein complex
75948245 Proteasome (prosome, macropain) subunit, beta type, 6
74003011 PREDICTED: chaperonin containing TCP1, subunit 5 (epsilon)
76648175 PREDICTED: similar to programmed cell death 6 interacting protein isoform 1
27806257 collagen, type I, alpha 2
76620202 PREDICTED: similar to E-1 enzyme isoform 1
76610565 PREDICTED: similar to aspartyl aminopeptidase isoform 7
76678376 STK25 protein
81674303 Unknown (protein for MGC:134348)
76658398 cathepsin D
76632304 PREDICTED: similar to selenophosphate synthetase isoform 2
76622026 PREDICTED: similar to thyroid hormone receptor interactor 10 isoform 4
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groupNun numSpect unique peptide scoreUnique % coverage totalintensity mw
38.98
38.89
38.71
38.7
38.63
38.55
38.43
38.39
38.38
38.05
37.85
37.81
37.8
37.52
37.32
37.3
37.19
37.14
37.08
37.07
37.04
37.03
36.86
36.71
36.71
36.69
36.66
36.54
36.26
36.21
36.19
36.02
35.96
35.9
35.83
35.82
35.75
35.73
35.64
35.63
35.63
35.56
35.55
35.51
35.26
35.25
35.08
34.93
34.88
34.87
34.76
34.68
7.18E+03
2.39E+04
9.67E+03
1.07E+04
6.41E+03
1.21E+04
8.93E+04
9.45E+03
1.16E+04
3.90E+04
1.27E+04
8.39E+03
3.14E+04
1.36E+05
1.60E+04
1.89E+04
1.60E+04
6.50E+03
6.43E+03
3.51 E+03
1.08E+04
8.67E+03
2.12E+04
4.78E+04
2.52E+04
1.02E+04
1.67E+04
5.99E+03
2.60E+04
1.79E+04
5.74E+04
2.13E+04
1.79E+04
1.93E+04
5.09E+04
8.38E+03
1.22E+04
4.65E+03
2.04E+04
1.22E+04
1.67E+04
5.70E+03
9.29E+03
3.13E+04
7.03E+03
2.37E+04
7.83E+03
3.33E+04
1.37E+04
2.16E+04
1.32E+04
1.44E+04
56428.8
30606.6
25944.8
44962.9
26723.4
25976.7
103253.3
32477.3
56493.4
87052.1
39232.3
70825.1
311133.9
15973.6
21673.6
44542.9
208347.6
19825.2
27997.3
36687.9
24167.5
83035.5
21856.2
83596.7
49882.3
54824.9
57927.5
64520.5
22262.6
65453.1
61049.6
64847
24907.9
37164.7
63827.5
9249.8
17512.3
80098.4
37493.2
32538.7
44891.7
27901.6
45274.9
37476.3
19860.3
7348.3
73498.3
17337.1
42761.7
68576.8
77182.6
28749
pi species database
6.42 Bos taurus NCBlnr
4.75 Bos taurus NCBInr
6.91 Bos taurus NCBInr
4.8 BOVIN NCBInr
4.42 Bos taurus NCBInr
6.07 Bos taurus NCBlnr
7.23 Bos taurus NCBInr
6.27 Bos taurus NCBInr
5.84 Bos taurus NCBinr
4.92 Homo sapiel NCBInr
5.29 Bos taurus NCBinr
8.75 Bos taurus NCBlnr
8.68 Pan troglody NCBlnr
8.55 Canis familiE NCBInr
5.13 Bos taurus
5.85 Bos taurus
5.97 Bos taurus
4.7 Bos taurus
6.02 Bos taurus
4.76 Bos taurus
6.6 Bos taurus
6.11 Bos taurus
8.86 Bos taurus
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBInr
6.47 Homo sapiei NCBInr
8.62 Bos taurus
4.81 Bos taurus
5.93 Bos taurus
6.77 Bos taurus
5.96 Bos taurus
8.23 Bos taurus
5.7 HUMAN
5.59 Bos taurus
5.62 Bos taurus
6.34 Bos taurus
NCBlnr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
SwissProt
NCBInr
NCBInr
NCBInr
7.66 Canis familiE NCBInr
5.69 Bos taurus NCBlnr
5.75 Bos taurus NCBInr
6.68 Bos taurus NCBInr
4.74 Homo sapiei NCBInr
6.85 Bos taurus NCBInr
7.65 Bos taurus NCBInr
9.2 Bos taurus NCBInr
9.35 Bos taurus NCBInr
6.57 Rattus norve NCBInr
6.44 Bos taurus NCBlnr
9.82 Bos taurus NCBlnr
5.77 Homo sapiel NCBInr
4.83 Bos taurus NCBInr
5.28 BOVIN NCBInr
5.99 Canis famili. NCBInr
8.16 Canis familie NC BInr
4.57 Bos taurus NCBInr
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accession Protein name
76634486 PREDICTED: similar to Serine/threonine-protein kinase Sgk3 (Serum/glucocc
74354078 Hypothetical protein LOC518321
61810775 PREDICTED: similar to Proteasome subunit alpha type 2 (Proteasome comp<
125197 cAMP-dependent protein kinase type l-alpha regulatory subunit
27806687 clathrin, light polypeptide (Lca)
74267640 Mesoderm development candidate 2
76638698 RPS27A protein
76632643 PREDICTED: similar to isopentenyl-diphosphate delta isomerase isoform 2
76648361 PREDICTED: similar to Dynein light intermediate chain 1, cytosolic (Dynein lis
51470849 PREDICTED: heat shock 90kDa protein 1, alpha-like 3
76621211 PREDICTED: similar to N-acylglucosamine 2-epimerase (GIcNAc 2-epimeras
76645718 PREDICTED: similar to signal recognition particle 68kDa isoform 1
55666933 WD repeat domain 1
73952614 PREDICTED: similar to Glyceraldehyde-3-phosphate dehydrogenase (GAPDI
74354937 Hypothetical protein LOC539524
74353978 Lysosomal-associated membrane protein 2
76617277 PREDICTED: similar to Plexin B2 precursor (MM1) isoform 4
76610984 PREDICTED: similar to MARCKS-like protein
74267695 Phosphomannomutase 2
27805823 dermatan sulfate proteoglycan 3
76627105 PREDICTED: similar to RAB2B protein isoform 1
76629583 PREDICTED: similar to inner membrane protein, mitochondrial, partial
76679364 PREDICTED: similar to 3-oxoacid CoA transferase 1, partial
16741721 Lysyl hydroxylase, precursor
73587285 Solute carrier family 29 (nucleoside transporters), member 1
83405836 Hypothetical protein LOC511198
76648284 Ste-20 related kinase SPAK
76685863 PREDICTED: similar to Beta-glucuronidase precursor (Beta-G1), partial
76644487 PREDICTED: similar to Coatomer zeta-2 subunit (Zeta-2 coat protein) (Zeta-2
76639264 PREDICTED: similar to Y37D8A.2 isoform 3
P13674 Prolyl 4-hydroxylase alpha-1 subunit precursor (EC 1.14.11.2) (4-PH alpha-1)
62460512 hypothetical protein LOC512642
41386729 high-mobility group box 1
27806265 chondromodulin I precursor [leukocyte cell-derived chemotaxin 1]
73955102 Pafah1b2 protein
76647179 PREDICTED: similar to Electron transfer flavoprotein alpha-subunit, mitochon
76611597 PREDICTED: similar to cell division cycle 42, partial
76607875 PREDICTED: similar to Importin alpha-4 subunit (Karyopherin alpha-4 subuni
37181971 MWRP239
74354146 Hypothetical protein LOC512891
76639484 PREDICTED: similar to dolichyl-di-phosphooligosaccharide-protein glycotranE
74354925 Hypothetical protein LOC533949
76623702 PREDICTED: similar to ubiquitin-like domain containing CTD phosphatase 1
12002054 transaldolase
76619843 PREDICTED: similar to sec1 family domain containing 2
45645223 cell division cycle 10
28317368 TPA: aminopeptidase B
76677759 PREDICTED: similar to NADP-dependent malic enzyme (NADP-ME) (Malic e
125192 cAMP-dependent protein kinase type I-alpha regulatory subunit
73984484 Ribophorin 1
73988830 SWA-70 protein
73587053 Hypothetical protein LOC515499
groupNun numSpecl unique peptide scoreUnique % coverage totalintensity mw
34.66
34.61
34.49
34.48
34.3
34.24
34.17
34.06
33.86
33.8
33.7
33.69
33.66
33.65
33.58
33.56
33.47
33.45
33.43
33.19
33.18
33.12
33.05
33.05
32.89
32.85
32.83
32.79
32.78
32.76
32.71
32.71
32.67
32.53
32.52
32.48
32.06
31.82
31.67
31.61
31.44
31.44
31.36
31.34
31.3
31.26
31.22
31.2
31.13
31.07
31.04
30.98
1.12E+04
1.79E+04
9.31 E+03
1.15E+04
1.01E+04
3.39E+04
1.17E+04
1.32E+04
1.13E+04
1.28E+04
9.77E+03
1.75E+04
1.13E+04
4.89E+03
1.28E+04
2.21 E+04
9.03E+03
1.04E+04
8.22E+03
4.27E+04
1.81 E+04
1.18E+04
1.63E+04
1.43E+04
5.54E+03
1.38E+04
3.37E+04
1.71 E+04
1.92E+04
1.52E+04
1.70E+04
1.11E+04
1.28E+04
1.92E+04
5.48E+03
7.88E+03
8.39E+03
1.30E+04
4.87E+03
5.46E+03
3.01E+04
9.11E+03
1.43E+04
1.71 E+04
7.21 E+03
1.38E+04
4.79E+03
1.51E+04
9.81 E+03
4.83E+03
1.09E+04
7.51 E+03
25377.4
47412.1
74236.8
34525
73260
26892.9
40654
22487.2
66269.4
50287.4
73144.5
23421.5
86469.6
96894.1
47629.2
25258
54118.8
49063.7
22896.4
35836.2
35155.5
33340.2
81297.4
63931
28024.8
88772.6
21920.1
69306.6
49407.5
40921.5
54187.5
55465.2
31521.4
43803.2
64888
59125.7
31905.9
40638.9
23626.9
58428.9
71187
38032.8
28594
53807.4
53650.8
55199.6
75541.5
40619.9
19934.4
12547.9
31414.4
27735
pi species database
5.38 Bos taurus NCBInr
10.96 Bos taurus NCBlnr
6.47 Bos taurus NCBInr
5.02 Bos taurus NCBlnr
8.91 Bos taurus NCBInr
8.4 Bos taurus NCBInr
5.08 Bos taurus NCBlnr
8.07 Bos taurus NCBInr
5.94 Canis familie NCBInr
8.72 Pan troglody NCBlnr
6.32 Bos taurus NCBInr
5.12 Bos taurus NCBInr
5.82 Bos taurus NCBInr
6.12 Canis familiE NCBlnr
9.21 Bos taurus NCBInr
6.31 Bos taurus NCBInr
5.41 Bos taurus NCBInr
5.16 Pan troglody NCBlnr
6.52 Bos taurus NCBlnr
8.57 Sus scrofa NCBInr
6.01 Bos taurus NCBInr
8.38 Bos taurus NCBlnr
5.84 Canis familie NCBInr
5.78 Bos taurus NCBlnr
11.04 Bos taurus NCBInr
7.93 Bos taurus NCBInr
8.25 Bos taurus NCBlnr
5.95 Bos taurus NCBInr
6.75 bovine NCBInr
9.06 Canis familiE NCBlnr
7.59 Bos taurus
6.34 Bos taurus
6.74 Bos taurus
6.13 Bos taurus
9.6 Bos taurus
6.4 Bos taurus
9.93 Bos taurus
6.29 Bos taurus
5.98 Bos taurus
6 Bos taurus
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
NCBInr
NCBlnr
7.54 Rattus norve NCBlnr
7.13 Bos taurus NCBlnr
6.18 Bos taurus NCBInr
5.04 Bos taurus NCBlnr
5.6 Homo sapiei NCBInr
6.77 Bos taurus NCBlnr
5.6 Bos taurus NCBInr
8.71 Bos taurus NCBlnr
5.69 Bos taurus NCBInr
9.07 Bos taurus NCBlnr
5.92 Bos taurus NCBInr
5.37 Bos taurus NCBlnr
accession Protein name
76654970 PREDICTED: similar to glutathione-S-transferase omega 1
62460480 hypothetical protein LOC510547
76639900 Craniofacial development protein 2 (p97 bucentaur protein)
76664539 PREDICTED: similar to vesicle transport-related protein isoform a
76616889 PREDICTED: similar to DEAD box polypeptide 17 isoform 1 isoform 9
76701956 PREDICTED: similar to RAN, member RAS oncogene family
74268122 Hypothetical protein LOC526612
76655610 caspase-3
74006523 CTP synthase il
55620724 Coproporphyrinogen oxidase
76659559 PREDICTED: similar to DEAD-box protein 3, X-chromosomal (Helicase-like p
28603774 Rho GDP dissociation inhibitor (GDI) alpha
76653827 PREDICTED: similar to procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 pi
73998369 NF-kB2 splice variant 4
76656245 PREDICTED: similar to coiled-coil domain containing 6
27806911 CD9 antigen (p24)
81673074 Unknown (protein for MGC:127205)
55648517 tropomyosin 4-anaplastic lymphoma kinase fusion protein
74354591 Proteasome (prosome, macropain) subunit, beta type, 2
2407184 glyceraldehyde 3-phosphate dehydrogenase
76656965 PREDICTED: similar to CG9119-PA
28603744 mitochondrial carrier homolog 2
74001097 glycogen branching enzyme
74354907 Eukaryotic translation initiation factor 3, subunit 7 zeta, 66/67kDa
74267654 Hypothetical protein LOC535056
76626705 PREDICTED: similar to ADP-dependent glucokinase
76689040 PREDICTED: similar to Tissue alpha-L-fucosidase precursor (Alpha-L-fucosic
74355010 Leukotriene A4 hydrolase
2119917 translation elongation factor EF-Tu precursor
73990431 muscleblind-like 1
76615127 PREDICTED: similar to Dihydrolipoyl dehydrogenase, mitochondrial precurso
76616970 PREDICTED: similar to adenylosuccinate lyase isoform 2
74354619 ATPase, Na+/K+ transporting, beta 3 polypeptide
73587133 Hypothetical protein LOC540272
76625300 PREDICTED: similar to Plasminogen activator inhibitor 1 RNA-binding proteir
66792842 dihydroxyacetone kinase 2 homolog
76615572 PREDICTED: similar to transmembrane emp24 protein transport domain cont
72536789 MHC class I antigen
83638639 Unknown (protein for MGC:133754)
27805931 intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
12018252 transketolase
81673705 Hypothetical protein LOC515837
73587251 Hypothetical protein LOC505403
76617221 PREDICTED: similar to Arylsulfatase A precursor (ASA) (Cerebroside-sulfata:
12654479 UBX domain containing 8
75775064 Hypothetical protein LOC525106
2920652 GTP-binding protein
633 protein kinase
74354962 Hypothetical protein LOC534704
76646969 PREDICTED: similar to Ras GTPase-activating-like protein IQGAP1 (p195)
76633047 PREDICTED: similar to Vesicle-associated membrane protein-associated pro
76646451 PREDICTED: similar to 3-oxoacid CoA transferase 1
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groupNun numSpeci unique peptidescoreUnique % coverage totalintensity mw
625 3 3 30.87 3 2.19E+04 67
626 3 2 30.81 5 6.24E+03 69
627 2 2 30.81 6 1.84E+04 38
628 2 2 30.68 7 8.55E+03 35
629 3 2 30.68 8 4.37E+04 32
630 4 2 30.63 3 5.14E+03 94
631 2 2 30.62 12 9.46E+03 21
632 2 2 30.57 9 1.12E+04 31
633 2 2 30.52 3 1.22E+04 56
634 2 2 30.47 4 1.51E+04 43
635 3 3 30.34 4 2.36E+03 103
636 2 2 30.25 2 1.24E+04 81
637 2 2 30.05 3 9.53E+03 117
638 11 2 30.05 8 3.66E+04 21
639 2 2 30.03 11 9.85E+03 21
640 2 2 30 5 2.84E+03 3
641 2 2 29.98 3 6.59E+03 8
642 2 2 29.89 9 5.04E+03 51
643 3 3 29.77 7 5.46E+03 3E
644 2 2 29.7 10 6.93E+03 3
645 2 2 29.69 4 9.77E+03 5
646 3 2 29.6 5 7.71E+03 2
647 3 2 29.45 5 3.71E+03 6(
648 3 2 29.18 6 1.48E+04 4
649 3 3 29.18 8 4.69E+03 3
650 2 2 29.13 8 3.47E+03 2
651 4 2 29.04 7 2.34E+04 3
652 2 2 29.04 6 3.15E+03 4
653 2 2 29.01 7 1.39E+04
654 2 2 28.94 5 9.57E+03 3
655 8 2 28.93 6 1.28E+04 2
656 3 2 28.79 0 1.65E+04 38
657 2 2 28.75 6 9.48E+03 4
658 2 2 28.52 5 3.84E+03 3
659 2 2 28.48 2 3.21E+03 1
660 2 2 28.37 3 9.57E+03
661 2 2 28.3 8 8.55E+03 2
662 3 3 28.23 1 1.98E+03 22
663 2 2 28.15 6 5.61E+03 3
664 2 2 28.08 4 1.89E+04 4
665 2 2 28.07 2 1.45E+04 8
666 2 2 28.02 9 1.08E+04 3
667 2 2 28.01 5 1.03E+04 4
668 2 2 27.74 8 1.03E+04 4
669 3 2 27.66 8 1.86E+04 2
670 2 2 27.62 2 6.44E+03 6
671 3 2 27.4 6 1.29E+04 3
672 2 2 27.35 13 1.13E+04 2
673 2 2 27.33 1 3.18E+03 1
674 2 2 27.2 7 1.44E+04 3
675 2 2 27.17 2 9.48E+02 12
676 2 2 27.15 2 8.74E+03 9
569.3
214.4
631.6
5178.6
117.1
235.5
535.5
537.4
6776.2
1877.4
1926.2
7539.8
7520.9
5692.1
5073.9
3216.7
2249.9
5762.9
6914.3
3049.7
1979.2
9728.1
0619.4
3114.1
3154.1
8761.3
5655.3
7302.5
37298
9221.2
5111.5
7090.7
1384.6
3886.4
48222
74705
9943.5
9100.4
1201.7
5444.5
7335.2
6988.4
6091.3
1388.3
8311.9
3683.6
5471.7
4489.6
96523
8217.5
7328.6
0828.4
pl species database
7.06 Bos taurus NCBInr
5.48 Bos taurus NCBInr
6.2 Homo sapiel NCBInr
5.98 Bos taurus NCBInr
4.12 Bos taurus NCBInr
8.27 Pan troglody NCBInr
11.69 Bos taurus NCBInr
8.56 Bos taurus NCBInr
5.94 Bos taurus NCBInr
9.56 Bos taurus NCBInr
8.07 Bos taurus NCBInr
9 Pan troglody NCBlnr
7.18 Bos taurus NCBInr
4.88 Bos taurus NCBInr
4.81 Bos taurus NCBlnr
8.74 Bos taurus NCBInr
5.42 Bos taurus NCBInr
9.03 Bos taurus NCBInr
4.88 Bos taurus NCBInr
6.1 Bos taurus NCBInr
7.19 Bos taurus NCBInr
9.47 Bos taurus NCBlnr
5.49 Bos taurus NCBInr
9.36 Bos taurus NCBInr
6.26 Bos taurus NCBinr
4.75 Canis famili NCBInr
5.87 Bos taurus NCBInr
4.85 Bos taurus NCBInr
5.55 Bos taurus NCBInr
4.83 Bos taurus NCBlnr
10.06 Bos taurus NCBInr
8.9 Pan troglody NCBInr
4.68 Bos taurus NCBlnr
6.55 Bos taurus NCBInr
6.09 Pan troglody NCBlnr
5.81 Bos taurus
6.72 Bos taurus
5.44 BOVIN
5.44 Bos taurus
4.91 Bos taurus
5.74 HUMAN
5.36 Bos taurus
6.57 Bos taurus
4.86 Bos taurus
4.16 Bos taurus
6.23 Bos taurus
5.21 Bos taurus
5.65 MOUSE
NCBInr
NCBInr
SwissProt
NCBInr
NCBInr
SwissProt
NCBInr
NCBInr
NCBInr
NCBlnr
NCBInr
NCBInr
SwissProt
6.09 Rattus norve NCBInr
8.75 Bos taurus NCBInr
5.87 Bos taurus NCBlnr
6.28 Bos taurus NCBInr
accession Protein name
76608746 PREDICTED: similar to Mitochondrial precursor proteins import receptor (Trat
74267729 Hypothetical protein LOC534231
56790945 protein phosphatase 1, catalytic subunit, alpha isoform 3
76654275 PREDICTED: similar to JTV1 isoform 2
83638675 MGC134241 protein
55588614 PREDICTED: a disintegrin and metalloproteinase with thrombospondin motifs
75775560 Ribosomal protein L18
73586945 Unknown (protein for MGC:126965)
76629869 PREDICTED: similar to prenylcysteine oxidase 1
27807207 plasminogen activator inhibitor type 1, member 2
76607473 PREDICTED: similar to Eukaryotic translation initiation factor 4 gamma 1 (elF
55633929 CCDC6 protein
76607227 PREDICTED: similar to optic atrophy 1 isoform 8 isoform 16
76651328 PREDICTED: similar to Translocon-associated protein alpha subunit precursc
74354266 Hypothetical protein LOC515326
76652799 PREDICTED: similar to 3,2-trans-enoyl-CoA isomerase, mitochondrial precun
18652676 micromolar calcium activated neutral protease 1
76657043 PREDICTED: similar to phosphatidylinositol-binding clathrin assembly protein
83638659 MGC133704 protein
76656104 PREDICTED: similar to translin-associated factor X
61817521 cathepsin C
27807365 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
76665976 PREDICTED: similar to Tenascin precursor (TN) (Hexabrachion) (Cytotactin)
76626004 PREDICTED: similar to SH3-domain GRB2-like B1 (endophilin) (predicted), p
76652711 PREDICTED: hypothetical protein XP_880973 isoform 5
74000397 Tropomyosin 1, alpha, isoform h
73586725 Unknown (protein for MGC:128341)
78174362 Hypothetical protein LOC508273
78042550 thioredoxin-like
74268242 ADP-ribosylhydrolase like 2
16418492 cyanogen bromide
55620347 Galphai2 protein
61554723 proteasome 26S non-ATPase subunit 4 isoform 1
76632995 PREDICTED: similar to cathepsin Y isoform 1
55633999 PREDICTED: vinculin
77404189 thimet oligopeptidase
74267697 Hypothetical protein LOC509643
Q27991 Myosin heavy chain, nonmuscle type B (Cellular myosin heavy chain, type B)
28461185 mannose-6-phosphate receptor (cation dependent)
76671220 MGC129137 protein
P42224 Signal transducer and activator of transcription 1-alpha/beta (Transcription fa<
74353904 MGC127154 protein
74268319 Hypothetical protein LOC535740
74267606 Protein phosphatase 1, regulatory subunit 7
76647200 PREDICTED: similar to Reticulocalbin-2 precursor (Calcium-binding protein E
76625619 PREDICTED: fibroblast growth factor receptor 3, partial
73586980 Unknown (protein for MGC:127895)
P46638 Ras-related protein Rab-1 1 B
62640787 IQ motif containing GTPase activating protein 1
75773792 DnaJ (Hsp40) homolog, subfamily B, member 1
76629029 PREDICTED: similar to latent transforming growth factor beta binding protein
76613142 PREDICTED: similar to upstream of NRAS isoform 2
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groupNun numSpecl unique peptide scoreUnique % coverage totalIntensity mw
677 2 2 27.15 6 9.62E+03
678 3 2 27.07 2 8.18E+03 131
679 3 2 27.04 1 1.58E+04 132
680 2 2 26.96 10 8.74E+03 28
681 3 2 26.76 3 9.01E+03
682 2 2 26.55 1 3.12E+03 226
683 2 2 26.48 3 5.64E+03 88
684 2 2 26.48 2 1.08E+03 140
685 2 26.41 3 1.31 E+04 52
686 2 2 26.41 2 1.40E+04 65
687 5 2 26.35 2 1.81E+04 75
688 2 2 26.34 8 4.45E+03
689 2 2 26.27 4 6.83E+03 5(
690 2 2 26.25 4 4.89E+03 3-
691 2 2 26.23 4 5.60E+03 5
692 2 2 26.09 6 1.35E+04 31
693 2 2 26.07 3 4.48E+03 6
694 2 2 26.03 12 6.54E+03 2;
695 3 2 25.74 4 8.97E+03
696 2 2 25.67 1 4.87E+03 10
697 3 2 25.61 3 2.49E+04 5
698 2 2 25.57 2 2.01E+03 13
699 2 2 25.21 2 1.26E+04 7
700 2 2 25.11 12 2.50E+03 2(
701 2 2 25.04 6 6.78E+03 31
702 3 2 24.99 3 4.61E+03 6
703 4 2 24.98 7 6.80E+03 21
704 2 2 24.77 6 1.01E+04 51
705 2 2 24.76 2 3.95E+03 10(
706 2 2 24.74 2 4.59E+03 10
707 2 2 24.73 2 6.70E+03 81
708 2 2 24.56 16 1.46E+03 1
709 3 2 24.51 2 6.68E+03 9
710 2 2 24.46 7 3.54E+03 3
711 2 2 24.44 5 5.28E+03 7
712 2 2 24.34 6 6.85E+03 3
713 2 2 24.25 10 2.54E+04 3
714 2 2 24.17 7 1.01E+04 3
715 2 2 24.09 12 1.12E+04 2
716 2 2 24.07 2 2.95E+03 10
717 2 2 24.02 9 4.84E+03 2
718 2 2 23.98 20 2.50E+03 2
719 2 2 23.92 0 1.22E+03 26
720 2 2 23.86 2 4.95E+03 10
721 2 2 23.83 5 1.06E+04 5
722 2 2 23.8 5 2.46E+04 4
723 2 2 23.75 5 1.46E+04 6
724 2 2 23.44 0 1.17E+04 41
725 2 2 23.27 2 6.82E+03 9
726 2 2 23.2 7 1.03E+04 2
727 2 2 23.07 3 2.15E+03 12
728 1 1 22.92 5 8.39E+03
52378
855.5
117.9
1857.5
57142
339.3
1268.8
1787.5
2243.2
5294.2
5818.7
31738
0875.8
7231.8
2191.1
1667.9
3206.9
2018.6
44010
4841.9
3942.3
7001.2
3338.4
6722.2
5742.5
5238.8
5623.7
1447.6
6671.1
6655.5
1315.3
8988.1
4316.8
2657.1
3213.2
2050.6
3978.1
3876.6
1258.8
7968.2
4708.9
1139.4
5650.8
1607.2
0974.1
3079.1
5236.8
0108.1
3890.7
9031.3
3630.7
45712
pi species database
6.36 Bos taurus NCBInr
7.63 Pan troglody NCBinr
4.8 Bos taurus NCBInr
4.74 Pan troglody NCBInr
7.23 Bos taurus NCBInr
5.49 RAT SwissProt
5.25 Bos taurus NCBInr
8.15 Bos taurus NCBInr
4.99 Canis famili NCBInr
9.06 Bos taurus NCBInr
9.24 Pan troglody NCBInr
5.54 Bos taurus
5.43 Bos taurus
9.15 Bos taurus
5.71 Bos taurus
8.4 Bos taurus
9.43 Bos taurus
8.89 Bos taurus
6.44 Bos taurus
7.91 Bos taurus
5.46 RABIT
4.96 Bos taurus
NCBnr
NCBnr
NCBnr
NCBnr
NCBnr
NCBInr
NCBInr
NCBInr
NCBnr
SwissProt
NCBnr
5.21 Canis familie NCBlnr
5.38 Bos taurus
5.86 Bos taurus
5.16 Bos taurus
8.92 Bos taurus
8.3 Bos taurus
6.22 Bos taurus
5.3 Bos taurus
5.81 Bos taurus
6.86 Bos taurus
5.89 Bos taurus
5.88 Bos taurus
4.59 HUMAN
7 Bos taurus
5,68 Bos taurus
9.91 Bos taurus
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBInr
NCBnr
NCBnr
NCBnr
SwissProt
NCBnr
NCBnr
NCBInr
accession Protein name
76647377 PREDICTED: similar to vesicle transport-related protein isoform a
55621128 PREDICTED: transferrin
76629332 PREDICTED: similar to Reticulon 4 (Neurite outgrowth inhibitor) (Nogo protei
83674988 rcTPM3
76647423 PREDICTED: similar to sorting nexin 6
Q62812 Myosin heavy chain, nonmuscle type A (Cellular myosin heavy chain, type A)
27805959 integrin, beta 1 subunit (fibronectin receptor, beta polypeptide, antigen CD29
76611807 PREDICTED: similar to Coatomer alpha subunit (Alpha-coat protein) (Alpha-C
74006545 Chromatin assembly factor 1 subunit C (CAF-1 subunit C) (Chromatin assemi
76671059 Glutamine synthetase (Glutamate-ammonia ligase) (GS)
55640967 SPARC-related modular calcium-binding protein 1 precursor (Secreted modul
76615500 PREDICTED: similar to 3-hydroxyisobutyrate dehydrogenase, mitochondrial F
76642670 PREDICTED: similar to serine carboxypeptidase 1 precursor protein isoform
21450879 beta- 1,4-galactosyltransferase
74267627 Eukaryotic translation initiation factor 3, subunit 6 48kDa
76634058 PREDICTED: similar to tissue specific transplantation antigen P35B
76670135 PREDICTED: similar to Melanoma-associated antigen D2 (MAGE-D2 antigen
74354772 Hypothetical protein LOC509056
76639752 PREDICTED: similar to v-crk sarcoma virus CT1 0 oncogene homolog (avian).
12034659 ribeye
P28863 Stromelysin-1 precursor (EC 3.4.24.17) (Matrix metalloproteinase-3) (MMP-3)
76654996 PREDICTED: similar to serine/threonine kinase 2, partial
74004542 dynein, cytoplasmic, intermediate polypeptide 2
83588810 vinculin
76671392 PREDICTED: similar to 26S proteasome non-ATPase regulatory subunit 14 (
73587017 Hypothetical protein LOC534150
76657975 PREDICTED: similar to Protein FAM3C precursor (Protein GS3786) isoform
74356509 Integrin linked kinase
62084374 ATP-dependent Lon protease
76639846 PREDICTED: similar to Alanyl-tRNA synthetase (Alanine-tRNA ligase) (AlaR
73587129 minichromosome maintenance protein 7
81294235 Hypothetical protein LOC615197
76618599 signal transducer and activator of transcription 6
76629502 PREDICTED: similar to Trans-Golgi network integral membrane protein 2 pre
P19338 Nucleolin (Protein C23)
81673606 Unknown (protein for MGC:133821)
76655751 protein phosphatase 2, catalytic subunit, alpha isoform
27807191 solute carrier family 25 (mitochondrial carrier
74207606 cell division cycle 42 (GTP binding protein, 25kDa)
15559717 AP2A1 protein
P70470 Acyl-protein thioesterase 1 (EC 3.1.2.-) (Lysophospholipase 1)
76608281 PREDICTED: similar to Nucleoside diphosphate-linked moiety X motif 16 (Nu,
76640531 PREDICTED: similar to CCR4-NOT transcription complex, subunit 1 isoform
4.94 HUMAN SwissProt Q10567 Adapter-related protein complex 1 beta 1 subunit (Beta-adaptin 1) (Adaptor p,
8.9 Bos taurus NCBInr 76616245 PREDICTED: similar to Nedd8 ultimate buster-1, partial
5.86 Bos taurus NCBInr 76645595 PREDICTED: similar to Galactokinase (Galactose kinase) isoform 3
5.13 Bos taurus NCBInr 76609484 PREDICTED: similar to Dynein intermediate chain 2, cytosolic (DH IC-2) (Cyt
10.45 Macaca mul NCBInr 44893813 abnormal spindle-like
5.85 Bos taurus NCBInr 76651457 LOC533188 protein
5.52 Bos taurus NCBInr 74267624 Proteasome (prosome, macropain) subunit, beta type, 4
4.83 HUMAN SwissProt 000410 Importin beta-3 (Karyopherin beta-3) (Ran-binding protein 5) (RanBP5)
6.06 Canis familiE NCBInr 73969820 actin-related protein 2 isoform a
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6.73 Mus muscult NCBInr
7.73 Homo sapiei NCBInr
6.05 RAT SwissProt
6.6 Bos taurus NCBInr
6.61 Bos taurus NCBInr
groupNun numSpeci unique peptide scoreUnique % coverage totalintensity mw
729 2 2 22.76 1 1.83E+03 164586.7
730 2 2 22.72 3 5.45E+03 60387.5
731 2 2 22.66 7 1.36E+04 36899.9
732 2 2 22.52 4 1.95E+04 44401.4
733 1 1 22.5 3 1.21E+04 49269
734 2 2 22.45 3 8.69E+03 59673.8
735 2 2 22.44 3 2.76E+03 96885.8
736 2 2 22.28 1 2.44E+03 287831.3
737 2 2 21.7 5 1.90E+03 46690.1
738 1 1 21.63 3 4.20E+03 40463.4
739 1 1 21.57 7 3.31E+03 28134.7
740 2 2 21.48 2 9.95E+03 69276
741 2 2 21.36 1 1.03E+03 166628.5
742 2 2 21.29 14 7.36E+03 14465.6
743 1 1 21.2 4 2.34E+03 60055
744 2 2 21.01 3 1.91E+03 136658
745 1 1 20.92 2 4.63E+03 70872.9
746 1 1 20.89 7 5.86E+03 32120.3
747 1 1 20.87 5 5.52E+03 38305.9
748 1 1 20.75 2 5.46E+03 59915.6
749 1 1 20.65 2 2.89E+03 82978.1
750 1 1 20.65 8 7.22E+03 21376.3
751 1 1 20.5 3 2.83E+03 80998.7
752 1 1 20.44 1 6.43E+03 78675.7
753 7 1 20.4 9 7.11E+04 13401.5
754 1 1 20.16 1 5.06E+03 90121.5
755 2 2 20.15 4 5.04E+03 36163.7
756 2 2 20.15 5 5.38E+03 55003.7
757 1 1 20.09 9 4.23E+03 17439.7
758 1 1 12.58 4 7.87E+02 329984.3
pi species
9.18 Canis famili
5.46 Bos taurus
5.73 HUMAN
7.61 Bos taurus
9.11 Pan troglody
7.85 Bos taurus
5.46 Bos taurus
5.2 Bos taurus
10.32 Bos taurus
8.78 Bos taurus
4.82 Mus musculi
5.83 MOUSE
5.65 Bos taurus
7.98 Bos taurus
4.32 Bos taurus
6.54 Pan troglody
8.97 Bos taurus
4.84 HUMAN
5.15 Bos taurus
6.79 Bos taurus
6.26 Bos taurus
8.74 Bos taurus
9.79 Bos taurus
6.68 HUMAN
database accession Protein name
NCBInr 50978924 ribosome receptor
NCBInr 76689594 PREDICTED: similar to Transcription factor p65 (Nuclear factor NF-kappa-B F
SwissProt Q9NQG5 Protein C20orf77
NCBInr 76665742 PREDICTED: similar to stromal cell derived factor receptor 1 isoform b isoforr
NCBInr 55642977 PREDICTED: electn transfer flavoprotein, alpha polypeptide
NCBlnr 86438303 Unknown (protein for MGC:137200)
NCBInr 76633288 PREDICTED: similar to Band 4.1-like protein I (Neurona[ protein 4.1) (4.1 N)
NCBInr 76630702 PREDICTED: similar to Spectrin alpha chain, brain (Spectrin, non-erythroid al
NCBInr 76609486 PREDICTED: similar to cytochrome b reductase 1
NCBInr 83405025 Hypotheticl protein L0C514902
NCBInr 74219534 14-3-3 protein beta
SwiasProt P26040 Ezrin (p81) (Cytovillin) (Villin 2)
NCBInr 76627657 PREDICTED: similar to Nidogen-2 precursor (NID-2) (Osteonidogen)
NCBInr 76676769 PREDICTED: similar to LIN-7 homolog A (LIN-7A) (Mammalian LIN-seven prc
NCBlnr 83405382 Hypothetical protein LOC512427
NCBInr 55652893 CSE1 chromosome segregation 1-like protein, isoform a
NCBlnr 17941422 vitrin
SwissProt 043396 Thioredoxin-like protein 1 (32 kDa thioredoxin-related protein)
NCBnr
NCBnr
NCBInr
NCBInr
NCBlnr
SwissProt
8.52 Canis familie NCBlnr
8.33 Bos taurus NCBInr
5.47 HUMAN SwissProt
9.11 HUMAN SwissProt
5.06 Bos taurus NCBInr
5.33 Bos taurus NCBInr
76641888 PREDICTED: similar to Ubiquitin-like 1 activating enzyme ElA (SUMO-1 actii
78369302 hypothetical protein LOC531682
76624028 PREDICTED: similar to palladin
76614877 PREDICTED: similar to Cell division protein kinase 6 (Serne/threonine-protei
76631025 PREDICTED: similar to DEAD (Asp-Glu-Ala-Asp) box polypeptide 31 isoform
Q06210 Glucosamine-fructose-6-phosphate aminotransferase [isomerizing] 1 (EC 2.6
74006684 PREDICTED: similar to eukaryotic translation elongation factor 1 alpha 2 isofc
76616225 PREDICTED: similar to Cullin-1 (CUL-1) isoform 2
Q7L5N1 COP9 signalosome complex subunit 6 (Signalosome subunit 6) (SGN6) (JAB
095822 Malonyl-CoA decarboxylase, mitochondrial precursor (EC 4.1.1.9) (MCD)
76676232 PREDICTED: similar to golgi phosphoprotein 3, partial
76648072 PREDICTED: similar to AHNAK nucleoprotein isoform 1
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